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 ABSTRACT
HOX11 is a developmental regulator that plays a crucial role in the normal development
of the spleen and is also aberrantly activated by the t(10;14)(q24;q11) and variant
t(7;10)(q35;q24) translocations in a subset of T-cell acute lymphoblastic leukaemias (T-
ALLs). The recent finding that HOX11 is deregulated in up to 40% of childhood T-
ALLs when abnormalities not detected by cytogenetics are included, suggests that the
over-expression of HOX11 and subsequent deregulation of downstream target genes are
critical events in the progression of this tumour type. To date, three candidate HOX11
target genes have been reported, two of which are Aldehyde  Dehydrogenase  1a1
(ALDH1A1) and Four and a Half LIM domain Protein 1 (FHL1). This investigation
focused on two aspects of HOX11 function, namely its roles as a transcriptional
regulator and as a nuclear oncoprotein capable of inducing neoplastic transformation.
More specifically, we sought to further understand the role of HOX11 in tumorigenesis
by 1) Confirming target gene status of ALDH1A1 and FHL1 by assessing whether their
proximal promoter regions are transcriptionally regulated by HOX11, 2) Investigating
the  regulatory  elements/transcriptional  complexes  involved  in  the  response  of
ALDH1A1 to HOX11 in both a T-cell and an erythroid cell line in order to gain an
insight into the mechanism(s) responsible for mediating a HOX11 activity and 3)
Assessing  the  ability  of  ALDH1A1 and FHL1  to  perturb  normal  patterns  of
haematopoiesis, on the basis that the transforming capabilities of HOX11 are thought to
derive from its ability to affect haematopoietic cell differentiation.
To confirm ALDH1A1 and FHL1 as target genes, they were both characterised in terms
of the ability of their proximal promoters to be transcriptionally regulated by HOX11
using luciferase reporter assays. Significant repression of the proximal promoters of
ALDH1A1 and FHL1 by HOX11 was observed in PER-117 T-cells which provided
further evidence for their status as target genes. In the case of ALDH1A1, a CCAAT box
(-74/-70bp) was identified as the primary cis-regulatory element involved in ALDH1A1
transcription and repression by HOX11 appeared to occur, either directly or indirectly,
via interactions at the CCAAT box. Electromobility shift assays (EMSAs) revealed the
disruption of a specific complex at this site by HOX11, which also altered the formation
of complexes at a non-canonical TATA box (a GATA box at -34/-29bp). Significantly,v
HOX11 was shown to have the potential to interact with TFIIB, a member of the basal
transcriptional complex. This, together with the presence of a TFIIB responsive element
immediately 5’ of the GATA box, suggested that HOX11 may repress transcription by
interfering with members of a preinitiation complex on the ALDH1A1 promoter. The
transcriptional repression by HOX11 demonstrated in T-cells was dependent on DNA
binding helix 3 of the homeodomain, suggesting that repression may require DNA
binding.  Alternatively,  this  region  may  be  required  for  stable  protein-protein
interactions. In support of this, the in vitro association of HOX11 with TFIIB was
disrupted upon deletion of helix 3, and the HOX11∆H3 mutant switched from a
transcriptional repressor to a potent activator of transcription. Together, this data
supports a model whereby HOX11 represses transcription by interfering with activation
complexes at the CCAAT box and at the GATA box possibly via protein-protein
interactions involving the homeodomain helix 3, whereas deletion of the region disables
repressor-specific interactions, resulting in potent activation by HOX11.
Luciferase reporter gene assays investigating the response of nested deletions of the
ALDH1A1  promoter  to  HOX11  in  the  HEL900 erythroleukaemic cell line, also
identified the CCAAT box (-74/-70bp) as the primary cis-regulatory element involved
in ALDH1A1 transcription. However, in stark contrast to the its effect in T-cells,
HOX11 was shown to activate transcription in the HEL cell line, both from the empty
pGL3Basic luciferase reporter vector and from the ALDH1A1 promoter, in a manner
independent of the homeodomain DNA binding helix 3. HOX11 thus appears to be a
dichotomous  regulator,  capable  of  both  transcriptional  activation  and  repression
depending on the circumstances. The mechanisms underlying these two functions are
also appear to be distinct, with repression but not activation requiring the presence of
homeodomain helix 3.
ALDH1A1 encodes an enzyme involved in the irreversible conversion of retinaldehyde
to  the  biologically  active  metabolite,  retinoic  acid  (RA)  and  appears  to  be
physiologically regulated by Hox11 in the developing spleen. Since RA is a potent
modulator of cellular differentiation, proliferation and apoptosis, the dysregulation of
RA synthesis is likely to have severe consequences for the cell and may constitute a
mechanism  whereby  overexpression  of  HOX11  predisposes  T-cells  to  malignantvi
transformation. FHL1 also appears to have potential relevance to tumorigenesis, given
that it encodes protein isoforms with suspected roles in transcriptional regulation. As a
starting point to investigate a possible link between these HOX11 target genes and
leukaemogenesis,  the  effect  of  overexpressing  ALDH1A1 and FHL1 on murine
haematopoiesis was assessed following reconstitution of lethally irradiated mice with
retrovirally-transduced primary murine bone marrow cells. The enforced expression of
ALDH1A1 in bone marrow was associated with a marked increase in myelopoiesis and a
decrease in B and T-lymphopoiesis. By contrast, overexpression of FHL1 was not
associated with perturbations in myelopoiesis or lymphopoiesis, although a slight
increase in erythropoiesis was observed in the bone marrow. While further work is
required to clarify the possible oncogenic roles of both of these HOX11 target genes,
these findings have served to identify ALDH1A1 in particular, as a gene which could
potentially be involved in HOX11-mediated tumorigenesis.vii
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Chapter 1
General Introduction
1.1  T-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA (T-ALL)
1.1.1  Biology and Classification of Leukaemias
Haematopoiesis involves the formation of mature, circulating blood cells via the
progressive commitment of self-renewing pluripotent haematopoietic stem cells (HSCs)
along  lineage-specific  pathways  (reviewed  by  Yoder,  2004)(Figure  1.1).  The
requirement for strict control of transcriptional networks directing processes of cell
renewal, commitment, maturation and survival within each lineage is underscored by
the plethora of haematological disorders that result from the disruption of pathways
regulating normal blood cell development (reviewed by Sawyers et al., 1991). The term
leukaemia, derived from the Greek ‘white blood’, refers to cancers of the blood-forming
or  haematopoietic  tissues.  These  arise  from  the  malignant  transformation  of
haematopoietic cells arrested at various stages of development in the bone marrow,
which may then infiltrate the blood, lymph nodes, spleen, liver, central nervous system
(CNS)  and  other  organs  (Rabbitts, 1991,  Colby-Graham & Chordas, 2003). The
observation that certain non-leukaemic human blood disorders demonstrate only partial
leukaemic  phenotypes,  for  example  uncontrolled  proliferation  (myeloproliferative
syndromes) or differentiation block (myelodysplastic syndromes), suggests that full
leukaemic transformation requires disruptions affecting both cellular growth and
maturation (Tefferi, 2001). These cellular defects are the result of genetic alterations in
the form of point mutations, gene amplification, gene deletions or chromosomal
translocations that affect the expression of growth factors (e.g. GM-CSF, IL-3, IL-
7)(Meeker et al., 1990), growth factor receptors (e.g. tyrosine kinase transmembrane
receptors)(Heard et al., 1987), cell cycle regulators (e.g. p16, p15)(Kamb et al., 1994),
transcriptional regulators involved in cellular differentiation (e.g. E2A, PBX, SCL,
RAR, PLZF, PML) and genes involved in mediating programmed cell death (e.g. BCL-
2, BCL-XL, MCL-1)(McDonnell et al., 1989). Leukaemias can be divided into two
major classes based on the lineage from which each is derived; thus myeloid leukaemias2
Figure  1.1. Development  of  Lymphoid  and  Myeloid  Lineages  from
Pluripotent Haematopoietic Stem Cells (HSCs). HSCs can be subdivided into
long-term self renewing HSCs, short-term self renewing HSCs and multipotent
progenitors  which  give  rise  to  common  lymphoid  progenitors  (CLP),  the
precursors of lymphoid cells and common myeloid progenitors (CMP), the
precursors of myeloid cells.
(Adapted from Reya et al., 2001)3
originate  from  progenitors  giving  rise  to  granular  leukocytes  whereas  lymphoid
leukaemias are derived from T-cell or B-cell lymphoid progenitors (Colby-Graham &
Chordas, 2003). These can be further sub-classified according to the clinical nature of
the disease, such that chronic leukaemias, which are characterised by slow onset and the
production of more mature, differentiated cells, are distinct from acute leukaemias,
which have a rapid onset and a predominance of highly immature (blastic) cells, and
consequently represent a more severe form of the disease (Rabbitts, 1991, Colby-
Graham & Chordas, 2003). Acute lymphoblastic leukaemia (ALL) represents the
predominant type of leukaemia in children, accounting for approximately one-quarter of
all juvenile tumours, with a peak incidence occurring between the ages of 2-5 years
(Uckun et al., 1998, Pui, 2000). Recent advances in molecular genetic techniques, for
example the use of oligonucleotide microarrays to profile patterns of gene expression in
the  leukaemic blasts of multiple paediatric ALL patients, confirms that ALL is a
heterogeneous disease that can be divided into either B-lineage or T-lineage ALL on the
basis of cell surface antigen expression differences (B-lineage markers; CD19, CD22 or
T-lineage markers; CD2, CD3, CD8). ALL can also be classified on the basis of distinct
genetic lesions affecting specific transcriptional pathways (Yeoh et al., 2002, Ross et
al., 2003). For example, B-ALL consists of genetically distinct subtypes including
t(9;22)[BCR-ABL],  t(1;19)[E2A-PBX1],  t(12;21)[TEL-AML1],  rearrangements
affecting the MLL gene at 11q23 and hyperdiploid karyotype (>50 chromosomes),
whereas T-ALL involves chromosomal translocations affecting the expression of
various transcription factors including TAL1, LMO1, LMO2 and HOX11 (reviewed by
Raimondi, 1993). It has been found that the molecular aberrations underlying these
individual subtypes can influence the differential response of patients to chemotherapy
(Yeoh et al., 2002, reviewed by Faderl et al., 2003). This highlights the usefulness of
expression profiling as a powerful diagnostic tool in the treatment of ALL by aiding the
accurate stratification of patients into biologically distinct subtypes with significant
prognostic value. Such technologies are likely to supercede conventional diagnostic
approaches which require a combination of clinical characteristics (age, sex), laboratory
analyses  (white  blood  cell  count)  and  characterisation  of  leukaemic  blasts  (via
immunophenotyping, cytogenetic analysis, cytochemical staining and morphological
analyses), since these are labour intensive and costly.4
1.1.2 Molecular Genetics of Childhood T-ALL
T-cell acute lymphoblastic leukaemia (T-ALL) is a malignant disease of thymocytes,
accounting  for  approximately  10-15%  of  paediatric  and  25%  of  adult  acute
lymphoblastic leukaemia cases (Heerema et al., 1998, Ferrando et al., 2002). T-lineage
ALL patients are predominately male, non-white, usually older in age (>10 years old),
and are characterised by a number of unfavourable presenting features including high
white  blood  cell  count  (>50,000/ul),  CNS  infiltration,  a  medistinal  mass  and
enlargement of the spleen, liver and lymph nodes (Uckun et al., 1998, van de Berg et
al.,  1998,  Heerema  et  al.,  1998).  Although  the  majority  of  ALL  cases  are
immunophenotypically classified as B-lineage (~85%), considerable interest in the
aetiology, biology and treatment of T-ALL exists, particularly as children with T-ALL
have a worse prognosis compared to children with B-cell ALL (B-ALL)(reviewed by
Uckun et al., 1998, van de Berg et al., 1998). Recent therapeutic advances following the
use  of risk-adapted treatment protocols, which involves the tailoring of doses and
combinations of anti-leukaemic drugs according to each patient’s risk of relapse, has
significantly improved the clinical outcome of T-ALL in children and adolescents, with
5 year relapse-free survival rates now ranging between 60-75%. However, further
advances in diagnosis and treatment will require an improved knowledge of the biology
of T-ALL at a molecular level (Schrappe et al., 2000, Silverman et al., 2001).
T-ALL  is  commonly  associated  with  recurrent  chromosomal  translocations  and
intrachromosomal rearrangements that activate developmentally important transcription
factors (Rabbitts, 1991). These translocations typically juxtapose strong promoter or
enhancer elements driving high levels of expression from the TCR β locus (7;q34) or
the TCR α/δ locus (14;q11), next to transcription factor genes including HOX11/TLX1
(Dube et al., 1991), HOX11L2 (Bernard et al., 2001), TAL1/SCL (Begley et al., 1989),
TAL2, LYL1 (Mellentin et al., 1989), BHLHB1 (Wang et al., 2000) and LMO1/LMO2
(Boehm et al., 1991)(Table 1.1). The mechanism underlying these translocations likely
involves errors in T-cell DNA recombinase activity during rearrangement of TCR V, D
and J segments in developing cortical T-cells, since hallmarks of V(D)J recombinase
activity are often found at translocation breakpoints (Visvader & Begley, 1991). These
transcription  factors  are   normally  expressed  in  early  haematopoietic  cells,  but  are5
Transcription
Factor
Translocation Motif Reference
SCL (TAL1) t(1;14) bHLH Park et al., 1998,
Jonsson et al., 1991
TAL2 t(7;9) bHLH Xia et al., 1991
LYL1 t(7;19) bHLH Xia et al., 1991,
Mellentin et al., 1989
BHLHB1 t(14;21) bHLH Wang et al., 2000
MYC t(8;14) bHLH-ZIP Shima et al., 1986
LMO1 t(11;14) LIM McGuire et al., 1989,
Boehm et al., 1991
LMO2 t(11;14)
t(7;11)
LIM Boehm et al., 1991,
TCL1 t(7;14) unknown Laine et al., 2000,
Pekarsky et al., 2000
TCL1b t(7;14) unknown Pekarsky et al., 1999
HOX11
(TLX1)
t(10;14)
t(7;10)
homeodomain Hatano et al., 1991
Kennedy et al., 1991
HOX11L2
(TLX3)
t(5;14) homeodomain Bernard et al., 2001
      Table 1.1. Oncogenes Known to be Activated by Chromosomal Translocations
       in T-cell Acute Lymphoblastic Leukaemia (T-ALL).6
minimally expressed or absent in immature and mature T-cells, such that aberrant
expression of these putative oncoproteins in developing thymocytes may directly
interfere with transcriptional programmes regulating normal thymocyte proliferation,
differentiation and survival, thus setting the scene for leukaemic transformation. Two
distinct pathways are now emerging for the genes translocated in T-ALL. The first
involves the deregulation of target genes by transcriptional complexes comprising
members of both the basic helix-loop-helix (bHLH)(TAL1, TAL2, LYL1, BHLHB1)
and LIM-only (LMO)(LMO1, LMO2) families of transcription factors, while the
second involves dysregulation of target genes mediated by the HOX11 family, (HOX11
and the highly related family member, HOX11L2).
HOX11 (10q24) and its paralogs, HOX11L1 (2p13) and HOX11L2 (5q35), belong to the
NK-Like (NKL) family of homeobox genes (Dear & Rabbitts, 1994), which are located
outside of the four mammalian HOX clusters. Unlike the clustered homeobox genes,
which play important roles in segmental patterning or cell type specific differentiation,
the NKL genes appear to be required for processes involving organogenesis, growth
control and cell fate. HOX11 was originally identified as an overexpressed gene located
at the t(10;14)(q24;q11) or t(7;10)(q35;q24) breakpoints found in childhood T-ALL,
and it was subsequently shown that chromosomal translocations involving the HOX11
locus, together with that of HOX11L2,  constitute  the  most  common  cytogenetic
abnormalities in T-ALL (Hatano et al., 1991, Dube et al., 1991, Kennedy et al., 1991,
Lu et al., 1991, Bernard et al., 2001, Helias et al., 2002, Cave et al., 2004). HOX11 is
not detectable in normal T-cells and translocations involving 10q24 cluster tightly at the
5’ end of the gene, such that the coding capacity of the gene remains unaltered
(Kennedy et al., 1991). This supports the hypothesis that the overexpression of an intact
HOX11  protein  is  a  crucial  event  in  tumour  initiation.  Indeed,  the  constitutive
expression of HOX11 has been associated with the immortalisation of haematopoietic
progenitors in vitro (Hawley et al., 1997, Keller et al., 1998), and recent work by
Ferrando et al., (2002, 2003) and Kees et al., (2003) reveal that as many as 30% of T-
ALLs exhibit deregulated HOX11 expression when abnormalities other than cis-acting
chromosomal rearrangements are included. HOX11L2 was also shown to be aberrantly
expressed in a subset of T-ALL cases, following a novel cryptic recurrent translocation
t(5;14)(q35;q32)(Bernard et al., 2001). This rearrangement places HOX11L2 within the7
vicinity of the CTIP2 gene, which is strongly expressed in the thymus and implicated in
T-cell  differentiation  (Bernard  et al.,  2001).  Recent  studies  demonstrating  that
HOX11L2 is expressed in up to 60% of T-ALL cases, further supports the role of this
transcription factor as a T-cell oncogene and highlights the role of HOX11 and related
family members in T-cell oncogenesis (Bernard et al., 2001, Mauieux et al., 2002,
MacLeod et al., 2003).
A second distinct pathway leading to T-ALL commonly involves SCL, a gene expressed
in the erythroid and megakaryocytic haematopoietic lineages (reviewed by Begley &
Green,  1999).  This  suggests  a  function  in  haematopoiesis,  however  SCL is not
expressed in normal T-cells (Begley et al., 1989). The aberrant expression of SCL as a
result of t(1;14)(p33;q11) or t(1;7)(p33;q35) translocations or interstitial deletion of
approximately 90kB of DNA from chromosome 1, which places SCL under the control
of  the  ubiquitously  expressed  SCL  Interupting  Locus (SIL) gene, in developing
thymocytes, implicates it in a major pathway leading to the development of T-ALL
(Bash et al., 1995, Begley et al., 1989). These effects are mediated via the bHLH
domain  of  SCL,  which  is  capable  of  DNA  binding  and  dimerisation  with  other
transcription factors. These include the cysteine-rich LMO proteins LMO1 and LMO2,
which are also dysregulated in a subset of T-ALLs harbouring the t(11;14)(p15;q11)
and t(11;14)(p13;q11) chromosomal translocations, respectively (Boehm et al., 1991,
Wadman et al., 1994, Ono et al., 1997). The overlapping expression of LMO2 with SCL
in  developing  erythroid  cells  (Visvader  et al.,  1991),  coupled  with  experiments
demonstrating that mice lacking both SCL and LMO2 die at embryonic day 9.5 due to
the absence of yolk sac erythropoiesis (Warren et al., 1994, Robb et al., 1995), suggests
that these factors work in concert to regulate the erythroid cell lineage, and may also
function cooperatively to regulate sets of target genes normally quiescent in T-lineage
progenitors, resulting in T-cell transformation. Indeed, transgenic mice in which both
SCL and LMO1/LMO2 expression is directed to the thymus, develop T-cell tumours
with a shortened latency compared with mice expressing SCL alone (Robb et al., 1995,
Larson et al., 1996, Aplan et al., 1997). Transcriptional complexes involving SCL,
LMO2 and a third binding partner, GATA-1, which is also essential for normal
erythropoiesis are therefore likely to regulate not only erythroid-specific, but potentially
T-cell oncogenic target genes. However, unravelling these pathways requires a detailed8
investigation of downstream targets. The identification of the receptor tyrosine kinase c-
kit as a direct target gene of SCL, may provide crucial insights into the mechanisms by
which SCL, in conjunction with LMO2, may contribute to the T-ALL phenotype,
particularly as this gene plays an instrumental role in normal haematopoiesis (Lecuyer
et al., 2002). The gene for retinaldehyde dehydrogenase 2 (RALDH2/ALDH1A2), which
is one of a select few enzymes responsible for the biosynthesis of retinoic acid, a potent
modulator of cellular proliferation and differentiation, has also been identified as a
direct target of SCL and LMO, and coexpression of SCL and LMO in most T-ALL cell
lines was also associated with RALDH2 expression (Ono et al., 1998). In this case,
however, SCL and LMO act as cofactors for the T-cell specific GATA-3 transcription
factor (Ono et al., 1998). Other bHLH family members including BHLHB1, LYL and
MYC are also capable of promoting T-cell transformation. Aberrant expression of these
proteins by chromosomal translocation may facilitate leukaemic transformation by
dominant negative interference of E47 and E12 variants of E2A transcription factors,
thereby disrupting the equilibrium of transcription factor heterodimers required for
normal thymocyte development (Mellentin et al., 1989, Wang et al., 2000).
Although the clinical features of T-ALL are relatively uniform, translocations in T-ALL
involve  the  activation  of  distinct  oncogenes  at  various  stages  of  thymocyte
development.  This  molecular  heterogeneity  likely  accounts  for  the  dramatically
different responses of T-ALL patients when treated with the same intensive multi-drug
regimes (Ferrando et al., 2002). Indeed, recent studies have used DNA microarray
analysis to link the activation of specific T-cell oncogenes to defined stages in T-cell
development. This has revealed that these gene expression signatures have prognostic
relevance, since the stage of thymocyte arrest determined the susceptibility of cells to
drug induced programmed cell death (Ferrando et al., 2002). For example, the HOX11+
gene  signature  was  indicative  of  arrest  at  the  early  cortical  stage  of  thymocyte
development and was associated with a favourable clinical outcome (Ferrando et al.,
2002). This might be due to the lack of expression of antiapoptotic genes at this stage
(e.g. BCL2), rendering cells more susceptible to drug-induced apoptosis (Ferrando et
al.,  2002).  Gene  signature  profiles  were  also  obtained  for TAL1+ (late cortical
thymocyte) and LYL1+ (pro-T) T-cell oncogenes, which in contrast to HOX11, were
associated with less favourable outcomes, possibly due to the upregulation of BCL2 and9
other antiapoptotic molecules in these populations (Ferrando et al., 2002). The powerful
predictive nature of gene expression profiling is underscored by the discovery of novel
T-ALL oncogenic factors, which demonstrate gene signatures closely related to known
T-ALL oncogenes. For example, overexpression of HOX11L2, which belongs to the
HOX11 family of transcription factors, was associated with HOX11 negative samples
exhibiting a characteristic HOX11 gene expression signature (Ferrando et al., 2002).
1.2 HOMEOBOX GENES
1.2.1 The Role of Homeobox Genes in Development
The diversity of body design, which encompasses organisms of varying complexity, is
the result of genetic processes directing embryogenesis in different species (McGinnis
& Kuziora, 1994). Despite the obvious differences between the distinct members of the
animal kingdom, the genes controlling these developmental events retain structural and
organisational similarities, reminiscent of a common ancestral cluster (Hayashi & Scott,
1990, Krumlauf, 1994, Gehring et al., 1994, Mark et al., 1997). The discovery of
homeobox (HOX) genes as ‘master developmental control genes’, regulating spatial and
temporal aspects of morphogenesis and cell differentiation along the anterior-posterior
(AP) embryonic axis, occurred following an elegant series of homeotic transformation
experiments in the genome of the fruit fly Drosophila (Lewis, 1978, Kemphues, 1980,
Mark et al., 1997). Derived from the Greek word ‘homeo’ which means ‘alike’, the
homeotic (HOM) complex (or HOM-C) genes were named for their ability to transform
one insect body segment into the likeness of another, following specific (homeotic)
mutations (Castronovo et al., 1994, Mark et al., 1997). For example, a mutation in the
Antennapaedia (Antp) gene, the first of 25 Drosophila developmental control genes to
be identified, leads to the transformation of antennae on the head of a fly, to an extra
thoracic leg (Scott et al., 1989, Veraksa et al., 2000). Following their discovery in
Drosophila, similar clusters of homeobox genes have been identified in a wide range of
multicellular organisms including sponges, vertebrates, plants and fungi (Mark et al.,
1997).
In Drosophila, these genes are organised as a bipartite homeotic gene complex,
comprising the Antennapedia (Antp-C; labial (lab), proboscipedia (pb), Deformed10
(Dfd), Sex combs reduced, Antennapedia (Antp)) and Bithorax (Bx-C; Ultrabithorax
(Ubx), abdominal-A (abd-A) and Abdominal-B (Abd-B)) complexes, located on the right
arm of chromosome three at positions 84AB and 89E, respectively (reviewed by Jagla
et al., 2001). The mammalian homologs of Antp-C and Bx-C genes exist within distinct,
unlinked complexes on human chromosomes 7p15 (HOXA), 17q21 (HOXB), 12q13
(HOXC) and 2q31 (HOXD), with paralog groups 1-8 being most closely related to
Drosophila  Antp, and groups 9-13 most closely related to Drosophila Abd-B genes
(Veraksa et al., 2000, Owens & Hawley, 2002). The organisation of the HOX gene
complex is such that during embryonic development, the order of expression along the
anterior-posterior (AP) embryonic axis (3’ to 5’) is co-linear with the alignment of
genes on the chromosome (Paralogous groups 1-13)(Figure 1.2). The preservation of
position and the order of expression of genes within these clusters between invertebrates
and vertebrates suggests that mammalian HOX genes are likely to have evolved by two
successive genome duplications of a hypothetical, ancestral HOX cluster, and it is
postulated that their maintenance within these clustered arrangements is linked to the
dependence on central, regulatory regions (Jagla et al., 2001, Owens & Hawley, 2002).
Following the identification of these clustered HOX genes, a new family of homeobox
genes, referred to as the NK family, were identified in Drosophila (Kim & Nirenberg,
1989). Although genes within this cluster were originally referred to as ‘orphan’
homeobox genes, since they are not associated with the major HOX clusters, molecular
mapping and the identification of additional family members has defined a new cluster
of homeobox genes, known as 93DE/NK cluster (Kim & Nirenberg, 1989, Pollard &
Holland, 2000, Coulier et al., 2000, reviewed by Jagla et al., 2001)(Figure 1.3). The
93DE/NK cluster, which is also located on the right arm of the third chromosome, is the
second largest cluster of physically linked genes in Drosophila, and is composed of six
homeobox genes that have retained tight linkage over a region of 180kB, including (in
proximal to distal order) NK4/tinman (tin), NK3/bagpipe (bap), ladybird late (lbl),
ladybird early (lbe), 93bal/Hox11 and NK1/slouch (slou)(reviewed by Jagla et al., 2001,
Harvey, 1996). The discovery of vertebrate homologs of these genes (NKL cluster),
suggests that these genes are extremely ancient, and the co-localisation of some
vertebrate homologs, for example, HOX11/LBX1 genes to chromosome 10q24 and
HOX11L1/LBX2  genes  to  chromosome  2p13  is  reminiscent  of  such clustering. This11
Figure  1.2.  Organisation  of  the  Mammalian HOX Gene Complex. During
embryonic development, the order of expression along the anterior-posterior (AP)
embryonic axis (3’ to 5’) is spatially and temporally co-linear with the alignment of
genes on the chromosome (Paralogous groups 1-13).
Taken from Molecular Genetics and Metabolism (69): 85-100 (2000)
(http://www.idealibrary.com).
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implies that the vertebrate NKL genes arose from duplications of an ancestral NK
cluster, although further lateral dispersal has certainly occurred throughout evolution
(Holland, 2001). Additional homeobox genes have since been mapped to nearby
chromosomal bands in humans and mice, for example EMX2 maps to 10q25-26,
adjacent to the HOX11/LBX1 cluster, implying that these genes were also originally part
of a large NKL cluster (Holland, 2001).
Similar to the clustered HOX genes, which are required for cell fate specification during
mesoderm development, genes of the 93DE/NKL cluster are involved in mesoderm
differentiation programs and fulfil distinct roles in specifying the fate of muscle and
heart-forming cells (Jagla et al., 2001). For example, the NKX genes play important
roles in muscle patterning, lung and cardiac development, respectively (Knirr et al.,
1999, Zhu et al., 2004), LBX family members fulfil important functions in spinal cord
patterning, hindbrain development and skeletal muscle development (Jagla et al., 1995,
Mennerich et al., 1998, Schubert et al., 2001), and HOX11, HOX11L1 and HOX11L2
have overlapping functions in central nervous system development as well as individual
roles  in  spleen  organogenesis  (Roberts  et  al.,  1994),  enteric  nervous  system
maintenance (Hatano et al., 1997) and respiratory development (Shirasawa et al., 2002),
respectively. The dispersal of the vertebrate NKL cluster throughout evolution, however,
suggests that clustering may not be related to their regulation as for the HOX genes,
which demonstrate spatial and temporal co-linearity, although there is evidence to
suggest that temporal co-linearity of NKL genes exists in the developing mesoderm
(Jagla et al., 2001).
Given that most models of HOX target selectivity, structure and function have come
from  investigations  into  the  clustered  HOX  genes,  studies  of  genes  within  the
evolutionarily distinct 93DE/NKL family are likely to yield a more accurate insight into
HOX11-mediated mechanisms of gene regulation. For example, members of the 93DE
cluster harbour a short sequence motif (*PFSI*DIL***) in the amino terminal region,
which bears homology to the Eh1 repression domain required for the interaction of the
Engrailed  (En)  homeodomain  protein  with  transcriptional corepressors,  such  as
Groucho (Tolkunova et al., 1998). Thus, transcriptional repression via this domain may
represent a common mechanism of target gene regulation by members of 93DE family,14
including HOX11, which also shares this motif. Moreover members of the 93DE family
demonstrate  variations  in  their  affinity  for  the  canonical  TAAT homeobox core
recognition motif. For example, Tin preferentially binds a sequence with a CAAG core
as a result of the R to Y substitution at position 54 within the homeodomain (Damante
et al., 1996), and HOX11 recognises the TAAG core sequence in addition to the TAAT
consensus, due to the substitution of isoleucine for threonine at position 47 within the
homeodomain (Dear et al., 1993). Thus, target gene regulation by members of the 93DE
family may occur via the specific binding to these variant homeodomain sequences or
possibly via competition with HOX proteins for TAAT sites (Jagla et al., 2001).
1.2.2  Hox Proteins as Transcription Factors – Specificity of Homeotic Gene
Function
1.2.2.1  Binding of HOX Homeodomains
Members of the HOM/HOX gene family share a common sequence motif comprising
183 nucleotides, that encodes a 61 amino acid homeodomain capable of sequence-
specific DNA binding and subsequent transactivation of specific target genes (Ford,
1998). To elucidate the three dimensional structure of the homeodomain, a combination
of X-ray crystallography and nuclear magnetic resonance (NMR) spectroscopy was
employed  to  investigate  the  complex  structure  formed  between  operator  DNA
sequences and the homeodomains of engrailed (en), even-skipped (eve), MATα2 and
Antp proteins (Kissenger et al., 1990, Wolberger et al., 1991, Billeter et al., 1993).
These studies revealed the homeodomain to consist of three alpha helices folded into a
tight globular structure and a flexible N-terminal arm (Gehring et al., 1994, Mann,
1995). In the context of DNA binding, base-specific contacts are mediated by Helix 3,
which is positioned roughly parallel to the major groove of the DNA and by the flexible
N-terminal arm which makes additional base-specific contacts in the minor groove;
whereas Helices 1 and 2 are aligned in an antiparallel fashion above the DNA, such that
the 5 amino acid loop between these helices interacts with the DNA backbone to
stabilise binding.15
In conjunction with structural analyses, the DNA binding properties of homeodomain
proteins have been analysed by in vitro electromobility shift assays (EMSA), DNase1
footprinting  and  transactivation  studies.  These  have  revealed  that  Hox  proteins
demonstrate relatively low specificity for a 5’-T1A2A3T4 -3’ core that occurs at a high
frequency throughout animal genomes (Treisman et al., 1989, Gehring et al., 1994).
Conserved residues present in the third alpha helix of many homeodomain proteins, in
particular an isoleucine or valine at position 47 and an asparagine at position 51, contact
bases 4 and 3 of this recognition sequence respectively, whilst arginines at positions 5
and 3 of the N-terminal arm contact bases 1 and 2 of this sequence in the minor groove
(Figure 1.4)(Wilson et al., 1996).  Although differences in adjacent N-terminal residues
of the homeodomain may provide the basis for some sequence discrimination, thereby
accounting in part for the distinct regulatory properties of these proteins in vivo, these
subtle differences are unlikely to account for the exquisite specificity demonstrated by
these crucial regulators of development.
Figure 1.4. Conserved Residues Present in the Third Alpha Helix of the
Homeodomain  Contact  a  5’-T1A2A3T4
  -3’  Core  Sequence  Present  in  the
Majority of Homeodomain Binding Sites.
1.2.2.2 Hox Proteins and Cofactors
The question arises - how is target gene specificity achieved allowing homeodomain
proteins to fulfil their distinct regulatory roles in development, if all homeodomains
demonstrate similar DNA binding specificity? Increasing evidence suggests that the
most likely mechanism for the selective regulation of Hox target genes is through
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cooperative interactions with protein cofactors that increase the specificity and affinity
for larger compound binding sites (Wilson & Desplan, 1995, Biggin & McGinnis,
1997). In support of such a co-selective model in which other factors are required,
chimaeric and deletion analyses of HOM proteins in vivo suggest that at least some
functional specificity of HOM proteins resides in non-DNA contacting regions within or
immediately flanking the homeodomain (McGinnis & Kuziora, 1994). Numerous
studies have since demonstrated that HOX proteins form DNA binding complexes with
members of the TALE (Three-Amino-acid Loop Extension) subclass of homeodomain-
containing proteins including the PBC (mammalian PBX, Drosophila melanogaster
Extradenticle (Exd) and Caenorhabditis elegans CEH-20 proteins), MEIS (Myeloid
Ectopic Integration Site)(mammalian MEIS and PREP1 and Drosophila Hth proteins)
and TGIF (5’-TG-3’ Interacting Factor) families, whose members contain an extension
of three amino acids between α-helices 1 and 2 within the homeodomain (Saleh et al.,
2000, Burglin, 1997, Mann, 1995). Genetic evidence from Drosophila  reveals  a
functional role for Exd and Hth proteins in Hox-regulated developmental pathways,
since mutants that lack exd or hth have homeotic transformations resembling the loss of
multiple Hox genes (Rieckhof et al., 1997, Kurant et al., 1998). The importance of these
interactions in the regulation of gene transcription and maintenance of normal HOX
functions involving axial patterning and haematopoietic cell differentiation, is further
supported by the presence of mutations affecting the stoichiometry or stability of
members  comprising  HOX  transcriptional  complexes  identified  in  a  range  of
haematological malignancies (Lawrence et al., 1996).
Exd was first identified in a screen for zygotic lethal mutations that cause patterning
defects in Drosophila and encodes a homeodomain protein that interacts cooperatively
with HOM gene products such as Ubx to modify target gene selection (Rauskolb et al.,
1993).  In  a  similar  manner  to  exd, the mammalian orthologue Pbx1 (pre-B-cell
leukaemia transcription factor 1 gene), which was first identified as a proto-oncogene
disrupted by the chromosomal translocation t(1;19) in human paediatric pre-B-cell
leukaemias, also binds DNA cooperatively with Hox proteins (Paralog groups 1-
10)(Figure 1.5). This enhances their DNA binding specificity and affinity, resulting in
the selective regulation of target genes harbouring combinatorial responsive elements
(Kamps et al., 1990, Rauskolb et al., 1993, Popperl et al., 1995). Other family members17
FIGURE 1.518
including Pbx2 and Pbx3 were subsequently identified by DNA cross-hybridisation
(Monica  et al., 1991). The cooperative interaction of HOX and PBX proteins is
mediated in part by a conserved stretch of amino acids located 5 to 50 amino acids N-
terminal to the homeodomain in HOX proteins from paralogous groups 1-8, referred to
as the ‘pentapeptide’, ‘hexapeptide’ or ‘YPWM’ (Tyr/Phe-Pro-Trp-Met) motif (Phelan
et al., 1995, Mann & Chan, 1996), in addition to the homeodomain and adjacent C-
terminal 16 amino acids of Pbx1 (Mann & Chan, 1996, Lu & Kamps, 1996)(Figure 1.6).
Binding  is  thought  to  occur  through  a  ‘lock  and  key’  mechanism,  involving
hydrophobic  interactions  between  the  YPWM  motif  of  HOX  proteins  and  the
hydrophobic pocket of TALE proteins, which is formed by a three amino acid insertion
in between helices 1 and 2 of the homeodomain (Piper et al., 1999, Sprules et al., 2003).
According to studies performed by Phelan et al., (1995), cooperative DNA binding by
HOXD4 and PBX1A occurs via direct protein-protein contacts mediated by the HOXD4
pentapeptide, although the possibility that the pentapeptide also plays a role in DNA
recognition of HOX/PBX binding sites can not be ruled out. Further support for the role
of this motif in mediating heterodimer formation derive from studies in which the
binding of the HoxB1 hexapeptide in a pocket of the Pbx1 homeodomain facilitates the
binding of HoxB1 and Pbx1 to overlapping binding sites located on opposite sides of
the  DNA  (Piper  et al.,  1999).  In  addition  to  this  role  of  mediating  HOX/PBX
heterodimerisation, the YPWM motif has also been shown to inhibit DNA binding by
the Drosophila HOX protein labial (Lab), which is relieved by interaction with EXD or
PBX (Chan et al., 1996). Although HOX proteins contained within paralogous groups
9-13 do not possess a typical ‘YPWM’ motif, a number of these proteins are still
capable of interacting with PBX through conserved tryptophan residues in a conserved
ANW sequence located N terminal to the homeodomain (Chang et al., 1996).
 A model for the PBX-HOX-DNA ternary complex was proposed following binding site
selection, protein-DNA and mutagenesis experiments by several independent groups in
which PBX and HOX homeodomains are arranged as a head to tail heterodimer at the
consensus binding sequence 5’-[T1G2A3T4T5N6A7T8G9G10]-3’(Chan & Mann, 1996, Lu
& Kamps, 1996). According to this model, PBX occupies the 5’ half site (TGAT) and
the HOX partner binds the 3’ half site (TNATGG), with differential binding specificity
by  HOX  proteins  occurring  via  interactions with the variable nucleotide at position 619
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Figure 1.6. Hox Transcription Factors Bind DNA Cooperatively with PBC and
Meis  TALE  Homeodomain  Family  Members.  Protein-protein  interactions  are
mediated via conserved motifs shared between related members.
(Adapted from Allen et al., 2000)20
(Chan & Mann, 1996, Lu & Kamps, 1996). The formation of HOX-PBX heterodimers
alters  the  conformation  of  the  HOX  homeodomain  N-terminal  arm,  which  upon
restructuring  leads  to  extended  DNA  contacts,  thereby  refining  DNA  sequence
specificity (Mann & Chan, 1996). Indeed, specific residues contained within the N-
terminal arm of the homeodomain (Arg3), that are important for binding of HOX
monomers,  are  not  required  for  DNA  binding  in  heterodimers  with  PBX.  This
demonstrates the effect of homeodomain structural rearrangement due to complex
formation on target specificity (Phelan & Featherstone, 1997).
In addition to PBX, the MEIS subfamily of homeodomain proteins, which include
MEIS1, MEIS2, MEIS3, TGIF and PREP1 have also been shown to interact and bind
cooperatively to DNA with HOX gene products (Shen et al., 1997)(Figures 1.5, 1.6).
Meis1 was originally identified as a gene whose expression was activated by proviral
integration in myeloid leukaemias occurring in BHX-2 strain of mice, suggesting a link
between these genes and the regulation of cell proliferation (Moskow et al., 1995,
Nakamura et al., 1996). Murine Meis2 and Meis3 were subsequently isolated by cross-
hybridisation with the Meis1 homeodomain (Nakamura et al., 1996). The concomitant
proviral activation of Hoxa7 or Hoxa9 with Meis1 in malignant cells derived from these
mice provided the first evidence of biological synergy between Hox proteins and Meis1
(Nakamura et al., 1996). Using a series of in vitro binding assays, it has since been
shown  that  Meis1  forms  heterodimeric DNA  binding  complexes  with  Hoxa9,  in
addition to other members of the AbdB-like subset of Hox proteins, on a DNA sequence
harbouring both Meis1 (TGACAG) and AbdB-like Hox (TTTTACGAC) sites (Shen et
al., 1997). Unlike the interactions described for Pbx1, which serve to increase the
binding affinity and specificity of Hox proteins (Paralog groups 1-8), the affinity and
specificity of AbdB-like Hox (9-13) proteins is not enhanced by interactions with either
Pbx or Meis1 (Shen et al., 1997). Instead, the relatively weak affinity of Meis1 for DNA
is greatly stabilised by interactions with AbdB-like Hox proteins, involving the N-
terminal region of the Hox protein (Shen et al., 1997).
This model is not universal for all Hox-Meis interactions however, since there have
been documented cases where the Meis component does indeed contribute to the
binding specificity of Hox complexes. For example, the association of a ternary21
complex involving Hoxb1, Pbx and Meis on the Hoxb2 hindbrain enhancer, r4, requires
the specific binding of Meis to a DNA sequence located upstream of a consensus Hox-
Pbx binding site and mutations of this distal Meis site recapitulate the effect of mutating
the Pbx-Hox site (Jacobs et al., 1999)(Figure 1.7). These studies revealed that DNA
binding by Meis (as opposed to being tethered to a functional complex via protein-
protein interactions with Pbx) increases the binding site selectivity of ternary complexes
involving Hox and Pbx, and is required for the r4 enhancer-directed expression of a
reporter transgene in the developing hindbrain (Jacobs et al., 1999). In the absence of
DNA binding, Meis proteins may also function to negatively affect the binding of Pbx-
Hox heterodimers to dimeric sites, by interacting with regions adjacent to the Pbx
homeodomain,  causing  alterations  in  the  DNA  binding  capabilities  of  Hox-Pbx
complexes (Jacobs et al., 1999). In addition to the role of TALE homeodomain proteins
in directing the binding specificity of ternary complexes involving HOX members, a
functional role for Hth (MEIS) proteins in the nuclear localisation of Exd (PBX) has
also been documented in Drosophila  (Pai et al., 1998).  This suggests that MEIS
proteins may also control HOX function via the regulation of subcellular distributions
of PBX cofactors, in addition to mechanisms involving the formation or disruption of
gene-specific  transcription  complexes  -  yielding  the  potential  for  even  greater
transcriptional diversity (Chang et al., 1997, Shanmugam et al., 1999).
It  should  be  noted  however,  that  most  of  our  knowledge  regarding  HOX  target
selectivity derives from studies involving the clustered HOX genes, and may not be
applicable  to HOX genes located in evolutionarily distinct clusters, for example
HOX11, which belongs to the NKL family of proteins. Thus, HOX11 may act via
mechanisms distinct from models of ‘co-selective binding’. An alternative, but not
mutually exclusive model proposed by Galant et al., (2002), postulates that Hox
proteins may regulate targets in the absence of cofactors, by binding to multiple
monomer sites within cis-regulatory elements. For example, in Drosophila, the Hox
protein Ultrabithorax suppresses wing development by repressing a cis-regulatory
element of the spalt (sal) gene in the halteres, through multiple monomer Ubx-binding
sites (Galant et al., 2002). The selective regulation of certain HOX target genes in the
absence of PBC/MEIS cofactors appears to be restricted to genes involved in the
development of distal appendages, a theme previously  described  in  Drosophila (Mann22
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Figure 1.7. Trimeric Association of Hoxb1, Pbx1a and Meis Factors on the
Hoxb2 Gene r4 Enhancer. Pbx-Meis-Hoxb1 heterotrimeric complexes assemble
on the Hoxb2 enhancer containing a Meis site located upstream and in the reverse
orientation with respect to the Pbx-Hox consensus core sequence. Pbx and Meis
components  heterodimerise  via  their  amino  terminal  motifs,  allowing  their
homeodomains to bind DNA in a flexible configuration. This enables Pbx-Hoxb1
complexes to bind the more stringently spaced Hox-Pbx core sequence. Interaction
between  Pbx  and  Hox  components  occurs  via  the  lock  and  key  mechanism
involving the homeodomain of Pbx (pink shaded oval) and the YPWM motif of Hox
(blue shaded oval).
(Adapted from Jacobs et al., 1999)
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& Morata, 2000), other arthropods (Gonzalez-Crespo & Morata, 1996) and vertebrates
(Selleri  et al., 2001). Examples of this widespread-binding model have since been
observed in mammals, with the NKL family members NKX2.1 and NKX2.5 both
having been shown to regulate target genes directly via single or multiple monomeric
sites (Ramirez et al., 1997, Sepulveda et al., 1998, Kim et al., 2002). In addition, the
ability of HOX proteins, particularly those from NKL and POU families to form
functional homodimers, provides yet another mechanism by which HOX proteins can
regulate target gene expression. For example NKX2.5 homodimerises on the atrial
natiuretic factor  promoter  (Kasahara  et al.,  2001)  and  PIT1  regulates  promoters
controlling the expression of the prolactin and growth hormone genes via the formation
of functional homodimers (Day et al., 1998).
1.2.3  Homeobox Genes – Roles in Haematopoiesis and Leukaemogenesis
The process of haematopoiesis involves the generation of highly specialised effector
cells constituting the lymphoid and myeloid lineages, from a small pool of multipotent,
self-renewing HSCs. A complete understanding of the genes that play a definitive role
in the initiation and maintenance of this tightly regulated process, is crucial in order to
gain further insight into disrupted mechanisms underlying diseases of the blood. In
addition to the role of growth factors in signalling pathways directing haematopoiesis, a
number of nuclear transcriptional regulators have been shown to participate directly in
haematopoietic processes of stem cell-self renewal, lineage commitment, progenitor cell
expansion and terminal differentiation. These include genes belonging to Notch, Wnt
and Hox families (Austin et al., 1997, Carlesso et al., 1999, van Oostveen et al., 1999).
In particular, members of the Hox family of transcription factors have emerged as
strong candidates as regulators of haematopoiesis, following studies demonstrating that
these genes are expressed in haematopoietic progenitors and are capable of affecting the
proliferative, differentiative and phenotypic characteristics of haematopoietic cells
(Shen et al., 1989, Kongsuwan et al., 1998).
The expression of Class I HOX genes from paralogous groups A, B and C has been
detected in primary human haematopoietic cells, with enhanced expression of genes
from the 3’ regions of the A and B complexes (for example HoxB3) found in the most24
primitive subsets of haematopoietic stem cells, whereas genes at the 5’ end of the
cluster (e.g. HoxA10) were expressed at equal levels in all the CD34+ populations tested
(Sauvageau et al., 1994). Given that these genes were no longer detectable in CD34-
fractions, it appears that the expression of specific HOX genes is required during
different stages of blood cell progenitor development and that commitment to myeloid
or erythroid lineages is accompanied by global downregulation of HOX gene expression
(Sauvageau et al., 1994, Look, 1997, Pineault et al., 2002). This ordered 3’to 5’ wave of
HOX gene activation has also been observed during T-cell activation (Care et al., 1994)
and bears striking resemblance to the 3’ to 5’ sequential activation of HOX genes along
the AP axis in embryogenesis and in retinoic acid treated EC cells. It has been
suggested that the expression of Hox genes in primitive bone marrow sub-populations is
required for the enhanced proliferation and self-renewal capacity of these cells, perhaps
by inhibiting differentiation. In support of this hypothesis, overexpression of certain
Hox genes in bone marrow is associated with proliferative syndromes demonstrating
various differentiation blocks.
In contrast to normal haematopoiesis, the involvement of HOX genes from all clusters
has been demonstrated in leukaemic cells (reviewed by Magli et al., 1997). The role of
individual HOX genes in regulating the proliferation and differentiation of specific
haematopoietic lineages is supported by various studies in which perturbations in
normal haematopoiesis were observed following modulation of Hox gene expression.
This occurred via the overexpression of specific genes in transgenic mouse models or
from retroviral vectors in murine haematopoietic stem cells and targeted disruption of
genes in knockout mouse models or by using antisense oligonucleotides (Lawrence et
al., 1997, reviewed by Buske & Humphries, 2000). Initial evidence for the role of HOX
genes in haematopoiesis stemmed from the discovery that Hoxb8 is dysregulated in
myeloid leukaemia cells (Blatt et al., 1988), and it was subsequently revealed that over-
expression of Hoxb8 in murine bone marrow causes leukaemia in irradiated hosts
(Perkins et al., 1990). It has since been shown that deregulated expression of a number
of homeobox genes including HOXA10, HOXB3 and HOXA9 results in the disruption of
normal transcriptional pathways directing haematopoiesis, in some cases facilitating
leukaemic transformation. For example, over-expression of Hoxa10 leads to disrupted
myeloid and B-cell differentiation, and the selective expansion of megakaryocytic25
progenitors, ultimately leading to acute myeloid leukaemia (AML)(Thorsteinsdottir et
al., 1997). Similarly, mice over-expressing Hoxb3 exhibit disrupted B-cell development
and develop myeloproliferative disease (MPD)(Savageau et al., 1997), whilst over-
expression of Hoxa9 results in perturbations in T-cell development and AML (Izon et
al., 1998).
The deregulation of specific HOX genes via chromosomal translocations has been
directly implicated in human AML. Specifically, HOXA9 and HOXD13 are involved
through the t(7;11) and t(2;11) translocations respectively, and there are numerous
examples of cancers which exhibit alterations in HOX gene expression (Table 1.2).
Taken together these data demonstrate that the lineage- and stage-specific expression of
various  combinations  of  HOX  genes  is  required  for  normal  haematopoietic
development. Future investigations in this area are likely to involve more detailed
analysis of expression patterns of HOX genes during haematopoietic differentiation, the
level and significance of functional redundancy between related members in controlling
haematopoietic processes and the specific genes regulated by HOX  proteins and
associated cofactors.
1.3    HOX11
1.3.1    The Normal Role of HOX11
1.3.1.1  The HOX11 Family
HOX11  belongs  to  a  subfamily  of  divergent  homeobox  genes  including
HOX11L1/Ncx/Enx and HOX11L2/Rnx, that are characterised by an unusual threonine
in place of the more common isoleucine or valine at position 47, within the highly
conserved third helix of the homeodomain (Dear et al., 1993, Hatano et al., 1997,
Cheng  &  Mak,  1993).  Like  other homeodomain proteins, the HOX11 family are
involved in the regulation of cellular growth and differentiation. Given the high degree
of sequence conservation between these members in the homeodomain and in motifs
found in known transcription factors, it is likely that this family functions similarly at
the molecular level (Allen et al., 1991, Lawrence & Largman, 1992, Higashijima et al.,
1992, Cheng & Mak, 1993). Analysis of the expression pattern of Hox11, Hox11L1 and26
Gene Cancer Alteration References
PAX2 Wilms’ OE
PAX3 Rhabdomyosarcoma trans
PAX5 Glioblastoma OE
PAX7 Rhabdomyosarcoma trans
PAX8 Wilms’ thyroid OE
HOXA1 Breast OE Chariot & Castronovo (1996)
HOXA9 Myeloid Leukaemia trans
HOXA10 Myeloid Leukaemia OE
HOXB5 Renal UE
HOXB7 Colorectal mRNA size
HOXB8 Myeloid Leukaemia OE Lawrence et al. (1996)
HOXC11 Wilms’ OE
HOXD4 Renal, colorectal mRNA size
HOX11 T-cell leukaemia trans Hatano et al. (1991)
HOX11L2 T-cell leukaemia trans Bernard et al., (2001)
HSIX1 Breast OE Ford et al. (1998)
Cdx1, 2 Colorectal UE Mallo et al. (1997)
GBX2 Prostate OE Gao et al. (1996)
PBX1 Pre-B ALL trans Nourse et al. (1990)
Table 1.2. Involvement of HOX Genes  in  Cellular  Transformation.  (OE;
overexpressed, UE; underexpressed, trans; translocated).
(Taken from Ford, 1998)27
Hox11L2 in early mouse and Xenopus development reveals significant overlap within
the cranial ganglia, and since individual knockouts for each of these genes do not
demonstrate CNS abnormalities, it is likely that a level of functional redundancy exists
between these family members in CNS development (Roberts et al., 1994, Shirasawa et
al., 1997, Patterson & Krieg, 1999, Shirasawa et al., 2000). As development proceeds,
however, distinct patterns of expression emerge and these functions are exemplified by
nullizygous phenotypes. Thus, mice deficient in Hox11 are asplenic, in accordance with
high expression in the primitive spleen (Roberts et al., 1994) and Hox11L1
-/- mice
develop myenteric neuronal hyperplasia and megacolon, consistent with expression in
the neuronal subset of neural crest-derived tissues including the dorsal root ganglia,
cranial ganglia, sympathetic ganglia, adrenal medulla and enteric ganglia (Shirasawa et
al., 1997). By contrast, Hox11L2 knockout mice develop a syndrome resembling
congenital central hypoventilation, consistent with expression in the ventral medullary
respiratory centre (Shirasawa et al., 2000).
1.3.1.2 The Hox11 Protein
The HOX11 gene encodes a 34kDa homeoprotein that possesses a number of features
required of a transcription factor, in that it is predominantly localised to the nucleus and
demonstrates  both  sequence  specific  DNA-binding  and  transactivation/repression
potential (Dear et al., 1993, Zhang et al., 1996, Owens et al., 2002). Using a random
oligonucleotide  selection  technique,  an  optimal  monomeric  binding  sequence
(TAAGTG)  for the full length Hox11 protein was determined in  vitro  (Tang  &
Breitman, 1995). The compatibility of this motif with the predicted HOX binding
sequence (TAANTG), which is based on the engrailed homeodomain-DNA model,
highlights  the  consistency  of  homeodomain-DNA  interactions,  even  when  the
homeodomains share little sequence homology (En and Hox11 homeodomains share
38% protein sequence identity; Tang & Breitman, 1995). Despite this lack of homology,
a number of critical DNA contacting residues present in the homeodomain N-terminal
arms and the recognition helices of both proteins are conserved including Arg5, Gln50
and Asn51. The Hox11 protein is unusual, however, in that it contains a threonine at
position 47 (Thr47) within helix 3 of the homeodomain, in place of the more common
isoleucine  or  valine  residues.  This  suggests  the  involvement  of  this  residue  in28
determining a distinct specificity of homeodomain binding by Hox11 and it’s other
family members, since Thr47 contacts DNA via a hydrophilic hydroxyl group in its side
chain in addition to the hydrophobic methyl group present in other Hox proteins (Dear
et al., 1993, Tang & Breitman, 1995)(Figure 1.8).
Figure 1.8. Prediction of the HOX11 Homeodomain Recognition Motif by Analogy
to the DNA  Base Contacts Proposed in the X-ray Crystal Model of the En
Homeodomain-DNA Complex. According to the En homeodomain-DNA model (left),
conserved residues within the homeodomain play an important role in DNA recognition
including Arg5 to thymine at the first position, Arg3 to the complementary thymine at
the second base pair, Asn51 to adenyl at the third position, Ile47 to thymine at the fourth
position and either Gln50 or Lys50 to the TG or CC dinucleotide following the TAAT
core. In the HOX11 homeodomain (right), the substitution of Thr47 for Ile47, affects the
DNA binding specificity.
(Adapted from Tang & Breitman, 1995)
In vitro reporter assays investigating the transactivation potential of Hox11, revealed
that optimal transactivation of reporter genes through promoters in both yeast and
mammalian cells requires the involvement of three distinct domains, including a
glycine-proline rich region at the NH2 terminus, the homeodomain and a glutamine rich
region at the COOH terminus (Zhang et al., 1996)(Figure 1.9). The importance of these
domains in the HOX11-dependent transcriptional activation of an endogenous target
gene, HOX11 dependent gene-1 (Hdg-1/Aldh1a1) in NIH 3T3 cells, was subsequently
tested by two independent groups (Masson et al., 1998, Owens et al., 2002). The role of
the homeodomain and the glycine-proline rich NH2 terminus, in particular the first 50
amino  acids  which  harbour  a  conserved  FIL  motif  (Jagla  et  al.,  2001),  in  the
transcriptional activation of Hdg-1 by HOX11, was confirmed by both groups (Masson
et al., 1998, Owens et al., 2002). The contribution of the COOH-terminus domain to
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transactivation remains unclear however, since deletion of this region had only a minor
effect on Aldh1a1 induction in studies performed by Masson and co-workers (1998),
whereas deletion of this region by Owens and co-workers (2002) abrogated Aldh1a1
expression.
Figure 1.9. The HOX11 Homeodomain Protein Featuring a Number of Regions
Contributing to the Transactivation Potential of HOX11.
HOX11 appears not to be a simple activator of transcription since it is also capable of
repressing transcription in a DNA binding-independent manner (Owens et al., 2003).
Structure-function analyses, in which the ability of HOX11 mutants to repress basal
transcription from the SV40 early promoter in HeLa cells was assessed, revealed that
the  NH2  and  COOH  terminal  domains  of  HOX11,  that  also  contribute  to  the
transactivation of Aldh1a1 were likewise necessary for transcriptional repression
(Owens et al., 2003). However, although HOX11-mediated repression required a
structurally intact homeodomain, point mutations within helix 3 (T47I, K55Q) affecting
the DNA binding specificity of HOX11, had no significant effect on repressor activity,
suggesting that repression may be mediated via protein-protein interactions as opposed
to sequence-specific DNA binding (Owens et al., 2003). In contrast, these point
mutations, which change the in vitro HOX11 DNA target sequence from TAAC/TAAT
to TAAT alone, significantly affected the ability of HOX11 to induce Aldh1a1 gene
expression (Owens et al., 2003). Taken together, these results suggest that the activation
and repression functions of HOX11 may occur via distinct mechanisms, in which the
transactivation of Aldh1a1 in NIH 3T3 cells requires DNA binding involving a TAAC-
type DNA sequence, whereas repression may occur in the absence of homeodomain-
specific DNA binding, possibly via protein-protein interactions with members of the
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basal transcriptional complex, by competing with factors for a common binding site or
by quenching (Owens et al., 2003).
In accordance with other Hox family members, HOX11 also possesses a functional
FPWME PBX-interaction motif (PIM), related to the Y/F-PWM-K/R pentapeptide
motif of Class I HOX proteins, required for cooperative interactions with Pbx/exd
proteins. However, this motif did not appear to be required for activation of Aldh1a1 or
for inhibition of promoter activity, implying that if HOX11 does require interaction with
a cofactor, other protein interaction motifs must be involved (Masson et al., 1998,
Owens et al., 2003). In addition to these studies, which were designed to dissect the role
of  functional  domains  of  HOX11  required  for  transcriptional  activation  and/or
repression of downstream targets, the involvement of these regions in HOX11-mediated
immortalisation  was  also  assessed  using  in  vitro  haematopoietic  progenitor
immortalisation assays (Owens et al., 2003). These experiments highlighted differences
between transcriptional pathways resulting in the activation of Aldh1a1 and those
contributing to the ability of HOX11 to give rise to IL-3 dependent cell lines, since
deletion of the NH2 terminal 50 amino acids and the Gln-rich domain near the COOH
terminus abrogated Aldh1a1 induction, but not the immortalising capacity of HOX11
(Owens et al., 2003). In addition, although Aldh1a1 induction and immortalisation by
HOX11 required DNA binding activity, the T47 point mutation only affected the ability
of HOX11 to transactivate Aldh1a1, suggesting distinct mechanisms for HOX11-
mediated transactivation (via a ‘TAAC’ pathway) as opposed to immortalisation (via a
‘TAAT’ pathway)(Owens et al., 2003). Finally, the involvement of the PIM in HOX11-
mediated immortalisation, and associated dispensability in Aldh1a1 transactivation,
further supports the distinction between these transcriptional pathways and highlights
the multiple activities of HOX11 in the regulation of target genes controlling processes
of hematopoietic differentiation, progenitor cell immortalisation and leukaemogenesis
(Owens et al., 2002). It should be noted, however, that although Aldh1a1 was identified
as a gene transcriptionally upregulated by HOX11 in NIH 3T3 cells, the effect of
HOX11 on ALDH1A1 expression in the context of human T-ALL remains unknown,
and as such mechanisms of regulation derived from studies by Owens et al., (2003) may
not be applicable to models of leukaemogenesis involving modulation of ALDH1A1
expression. Moreover, the relevance of an immortalisation assay whereby HOX1131
induces  the  development  IL-3  dependent  cell  lines  with  an  immature  myeloid
phenotype, as the model system to discriminate the regulation of ALDH1A1 by HOX11
from HOX11-mediated leukaemogenesis is questionable. These discrepancies highlight
the requirement for a model that accurately reflects the tumorigenic activity of HOX11
in T-cells.
1.3.1.3  HOX11 and Cofactors
In concordance with other members of the HOX protein family, experimental data
suggests that HOX11 also interacts with specific members of the TALE homeodomain
family in order to direct cell-type specific gene expression. Expression profiling of PBX
and MEIS homeobox genes in a panel of murine haematopoietic cell lines and human T-
ALL cell lines harbouring the t(10;14) translocation (T-ALL Sil, K3P), revealed that
HOX11-expressing murine cells were always associated with expression of at least one
PBX member (PBX1, PBX2, PBX3), whereas in the case of the two human T-ALL cell
lines,  only  PBX2  transcripts  were  detected  (Allen  et al.,  2000).  Evidence  of  a
functionally relevant interaction with PBX2 was revealed following the discovery that
overexpression of both HOX11 and PBX2 led to reduced contact-dependent growth
inhibition in NIH 3T3 cells (Allen et al., 2000). Furthermore, this same group identified
the in vitro formation of a trimeric complex involving HOX11, PBX and MEIS1 on a
DNA  sequence  harbouring  a  HOX/PBX  binding  site  (Allen  et al., 2000).   This
suggested the potential for in vivo regulatory transcription by higher order, multi-
component transcriptional complexes involving HOX11, although the role of this
complex in leukaemic transformation remains unclear since no expression of MEIS
genes was detected in the two T-ALL cell lines tested (Allen et al., 2000). Given that a
PBX-containing complex larger than a HOX11/PBX heterodimer was identified in the
HOX11 expressing T-ALL Sil and K3P cell lines, Allen et al., (2000) postulated the
involvement of a ubiquitously expressed MEIS family member, PREP1 in this complex.
Cooperative interactions between HOX11 and members of the PBX homeodomain
family may also play important roles in embryonic development as well as in the
deregulation of normal growth control mechanisms, since Pbx1 is also required for
spleen development. Strikingly, Pbx1
-/-  knockout  mice  recapitulate  the  asplenic
phenotype  of nullizygous Hox11 mice, and double heterozygotes of Pbx1
+/-  and32
Hox11
+/- have reduced spleen size (Roberts et al., 1994, Dear et al., 1995, Selleri &
Cleary, 1999).
In addition to members of the TALE family of homeodomain transcription factors,
HOX proteins also cooperate with additional cofactors to regulate transcription. For
example HOX proteins from 11 paralog groups were shown to bind CBP or p300
through  interactions  mediated  by  the  homeodomain (Shen  et  al.,  2001).  Unlike
interactions involving HOX, PBX and MEIS, which regulate transcription via sequence-
specific DNA binding, HOX proteins do not bind DNA cooperatively with CBP, but
instead  inhibit  the  histone  acetyltransferase  (HAT)  activity,  thereby  repressing
transcription (Shen et al., 2001). The cardiac homeodomain factor Nkx2.5 has also been
shown to physically associate with GATA-4 to activate the cardiac  alpha-actin
(alphaCA) promoter in CV-1 fibroblasts (Sepulveda et al., 1998). With regard to
association with non-HOX factors, HOX11 has been shown to cooperatively bind
CTF1, a ubiquitously expressed CCAAT-box-binding transcription factor involved in
the regulation of a variety of eukaryotic genes (Santoro et al., 1988, Zhang et al., 1999).
The identification of consensus CTF1 binding sites in a DNA binding site selection
assay using Flag-tagged HOX11, and the subsequent demonstration that CTF1 and
HOX11  physically  associate  in vivo  in  a  HOX11-immortalised  haematopoietic
precursor  cell  line  HX3,  suggests  a  collaborative  role  for  these  proteins  in
transcriptional regulation (Zhang et al., 1999). Indeed, transduction of recombinant
retrovirus expressing an antisense CTF1 cDNA into HX3 cells, resulted in the reduction
of colonies when cells were grown in soft agar, suggesting that HOX11 may collaborate
with CTF1 to mediate haematopoietic precursor cell immortalisation (Zhang et al.,
1999). CTF1 also recruits TFIIB, a member of the preinitiation complex, thus a model
in which the inappropriate expression of HOX11 in haematopoietic precursor cells leads
to complex formation between HOX11, CTF1 and TFIIB and subsequent deregulation
of CTF1 target genes has been postulated (Zhang et al., 1999).
In a completely novel and as yet uncorroborated role, HOX11 has also been identified
as a protein partner for the serine-threonine phosphatase 2A (PP2AC) and protein
phosphatase 1 (PP1C) catalytic subunits in mammalian cells (Kawabe et al., 1997). PP1
and PP2A are capable of maintaining the G2 meiotic arrest of Xenopus oocytes and33
thus, may represent targets for oncogenic transformation (Kawabe et al., 1997). The
possibility that HOX11 may disrupt a G2 checkpoint maintained by PP2A and PP1, by
allowing cells to proceed inappropriately through M phase in Xenopus oocytes and in
the Jurkat T-cell line, suggests a model where HOX11 contributes to genomic instability
by altering cell cycle regulation (Kawabe et al., 1997). Support for the possible role of
HOX11 in cell cycle progression also comes from studies demonstrating that levels of
HOX11 RNA and protein fluctuate during different phases of the cell cycle, with the
highest levels coinciding with a G1 restriction point, suggesting that HOX11 may play a
role in cell cycle progression into the S phase (Zhang et al., 1993).
1.3.1.4  The Role of HOX11 in Development
The role of HOX11 in development has been studied in mice, which express the murine
HOX11 orthologue, Tlx1/Hox11 (Raju et al., 1993). Hox11 is expressed in various
embryological  tissues  including  the  muscle  plates  of  the  branchial  arches  and
subsequently in the cranial nerves that innervate them, the developing hindbrain, spinal
cord, outflow tracts of the heart, pharynx, genticulate, pancreas, thymus and within a
portion of the splenic mesoderm  (Cheng & Mak, 1993, Raju et al., 1993, Roberts et al.,
1994, Dear et al., 1995).  Despite the expression of Hox11 in these tissues, homozygous
null mutant mice (Hox11
-/-) are only affected in spleen organogenesis and are otherwise
phenotypically normal, suggesting that other genes may functionally compensate for the
lack of Hox11 in these tissues or that the expression of Hox11 in these areas is merely
reminiscent of its homeobox evolutionary origin but has no residual function (Roberts et
al., 1994, Hatano et al., 1997, Shirasawa et al., 1997). In support of the former
hypothesis, the expression of Hox11/Tlx1, Hox11L1/Tlx2 and Hox11L2/Tlx3 overlaps
considerably in the central nervous system, suggesting that a degree of functional
redundancy exists between these highly related family members.
Hox11 is initially expressed in the splanchnic mesoderm at embryonic day 11.5
(dE11.5). Continued expression is observed in the developing spleen through dE13.5,
but is downregulated thereafter (Roberts et al., 1994). In order to dissect the function of
Hox11 in spleen organogenesis, the fate of the cells contributing to the developing
spleen was analysed in Hox11
-/- mice and Hox11
-/-
 
-+/+ chimeras (Kanzler & Dear, 2001).34
In the absence of Hox11, cells of the spleen anlage were unable to develop normally
past dE13, and eventually contributed to the pancreatic mesenchyme and the splenic
blood vessels, suggesting that although Hox11 is not required for the formation of the
spleen  primordium,  expression  is  required  for  cells  to  proceed  past  a  specific
developmental stage (Kanzler & Dear, 2001). The asplenic phenotype observed in
Hox11
-/- mice is therefore a result of halted spleen morphogenesis and subsequent
redirection of Hox11
-/- splenic precursors to neighbouring organs, as opposed to organ
involution (Kanzler & Dear, 2001). The role of Hox11 in spleen development from
dE13 onwards is cell autonomous, since wild-type cells were unable to rescue Hox11-
null cells from spleen exclusion in Hox11
-/- - +/+ chimeras (Kanzler & Dear, 2001).
Hox11 null mice displayed normal B-cell and T-cell profiles in thymus, lymph node and
peripheral blood tissues and normal red blood cell counts, however, increased numbers
of white blood cells, including neutrophils and lymphocytes were observed (Roberts et
al., 1994). In addition, erythrocytes from Hox11
-/- mice were found to contain Howell-
Jolly bodies, typically found in asplenia.
1.3.2 The Abnormal Role of HOX11
1.3.2.1 Expression of HOX11 in Normal T-cells
In addition to the role of HOX11 in spleen organogenesis, it has been postulated that
HOX11 may be expressed in normal lymphocytes (Lu et al., 1992, Yamamoto et al.,
1995). Analysis of HOX11 mRNA expression in selected tissues and cell lines by
quantitative reverse transcriptase polymerase chain reaction (RT-PCR), however,
yielded mixed results (Lu et al., 1992, Zhang et al., 1993, Yamamoto et al., 1995).
According  to  studies  by  Lu  et al.,  (1992), HOX11 mRNA  was  detected  in  two
leukaemic T-cell lines, Jurkat and HPB-ALL, as well as in normal T-cells - although
expression in the latter was significantly lower.
It has been suggested that the low level of HOX11 expression observed in transformed
cell lines such as Jurkat, in which cells expressed <1/100 of the amount of HOX11
mRNA found in embryonic spleens (dE17.5), may simply be the result of abnormalities35
in these leukaemic lines. As such, it may not reflect the physiological conditions of their
normal counterparts (Yamamoto et al., 1995). In addition, Yamamoto et al., (1995),
were unable to detect HOX11 mRNA in normal T-cells using RT-PCR analysis and
HOX11 was not induced in T-cells stimulated with PMA and ionomycin, or following
pro-apoptotic  stimulation  with  glucocorticoids,  gamma  irradiation  and  anti-FAS,
suggesting that HOX11 is not involved in major signal transduction or cell death
pathways in normal thymocytes (Yamamoto et al., 1995). Thus, in conjunction with
evidence from other independent groups, the consensus view is that HOX11, like
several other T-ALL oncogenes, is not normally expressed in T-cells at any stage of
development, and that ectopic expression of HOX11 in T-cells is a primary event in the
development of T-lineage tumours (Zutter et al., 1990, Hatano et al., 1991, Salvati et
al., 1995, Yamamoto et al., 1995).
1.3.2.2   Involvement of HOX11 in T-ALL
The HOX11 proto-oncogene was originally identified from chromosomal translocation
breakpoints in T-ALL, which involve a reciprocal exchange between the HOX11 locus
at 10q24 and either TCRδ (14q11) or TCRβ (7q35)(Hatano et al., 1991, Kennedy et al.,
1991, Dube et al., 1991, Lu et al., 1992). These translocations, which are present in
approximately 5-10% of patients with T-ALL, occur within a 15kb breakpoint cluster
region at the 5’ end of the HOX11 gene, such that the coding capacity of the gene
remains intact, resulting in the inappropriate expression of HOX11 in T-cells (Kennedy
et al., 1991). Deregulated expression of HOX11 has since been identified in as many as
30% of T-ALLs, when abnormalities not detectable by cytogenetics are included
(Salvati et al., 1995, Kees et al., 2003). One proposed mechanism for the reactivation of
HOX11 in T-ALL specimens lacking the translocation, involves CpG demethylation of
the proximal HOX11 promoter, possibly in concert with other derepression mechanisms
(Watt et al., 2000). Given the precedent for deregulation of transcription factors in T-
cell leukaemia by translocation into TCR loci, it is likely that the ectopic expression of
HOX11 in T-cells is a crucial event in tumour initiation or progression (McGuire et al.,
1989, Mellentin et al., 1989, Begley et al., 1989). The localisation of HOX11 protein in
the nucleus of T-cells, in conjunction with the DNA binding and transcriptional
transactivating potential of HOX11, suggests that HOX11 may function in vivo as an36
oncogenic transcription factor by perturbing normal patterns of gene expression in T-
cell tumour precursors, thus leading to the development of leukaemia (Dear et al., 1993,
Zhang et al., 1993, Dear et al., 1995).
In order to investigate the mechanism by which a nuclear oncogene like HOX11 can
contribute to the genesis of human T-cell tumours, transgenic mice in which the
expression of HOX11 was targeted to the thymus using CD2 regulatory elements were
created, however no tumours were observed even after an extended time period (20
months)(Greene & Rabbitts, unpublished observations). Furthermore, attempts to
ectopically express HOX11 in the developing thymocytes of LCK-HOX11 transgenic
mice, resulted in an apparent embryonic lethality (Hough et al., 1998). Thus, to date,
attempts to accurately recapitulate the tumorigenic activity of HOX11 in T-cells have
been unsuccessful. Despite this, several groups have demonstrated that HOX11 harbours
the capacity for widespread immortalisation of various haematopoietic precursors,
which may be a significant contributory factor in T-cell leukaemogenesis, (Hawley et
al., 1994, Hough et al., 1998). For example, constitutive expression of HOX11 in
murine  haematopoietic  precursors  blocks  the  differentiation  of  IL-3-responsive
progenitors, resulting in the generation of myeloid progenitor cell lines (Hawley et al.,
1994). DNA binding was shown to be essential for the immortalisation function of
HOX11 in this study. This is in keeping with a model whereby the transforming
capability of HOX11 involves dysregulation of specific HOX11 target genes involved
in the regulation of normal haematopoietic differentiation programmes. Although over-
expression of HOX11 resulted in the immortalisation of myeloid progenitors, the
inability of MSCV-HOX11 bone marrow transplant recipients to develop leukaemias
during the 6-month observation period, highlighted the requirement for secondary
mutations in addition to HOX11 over-expression for full acquisition of the malignant
phenotype. This might involve, for example, mutations promoting cellular survival or
proliferation (Hawley et al., 1994). The tumorigenic activity of HOX11 in lymphoid
progenitors was supported by studies in which transgenic mice expressing low levels of
HOX11 under the control of the Ig heavy chain regulatory sequence in B-lymphocytes,
led to the development of large cell lymphomas (IgM+IgD+ mature B-cells) in the
spleen, that were not transplantable into SCID recipients (Hough et al., 1998). The
immortalisation capacity of HOX11 in adult bone marrow-derived precursors has also37
been extended to embryonic haematopoietic precursors (Yu et al., 2002, Keller et al.,
1998).  Overexpression  of  HOX11 in embryoid bodies (EB), which represent the
embryonic or yolk sac stage of haematopoiesis, resulted in the establishment of novel
haematopoietic cell lines (EBHX), a number of which were capable of generating
primitive and definitive erythroid progeny (Keller et al., 1998).  In addition, the ectopic
expression of HOX11 was associated with an immature phenotype in J2E erythroid
cells, supporting the concept that the transforming capacity of HOX11 may stem from
its ability to alter haematopoietic cell differentiation (Greene et al., 2002).
Taken together, these results suggest that although the ectopic expression of HOX11 is
clinically associated with the development of T-cell tumours, the immortalisation
activity of HOX11 is non-lineage specific. Indeed, HOX11 mRNA has also been
detected in blast cells from patients with acute myeloid tumours in addition to the
erythroleukaemic cell line, K562 (Lu et al., 1992, Hawley et al., 1994). The disruption
of  haematopoietic  differentiation  via  a  HOX11-mediated  pathway  may  therefore
predispose cells of various lineages to leukaemic transformation, however the specific
mechanisms by which HOX11 induces tumour growth remain enigmatic.
1.4 HOX11 TARGET GENES
1.4.1   Identification of Downstream Target Genes of HOX11
The transforming capacity of HOX11 likely involves the dysregulation of target genes
involved in transcriptional networks that normally regulate thymocyte proliferation,
differentiation and survival during T-cell development. Three putative HOX11 target
genes have been identified so far, namely aldehyde dehydrogenase 1a1 (Aldh1a1) and
the Wilm’s Tumour gene (Wt1), which appear to be physiologically regulated by Hox11
in the developing spleen, and Four and a half LIM domain protein 1 (Fhl1), which
encodes a LIM domain protein normally highly expressed in skeletal muscle (Greene et
al., 1998, Koehler et al., 2000). Aldh1a1 encodes an enzyme involved in retinoic acid
synthesis and was originally identified as a gene activated by HOX11 in NIH 3T3 cells
in a cDNA representational difference analysis (RDA) screen for HOX11 target genes
(Greene et al., 1998). Conversely, Aldh1a1 appears to be repressed by Hox11 during38
spleen organogenesis since Aldh1a1 mRNA levels are elevated in the spleen anlagen of
Hox11-null mouse embryos (Greene et al., 1998). Furthermore, a study of ALDH1A1
expression in cell lines stably transfected with HOX11, revealed that ALDH1A1 is
positively regulated by HOX11 in the immature T-cell line, PER-117 and negatively
regulated by HOX11 in the human erythroleukaemic cell line, HEL (Greene et al.,
1998, Greene unpublished observations). Thus, it appears that HOX11 is a bifunctional
transcriptional  regulator,  capable  of both  transcriptional  activation  or  repression
depending on the cellular context. Subsequently it was shown that Wt1, which is also
required for spleen development, represents a physiological target of Hox11, and
furthermore, WT1 is over-expressed in 75% of ALL cases and is also associated with
various other cancer subtypes (Hastie, 1994, Loeb et al., 2001). Although the specific
relevance  of  WT1, ALDH1A1 and FHL1  as  targets  of  HOX11  in  neoplastic
transformation has yet to be established, several studies suggest functional interplay
between highly related gene members during normal development. For example, both
WT1 and RALDH2/ALDH1A2 are coexpressed during cardiac development in avian
epicardially derived cells (EPCDs), and it is postulated that WT1 is responsible for
maintaining the EPCDs in an undifferentiated, retinoic acid (RA)-synthesising state,
required for normal differentiation of the ventricular myocardium (Perez-Pomares et al.,
2002). Moreover, the LIM-only coactivator, FHL2, has been shown to cooperate in vivo
with WT1 to regulate the expression of Mullerian Inhibiting Substance (MIS) and the
nuclear receptor DAX1, which control the differentiation of the Mullerian duct during
sex determination (Du et al., 2002). A detailed understanding of the network of genes
affected by HOX11 is therefore crucial in order to gain insights into the molecular
pathways perturbed by HOX11 in the leukaemic transformation process.
1.4.2   ALDH1A1 as a Target Gene of HOX11
1.4.2.1 The Role of ALDH1A1 in Normal Development
1.4.2.1.1  Retinoid Metabolism
Vitamin A (retinol) is the parent compound of a family of signalling molecules
(retinoids)  which  are  responsible  for  regulating  diverse  aspects  of  cellular39
differentiation, proliferation, apoptosis, reproduction and embryonic development,
through its biologically active metabolite, RA (reviewed by Napoli, 1999, Maden, 1999,
Haselbeck et al., 1999). The process of retinoid metabolism begins with the acquisition
of retinol, in the form of retinyl esters (animal fat) or as a provitamin carotenoid
(plants), which are mobilised from the liver to target cells via high affinity retinol
binding proteins (RBP)(Gaines & Berliner, 2003). Upon internalisation, retinol is bound
to the cellular retinol binding proteins (CRBP, CRBPII) and is subsequently converted
to the biologically active derivatives, retinal and RA, which are released by CRBP in
order to enter the nucleus. The pleiotropic effects exerted by RA (which include the
structural variants, all-trans-RA (ATRA) and 9-cis-RA) in various cell types may then
occur via the regulation of gene transcription mediated by a family of ligand-dependent
receptors, which include the retinoic acid receptors (RAR) and retinoid X receptors
(RXR)(McCaffery & Drager, 1995, Maden, 1999, Haselbeck et al., 1999, Collins,
2002).  These  nuclear  receptors,  which  comprise  a  DNA-binding  domain  (DBD)
connected to a high affinity ligand-binding domain (LBD) which also harbours an
activation function (AF-2) domain, form transcriptionally active heterodimers, that
recognise specific RA Responsive Elements (RAREs) located in the regulatory regions
of RA-induced target genes (Bourguet et al., 2000, Gaines & Berliner, 2003). Upon
binding of cognate ligand (RAR can be activated by all-trans RA or 9-cis RA, whereas
RXRs are activated by 9-cis  RA  alone),  these  receptors  undergo  conformational
changes that facilitate the release of co-repressors, and subsequent interaction with
transcriptional co-activators and members of the basal transcriptional machinery in
order to activate gene transcription (Torchia et al., 1998)(Figure 1.10). Thus, in the
absence of ligand binding, the RAR/RXR heterodimer recruits nuclear co-repressors
NcoR (Nuclear receptor CoRepressor) and SMRT (Silencing Mediator of Retinoid and
Thyroid Hormone Receptor), which in turn bind histone deacetylases (HDACs), leading
to the establishment of repressive chromatin structure; whereas in the case of RA
binding, the recruitment of co-activators and associated histone acetyl transferases
(HATs) is favoured, resulting in transcriptionally permissive chromatin structure and
gene activation (Chen & Evans, 1995, Chen et al., 1997, reviewed by Xu et al., 1999).
The existence of three receptor subtypes (RAR/RXRα, β and γ), each of which contains
multiple isoforms generated by alternative splicing or utilisation of different promoters,
increases the potential for various heterodimeric combinations responsible for complex40
RA-mediated  target  gene  regulation  (Chambon,  1996).  Given  the  complexity  of
receptor family members and the differential spatio-temporal expression patterns of
these receptors in various cell types, it is therefore not surprising that the focus in
unravelling the diversity of effects mediated by RA, has concentrated primarily on
aspects involving RAR/RXR signalling (Maden, 1999).
Figure 1.10. Mechanism of Retinoic Acid Action. (A) In the absence of retinoic acid
(RA; all-trans-RA, 9-cis-RA, didehydro-RA or 4-oxo-RA), the RAR/RXR heterodimer
recruits nuclear co-repressors, which bind histone deacetylases (HDACs), leading to
transcriptional repression. (B). Upon ligand binding, gene transcription is initiated by
the recruitment of co-activators and associated histone acetyl transferases (HATs). The
various RAR and RXR subtypes (α, β and γ) are encoded by distinct genes and encode
multiple isoforms via alternative splicing, resulting in 48 possible heterodimeric
combinations, accounting for the diversity of RA-mediated effects. In addition, RXR is
also a partner for other receptors belonging to the steroid/retinoid/vitamin D/thyroid
hormone superfamily.
(Taken from Napoli, 1999)
The discovery by Niederreither et al., (1999) that a single mutation affecting the RA
synthesising enzyme, RALDH2 in embryonic mice yielded a phenotype bearing striking
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similarities to those described for RAR/RXR knockouts, emphasised the importance of
retinoid metabolism in contributing to the local diversity in RA actions.  Such aspects
include the processes of retinol circulation and cellular uptake mediated by CRBPs,
bioavailability of RA as regulated by cellular retinoic acid binding proteins (CRABPs),
mechanisms of RA degradation and of particular interest within the scope of this
project, the control of RA biosynthesis (Leid et al., 1992, McCaffery & Drager, 1995,
Maden, 1999).
1.4.2.1.2    Aldehyde Dehydrogenases (ALDHs)
Aldehyde dehydrogenases (ALDHs) are a group of enzymes present in organisms
ranging from bacteria to humans, that are responsible for catalysing the pyridine
nucleotide-dependent oxidation of aldehydes to their corresponding carboxylic acids
(Yoshida et al., 1998, Sladek, 2002). As a general rule, NAD serves as the hydrogen
acceptor in this essentially irreversible reaction, although in the case of some enzymes,
NADP may perform this function (Figure 1.11)(Sladek, 2003).
Figure  1.11.  Aldehyde  Dehydrogenases  (ALDHs)  Catalyse  the  Oxidation  of
Aldehyde to Carboxylic Acid. ALDH exists as an active enzyme in dimeric form, with
each  subunit  harbouring  an NAD(P)-binding pocket, a catalytic and an arm-like
bridging domain.
(Taken from Liu et al., 1997)
In mammals, the general detoxification of aldehydes, in addition to other specific
catalytic functions are performed by members of the human aldehyde dehydrogenase
superfamily, which to date, comprise seventeen enzymes (Sophos et al., 2001, Sladek,
2003)(Table 1.3). These enzymes, which are critical for normal biological development
and  physiological  homeostasis,  are  predominantly  located  in  the  cytosol  and
mitochondrial compartments and can be broadly sub-divided  into two groups. The first
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Class Family Gene Name Trivial Name Chromosomal
Location
ALDH1A1 ALDH1/RALDH1 9q21
ALDH1A2 ALDH1A7/RALDH2 15q21.2
ALDH1A3 ALDH6/RALDH3 15q26
ALDH1B1 ALDH5/ALDHx 9p13
Class 1 ALDH1
ALDH1L1 FOLATEDH 3q21.3
Class 2 ALDH2 ALDH2 ALDH1/ALDH2 12q24.2
ALDH3A1 ALDH3/ALDH-III 17p11.2
ALDH3A2 ALDH5/ALDH10 17p11.2
ALDH3B1 ALDH-7 11q13
Class 3 ALDH3
ALDH3B2 ALDH-8 11q13
Class 4 ALDH4 ALDH4A1 ALDH-4 1p36
Class 5 ALDH5 ALDH5A1 E5/SSDH 6p22
Class 6 ALDH6 ALDH6A1 MMSDH 14q24.3
Class 7 ALDH7 ALDH7A1 ATQ1 5q31
Class 8 ALDH8 ALDH8A1 ALDH-12 6q24.1-25.1
Class 9 ALDH9 ALDH9A1 ALDH-9/E3 1q22-q23
Class
18
ALDH18 ALDH18A1 P5cS 10q24.3-q24.6
(Compiled from Sladek, 2003)
Table  1.3. Nomenclature  and  Chromosomal  Locations  of  Human  Aldehyde
Dehydrogenases.43
category comprise ‘dedicated’ enzymes that are crucial for the relatively specific
conversion of a single endobiotic to an essential metabolite in the absence of insult. This
includes ALDHs 1A1, 1A2, 1A3, 8A1, 1L1, 3A2, 4A1, 5A1, 6A1, 9A1 and 18A1). By
contrast, the second group encapsulates those enzymes which are relatively non-
substrate specific and provide protection against the plethora of potentially cytotoxic,
mutagenic, genotoxic and carcinogenic aldehydes encountered as either physiologically
derived intermediates of metabolism (e.g. during lipid peroxidation) or when the
organism encounters a hostile environment (e.g. ultraviolet (UV) light, toxic chemicals).
Enzymes in this category include ALDH3A1 and ALDH5A1 (Lui et al., 1997, Sladek,
2003).
It should be noted, however, that exceptions to this general classification scheme do
exist, such as in the case of ALDH1A1, which catalyses the oxidation of retinaldehyde
to retinoic acid (a bioactivation function necessary for normal development), in addition
to performing a detoxification function by catalysing the oxidation of the anti-cancer
pro-drug  intermediates  aldophosphamide  and  aldoifosfamide  (Sladek,  2003).  In
addition, a number of ALDH enzymes remain to be categorised. This is because their
identification as members of the ALDH superfamily in the wake of the Human Genome
sequencing project preceded a complete understanding of the physical properties, tissue
distribution, sub-cellular localisation and substrate/co-factor preferences demonstrated
by these enzymes (Sladek, 2003).44
1.4.2.1.3   ALDH1A1 – A Crucial Regulator of Retinoic Acid Biosynthesis During
  Embryogenesis and Adulthood
The biosynthesis of RA from retinol involves two sequential steps (Figure 1.12).
Figure 1.12. Biosynthesis of Retinoic Acid. The reversible interconversion of retinol
to retinal is catalysed by members of the alcohol dehydrogenase (ADH) and short-chain
dehydrogenase/reductase (SDR) enzyme family, whereas the members of the ALDH
and cytochrome P450 families (CYP450) catalyse the irreversible oxidation of retinal to
RA.
The first step encompasses the reversible oxidation of retinol to retinaldehyde, and is
catalysed  by  either  cytosolic  retinol  dehydrogenases  (members  of  the  alcohol
dehydrogenase (ADH) family) or by microsomal retinol dehydrogenases (members of
the short-chain dehydrogenase/reductase (SDH) family)(Haselbeck et al., 1999). The
rate-limiting second step however, involves the irreversible oxidation of both all-trans
and 9-cis retinal to their corresponding RA isomers, and is catalysed by a select group
of  enzymes  within  the  family  of  ALDHs,  namely  human  Class  1  Aldehyde
Dehydrogenase  1A1  (ALDH1A1),  1A2  (ALDH1A2),  1A3  (ALDH1A3)  and
ALDH8A1, in addition to members of the cytochrome P450 family (CYP450) including
P4501A1 and 1A2 (Duester, 1996, Raner et al., 1996, Sladek, 2003). In mice these
activities are performed by the murine homologs, which include Aldh1a1 (Raldh1),
Aldh1a2 (Raldh2) and Aldh1a3 (Raldh3)(Zhao et al., 1996, Haselbeck et al., 1999).
ALDH1A1  is  a  cytosolic  enzyme  of  approximately  54.7kDa,  that  exists  as  a
homotetramer present in a wide range of human foetal and adult tissues including the
liver, kidney, erythrocytes, skeletal muscle, lung, breast, lens, stomach mucosa, brain,
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pancreas, testis, prostate and ovary (Sladek, 2003).  Analysis of the crystal structure of
ALDH1A1 isolated from sheep liver, revealed the presence of a unique ‘substrate
tunnel’ capable of specifically binding retinaldehyde (Moore et al., 1998). Further
studies revealed that this channel was also present in another RA synthesising enzyme,
ALDH1A2 but absent in ALDH2 and ALDH3A1 enzymes, suggesting that the major
role for ALDH1A1 is in the biosynthesis of RA - the tightly controlled synthesis of
which is crucial to ensure correct gene expression at appropriate developmental stages
(Yoshida et al., 1992, Lamb et al., 1999).
During embryogenesis, RA gradients are likely to play a crucial role in AP patterning
by regulating members of the Hox gene family, which are RA-inducible and selectively
expressed  in posterior tissues  (trunk  and posterior hindbrain) along the AP  axis
(Haselbeck et al., 1999).  In addition to this role in AP patterning, RA is also involved
in other aspects of embryonic development and co-localisation studies examining the
distribution of RA and RA-synthesising enzymes in mice, reveal distinct roles for two
different enzymes in RA synthesis. The first enzyme, Aldh1a2, demonstrates a high
catalytic efficiency for RA synthesis and is the predominant RA synthesising enzyme in
the trunk and frontonasal region of mid-gestation mouse embryos; whereas the second
enzyme, Aldh1a1, which is of particular interest in the context of this project, displays a
lower catalytic activity and is important for regulating low-level RA synthesis in the
cranial tissues including the optic vesicles, ventral mesencephalon, otic vesicles and
thymic primordia (Maden et al., 1996, Dickman et al., 1997, Haselbeck et al., 1999,
Niederreither et al., 1999). Further studies in Xenopus demonstrate that the synthesis of
RA by ALDH1A1 is crucial during embryogenesis for the development of certain
anterior structures including the olfactory placodes, dorsal retina and lens placode as
well as for trunk structures, which include the pronephros and pronephric duct (Ang &
Duester, 1999). A number of adult tissues are also dependent on ALDH1A1 for RA-
mediated transcriptional regulation, including the skin (keratinocyte differentiation),
testes (spermatogenesis), brain, liver and kidney (McCaffery & Drager, 1995) and the
specific expression of Aldh1a1 in adult mouse organs suggests that this enzyme may
also  function  as  the  predominant  regulator  of  RA  synthesis  in  adult  organisms
(Haselbeck et al., 1999).46
The conserved expression patterns of the various RA synthesising enzymes reflects the
importance  for  strict  regulation  of  RA  synthesis  required  for  normal  embryo
morphogenesis and distinct adult functions (Ang & Duester, 1999, Russo et al., 2002).
Indeed, the requirement for such fine tuning in the synthesis of this highly potent,
lipophilic signalling molecule is exemplified by the pleiotrophic effects on embryonic
limb development observed following the application of ATRA at different stages of
embryonic development. When pharmacological doses of ATRA were administered 5.5
days postcoitum (dpc), limb duplication was observed, however if ATRA was applied
later  in  development  at  10  and  12.5dpc  limb  development  was  stunted,  further
emphasising the requirement for correct spatio-temporal regulation of RA synthesis
(Kochhar, 1980, Niederreither et al., 1996).
In addition to its function as a RA synthesising enzyme, ALDH1A1 also plays a role in
alcohol detoxification. Additional detoxification roles for ALDH1A1 include the
elimination of peroxidic aldehydes produced in the eye lens, as well as protection of
human  and  murine  cells  against  the  anti-cancer  agents  cyclophosphamide  and
ifosfamide which were commonly used in tumour cell purging regimens during bone
marrow transplantation (Yoshida et al., 1998, Sladek, 2003).
1.4.2.1.4 The Role of Retinoid Signalling in Haematopoiesis
Haematopoiesis involves the continuous generation of blood forming cells, which
include granulocytes, macrophages, platelets and red blood cells (RBCs), as well as
cells comprising the immune system, which include B-cells, T-cells, dendritic cells
(DC) and natural killer cells (NK), from a limited pool of pluripotent HSCs (Reya et al.,
2001, Russo et al., 2002). Interest in the processes governing normal HSC development,
particularly from the perspective of gaining insights into mechanisms governing ‘cancer
stem cell’ self renewal, has led to the identification of specific growth factors and
transcriptional regulators required for the survival, differentiation and proliferation of
HSCs (Metcalf, 1998, Herault, 2002). A number of transcription factors are exclusively
expressed in haematopoietic cells, and roles for SCL (Shivdasanl et al., 1995), LMO2
(Warren et al., 1994), PU.1 (McKercher et al., 1996), GATA-1 (Weiss et al., 1994),
E2A (Zhuang et al., 1994), C/EBP and Ikaros (Georgopoulos et al., 1994), in lineage47
commitment during haematopoiesis have been proposed following gene targeting
experiments in mouse embryonic stem cells and by generating knockout mice, despite
the inherent limitations of such studies (e.g. lack of phenotype due to functional
redundancy, loss of function resulting in early effects thereby obscuring functional roles
later in development)(Figure 1.13).
Figure 1.13. Key Transcription Factors Involved in Lineage Commitment During
Haematopoiesis. HSC,  pluripotent  haematopoietic  stem  cell,  Lym,  lymphoid
progenitor, M/E, myeloerythroid progenitor.
(Adapted from Orkin, 1995).
In addition to these lineage-specific transcription factors, the retinoic acid receptors,
RAR and RXR, function as ligand inducible transcriptional regulators within retinoid
signalling pathways that have established roles in haematopoiesis. Gene targeting
experiments designed to dissect the specific involvement of various RAR subtypes in
haematopoiesis, reveal crucial roles for RARα and RARγ isoforms in granulopoiesis,
since mice lacking both receptors display a block to granulocytic differentiation
(Labrecque et al., 1998). The role of retinoids and RARs in myelopoiesis has been
extensively studied, following the discovery that pharmacological doses [1uM] of
ATRA  are  able  to  induce  the  terminal  differentiation  of  immature,  malignant
promyelocytes which accumulate in the bone marrow and peripheral blood of patients
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with acute promyelocytic leukaemia (APL)(Collins, 2002). APL is a subtype of acute
myeloid  leukaemia  (AML),  in  which  patients  typically  harbour  the  t(15;17)
chromosomal translocation (~90%), resulting in the production of a hybrid fusion
protein, comprising the DNA/ligand binding and transactivation portion of the retinoic
acid receptor alpha (RARα)(17q21) and the transactivating N-terminal region of the
promyelocytic leukemia (PML) transcription factor (15q22)(Kakizuka et al., 1991).
This chimaeric oncoprotein acts by antagonising wild type RARα and constitutively
repressing RARα target genes via the recruitment of histone deacetylases that are not
released at physiological concentrations of ATRA (Grignani et al., 1998). In addition to
these clinical observations, studies in which murine bone marrow cells were transduced
with a mutant RARα demonstrating dominant negative activity, generated myeloid cell
lines stunted at various stages of differentiation, providing further evidence that retinoid
signalling may also be involved in normal granulopoiesis (Collins, 2002).
The effects of ATRA on the development of various haematopoietic lineages from
pluripotent stem cells appears complex, with some studies reporting that ATRA
enhances the growth of erythroid and myeloid progenitors, as well as the long- and
short-term repopulating activity of cells derived from lin
-c-kit
+Sca-1
+ precursors; while
other  reports  suggest  an  inhibitory  role  for  ATRA  in  HSC  proliferation  and
differentiation (Douer & Koeffler, 1982, Smeland et al., 1994, Purton et al., 1999).
Although these varied effects of RA on haematopoiesis may be due to the pleiotrophic
effects of RA on cultured target cells present at varying maturational stages, Tocci and
co-workers  (1996)  also  demonstrate  the  dual  action  of  RA  on  human  foetal
haematopoietic progenitor cells. In keeping with other related studies, this group
demonstrate that ATRA and 9-cis RA inhibits the proliferative capacity of HSCs and
modulates  the  growth  of  purified  HSCs  by  redirecting  cells  from  the
multipotent/erythroid, monocytic to the granulocytic-neutrophilic differentiation lineage
programme (Tocci et al., 1996). To add a further layer of complexity, the effects of RA
on the survival of adult human marrow CD34
+ stem cells also appear to be dependent on
the presence of growth factors, such that in the presence of growth factors, ATRA
promotes apoptosis of CD34
+ bone marrow (BM)  cells, whereas ATRA  exerts a
protective effect on CD34
+ cells deprived of growth factors and hence subject to
apoptotic stress (Herault et al., 2002). Although the exact mechanisms by which ATRA49
is able to exert these opposing effects have yet to be clarified, it is clear that ATRA
alone has a direct effect on the survival of adult HSCs, and in keeping with the notion
that RA may regulate HSC development in vivo, highly elevated levels of ALDH1A1
have been documented in these multipotent progenitors (Kastan et al., 1990, Jones et
al., 1995, Storms et al., 1999).
The role of retinoic acid signalling in lymphopoiesis, is less well documented, however
a number of studies report that physiological levels of retinoids inhibit the proliferation
of normal peripheral blood B-cells and B-cell precursors from bone marrow, by
inhibiting cell cycle machinery responsible for the progression of cells from G1 into the
S phase (Blomhoff et al., 1992, Fahlman et al., 1995, Lomo et al., 1998, Naderi &
Blomhoff, 1999). Progression through the cell cycle involves the phosphorylation of the
retinoblastoma protein (pRB)  by  cyclin  D,  E  and  A-  associated  kinases,  thereby
stimulating the release of transcriptional regulators like E2F from complexes with pRB,
facilitating the transcription of S-phase genes (Weintraub et al., 1992). ATRA inhibits
B-cell proliferation by rapidly inducing dephosphorylation of pRB, through decreased
levels of cyclins E and A and increased levels of p21
Cip1 kinase inhibitor (Naderi &
Blomhoff, 1999). Conversely, ATRA stimulates the proliferation of peripheral blood T-
cells by increasing pRB phosphorylation, through increased levels of cyclin D3, E and
A and decreased levels of p27
Kip1. However, since the effect on cell cycle machinery
was delayed (~ 20h post treatment), the effect of RA on T-cell proliferation is thought
to be indirect and possibly due to increased production of IL-2 (Ertesvag et al., 2002).
1.4.2.2  The Abnormal Role of ALDH1A1
1.4.2.2.1  Relevance of ALDH1A1 as a Target Gene of HOX11
The importance of retinoid signalling in processes governing haematopoietic cellular
proliferation and differentiation is exemplified by the block to granulopoiesis as a result
of overexpressing a truncated form of RARα or the PML/RARα fusion gene, typically
found in a subtype of APL (de The et al., 1991). However, although RARs and RAR-
binding proteins are key players in retinoid signalling, the availability of RA, which is
determined by the expression of specific RA-synthesising enzymes, also plays a crucial50
role in determining the biological function of RA within the cell. The second step in RA
synthesis, catalysed by ALDH1A1, is particularly important since it represents the
irreversible step at which the active metabolite is made available to the cell (McCaffery
& Drager, 1995). Previous studies reveal that changes in ALDH activity, in particular
an increase in the activities of Class 1 and 3 ALDHs, coincide with experimental liver
and bladder carcinogenesis and have also been observed in a number of human tumours
including mammary, liver and colon cancers (Lindahl, 1992). This increase in ALDH
activity is associated with enhanced tumour cell growth and drug resistance, and
inhibition of ALDH1/3 activities in hepatoma cells resulted in a 15% reduction in cell
number, suggesting that these isozymes play important roles in processes governing cell
death (Canuto et al., 2001).
The ectopic expression of HOX11 in T-cell leukaemias bearing t(10;14)(q24;q11) or
t(7;10)(q35;q24), is a significant contributory factor in the initiation of tumorigenesis
(Kennedy et al., 1991). To date, the regulatory effects of HOX11 on ALDH1A1
expression have been examined in a number of cell types including murine spleen cells,
NIH 3T3 murine fibroblasts, the T-ALL cell line PER-117, the human erythroleukaemic
cell line, HEL and the murine erythroleukaemic cell line J2E (Greene et al., 1998,
Greene et al., 2002). Although HOX11 was found to activate Aldh1a1 expression in
NIH 3T3, J2E and PER-117 cells, levels of Aldh1a1 were significantly reduced in cells
of the developing spleen and in HEL cells transfected with HOX11 (Greene et al., 1998;
Greene, unpublished observations). A possible link between ALDH1A1 downregulation
and tumorigenesis has been previously demonstrated in mouse hepatocellular tumours,
human prostate tumours and other various tumour cell lines (Ryzlak et al., 1992,
Dragani et al., 1996). It is therefore plausible that a similar mechanism of tumour
progression may exist in T-cells ectopically expressing HOX11.
It appears that the repression of Aldh1a1 in splenic precursor cells is essential for
normal  spleen  development,  however  the  inappropriate  activation/repression  of
ALDH1A1 in developing T-cells may potentially result in a block in cell differentiation,
thereby facilitating leukaemogenesis. The potential significance of altered Class 1
ALDH activity in the development of T-ALL is also exemplified by recent studies in
which the TAL1 and LMO1/LMO2 oncoproteins were shown to synergistically activate51
the transcription of the related RA-synthesising enzyme, ALDH1A2 (RALDH2)  in
leukaemic T-cells by acting as cofactors for GATA-3 (Ono et al.,  1998).  In  the
erythroid lineage, these factors function synergistically in conjunction with erythroid-
specific GATA-1 to regulate erythroid cell differentiation. The inappropriate expression
of SCL and LMO proteins in the T-lineage provides a plausible mechanism for
dysregulated gene  expression,  by  mimicking an  erythroid-specific transcriptional
complex, where GATA-1 is replaced by T-cell specific GATA-3 (Ono et al., 1998). In
light of the key roles played by retinoic acid, it is evident that ALDH1A1, the enzyme
regulating the delicate balance of RA within the cell, fulfils a crucial role in maintaining
normal  processes  affecting  proliferation,  quiescence  and  differentiation.  Thus,
alterations affecting the cellular availability of ALDH1A1, may disrupt a homeostatic
control point in RA synthesis, with potentially serious consequences for the cells
affected.
1.4.3 FHL1 as a Target Gene of HOX11
1.4.3.1 LIM Domain Proteins
LIM domain proteins can be classified as either 1) LIM-homeodomain (LIM-HD)
proteins, 2) LIM-functional domain proteins, 3) C-terminal LIM proteins and LIM-only
(LMO) proteins, and derive their name from the presence of a consensus amino acid
sequence (C-X2-C-X17-19-H-X2-C)-X2-(C-X2-C-X16-20-C-X2-H/D/C) originally identified
in the homeodomain-containing transcription factors Lin-11, Isl-1 and Mec-3 (Freyd et
al., 1990).  The LIM domain comprises 50-60 amino acids and encodes a cysteine-rich,
double zinc finger motif reminiscent of the DNA-binding zinc fingers of GATA1-like
transcription factors (Brown et al., 1999). Despite the similarity between these motifs,
however, LIM domains have not been shown to bind DNA directly and instead mediate
protein-protein interactions between transcription factors, signalling and cytoskeleton-
associated proteins (Dawid et al., 1998, Curtiss & Heilig, 1998). The presence of
multiple LIM domains in most LIM proteins enables them to act as molecular scaffolds
to bridge the interactions between transcription factors, thus providing a backbone for
the coordinated assembly of specific protein complexes involved in the regulation of
processes such as embryonic development, cellular differentiation and cytoskeletal52
structure (Schmeichel & Beckerle, 1994). The involvement of LIM domain proteins in
such diverse processes may be attributed to the ability of LIM domains to interact with
multiple  protein  families;  LIM  domains  have  been  shown  to  form  homo-  and
heterodimers, bind tyrosine-containing motifs, PDZ domains, and helix-loop-helix
domains in transcription factors, kinases and cytoskeletal proteins (Kuroda et al., 1996,
Tu et al., 1999).
1.4.3.2   FHL1
1.4.3.2.1   Family members and Related Isoforms
FHL1, previously SLIM1, is a member of the four and a half LIM (FHL) domain
protein family, which also includes FHL2/SLIM3/DRAL (47% amino acid homology),
FHL3/SLIM2 (45% amino acid homology), FHL4 and ACT (Activator of the cAMP
Response Element Modulator in Testis), that fulfil essential roles in the development
and  maintenance  of  the  cardiovascular  system  and  striated  muscle  (Morgan  &
Madgwick, 1996, Chu et al., 2000). Each member contains an N-terminal zinc finger
followed by four complete LIM domains and no other associated motifs (Morgan &
Madgwick, 1996). To date, three alternative splice variants of FHL1  have  been
identified, including the murine isoform, named KyoT2 (Taniguchi et al., 1998), as well
as a human variant, designated SLIMMER/FHL1B (SLIM1 with Extra Regions)(Brown
et al., 1999, Lee et al., 1999)(Figure 1.14). KyoT2 contains the NH2-terminal two and a
half LIM domains of FHL1 followed by 27 novel C-terminal amino acids, which
mediate binding to RBP-J/RBP-Jk/Su(H), a DNA-binding protein involved in the Notch
signalling pathway. The displacement of RBP-J from DNA as a result of binding
KyoT2, leads to a block in differentiation suppression mediated by Notch (Taniguchi et
al., 1998). FHL1C, the transcript corresponding to KyoT2 in humans, was subsequently
identified in a human testis cDNA library, and shares 91% homology at the nucleotide
sequence level and 96% homology at the amino acid sequence level with its murine
counterpart (Ng et al., 2001). Given that FHL1C contains the RBP-J binding region, it
is likely that this isoform also interacts with RBP-J to repress the transcriptional activity
of RBP-J (Ng et al., 2001). SLIMMER/FHL1B contains the NH2-terminal three and a
half  LIM  domains   of  FHL1   followed   by    a  novel  C-terminal   96   amino   acids53
Figure 1.14. FHL1 Isoforms. (A). Splice variants of FHL1. Exons are represented
by open boxes. Splicing of the predominantly expressed FHL1  transcript is
indicated by a solid line. FHL1B which contains exon 4b, results in a translation
frameshift to generate a novel C-terminus that does not include the fourth LIM
domain but encodes a nuclear localisation signal, a nuclear export signal and an
RBP-J binding region and is represented by a solid blue line. FHL1C lacks exon 4
and 4b resulting in a frameshifted exon 5 to produce an RBP-J binding region and
is represented by a dashed line. (B). The human cDNAs encoding FHL1, FHL1B,
FHL1C and their corresponding translated proteins. Amino acid domains are
represented as follows; single zinc finger (Z), LIM Domains (LIM1-4), Nuclear
Localisation Signals (NLS), Nuclear export signal (NES), RBP-J binding region
(R).54
encompassing three putative bipartite nuclear localisation signals (NLS), a leucine rich
sequence consistent with a nuclear export sequence (NES) and 27 amino acids identical
to the RBP-J binding region of KyoT2 (Brown et al., 1999, Lee et al., 1999). The
localisation of SLIMMER to the nucleus of myoblasts and the cytoplasm of myotubes
suggests a role for this isoform in differentiation associated transcriptional regulation of
muscle cells (Brown et al., 1999).
1.4.3.2.2   Expression and Function
FHL1 was first identified as a 2.3kb transcript highly expressed in skeletal muscle, and
was later shown to be expressed in cardiac muscle and at relatively lower levels in a
range of tissues including prostate, testis, ovary, small and large intestine, placenta and
lung (Morgan et al., 1995, Greene et al., 1999). In the developing mouse embryo, Fhl1
is expressed specifically in the cardiac outflow tract of the heart and is subsequently
restricted to the aortic arch and atria in adult rabbit heart tissue (Brown et al., 1999).
The structural and regulatory roles played by FHL1 in the differentiation of human heart
muscle is further supported by microarray studies which suggest that FHL1 may play a
role in the pathogenesis of cardiomyopathy (Yang et al., 2000, Lim et al., 2001). Thus,
FHL1 expression was shown to be significantly reduced in patients with ischemic
dilated  cardiomyopathy  and  conversely,  increased  in  cases  of  human  congenital
hypertrophic cardiomyopathy (Yang et al., 2000, Lim et al., 2001). Intriguingly, the
localisation of FHL1 to human chromosome Xq27.2 may also provide evidence of the
important functional role played by FHL1 in the differentiation of the cardiac outflow
tract to form the aortic and pulmonary outflow tracts. Specifically, in the case of Turner
Syndrome (45, XO) in which females lack a complete or partial X chromosome, the
most common cardiac malformations are those involving aortic function (Lin et al.,
1998).
Despite increasing evidence that FHL1 has an important role in regulating skeletal and
cardiac muscle cytoskeleton, very few studies have addressed the intracellular location
and normal cellular function of FHL1. Studies by Brown et al., (1999) demonstrated
that FHL1 is predominantly expressed in the cytosol of skeletal muscle-derived Sol8
myocytes and localised to focal adhesions and actin cytoskeleton in COS-7 cells,55
suggesting  a  regulatory  role  in  cytoskeletal structure. More recently, studies by
McGrath et al., (2003) revealed that FHL1 demonstrates integrin-mediated localisation
in both the nucleus and within the cytoplasm, specifically at focal adhesions and stress
fibers within skeletal myoblasts, where it acts to regulate integrin-mediated cellular
functions.  Integrin  signalling  regulates  muscle  migration,  differentiation  and
proliferation, and it is postulated that FHL1 functions by inhibiting integrin-mediated
myoblast adhesion, to promote spreading and migration (McGrath et al., 2003).
Although a function for FHL1 in the regulation of integrin signals to the cytoskeleton is
apparent, the nuclear localisation of FHL1 suggests that it may also play a role in
transcriptional regulation, however there is no evidence to support this hypothesis to
date. The observation that both FHL1 isoforms, KyoT2/FHL1C and SLIMMER, harbour
a domain capable of binding the transcription factor RBP-J, however, strengthens the
notion that transcriptional regulation may be shared mechanism of action between the
three isoforms (Brown et al., 1999).
1.4.3.2.3 Relevance of FHL1 as a Target Gene of HOX11
In addition to ALDH1A1, FHL1 was also identified as a possible target for regulation by
HOX11, following cDNA RDA experiments to compare differential gene expression
profiles between NIH 3T3 cells and NIH 3T3 cells ectopically expressing HOX11
(Greene  et  al.,  1998).  Unlike  ALDH1A1 however, FHL1 was not consistently
upregulated by HOX11 in subsequent screening experiments of additional NIH 3T3
HOX11-expressing clones (activated in ~50%), suggesting that factors other than
HOX11 expression may be required for FHL1 upregulation (Greene et al., 1998). The
possibility that FHL1 may represent an oncogenically relevant target, is highlighted by
the fact that the LIM-only proteins, LMO1 and LMO2, are also implicated in T-cell
leukaemogenesis, and intriguingly, FHL1 was shown to be expressed in 7 of 12 T-ALL
cell lines examined by Northern blot (Greene et al., 1998). Moreover, FHL1 maps to the
long arm of chromosome Xq26, which is frequently amplified in B-cell neoplasms
(Werner et al., 1997). Further characterisation of the expression patterns and regulation
of FHL1  by  HOX11  is  necessary  to  investigate  the  potential  role  of  FHL1  in
haematopoietic malignancies.56
1.5 THESIS AIMS
The identification and characterisation of relevant target genes is crucial if we are to
completely understand the mechanism(s) by which nuclear oncogenes like HOX11
cause cellular transformation. Two such genes were identified as being transcriptionally
upregulated  by  HOX11  in  NIH  3T3  murine  fibroblasts,  namely  aldehyde
dehydrogenase 1a1 (Aldh1a1), which also appears to be physiologically regulated by
Hox11  in  the  developing  spleen,  and  four  and  a  half  LIM  domain  protein  1
(Fhl1)(Greene et al., 1998). Although HOX11 has been shown to modulate endogenous
ALDH1A1 expression in numerous cell types, the mechanism by which HOX11
regulates ALDH1A1 and FHL1 gene expression remains unclear. Thus, in order to
confirm the status of ALDH1A1 and FHL1 as transcriptional targets of HOX11, and to
investigate a possible link between these targets and leukaemogenesis, this study aimed
to:
(1) Assess the transcriptional response of the 5’ regulatory regions of ALDH1A1 and
FHL1 to HOX11.
(2) Investigate the regulatory elements/transcriptional complexes involved in the
response of ALDH1A1 to HOX11.
(3)  Determine  the  effect  of  overexpressing  ALDH1A1 and FHL1  on  murine
haematopoiesis, as a starting point to investigate whether either of these genes might
account for the tumorigenic potential of HOX11.57
Chapter 2
Assessment of ALDH1A1 as a Transcriptional Target of HOX11
2.1  INTRODUCTION
The ectopic expression of HOX11 in T-cell leukaemias bearing the t(10;14)(q24;q11) or
variant t(7;10)(q35;q24) translocations, is a significant contributory factor to the
progression of tumorigenesis (Kennedy et al., 1991). In its normal role, HOX11 is also
crucial for the development of the spleen (Roberts et al., 1994, Dear et al., 1995). The
identification and study of relevant target genes is therefore essential in order to
elucidate the mechanism(s) by which HOX11 induces tumour growth and controls
normal development. Two genes have been identified by Greene et al., (1998) as being
HOX11 dependent - Four and a half LIM domain protein 1 (Fhl1, formerly Slim1),
which encodes a LIM domain protein involved in muscle development and function
(Yang et al., 2000, Lim et al., 2001, Robinson et al., 2003) and Class 1 Aldehyde
Dehydrogenase (Aldh1a1),  which  appears  to  be  physiologically regulated in  the
developing spleen and codes for an enzyme responsible for the irreversible oxidation of
retinaldehyde to retinoic acid (RA)(Duester, 1996, Raner et al., 1996, Sladek, 2003).
RA is a key regulator of transcriptional pathways governing processes of cellular
proliferation, differentiation and apoptosis, thereby controlling various aspects of
vertebrate embryo patterning, organogenesis and haematopoiesis. It is therefore evident
that ALDH1A1, an enzyme regulating the balance of RA within the cell, fulfils a crucial
role in maintaining normal cellular processes. Thus, alterations affecting the expression
of ALDH1A1, and therefore the rate-limiting step in RA synthesis, may have adverse
effects on cellular development, as exemplified by studies in which the perturbation of
RA concentrations leads to homeotic transformations and morphological abnormalities
(Mavilio, 1993, Duester, 1996).
The human cytosolic ALDH1A1 gene is located on chromosome 9q21 and comprises 13
exons, spanning a region of approximately 53 kilobases (kb)(Hsu et al., 1989)(Figure
2.1). Primer extension analysis defined the transcription initiation start site (+1) to a
position 53 base pairs  (bp)  upstream  of  the  ATG  initiation codon, yielding a 2,116bp58
FIGURE 2.159
transcript (Hsu et al., 1989). Northern blot analysis of a panel of human tissues
demonstrated that a transcript of this size is highly expressed in liver and pancreas,
moderately expressed in skeletal muscle and kidney and expressed at low levels in the
brain,  heart  and  lung  (Yanagawa  et al., 1995). Preliminary studies attempting to
delineate cis-regulatory elements responsible for the tissue-specific gene expression of
ALDH1A1, were subsequently performed by Yanagawa et al., (1995), by analysing the
expression of nested deletions of a 2,536bp region of the ALDH1A1 promoter (pCAT-
2536/+42  to  pCAT-50/+42)  in ALDH1A1-expressing Hep3B cells. These studies
identified a minimal regulatory region (-91/+53bp) responsible for the cell type-specific
expression of ALDH1A1, containing several putative regulatory elements conserved
across human, marmoset, mouse and rat species, including a CCAAT box (-74/70bp),
Octamer sequence (-58/-51bp) and an ATAAA box (-32/-27bp). Further mutational
analysis and gel retardation assays revealed that the CCAAT box was the primary cis-
regulatory element required for basal promoter activity in Hep3B cells, possibly via
binding the nuclear factor NF-Y, whereas the non-canonical TATA box (ATAAA) did
not  appear  to  be  a  necessary  for  promoter  activation  (Yanagawa et al.,  1995).
Subsequent analysis of the ALDH1A1 promoter (pCAT-2536/+42) by Elizondo et al.,
(2000), revealed that RARα and the CCAAT/Enhancer-Binding Protein β (C/EBPβ)
stimulate ALDH1A1 reporter gene expression in the presence of endogenous levels of
RA in Hepa-1 mouse hepatoma cells through a Retinoic Acid Response-like Element
(-91/-75bp) and the previously identified CCAAT box (-74bp). Exogenously applied
RA was capable of inhibiting this activation, in a negative feedback mechanism to
control RA biosynthesis in Hepa-1 cells, possibly by decreasing cellular levels of
C/EBPβ.
Thus far, the regulatory effects of HOX11 on ALDH1A1  expression  have  been
examined in a number of cell types including developing spleen, NIH 3T3 fibroblasts,
the T-ALL cell line PER-117, the human erythroleukaemic cell line HEL and the
murine erythroleukaemic cell line J2E (Greene et al., 1998, Greene et al., 2002, Greene,
unpublished observations). Although HOX11 was consistently shown to upregulate the
expression of ALDH1A1 in NIH 3T3 and PER-117 cells, a significant downregulation
was observed in HEL cells and cells of the developing spleen, reflecting the ability of
HOX11 to act as both a positive and negative regulator of transcription, possibly as a60
result of differential interactions with cell-type specific cofactors (Pinsonneault et al.,
1997, Greene et al., 1998).
Despite the ability of HOX11 to affect ALDH1A1 expression in a variety of different
cell lines, screening of a panel of T-ALL cell lines failed to reveal a correlation between
HOX11 and ALDH1A1 expression levels (Greene et al., 1998). Thus, the significance of
ALDH1A1 as an oncogenically relevant target gene of HOX11 remains unclear. The
notion  that  HOX11  may  alter  retinoic  acid  synthesis  in  T-cell  tumorigenesis by
modulating  ALDH1A1 expression is given added intrigue by the observation that
ALDH1A2/RALDH2, a second enzyme involved in the irreversible conversion of
retinaldehyde to RA, is a target gene of a transcriptional complex involving SCL/LMO
and GATA-3 in leukaemic T-cells (Ono et al., 1998). Like HOX11, SCL (TAL1) and
LMO1/2 are transcription factors specifically implicated in childhood T-ALL. This
hints at a possibility that a common mechanism for  the development of T-ALL
involving disrupted retinoic synthesis may exist. However, regardless of whether the
regulation of ALDH1A1 by HOX11 is confined to normal developmental processes or
also  incorporates  pathways  leading  to  neoplastic  transformation,  delineating  the
molecular mechanism(s) by which HOX11 affects ALDH1A1 expression would greatly
add to our understanding of HOX11 function.
In  order  to  begin  to  elucidate  the  mechanism(s)  by  which  HOX11  affects  the
transcriptional activity of ALDH1A1, the effect of HOX11 was examined on a 2.2kb
region of the ALDH1A1 promoter in both an ALDH1A1-expressing (HEL900) and non-
expressing (PER-117) cell line. The specific aims of this chapter were 1) to perform
luciferase reporter assays to investigate the activity of the ALDH1A1 promoter and
delineate  any  HOX11-responsive  elements  and  2)  to analyse the transcriptional
complexes involved in any HOX11-mediated effect by electrophoretic mobility shift
assays.61
2.2 METHODS
2.2.1  pGL3Basic-ALDH1A1 Promoter Vector Construction
2.2.1.1  Preparation of pGL3Basic Luciferase Reporter Vector
The pGL3Basic luciferase reporter vector (4.8kb) lacks eukaryotic promoter and
enhancer sequences, allowing the cloning of putative regulatory sequences upstream of
the reporter gene (deWet et al., 1987)(Promega; Genbank
®/EMBL Accession Number:
U47295)(Appendix 2). The reporter gene is a modified coding region for the firefly
(Photinus pyralis) luciferase that has been optimised for monitoring transcriptional
activity in transfected eukaryotic cells. The vector contains the F1 origin of replication,
the SV40 late poly(A) signal and the ampicillin (Amp) gene as a selectable marker. The
pGL3Basic Luciferase Reporter Vector was prepared for sub-cloning by restriction
digestion of supercoiled, pGL3Basic plasmid DNA with Sac I/Nhe I and Sac I/Hind III
restriction endonucleases (Promega). Reactions were assembled in 1.5ml polypropylene
microcentrifuge tubes in a final volume of 100µl, comprising MULTICORE
TM Buffer
[1x](Promega),  0.1mg/ml  nuclease-free  acetylated  bovine  serum  albumin  (BSA)
(Promega), 2µg of supercoiled pGL3Basic plasmid DNA, and either 60U of Sac I/20U
of  Nhe  I  restriction  endonucleases  or  60U  of  Sac I/20U of Hind  III restriction
endonucleases for 3.5h at 37
oC. Following digestion, restriction endonucleases were
heat inactivated by incubation at 65
oC for 20min.
2.2.1.2 Agarose Gel Electrophoresis
The digested pGL3Basic plasmid vector was analysed by agarose gel electrophoresis on
0.6-1.5%  (w/v)  agarose  gels  containing  0.2µg/ml  ethidium  bromide  (Bio-Rad
Laboratories). Agarose gels were prepared in 1x Tris-Acetate-EDTA (TAE) Buffer
[50mM Tris-acetate (pH 8.0), 1mM EDTA (pH 8.0)] using RNase-DNase-free agarose
(Progene). DNA samples were combined with 5x Nucleic Acid Sample Loading Buffer
[1x;  10mM  Tris-HCl  (pH  8.0),  5%  (v/v)  glycerol,  1mM  EDTA,  0.04%  (w/v)
bromophenol  blue,  0.04%  (w/v)  Xylene  Cyanole  FF](Bio-Rad  Laboratories)
immediately prior to loading and electrophoresis was performed in 1x TAE buffer62
containing 0.1µg/ml ethidium bromide using a Mini-sub horizontal gel apparatus (Bio-
Rad Laboratories) at constant voltage (70-80V) for 1h. Following electrophoresis, DNA
was visualised using an ultraviolet UV transilluminator (Gel Doc 1000) and Molecular
Analyst software (Bio-Rad Laboratories). The concentration and molecular size of
electrophoresed  DNA  samples  was  estimated  by  direct  comparison  with  known
molecular weight standards, PhiX174/Hae III and/or Lambda/Hind III molecular weight
markers (Promega)[250ng/lane], which were electrophoresed in parallel with samples
being analysed.
2.2.1.3 Agarose Gel Purification of Digested DNA Fragments
Digested pGL3Basic vector DNA was gel purified using the Qiaex II Gel Purification
Kit  (Qiagen) according to the manufacturer’s instructions. DNA fragments were
resolved by agarose gel electrophoresis (Section 2.2.1.2) on a 1.3% (w/v) agarose gel.
The desired fragments were then excised from the gel using a sterile scalpel blade and
transferred to 1.5ml polypropylene microcentrifuge tubes (~300mg of gel/tube). In
order to recover the DNA, Buffer QX1 (3 volumes), dH20 (2 volumes) and QIAEX II
beads (15ul) were combined with the gel slices and incubated at 50
oC for 10min with
vortexing at regular intervals to aid solubilisation of agarose and binding of DNA to
QIAEX II beads. Following this, the QIAEX II beads were pelleted by centrifugation
(2,720 x g, 1min, room temperature)(PMC-060, Capsulefuge) and washed with 500µl
Buffer QXI (x1) and 500µl Buffer PE (x2). The pellet was air-dried and the DNA was
eluted in 50-100µl dH2O depending on the starting quantity of product by incubating at
room temperature for 10min. The QIAEX II beads were pelleted and the supernatant
containing DNA removed into a fresh tube and stored at -20
oC until required. DNA
concentration was estimated by electrophoresis of a sample of the purified DNA
fragment  on  a  1.3%  (w/v)  agarose  gel  (Section  2.2.1.2)  alongside  quantitative
PhiX174/Hae III molecular weight markers.
2.2.1.4  Generation of ALDH1A1 Promoter Fragments
For the construction of pGL3BasicALDH1A1P luciferase reporter constructs, nested
deletions of the ALDH1A1 proximal promoter ranging from -2159/-146bp to +42bp63
with respect to the transcription initiation start site (TSS) identified by Yanagawa et al.,
(1995), were generated by polymerase chain reaction (PCR) using ADPF-2159, -1968,
-978, -303, -201 and -146 forward primers, in conjunction with a common reverse
primer (ADPR+42)(Table 2.1). ADPF forward and ADPR+42 reverse primers contain
Sac I and Nhe I restriction endonuclease sites respectively, to enable cohesive ligation
into  the Sac I/Nhe I site of the pGL3Basic luciferase reporter vector (Table 2.1;
underline). The ALDH1A1P-91∆CAT deletion construct was generated using the
ADPF-91∆CAT forward primer, which contains a deletion of the CAAT box (-74/
-70bp) and the ADPR+42 reverse primer described above (Table 2.1). Fragments were
amplified  from  human  genomic  DNA  using  the  high  fidelity  DNA  polymerase
PfuTurbo
® (Stratagene). Reactions were performed in thin-walled, 0.5ml polypropylene
tubes in a final volume of 50µl comprising 10x Cloned Pfu Reaction Buffer [1x; 20mM
Tris-HCl (pH 8.8), 10mM KCl, 10mM (NH4)2SO4, 2mM MgSO4, 0.1% (v/v) Triton
® X-
100, 0.1mg/ml BSA](Stratagene), 0.2mM dNTPs (Fisher Biotech), 20pmol each of
forward and reverse primers, 530ng of human genomic DNA and 2.5U of PfuTurbo
®
DNA Polymerase (Stratagene). For fragments -2159/+42 and -1968/+42, samples were
denatured for 2min at 94
oC and then amplified by 10 cycles (94
oC for 10s, 60
oC for 30s
and 72
oC for 2min), with additional cycle extension times increasing by 20s up to 8:40s,
followed by a final extension of 72
oC for 7 min (EXTEND72; Appendix 1). For
fragments -978/+42, -303/+42 and -201/+42, samples were denatured for 3min at 95
oC
and then amplified by 30 cycles (95
oC for 40s, 60
oC for 40s and 72
oC for 3min), with a
final extension of 72
oC for 8min (KIM60; Appendix 1). All reactions were performed
using a PTC-100 (Programmable Thermal Controller-100; MJ Research Inc). PCR
products were analysed by agarose gel electrophoresis on 0.6-1.5% (w/v) agarose gels
as described in Section 2.2.1.2. ALDH1A1P promoter fragments were subsequently gel
purified as described in Section 2.2.1.3.
For  the  generation  of  pGL3BasicALDH1A1P-91/+42, the pGL2BasicALDH1A1P-
91/+42  vector  was  digested  with  Sac  I  and  Hind  III restriction endonucleases
(Promega), to facilitate sub-cloning of the ALDH1A1P-91/+42 promoter fragment into
the Sac I/Hind III site of the pGL3Basic vector. Digestion reactions were performed in
1.5ml polypropylene microcentrifuge tubes in a final volume of 50µl comprising 10x
MULTICORE
TM  Reaction Buffer  [1x;  25mM  Tris acetate  (pH  7.8),  0.1M potassium64
TABLE 2.165
acetate,  10mM  magnesium  acetate,  1mM  DTT](Promega),  20µg  of
pGL2BasicALDH1A1P-91/+42 plasmid DNA, 0.1mg/ml nuclease-free acetylated BSA
(Promega), 60U of Sac I restriction endonuclease and 20U of Hind III restriction
endonuclease  and  incubated  at  37
oC  for  3h.  Restriction  endonucleases  were
subsequently heat inactivated by incubation at 65
oC for 20min. The ALDH1A1P-91/+42
promoter fragment was subsequently gel purified as described in Section 2.2.1.3 and
stored at -20
oC prior to ligation.
ALDH1A1P-50/+42, -36/+42 and +1/+42 promoter inserts were generated by annealing
complementary oligonucleotides encompassing the promoter region of interest (Table
2.1).  Antisense (AS) oligonucleotides were synthesised with Sac I/Nhe I overhangs to
facilitate cohesive ligation into the pGL3Basic luciferase reporter vector. Equimolar
quantities of sense (S) and antisense DNA strands were combined in thin-walled, 0.5ml
polypropylene microcentrifuge tubes and annealed in TES Buffer [1x; 10mM Tris-HCl
(pH 7.4), 50mM NaCl, 1mM EDTA] by heating to 90
oC for 5min and cooling to 22
oC at
a rate of 1
oC/min in a PTC-100 thermocycler and stored at -20
oC prior to ligation.
2.2.1.5  Restriction Digestion and Purification of Purified ALDH1A1 Promoter
PCR Products
Gel purified ALDH1A1P DNA fragments generated in Section 2.2.1.4 were prepared for
sub-cloning into the pGL3Basic luciferase reporter vector by digestion with Sac I and
Nhe I  restriction  endonucleases  (Promega).  Reactions  were  assembled  in  1.5ml
polypropylene microcentrifuge tubes in a final volume of 100µl, comprising 10x
MULTICORE
TM Reaction Buffer [1x](Promega), 0.1mg/ml nuclease-free acetylated
BSA  (Promega),  50µl  of  gel  purified  DNA  fragment,  60U  of  Sac  I restriction
endonuclease and 20U of Nhe I restriction endonuclease for ~16h at 37
oC to ensure
complete digestion. Restriction endonucleases were subsequently heat inactivated by
incubation at 65
oC for 20min. Digested fragments were subsequently purified from
unwanted  digestion  products,  polymerases  and  salts  using  the  QIAquick  PCR
Purification Kit (Qiagen) according to the manufacturer’s instructions. In order to purify
the DNA, Buffer PB (5 volumes) was combined with the digestion reaction (1 volume)
in a 1.5ml polypropylene microcentrifuge tube and the sample was applied to the66
QIAquick spin column and centrifuged at 10,000 x g for 1min at room temperature
(Biofuge Pico, Heraeus Instruments). The flow-through was discarded and the column
was washed by applying 750µl Buffer PE to the column and centrifuging at 10,000 x g
for 1min at room temperature. The flow-through was discarded and the column was re-
centrifuged (10,000 x g, 1min, room temperature) to remove traces of residual ethanol.
The DNA was then eluted in a fresh 1.5ml polypropylene microcentrifuge tube by
applying  50µl  sterile  dH20  to  the  column,  incubating  for  1min,  followed  by
centrifugation (10,000 x g, 1min, room temperature) and stored at -20
oC. An aliquot of
the purified insert was then electrophoresed on a 1.3% (w/v) agarose gel (Section
2.2.1.2) to estimate DNA integrity and concentration prior to ligation.
2.2.1.6. Ligation of Promoter Fragments into pGL3Basic Luciferase Reporter Vector
Ligation reactions were typically performed in a 20µl reaction volume comprising a
linearised plasmid to insert molar ratio of 3:1. Thus, for a ligation reaction using 40ng
pGL3Basic vector plasmid, the following equation was utilised to determine the amount
of insert DNA required to achieve the required molar ratio;
Insert (ng): Insert size (bp)/Plasmid size (bp) x 120
Ligation reactions were performed in 0.5ml polypropylene microcentrifuge tubes and
comprised 40ng of linearised pGL3Basic vector DNA, insert DNA [3:1 molar ratio],
10x T4 DNA Ligase Buffer [1x; 30mM Tris-HCl (pH 7.8), 10mM MgCl2, 10mM DTT,
1mM ATP](Promega), 6U of T4 DNA Ligase (Promega) and incubated at 15
oC for 16-
24h. Mock ligations replacing insert DNA with dH20 were also performed in parallel to
assess background levels due to incomplete vector digestion or re-circularisation.
2.2.1.7 Preparation of Competent Cells
All recombinant cloning procedures were performed using the Escherichia coli (E. coli)
strain dDH5α-T1
R  [F
-Ø80LacZ∆M15∆ (lacZYA-argF)  U169  deoR recA1 endA1
hsdR17  (rk
-,  mk
+) phoA  supE44  thi-1  gyrA96  relA1 tonA](Invitrogen  Life
Technologies). Chemically competent DH5α-T1
R cells were prepared using the calcium67
chloride method as described in Sambrook and Russell (2001). In brief, a single
bacterial colony from a freshly streaked Luria-Bertani (LB) agar plate [1% (w/v)
tryptone, 0.5% (w/v) yeast extract, 1% (w/v) NaCl, 1.5% (w/v) agar] was inoculated
into a 50ml polypropylene tube containing 5ml of 2YT media [1.6% (w/v) tryptone,
1.0% (w/v) yeast extract, 0.5% (w/v) NaCl] and incubated for ~16h at 37
oC with
vigorous shaking (225rpm). The starter culture was subsequently diluted (1:100) in
fresh 2YT media and cultured to mid-logarithmic phase (Optical Density (O.D) ~ 0.45-
0.55) at 37
oC with vigorous shaking (225rpm; ~2-3h). The cells were transferred to a
50ml polypropylene tube and recovered by centrifugation (820 x g, 10min, 4
oC)(IEC
Centra GP8R). The cells were then resuspended in 50ml of ice cold 100mM CaCl2 and
incubated on ice for 20min. Following centrifugation (460 x g, 10min, 4
oC), the cells
were  resuspended  in  10ml  ice-cold  100mM  CaCl2  and  15%  (v/v)  glycerol.  The
competent cells were dispensed in 240µl aliquots in 1.5ml polypropylene tubes, snap
frozen in liquid N2 and stored at -80
oC.
2.2.1.8 Bacterial Transformations
Ligation reactions were transformed into chemically competent DH5α E. coli prepared
in Section 2.2.1.7.  To transform recombinant plasmid DNA, pre-aliquoted competent
cells (240µl) were thawed on ice and gently mixed with ligation or mock ligation
reactions (5-10µl). Transformation reactions were incubated on ice for 1h, followed by
heat shock at 42
oC for 90s and immediately placed on ice for a further 2min. To
facilitate the growth of transformed bacteria, 300µl of pre-warmed 2YT growth media
was added to the cells, which were then incubated at 37
oC for 30min. A sample of the
recombinant culture was spread onto LB agar plates containing 0.1mg/ml ampicillin
(Austrapen
®)(125µl, 375µl/plate) and the bacterial colonies were incubated at 37
oC for
16-20h to allow growth of the transformant bacterial colonies. Plates were stored at 4
oC
for up to 1 month.
2.2.1.9 Small Scale Plasmid Purification
Plasmid Mini-Preps of selected colonies were prepared for restriction digest analysis
and sequencing using the GenElute
TM Plasmid Miniprep Kit (Sigma) according to the68
manufacturer’s  specifications.  In  brief,  randomly  selected  colonies  were  used  to
inoculate 5ml of 2YT media containing 0.1mg/ml ampicillin and grown with vigorous
shaking (225rpm) for 16h. Cells were harvested (2ml) by centrifugation (13,000 x g,
1min, room temperature)(Biofuge Pico, Heraeus Instruments) and the supernatant was
removed using a pipette. The bacterial pellet was then completely homogenised in
200µl Resuspension Solution and the cells were lysed by adding 200µl Lysis Solution.
The tubes were inverted gently between 8-10 times to ensure complete mixing and
incubated at room temperature for 5min. The reaction was then neutralised by the
addition of 350µl Neutralisation Buffer and the tubes inverted gently between 4-6 times.
The lysate was subsequently cleared of bacterial debris by centrifugation (13,000 x g,
10min, room temperature) and loaded onto a pre-assembled GenElute
TM Miniprep
binding column. Following centrifugation (13,000 x g, 1min, room temperature), the
flow through liquid was discarded and the column was washed with 750µl Wash
Solution. The flow through liquid was discarded and the column was centrifuged for an
additional 2min (13,000 x g, room temperature) to remove residual ethanol. The
GenElute
TM Miniprep binding column was then transferred to a fresh collection tube and
the DNA was eluted by applying 100µl of sterile dH20 to the column followed by
centrifugation (13,000 x g, 1min, room temperature).
2.2.1.10  Screening Recombinant Colonies for the Presence of Promoter Inserts
Cloning  verification  was  performed  by  screening  small-scale  DNA  preparations
generated in Section 2.2.1.9 (between 10-20/construct) by restriction digest analysis; the
number of colonies screened depending upon the level of background as indicated by
comparing colony numbers on test versus mock ligation plates. Restriction digests were
performed in 1.5ml polypropylene microcentrifuge tubes in a final volume of 30µl
comprising MULTICORE
TM  Restriction  Buffer  [1x](Promega),  1µg  of  plasmid
miniprep DNA, 0.1mg/ml nuclease-free acetylated BSA (Promega), and either 60U of
Sac I/20U of Nhe I restriction endonucleases (Promega) or 60U of Sac I/20U of Hind III
restriction endonucleases (Promega) for 1.5h at 37
oC. The products of digestion were
electrophoresed on a 1.3% (w/v) agarose gel (Section 2.2.1.2) and preparations positive
for an insert of the correct size were sequenced verified.69
2.2.1.11 DNA Sequencing
All DNA sequencing was performed by the DNA Sequence Service located at Royal
Perth Hospital (RPH), on a fully automated ABI PRISM
TM 310 Genetic Analyzer (PE
Applied Biosystems) using the ABI PRISM
TM Big Dye
TM Version 3.1 Terminator Cycle
Sequencing Ready Reaction Kit (PE Applied Biosystems). The ABI PRISM
TM system is
based on a modified dideoxy method of DNA sequencing in which a complementary
primer is annealed to the DNA template of interest and temperature cycling is used to
generate a fluorescently labelled complementary cDNA strand by random incorporation
of deoxynucleotide triphosphates (dNTPs) and fluorescently labelled dideoxynucleotide
triphosphates  (ddNTPs).  These  ddNTPs  lack  the  3’-hydroxyl  group  required  for
phosphodiester bond formation during strand elongation by DNA Polymerase I, such
that incorporation of a ddNTP into the growing strand results in the termination of
complementary  strand  synthesis.  Sequence  verification  was  performed  using
GL3For/GL3Rev primers flanking the multiple cloning site of the pGL3Basic luciferase
reporter vector (Table 2.1).
Analysis of raw sequence data was performed using SeqEdT
M (V1.0.3) sequence
analysis software from PE Applied Biosystems (Australia). Comparative genome
database (NCBI GenBank; http://www.ncbi.nlm.nih.gov) and sequence alignment
analyses  were  performed  using  SeqEd
TM  and  Clustal  Alignment  programmes
(http://www.ebi.ac.uk/clustalw/).
2.2.1.12 Large Scale Purification of Plasmid DNA
Large scale preparations of highly purified, supercoiled plasmid DNA were isolated
using the QIAGEN
 Plasmid Midi/Mega Kits (Qiagen) which are based on a modified
alkaline lysis procedure, followed by the binding of plasmid DNA to QIAGEN Anion-
Exchange Resin (via gravity flow) under low salt and pH conditions. Following the
removal of RNA, proteins, dyes and other impurities by a medium salt wash, high
quality plasmid DNA is recovered by elution with a high salt buffer and concentrated
and desalted by isopropanol precipitation (Qiagen, 2000). Recombinant bacterial
cultures were propagated for plasmid purification by inoculating a 5ml starter culture in70
2YT media containing 0.1mg/ml ampicillin from a freshly streaked selective LB agar
plate and incubating at 37
oC for ~8h with vigorous shaking (225rpm). Starter cultures
were then diluted 1:500 in 2YTA media and grown for a further 12-16h at 37
oC with
vigorous shaking (225rpm). Bacterial cells were harvested from late log-phase cultures
in 35ml/500ml polypropylene microcentrifuge tubes (30ml, 200ml) by centrifugation at
6000 x g for 15min at 4
oC (AvantiTM J-25I Centrifuge, Beckman, JA-25-50, JA-14)
and all traces of culture medium were removed. Pelleted cells were resuspended in
Buffer P1 [50mM Tris.Cl (pH 8.0), 10mM EDTA, 100ug/ml RNase A](4ml, 25ml) and
subsequently lysed with the addition of Buffer P2 (4ml, 25ml) [200mM NaOH, 1%
(w/v) SDS] and the reaction was allowed to proceed at room temperature for 5min. The
lysis reaction was then neutralized with Buffer P3 (4ml, 25ml)[3.0M potassium acetate
(pH 5.5)] and incubated on ice for 30min to enhance the precipitation of from the DNA.
Following this incubation, the reaction was gently mixed and the lysate was cleared of
bacterial debris by centrifugation at 20,000 x g for 30min at 4
oC (JA-25-50, JA-14). The
supernatant was removed to a fresh tube and re-centrifuged at 20,000 x g for 15min at
4
oC to ensure removal of all particulate debris and immediately applied to a QIA-tip
column  equilibrated  with  Buffer  QBT  (4ml,  35ml)[750mM  NaCl,  50mM  3-[N-
morpholino] propanesulfonic acid (MOPS)(pH 7.0), 15% (v/v) isopropanol, 0.15% (v/v)
Triton
®X-100].  The  column  was  then  washed  with  Buffer  QC  (2  x  10ml,  2  x
100ml)[1.0M NaCl, 50mM MOPS (pH 7.0), 15% (v/v) isopropanol] to remove unbound
contaminants  and  the  purified  plasmid  DNA  eluted  with  Buffer  QF  (5ml,
17.5ml)[1.25M NaCl, 50mM Tris.Cl (pH 8.5), 12% (v/v) isopropanol]. Plasmid DNA
was then precipitated by the addition of 0.7 volumes of isopropanol and pelleted by
centrifugation in 2ml/35ml polypropylene microcentrifuge tubes at 15,000 x g for
30min at 4
oC. The recovered DNA was then washed with 70% (v/v) ethanol, air dried
under sterile conditions and resuspended in sterile dH20 (120µl, 1ml).
 2.2.1.13 Standardisation of Plasmid DNA for Transient Transfection Experiments
In order to standardise the quality of DNA prepared in Section 2.2.1.12, which was to
be used in transfection experiments (Section 2.2.1.3.1), all DNA preparations were re-
precipitated according to Sambrook and Russell (2001). In brief, DNA samples were
combined in a 1.5ml polypropylene microcentrifuge tube with 0.1 volumes of 3M NaAc71
(pH 5.2) and 2 volumes of ice-cold ethanol. The samples were mixed thoroughly and
incubated at -20
oC for 2h to enhance DNA precipitation. The DNA was then recovered
by centrifugation at 12,000 x g for 15min at 4
oC (Sigma 1-15 centrifuge) and the pellets
were washed with 1ml of 70% (v/v) ethanol. The supernatant was removed under sterile
conditions and the pellets were air-dried and resuspended in sterile dH20 (250µl/pellet).
2.2.1.14 DNA Analysis Using UV Spectrophotometry
All plasmid DNA preparations used in transient transfection experiments were routinely
checked for concentration and purity using a combination of UV spectrophotometry and
agarose gel electrophoresis. DNA samples in solution were diluted 1/80 to a final
volume  of  160µl  in  dH20.  The  spectrophotometer  (Shimadzu  UV  Mini  1240
Spectrophotometer) was blanked with a 160µl aliquot of the sample diluent. Ultraviolet
light absorbance of the diluted DNA sample was then determined at 260nm and 280nm
wavelengths, and DNA concentration and purity was determined using the calculations
described below.
      where (1 O.D unit = 50µg/ml of double stranded DNA)
2.2.1.15 DNA Analysis by Restriction Digestion
DNA samples were qualitatively analysed by restriction endonuclease digestion prior to
use in transfections. The applicable DNA sample (1-2µg) was digested in a final volume
of 30µl comprising 10x MULTICORE
TM Restriction Buffer [1x](Promega), 0.1mg/ml
nuclease-free acetylated BSA (Promega), either 20U of Sac I/20U of Nhe I restriction
endonucleases or 20U of Sac I/20U of Hind III restriction endonucleases at 37
oC for 2-
DNA Concentration [mg/ml]: O.D260nm x dilution factor x 50
DNA Purity: O.D260nm/O.D280nm72
4h or overnight (~16h). The products of digestion were subsequently analysed by
agarose gel electrophoresis on a 1.3% (w/v) agarose gel (Section 2.2.1.2).
2.2.2 Cell Culture
All cultured cell lines (summarised in Table 2.2) were provided by Dr Ursula Kees,
Division of Children’s Leukaemia and Cancer Research (CLCR) of the TVW Telethon
Institute  for  Child  Health  Research,  Western  Australia  and  were  shown  to  be
Mycoplasma-free at the level of PCR (performed by Jette Ford at the Division of
CLCR). Cells were typically cultured in 75cm
2 filter-top culture flasks (NUNC
TM) and
maintained in appropriate complete growth media at 37
oC with 5% CO2.
Cell Line Phenotype HOX11
Translocation
HOX11
Expression
Reference
HEL900 Foetal
Erythroleukaemia
- - Martin &
Papayannopoulo
1982
PER-117 T-ALL - - Kees et al.,
1987
NIH 3T3 Murine
embryonic
fibroblast
- - Jainchill et al.,
1969
Table  2.2.  Parental  Mammalian  Cell  Lines  Utilised  in  Transient  Luciferase
Reporter Analysis of the ALDH1A1 Promoter.
2.2.2.1 HEL-900 Cell Lines
HEL-900 (HEL) is a human erythroleukaemic cell line (Martin & Papayannopoulo,
1982). Cells were subcultured twice weekly (1:10) in RPMI-1640 Multi-cel Medium
(Trace) supplemented with 10% (v/v) foetal calf serum (FCS), 2mM L-glutamine
(Trace) and 50µg/ml of pencilllin/streptomycin (Trace). Clones HEL[1] and HEL-
HOX11[4]  were generated by stable transfection of the parent HEL-900 cell line with
the empty pEFBOS and pEFBOS-HOX11 plasmid constructs, respectively. Cells were
subcultured twice weekly (1:10) as per the parental cell line except that puromycin73
[1µg/ml](Trace) was also included in the growth media to maintain selection for stable
transfectants.
2.2.2.2 PER-117 Cell Lines
PER-117 is a human, childhood T-ALL cell line bearing markers of a T-cell precursor
phenotype (Kees et al., 1987). Cells were subcultured twice weekly (1:5) in RPMI-1640
Multi-cel Medium supplemented with 10% (v/v) FCS, 2mM L-glutamine, 50µg/ml of
pencilllin/streptomycin, 2mM non-essential amino acids (Trace) and 2mM pyruvate
(Trace).  Clones  PER-117[1]  and  PER-117HOX11[11]  were  generated  by  stable
transfection of the parent PER-117 cell line with the empty pEFBOS and pEFBOS-
HOX11 plasmid constructs respectively. Cells were subcultured twice weekly (1:5) in
RPMI-1640 Multi-cel Medium supplemented with 20% (v/v) FCS, 2mM L-glutamine,
50ug/ml of pencilllin/streptomycin, 2mM non-essential amino acids and 2mM pyruvate.
Puromycin [0.2µg/ml] was also included in the growth media to maintain selection for
stable transfectants.
2.2.2.3 The NIH 3T3 Cell Line
NIH 3T3 is an adherent, murine fibroblast cell line established from NIH Swiss mouse
embryo cultures (Jainchill et al., 1969). Cells were subcultured twice weekly (1:10) in
Dulbecco’s Modified Medium (DMEM) supplemented with 10% (v/v) FCS, 2mM L-
glutamine and 50µg/ml of penicillin/streptomycin. To passage cells, medium was
removed and the cells were trypsinised with a 0.05% (v/v) Trypsin/0.53mM EDTA
solution (Trace) until cells detached from flask surface. Trypsinisation was then
quenched using an equal amount of complete DMEM medium and the cells were
repeatedly aspirated to achieve a single cell suspension and sub-cultured into fresh
complete DMEM medium.
 
2.2.2.4 Cryopreservation of Mammalian Cell Lines
Mammalian  haematopoietic  cell  lines  were  maintained  in  long-term  storage  by
cryopreservation. Cells were cultured to mid-log phase (4-6 x 10
5 cells/ml) in complete74
growth medium and recovered by centrifugation in 50ml polypropylene tubes at 453 x g
for  5min  at  room  temperature  (Eppendorf  5810).  Cells  were  resuspended  at
approximately 5 x 10
6 cells/ml in freshly prepared cryopreservation medium [90% (v/v)
FCS, 10% (v/v) Dimethyl Sulfoxide (DMSO)] and 1ml aliquots were dispensed into
1.5ml polypropylene cryovials (NALGENE Cryoware). Cryovials were cooled for >24h
at -80
oC in a polystyrene container and subsequently transferred into liquid nitrogen for
long-term storage. To re-establish cryopreserved cell cultures, a vial of stock culture
was thawed rapidly in a 37
oC waterbath and the cells were transferred to pre-warmed
complete growth media (10ml) in a 50ml polypropylene tube and washed with complete
growth  media  to  remove  traces  of  DMSO.  The  cells  were  then  recovered  by
centrifugation at 290 x g for 5min at room temperature, resuspended in complete growth
media [suspension cell lines (5ml); adherent cells lines (10ml)] and transferred to a
25cm
2 filter top culture flask (NUNC
TM). Cells were incubated at 37
oC, 5% CO2 and
expanded upon reaching confluence.
2.2.3 Luciferase Assays
2.2.3.1 Transient Transfection of HEL and PER-117 Cell Lines
The conditions employed for transfection of HEL and PER-117 cell lines were as
previously determined (Brake, 1998). Cells were cultured to mid-logarithmic stage (~ 4-
5 x 10
5 cells/ml). Each transfection used 1 x 10
7 cells, which were washed (x2) in 5ml of
RPMI only prior to transfection and resuspended in 365µl of the same solution. Cells
were electroporated in a 0.4cm gap electroporation cuvette (Bio-Rad Laboratories) with
15µg of test luciferase reporter plasmid and 5µg of control pSV-β-Galactosidase
plasmid using the Gene Pulser System (Bio-Rad Laboratories) set at 300V, 960µF
capacitance.  Post-electroporation,  cells  were  immediately  resuspended  in  7ml  of
complete RPMI-1640 Multi-cel Medium and incubated in a humidified atmosphere at
37
oC in 5% CO2. Cells were then harvested approximately 22h post-transfection for
analysis of HOX11 expression (Section 2.2.1.3.3) or for luciferase/β-Galactosidase
assays (Section 2.2.1.3.6) as required.75
2.2.3.2 Transient Transfection of NIH 3T3 Cells
FuGENE  6  Transfection  Reagent  (Roche)  is  a  multi-component,  lipid-based
transfection reagent that complexes with and transports DNA into the cell to efficiently
transfect a wide variety of cell types. In order to achieve a cell monolayer of 50-80%
confluency on the day of transfection, approximately 2x10
5 cells/well were seeded in a
final volume of 2ml of complete DMEM Multi-cel Medium in 6-well plates (35mm
diameter)(NUNC
TM)  and  incubated  for  24h  at  37
oC,  5%  C02. Transfections were
performed based on a FUGENE 6 reagent (µl):DNA (µg) ratio of 3:1 by combining
93µl serum free DMEM medium only, with 7µl of FuGENE 6 Reagent in a sterile
1.5ml polypropylene tube. DNA solutions containing luciferase plasmid reporter and
pSV-β-Galactosidase internal control constructs (2.3µg total) were then added to the
pre-diluted FuGENE 6 reagent and the solution was incubated for 15min at room
temperature. The complex mixture was then added dropwise to the cells and the plates
were swirled to ensure even dispersal. Cells were incubated for 24h at 37
oC, 5% C02
and harvested for luciferase assays as outlined in Section 2.2.1.3.6.
2.2.3.3 Western Blotting
2.2.3.3.1  Preparation of Nuclear Cell Extracts
Nuclear extracts were prepared as outlined by Schreiber et al., (1989). Cells were
harvested at mid-log phase (approximately 5 x 10
5 cells/ml). Approximately 1 x 10
7
cells were collected by centrifugation in 50ml polypropylene tubes at 820 x g for 5min
at room temperature (Centra GP8R, IEC). The cells were washed once with 10ml of
cold Phosphate Buffered Saline (PBS) and resuspended in 1ml PBS. The cells were then
transferred to 1.5ml polypropylene microcentrifuge tubes and pelleted at 17,900 x g for
30s at 4
oC (Eppendorf Centrifuge 5417C, Crown Scientific). Following the removal of
PBS, the pellet was resuspended in 400µl of Buffer A [10mM Hepes pH 7.9, 10mM
KCl, 0.1mM EDTA, 0.1mM EGTA; supplemented with freshly added proteinase
inhibitors 0.5mM DTT, 1µg/ml aprotinin, 1µg/ml leupeptinin, 0.5mM PMSF, NaVO4]
by gentle pipetting, and allowed to swell on ice for 30min. Cells were then lysed by
brief vortexing following the addition of 0.5% (v/v) Nonident-40 (NP-40) detergent.76
The cells were pelleted by centrifugation at 17,900 x g for 1min at 4
oC and supernatants
were completely removed. The cell pellet was immediately resuspended in 100µl (25µl
for Western Blot analysis) of cold Buffer C [20mM Hepes (pH 7.9), 0.42M NaCl, 1mM
EDTA, 1mM EGTA, 20% (v/v) glycerol, containing freshly added proteinase inhibitors
0.5mM DTT, 1µg/ml aprotinin, 1µg/ml leupeptinin, 0.5mM PMSF, NaVO4] and nuclear
proteins were extracted by vigorous shaking for 30min at 4
oC. Cell debris was pelleted
by centrifugation at 17,900 x g for 5min at 4
oC and the supernatants were removed,
pooled  and  aliquoted  into  single  use  volumes  (20-40ul)  in  0.5ml  polypropylene
microcentrifuge tubes on ice. Nuclear extracts were snap frozen in liquid nitrogen and
stored at -80
oC.
2.2.3.3.2 Determination of Nuclear Protein Extract Concentration
Nuclear protein concentration was determined using the Bio-Rad DC Protein Assay Kit
(Bio-Rad Laboratories) according to the Microplate Protocol. A standard curve within
the range (0.2mg/ml-1.44mg/ml) was generated using the BSA provided. Nuclear
extract concentrations were determined by performing the protein assay over a range of
dilutions (neat, 1/3, 1/5 and 1/6). Both standards and tests were prepared using Buffer C
(protein extraction solution, see Section 2.2.3.3.1) as the diluent. In brief, a 5µl aliquot
of sample (BSA standards, nuclear extracts, Buffer C blank) was applied in duplicate to
the  wells  of  a  transparent  96-U  shaped  well  microtitration  multiwell  plate
(Linbro
®/Titretek
®, ICN Biomedical). 25µl of Reagent A’ was then added to each well,
followed by the addition of 200µl of Reagent B. Upon addition of reagents, the
microplate was gently agitated and incubated at room temperature for 15min. The
protein content of each sample was determined by measurement of absorbance at
655nm  (A655nm)  using  a  Bio-Rad  Model  3550-UV  microplate  reader  (Bio-Rad
Laboratories).  The mean absorbance values for the BSA standards were then used to
generate a standard curve from which the total protein content of each nuclear extract
was calculated.77
2.2.3.3.3 Analysis of HOX11 Expression by Western Blotting
Nuclear extracts of pEFBOSHOX11-transfected cells [~1x10
7 cells in 20µl]  were
combined with 2x SDS loading dye [1x; 31.25mM Tris (pH 6.8), 12.5% (v/v) glycerol,
1% (w/v) SDS, 0.005% (w/v) bromophenol blue, 2.5% (v/v) β-mercaptoethanol] in
1.5ml screwcap polypropylene microcentrifuge tubes and proteins were denatured by
boiling samples for 5min at 100
oC and placed on ice. Biotinylated molecular weight
markers (MWM)(Bio-Rad Laboratories) were prepared by combining 1µl MWM with
5x SDS loading dye [1x] in a final volume of 45µl and heating at 100
oC for 5min.
Prestained low range MWM (Bio-Rad Laboratories) were thawed and heated to 60
oC.
Samples  were  then  resolved  by  SDS-Polyacrylamide  Gel  Electrophoresis  (SDS-
PAGE)[loading order; biotinylated MWM (10µl), prestained MWM (5µl), nuclear
extract samples (40µl], in 5x TANK buffer (pH 8.3)[1x; 3g/L Tris, 14.4g/L glycine,
1g/L SDS] on a 12% polyacrylamide gel run at 180V for 1h.
SDS-PAGE was performed using the Mini-PROTEAN 3 Cell and 10.1 x 7.3/8.2cm
glass plates separated by 0.75mm spacers (Bio-Rad Laboratories). To prepare the 12%
(v/v) resolving gel, 3.2ml of 30% acrylamide solution (37.5:1)(Bio-Rad Laboratories)
was combined with 2ml of Lower Gel Buffer (pH 8.8)[1.5M Tris, 0.4% SDS (w/v)] and
2.8ml dH20. Gel polymerisation was initiated by the addition of 25µl of 10% APS
(w/v)(Univar Laboratories) and 10µl of TEMED (Bio-Rad Laboratories) immediately
prior to pouring. Resolving gels were poured to approximately 0.5cm below the inserted
comb, gently overlaid with 20% (v/v) ethanol in 1 x TANK Buffer and allowed to set
for 1h at room temperature. To prepare the 4.5% stacking gel, 440µl of 30% acrylamide
solution (37.5:1) was combined with 780µl of Upper Gel Buffer (pH 6.8)[0.5M Tris,
0.4% (w/v) SDS] and 1.78ml dH20. The stacking gel was polymerised by adding 25µl
of 10% (w/v) APS and 5µl of TEMED, then layered over the resolving gel and allowed
to set for 1h at room temperature.
Following  SDS-PAGE,  proteins  were  transferred  to  Hybond  ECL  membrane
(Amersham  Biosciences)  using  a  Trans-Blot
®  Semi-Dry  Transfer  Cell  (Bio-Rad
Laboratories). The gel sandwich was disassembled and the stacking gel was removed
using a scalpel blade. The resolving gel and nitrocellulose membrane were then78
equilibrated in Towbin transfer buffer (pH 8.3)[25mM Tris, 192mM glycine, 20% (v/v)
methanol] and the transfer was assembled by applying Whatman
® 3MM filter paper
(Whatman)(3 sheets pre-wetted in Towbin transfer buffer), nitrocellulose membrane,
polyacrylamide gel and Whatman
® 3MM filter paper (3 sheets pre-wetted in Towbin
transfer buffer). Transfer was performed at 15V for 30min and the membrane was
divided through the pre-stained MWM lane to facilitate incubation of nuclear extracts
and biotinylated MWM with appropriate antibodies. Membranes were then blocked for
1h at room temperature in 1x TBS-Tween buffer [1mM Tris, 7.5mM NaCl, 0.05% (v/v)
Tween-20] containing 3.5% (w/v) gelatin, with gentle rocking.
2.2.3.3.4  Detection of HOX11 Protein
For the detection of transfected HOX11 proteins, the blocked membrane was washed (3
x 5min) in 1x TBS-Tween buffer and incubated with 1
o anti-human HOX11 monoclonal
antibody (from mouse)(Santa Cruz Biotechnology) diluted 1:1200 in 1xTBS Buffer
containing 0.1% (v/v) Tween-20 and 0.5% (w/v) gelatin, for 1.5h at room temperature
with gentle agitation. The membrane was washed (3 x 5min) in 1x TBS-Tween buffer
and  incubated  with  2
o anti-rabbit-IgG, peroxidase-linked species-specific antibody
(from donkey)(Amersham Pharmacia Biotech), diluted 1:5000 in 1x TBS Buffer
containing 0.1% (v/v) Tween-20 and 0.5% (w/v) gelatin, for 1h at room temperature
with gentle agitation. The membrane containing the biotinylated protein MWM was
washed (3 x 5min) in 1x TBS-Tween buffer and incubated with streptavidin-horse
radish peroxidase (SA-HRP)(Amersham Pharmacia Biotech), diluted 1:2000 in 1x TBS
Buffer containing 0.1% (v/v) Tween-20 and 0.5% (w/v) gelatin, for 1.5h at room
temperature with gentle agitation. The membranes were then washed (3 x 5min) in 1x
TBS-Tween buffer and ECL detection was performed by incubating with 5ml/10cm
2 of
ECL substrate solution (Amersham Pharmacia Biotech) for 1min at room temperature.
The  membranes  containing  biotinylated  MWM  and  nuclear  extracts  were  then
reassembled in Saran wrap and exposed to ECL Hyperfilm (Amersham Pharmacia
Biotech) for 10s-2min, depending on the intensity of signal required and the film was
developed using an SPM 300 developer (Fuji).79
2.2.3.4  Luciferase and β-Galactosidase Reporter Gene Assays
The Tropix
® Dual-Light
® System (Applied Biosystems) employed for these assays, is a
chemiluminescent reporter gene assay system, which allows for the sequential detection
of  luciferase  and β-Galactosidase within the same sample volume. Harvesting of
transformed cells was performed as recommended by the manufacturer’s instructions.
For adherent lines (NIH 3T3), cells were washed (x2) in 2ml of PBS and lysed directly
by incubating with Dual-Light
® kit Lysis Solution containing freshly added DTT
[0.5mM] to cover cells (125µl/well) for 10min at room temperature. The cells were then
detached from the plate with a 23cm
2 blade cell scraper (NUNC
TM) and lysates were
transferred to 1.5ml polypropylene microcentrifuge tubes and pelleted by centrifugation
at 17,900 x g for 5min at 4
oC (Eppendorf Centrifuge 5417C, Crown Scientific). The
supernatants were collected on ice, and stored at -70
oC. For suspension lines (HEL,
PER-117), transformed cells were transferred to 15ml polypropylene tubes and washed
(x3) with 5ml of ice-cold PBS. The cells were then resuspended in 250µl of Dual-
Light
® kit Lysis Solution containing freshly added DTT [0.5mM]. The cells were lysed
passively in the hypotonic Lysis Solution by incubating on ice over a 10min period and
pelleted by centrifugation at 17,900 x g for 5min at 4
oC. The supernatants were
collected on ice, and stored at -70
oC. Prior to assaying, cell lysates were thawed and
briefly centrifuged to pellet any cellular debris. In the case of HEL and NIH 3T3,
lysates were diluted 1:2 with freshly prepared Dual-Light
® Lysis solution containing
0.5mM DTT, whereas PER-117 lysates were assayed neat. 20µl of lysate or lysis
solution alone (blank) was then assayed in an opaque 96-well microtitre plate (Ascent)
using the Luminoskan Ascent
® and Ascent
TM software (Labsystems). The assay was
performed according to the Chemiluminescent Detection Protocol (C). Buffers A and B
were equilibrated to room temperature and the Galacton Plus
® substrate was diluted
(1:100) in the appropriate amount of Buffer B required for the entire assay. In order to
maintain consistent timing for the addition of Buffers A and B to each sample on the
plate, appropriate quantities for Buffer A (25µl/well) and Buffer B (100µl/well) were
premixed and the relative light units (RLUs) of each luciferase reaction were read in
counts per second (cps) following automatic injection (125µl/well). The microtitre plate
was then incubated at room temperature for 1h and RLU measurements of the β-80
Galactosidase light reaction (cps) were taken using the same multi-label counter
following automatic injection of Accelerator II (100µl/well).
2.2.3.5 Data Processing
Transfections were normalised using a standard method. For each transfection being
assayed, the activity (cps) was first corrected for noise by subtracting background
(determined by assaying 20µl of Dual-Light
® Lysis Solution). The corrected luciferase
values  were  then  normalised  for  transfection  efficiency  by  dividing  by  the
corresponding corrected β-Galactosidase value to obtain normalised RLUs for each
transfection.
2.2.3.6 Statistical Manipulation of Data
Transfections were conducted a minimum of three times for each construct. Due to the
inherent  variability  encountered  in  luciferase  experiments,  which  include  both
transfection  (cell  specific  variables)  and  assay  parameters,  each  experiment  was
‘centred’ prior to data processing. This involved taking the mean average RLU value for
that experiment which was then used to divide the raw RLU values. Only those
constructs that were common to all experiments in a given cell line were used to
calculate the average RLU value. Centred data was then used to calculate the mean and
standard errors for each construct using Microsoft Excel. Statistical analysis was also
performed where indicated, using random effect models in SPLUS, by Dr Ross Taplin,
Division of Science and Engineering, Murdoch University.
2.2.4  DNase1 Footprinting
2.2.4.1  PCR Labelling of the ALDH1A1 Proximal Promoter
2.2.4.1.1 Radiolabelling the Primer Using 
32P-γATP
In order to generate radiolabelled ALDH1A1 promoter fragments for use in footprinting
reactions,  amplification  was  performed  using  radiolabelled  sense  (ALDHPF)  or81
antisense (ALDHPR) primers (Table 2.3). The labelling reactions were performed in
0.5ml polypropylene microcentrifuge tubes in a final volume of 15µl, containing 50ng
of either ALDHPF/ALDHPR primer, 5x Forward Reaction Buffer [1x; 70mM Tris-HCl
(pH  7.6),  10mM  MgCl2,  100mM  KCl,  1mM  2-mercaptoethanol](GIBCOBRL
®),
100µCi  of 
32P-γATP  (Geneworks)  and  10U  of  T4  Polynucleotide  Kinase
(PNK)(GIBCOBRL
®),  added  in  the  order  described.  This  reaction  mixture  was
incubated at 37
oC for 1h, and the enzyme was  subsequently heat inactivated by
incubation at 85
oC for 20min. The reaction volume was adjusted to a final volume of
50µl total with sterile dH20, and the radiolabelled primer was purified from non-labelled
primer using a Microspin G25 spin column, in accordance with the manufacturer’s
specifications (Amersham, Pharmacia Biotech). Briefly, the resin within the G25 spin
column was resuspended by inversion several times and a flicking motion. The bottom
of the column was removed, the cap loosened 1/4 turn and the column was placed in a
1.5ml  polypropylene  microcentrifuge  tube.  The  resin  was  then  pelleted  by
centrifugation at 725  x  g  for  1min  at  room  temperature  (Biofuge  Pico,  Heraeus
Instruments) and the column was transferred to a fresh tube. The radiolabelled sample
was then applied to the centre of the angled surface of the compacted resin bed and
centrifuged at 725 x g for 2min at room temperature. The exact volume collected was
determined for subsequent DNA quantitation calculations and stored at -20
oC.
2.2.4.1.2 Generation of Singly End-Labelled ALDH1A1P Fragments Using PCR
To generate double stranded, radiolabelled ALDH1A1 promoter fragments, high fidelity
PCR was performed using primer sets (ALDH1PF-344/ALDH1PR2-123; generating an
225bp product)(ALDH1PR+42/ALDH1PF2-193;  generating  a  237bp  product)
containing radiolabelled and non-labelled primers (Table 2.3). PCR Reactions were
performed  in  thin-walled  0.5ml  polypropylene  tubes  in  a  final  volume  of  50µl,
comprising 10x Pfu
TM Polymerase Reaction Buffer [1x; 20mM Tris-HCl (pH 8.8),
10mM KCl, 10mM (NH4)2SO4, 2mM MgSO4, 0.1% Triton
® X-100, 0.1mg/ml nuclease-
free  bovine  serum  albumin  (BSA)](Stratagene),  25ng  of  either ALDH1PF-
344/ALDH1PR+42  radiolabelled  primer,  30ng  of  either  ALDH1PR2-123  or
ALDH1PF2-193 unlabelled primer, 0.2mM dNTPs (Fisher Biotech), 100ng of pGL2-
484  DNA   template    and  1.25U   of   Pfu
TM  Turbo  (Stratagene).  Amplification  was82
TABLE 2.383
performed using a PTC-100 (MJ Research Inc.) using a Touchdown programme
comprising 30 cycles of 94
oC for 1min, 63-55
oC for 1min (temperature drops by 1
oC
every  second  cycle,  with  the  last  14  cycles  at  55
oC  and  72
oC for 1.5min)(TD1;
Appendix 1). The radiolabelled PCR product was purified using a Qiaquick PCR
Purification Kit (Qiagen) as described in Section 2.2.1.1.6, with the exception that the
DNA was eluted with 50µl Buffer EB. The exact volume retrieved from the column was
determined for DNA quantitation calculations and stored at -20
oC.
2.2.4.1.3 DNA Quantitation Using Activity
To measure the activity (reported in cpm/µl) of 
32P in the primers and ALDH1A1P PCR
product, dilutions of each test sample (1:10 dilution) were prepared using sterile dH20 in
1.5ml polypropylene microcentrifuge tubes and counted in a scintillation counter
(Bioscan/QC   2000). In order to determine the concentration of ALDH1A1P PCR
product the following equation was employed, where;
a = total activity of primer used per PCR reaction
b = total activity of labelled ALDH1A1P PCR product
c = pmol of labelled primer (3.155)
d = pmol of double stranded ALDH1A1P PCR product
0.66 = MWAverage of a base pair
n= total base pairs of PCR generated product
(b/a) x c = d
d x 0.66 x n = ng/volume of PCR product retrieved
2.2.4.2 Footprinting Reactions
A typical footprinting reaction is outlined in Table 2.4. Control reactions, containing no
nuclear extract, were treated in the same manner as tests. Reactions were performed in
1.5ml polypropylene microcentrifuge tubes in a final volume of 50µl comprising 5x
Binding Buffer [1x; 20mM Hepes (pH 7.9), 100mM KCl, 0.2mM EDTA, 1mM DTT,84
8mM MgCl2, 2% (v/v) glycerol], 1µg of polydeoxycytidylic acid (polydIdC)(ICN
Biomedicals) and 5-50µg of nuclear extract and incubated at 22
oC for 25min. Following
this, 15ng of end-labelled target DNA (
32P-ALDH1A1P) was added to all the tubes,
which were then incubated at 22
oC for a further 10min. The target DNA was then
subjected to DNase1 digestion. Tubes were digested in sets of 3-4 by adding 5x DNase1
Buffer  [1x;  25mM  NaCl,  10mM  Hepes  (pH  7.9),  5mM  MgCl2,  1mM  CaCl2]
immediately prior to digestion, then initiating digestion with the addition of 0.01U-0.3U
of DNase1 (Sigma), followed by a gentle vortex. The digestions were allowed to
proceed for precisely 1min 20s and terminated with the addition of 10µl of Stop Buffer
[100mM MES, 165mM EDTA, 4.95% (w/v) SDS, 0.025% (w/v) herring sperm DNA],
followed by thorough vortexing.
Tube Typical Reaction
5X Binding Buffer (µl) 10
PolydIdC (µg) 1
Nuclear Extract (µg) 10
dH20 (µl) Up to 50µl
Incubate at Room Temperature for 25min
Labelled ALDH1P (ng) 15
Incubate at Room Temperature for 10min
1x DNase1 Buffer (µl) 50
DNase1 (U) (0.01U – 0.3U)
Stop Buffer (µl) 10
Table 2.4. The Components of a Typical Footprinting Reaction. The order of
addition and incubation times and temperatures are indicated. Reactions were incubated
at 22
oC on a heating block to ensure reproducibility of DNase1 digestion conditions.
2.2.4.3 Phenol-Chloroform Extractions
DNA was extracted with 100µl of phenol:chloroform:isoamyl alcohol (25:24:1)(ICN
Biomedical) and centrifuged to separate the phases at 15,000 x g for 3min at room
temperature  (Biofuge  Pico,  Heraeus  Instruments).  The  upper  aqueous  layer  was85
removed and transferred to a new 1.5ml polypropylene microcentrifuge tube containing
0.1 volumes of 3M sodium acetate, 2 volumes of cold absolute ethanol and 20µg of
glycogen (ICN Biomedical). The tubes were incubated for 30min on dry ice and
centrifuged at 15,000 x g for 15min at room temperature. The supernatants were
carefully removed and discarded and the radioactive DNA pellets were overlaid with
cold 200µl of cold 70% (v/v) ethanol and centrifuged for an additional 5min at 15,000 x
g at room temperature. The ethanol was removed and the pellets were dried at 37
oC in a
preheated block and dissolved in the appropriate volume of formamide loading buffer
[10mM EDTA, 0.1% (w/v) bromophenol blue, 0.1% (w/v) xylene cyanole and 98%
(v/v) deionized formamide]. Reactions were loaded onto gels immediately or stored at
-20
oC until required.
2.2.4.4 Preparation of Sequencing Reactions
Footprints  were  localised  with  respect  to  the  DNA  sequence  using  the  Cycle
Sequencing Kit according to the manufacturer’s instructions (Pharmacia Biotech).
Cycle  sequencing  reactions  for  ‘A’,  ‘C’,  ‘G’  or  ‘T’  were  performed  in  0.5ml
polypropylene microcentrifuge tubes in a final volume of 7µl, comprising Termination
Mix, either [222.8µM ddATP], [6.86µM ddGTP], [85.7µM ddCTP] or [242.9µM
dTTP](Pharmacia Biotech), 5x Sequencing Buffer [1x; 70mM Tris-HCl (pH 9.0),
1.5mM  MgCl2,  10.4%  (v/v)  DMSO](Pharmacia  Biotech),  11/4µM  dNTP  Mix
(Pharmacia Biotech), 100fmol of pGL2-484 DNA template, 0.6pmol of labelled primer
and 0.2U of Taq DNA polymerase (Pharmacia Biotech). Reactions were overlaid with
one drop (~20µl) of paraffin oil and centrifuged for 20s to remove air bubbles. Cycle
sequencing reactions were performed using a PTC-100 thermocycler (MJ Research Inc)
and involved 25 cycles of 95
oC for 30s, 55
oC  for  36s  and  72
oC for 84s (SEQ1;
Appendix 1). Reactions were terminated by the addition of 3µl Stop Solution [97.5%
(v/v) deionized formamide, 10mM EDTA, 0.3% (w/v) xylene cyanol, 0.3% (w/v)
bromophenol blue](Pharmacia Biotech) to each tube and stored at -20
oC for use within
three days of preparation.86
2.2.4.5 Denaturing Polyacrylamide Gel Electrophoresis
DNase1  footprinting  reactions  were  analysed  under  denaturing  conditions  by
polyacrylamide gel electrophoresis using Sequi-Gen
R  GT  gel  apparatus  (Bio-Rad
Laboratories). Sequencing gel glass plates (38 x 50cm) were washed thoroughly with
detergent, rinsed and dried before use. Both plates were cleaned twice with 96% (v/v)
ethanol using lint- free towels (Kimwipes), and one plate was treated with a siliconising
agent (Rain-X, UNELKO Corp.) in between ethanol washes. A 6% polyacrylamide
sequencing gel consisting of 30% Acrylamide/Bis (19:1; w/v), 10x TBE Buffer [1x;
89mM Tris, 89mM Boric Acid, 2mM EDTA (pH 8.0)] and 7.5M urea was freshly
prepared and 750µl of a 10% (w/v) APS solution and 60µl of TEMED were added per
150ml gel solution, immediately prior to casting. The apparatus was assembled with
0.4mm spacers and the gel was cast according to the manufacturer’s instructions. A
0.4mm, 32-well comb was inserted and the gel was left to set for a minimum of 3h
before use. Electrophoresis was performed in 1x TBE buffer and pre-electrophoresed to
a temperature of 50
oC. Prior to electrophoresis, footprinting samples were denatured by
heating at 70
oC for 5min on a pre-heated block. Sequencing reactions were prepared by
removing the overlay of paraffin oil and heating at 80
oC for 3min. Footprinting samples
(4µl/lane) and sequencing reactions (3µl/lane) were loaded in preformed wells and
samples were electrophoresed at constant power (120W, 50
oC) for 1.5-4.5h depending
on the length of the run required.
2.2.4.6 Gel Drying and Autoradiography
Following electrophoresis, the gels were transferred to Whatman
® 3MM filter paper
(Whatman) and covered with Saran wrap. Gels were dried at 80
oC for 2h in a pre-heated
gel  dryer  (Model  583,  Bio-Rad  Laboratories),  and  autoradiographed  using  an
intensifying screen (Fuji G-8 EC-AWU Cassette, 27.9x 35.6cm; Fuji Medical X-ray
film super HRG30) at -70
oC for the appropriate length of time. Prior to developing,
cassettes were allowed to thaw for 1h at room temperature and films were developed
using an SPM 300 developer (Fuji).87
2.2.5 Electrophoretic Mobility Shift Assays (EMSAs)
2.2.5.1 Oligonucleotide Labelling and Annealing
Oligonucleotides used for EMSA experiments are outlined in Table 2.5. Labelling
reactions were performed in 0.5ml polypropylene microcentrifuge tubes a final volume
of 20µl comprising 5x Forward Buffer [1x; 70mM Tris-HCl (pH 7.6), 10mM MgCl2,
100mM KCl, 1mM 2-mercaptoethanol](GIBCOBRL
®), 20pmol of oligonucleotide,
40µCi  of  γ
32P-ATP  (Geneworks)  and  15U  of  T4  Polynucleotide  Kinase
(PNK)(GIBCOBRL
®) at 37
oC for 30min. The PNK was subsequently heat inactivated
by incubation at 65
oC for 10min. The reaction volume was adjusted to a final volume of
50µl with sterile dH20  and  the  radiolabelled  oligonucleotide  was  purified  using
Microspin G25 spin columns (Amersham Pharmacia Biotech) as described in Section
2.2.4.1.1. The reaction volume was adjusted to a final volume of 100µl with sterile dH20
and  stored  at -20
oC until required. Annealing reactions were performed in 0.5ml
polypropylene microcentrifuge tubes in a final volume of 30µl, with equimolar amounts
of both radiolabelled and unlabelled sense and antisense oligonucleotides respectively
[4pmol] in 5 x Annealing Buffer [1x; 10mM Tris-HCl (pH 7.4), 50mM NaCl, 1mM
EDTA] by heating the reaction to 90
oC for 5min and cooling to 22
oC at a rate of
1
oC/min using a PTC-100 thermocycler (MJ Research Inc). Following this, the reaction
was adjusted to a final concentration of 0.04pmol/µl with 1x Annealing Buffer.88
TABLE 2.589
2.2.5.2 EMSA Reactions
All EMSA reactions were performed in 1.5ml polypropylene microcentifuge tubes
using freshly thawed nuclear extracts. Binding reactions were performed in a final
volume of 15µl comprising 5 x EMSA Binding Buffer [1x; 20mM Hepes (pH 7.6),
50mM KCl, 1mM EDTA (pH 8.0), 5% (v/v) glycerol, 1mM DTT (added fresh)], 0.5µg
of polydIdC, 0.12pmol of 
32P-end labelled duplex oligonucleotide, 10µg of nuclear
extract and 1µl of antibody where appropriate. Competition experiments involved the
addition of either unlabelled duplex related competitor or unrelated competitor in molar
excess (5-35 fold) relative to the radiolabelled probe prior to the addition of nuclear
proteins. The reactions were incubated at 22-24
oC for 30min prior to electrophoresis.
2.2.5.3 Native Polyacrylamide Gel Electrophoresis
Electrophoresis of EMSA reactions was performed at 4
oC, using the PROTEAN II Gel
System (20cm cell)(Bio-Rad Laboratories). Glass plates (inner plate; 20cm x 20cm,
outer plate; 22.3cm x 20cm) were washed thoroughly with detergent, rinsed and dried
before use. Both plates were cleaned twice with 96% (v/v) ethanol using lint- free
towels, and the short plate was treated with a siliconising agent (Rain-X, UNELKO
Corp.) in between ethanol washes.  The gel apparatus was assembled using 1.5mm
spacers and a 1.5mm, 15 well comb according to the manufacturer’s instructions. A 4%
polyacrylamide gel consisting of 30% Acrylamide/Bis (37.5:1; 13.3%v/v) and 10x TBE
[0.5x; 44.5mM Tris, 44.5mM Boric acid, 1mM EDTA (pH 8.0)] was prepared and
525ul of a 10% (w/v) APS solution and 52.5ul of TEMED were added per 70ml of gel
solution, immediately prior to casting. The gel was left to set for a minimum of 2h and
stored at 4
oC overnight. Freshly prepared 0.5x TBE Buffer and the central cooling core
were also pre-incubated at 4
oC until required. Prior to loading, the gel was prepared by
pre-running with chilled 0.5x TBE Buffer at 17mA (constant current) for 1h. The entire
sample volume (~15µl/lane) was electrophoresed at 17mA constant current for 1.5-2h,
until the dye front measured ~2cm from the end of the gel and transferred to Whatman
®
3MM filter paper. Gels were dried for 2h at 80
oC under vacuum using a Bio-Rad Model
583  Gel  Dryer  (Bio-Rad  Laboratories)  and  subject  to  autoradiography  using  an
intensifying screen (Fuji G-8 EC-AWU Cassette, 27.9x 35.6cm; Fuji Medical X-ray90
film super HRG30) at -70
oC for the appropriate length of time. Prior to developing,
cassettes were allowed to thaw for 1h at room temperature and films were developed
using an SPM 300 developer (Fuji).
2.3  RESULTS
2.3.1 Identification of a HOX11 Responsive Element Within the ALDH1A1
Promoter
Previous studies have demonstrated that HOX11 consistently affects the expression of a
~2.1kb ALDH1A1 transcript in both the NIH 3T3 and HEL cell lines, as assessed by
Northern blot (Greene et al., 1998, Greene, unpublished observations). In the case of
NIH 3T3 cells there was a consistent upregulation, while in HEL cells there was a
consistent downregulation of ALDH1A1 expression. Moreover, HOX11 was shown to
upregulate ALDH1A1 expression at the level of RT-PCR in the T-ALL cell line, PER-
117 (Greene, unpublished observations). Given that the TSS of human cytosolic
ALDH1A1 had been previously determined by Hsu et al., (1989) and corresponds to the
2.1kb transcript observed in NIH 3T3 and HEL cell lines, preliminary investigations
utilised Chloramphenicol Acetyl Transferase (CAT) assays to determine the effect of
HOX11 on a 2536bp region 5’ to the transcriptional start site of ALDH1A1 (designated
+1)(Greene, unpublished observations). Overexpression of HOX11 in NIH 3T3 cells
stimulated  ALDH1A1  promoter  activity,  suggesting  the  presence  of  a  HOX11
responsive  element  within  this  region.  Thus,  in  order  to  identify  regions  of  the
ALDH1A1 promoter involved in the cell type-specific expression of ALDH1A1 in HEL
(human erythroleukaemia) and PER-117 (immature T-cell) cell lines, and to delineate
the specific element(s) responsible for mediating the effects of HOX11, with the
intention of gaining further insight into the molecular mechanism(s) by which HOX11
alters the transcriptional activity of ALDH1A1 (and possibly other target genes), a series
of luciferase reporter constructs containing progressive deletions of a 2,536bp region of
the ALDH1A1 promoter were transfected into the HEL and PER-117 cell lines. The
reporter gene activity of the various constructs was then assessed in both the presence
and absence of HOX11.91
The nested deletions of the ALDH1A1 promoter within the region -2159bp to +42bp
(relative to the TSS +1; Figure 2.2) were amplified from human genomic DNA and
cloned upstream of the firefly (Photinus pyralis) luciferase cDNA of the pGL3Basic
luciferase reporter vector (Figure 2.3). The basis for this assay lies in the ability of the
luciferase enzyme (a 61kDa protein) to oxidise the substrate D-luciferin in the presence
of ATP, oxygen and Mg
2+, yielding a fluorescent product that may be quantified by
detecting released light. Since the production of the luciferase enzyme is under the
control of the regulatory sequence of interest, the emission of light is therefore a
measure of the activity of the promoter under a given set of conditions. The sensitivity
of this assay, coupled with its relative simplicity and broad linear range, which spans
over  eight  orders  of  magnitude,  makes  the  luciferase  assay  an  ideal  system  for
preliminary investigations of gene regulatory sequences. The pGL3Basic vector utilised
in these studies, lacks eukaryotic promoter or enhancer sequences, allowing the cloning
and  functional  assessment  of  putative  regulatory  sequences,  and  also  contains  a
polyadenylation site upstream of the multiple cloning site to prevent read-through of
aberrant transcripts potentially initiating within the vector backbone, thereby reducing
background luciferase noise.
In order to assess the effect of HOX11 on ALDH1A1 promoter expression, individual
promoter reporter gene constructs were cotransfected with either the empty pEFBOS
mammalian  expression  vector,  which  served  as  a  negative  control  for  HOX11
expression, or with the pEFBOSHOX11 expression vector (kindly supplied by Dr T.H.
Rabbitts, MRC Laboratory of Molecular Biology, Cambridge, U.K). The pEFBOS
mammalian expression vector (5.8kb) is derived from the pUC119 plasmid and employs
the promoter of polypeptide chain elongation factor 1α (EF-1α) to drive the expression
of genes cloned into the multiple cloning site (Mizushima & Nagata, 1990)(Appendix
2). The vector also contains the polyadenylation signal from the human G-CSF gene as
well as the ampicillin (Amp)  gene  as  a  selectable  marker.  The  pEFBOSHOX11
construct is derived from the pEFBOS parental vector and contains a 1044bp human
HOX11 cDNA for the expression of full-length HOX11 (Masson et al., 1998). All
transfections also included the pSV-β-Galactosidase (pSV-β-Gal) vector as the internal
control to facilitate the normalisation  of  raw  luciferase output for individual samples.92
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Figure 2.3. Schematic Diagram of the Human ALDH1A1 Promoter  Luciferase
Fusion Constructs Employed in this Study. Nested deletions of the human ALDH1A1
promoter were amplified by high fidelity PCR using PfuTurbo
®  (Stratagene) and
inserted into the multiple cloning site of the pGL3Basic luciferase vector (Promega),
upstream of the cDNA encoding the modified firefly luciferase (LUC).
GATA Box (-34bp)
CCAAT Box (-74bp)
Putative HOX11 binding sites (-256, -706, -1677, -1717, -2085bp)
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The use of pSV-β-Gal allowed the efficiency of transfection of reporter constructs into
HEL and PER-117 cells and other variations to be taken into account. pSV-β-Gal
(6.8kb)(Promega; Genbank
®/EMBL Accession Number: X65335; Appendix 2) uses the
SV40 early promoter and enhancer sequences to drive the high-level expression of
bacterial lacZ. This encodes an enzyme (β-Galactosidase) responsible for catalysing the
hydrolysis of β-galactoside sugars such as the colorimetric substrate, o-nitrophenyl-β-
D-galactopyranoside (ONPG), which can be spectrophotometrically quantitated at a
wavelength of 410nm. Using the Dual Light
® reporter gene assay system (Applied
Biosystems), which incorporates luciferin and Tropix
® Galacton Plus
® substrates in
provided assay buffers, it was possible to concomitantly assay both experimental
(luciferase) and internal control (β-Galactosidase) gene products within the same cell
extract.
2.3.1.1  Optimisation of Luciferase Reporter Gene Assays
ALDH1A1 was originally identified as a gene upregulated following the overexpression
of HOX11 in NIH 3T3 murine fibroblasts (Greene et al., 1998), and subsequent CAT
reporter assays revealed the presence of a HOX11-responsive element within a 2159bp
fragment (-2159/+42bp) relative to the TSS of the ALDH1A1 promoter in NIH 3T3 cells
(Greene,  unpublished  observations).  Therefore,  prior  to  commencing  ALDH1A1
promoter analyses in the HEL and PER-117 cell lines, experiments were performed to
demonstrate the reproducibility of results obtained using the luciferase reporter assay as
compared to those obtained in previous studies utilising the CAT reporter assay. In
accordance with previous studies, HOX11 was shown to transactivate the ALDH1A1
promoter following cotransfection of the full-length pGL3BasicALDH1A1P-2159/+42
luciferase construct and the HOX11-expressing construct, pEFBOSHOX11 in NIH 3T3
cells (data not shown). Having confirmed the responsiveness of the ALDH1A1 promoter
to HOX11 in NIH 3T3 cells, all subsequent analyses were performed in the human
erythroleukaemic cell line HEL, which strongly expresses ALDH1A1, together with the
non-ALDH1A1 expressing cell line, PER-117, established from the leukaemic cells of a
patient with T-ALL. Although both of these cell lines do not normally express HOX11,
their leukaemic origins were likely to provide a relevant background with respect to
specific cofactors, growth factors and signal transduction pathways in which to study
the differential effects of HOX11 on ALDH1A1  expression. In stable transfection95
experiments, HOX11 was shown to repress the expression of the endogenous ALDH1A1
gene in HEL cells and upregulate it in PER-117 cells (Table 2.6).
Cell Line HEL HELHOX11 PER-117 PER-117HOX11
HOX11
Expression
- + - +++
ALDH1A1
Expression
++++ + - +
Table 2.6. Expression Status of HOX11 and ALDH1A1 in HEL and PER-117 Cell
Lines.  HELHOX11  and  PER-117HOX11  refer  to  clones  produced  by  stable
transfection with the HOX11-expressing construct pEFBOSHOX11. The expression
status of HOX11 and ALDH1A1 was compared to negative clones of HEL and PER-
117, which were produced by stable transfection with the empty pEFBOS vector alone
(Greene, unpublished observations).
2.3.1.2  ALDH1A1 Promoter Activity in PER-117 and HEL Cell Lines
To identify the region(s) important for ALDH1A1 promoter transactivation in HEL and
PER-117 and cells, the transcriptional activities of various deletions of the ALDH1A1
promoter were analysed using luciferase assays. Initial investigations tested constructs
ranging  from  -2159/+42  to  -146/+42  (Figure  2.4,  2.5).  Data  is  presented  in  the
conventional format which involves the normalisation of raw luciferase (cps) to raw β-
Galactosidase (cps)(raw luciferase - lysis solution blank)/raw β-Gal - lysis solution
blank), to yield normalised RLUs. Consistent with previous work (Yanagawa et al.,
1995), these analyses revealed that the main transcriptional activity resided within a
proximal region of the ALDH1A1 promoter, in this case within 146bp relative to the
TSS (+1) in both HEL and PER-117 (Figure 2.4A, 2.5A). Constructs containing 5’
extensions of the promoter sequence (-1968 and -2159) were associated with a modest
reduction in luciferase activity in both HEL and PER-117 cell lines, suggesting that
distal negative regulatory elements may exist between -146/-2159bp (Figure 2.4A,
2.5A). An additional negative element between -201 and -303 was also apparent in both
cell lines. In order to delineate the specific element(s) responsible for promoter activity,
a series of constructs ranging from -91 to +1 were subsequently tested (Figure 2.4B,
2.5B). This included the -91∆CAT construct, which harbours a deletion of the CCAAT
box (located at -74/-70bp), since this  element has previously  been  demonstrated to be96
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crucial  for  ALDH1A1  promoter  transactivation  in  Hep3B  human  hepatocellular
carcinoma cells (Yanagawa et al., 1995). Luciferase activity dramatically declined
following deletion of the CCAAT box in both HEL and PER-117, confirming the
importance of this cis-regulatory element for ALDH1A1 promoter activation in the HEL
and PER-117 cell lines (Figures 2.4B, 2.5B).
2.3.1.3  The Effect of HOX11 on the pGL3Basic Luciferase Vector and on the pSV-β-
Galactosidase Internal Control
Initial investigations into the effect of HOX11 on the activity of the ALDH1A1 promoter
in the HEL and PER-117 cell lines, involving the transient introduction of promoter
constructs, pEFBOS, pEFBOSHOX11 and the pSV-β-Gal internal control, revealed an
unexpected phenomenon. It appeared that raw β-Galactosidase (β-Gal) values (cps)
were  typically  lower  in  HOX11-transfected  cells  as  compared  to  their  matched
pEFBOS-transfected counterparts, although this effect was more pronounced in the
HEL  cell  line  (Figure  2.6A)  as  compared  to  PER-117  cells  (Figure  2.6B).  This
observation raised concerns that HOX11 was affecting the expression of the pSV-β-Gal
internal  control,  either  by  actively  repressing  the  SV40  promoter  driving  β-Gal
expression, by sequestering positive trans-acting factors to other regulatory elements or
by quenching mechanisms. The ability of certain transcription factors to affect the
transcriptional activity of β-Gal co-reporter plasmids driven by various constitutively
expressed promoters (RSV, CMV, pTK) has been previously documented (Huszar et
al., 2001). It was suggested that the use of internal control plasmids to normalise
luciferase activity in transient transfections is questionable and may lead to errors in
data analysis. Moreover, a recent publication by Owens et al., (2003), demonstrated the
ability of HOX11 to repress the SV40 viral promoter, thereby substantiating concerns
regarding the use of pSV-β-Gal as an unbiased, internal normalisation control. Based on
our evidence, which suggests that HOX11 represses the SV40 promoter driving β−Gal
expression, this method is likely to affect the data in two ways depending on whether
HOX11 activates or represses ALDH1A1 gene transcription. Thus, in a situation in
which HOX11 activates ALDH1A1 promoter activity, the fold activation of HOX11-
transfected samples compared to matched control samples is likely to be overestimated,
since normalised RLUs will be artificially large due to the effect of dividing HOX11-
transfected raw  luciferase values by  smaller β-Gal values.  Conversely,  in a situation99
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in which HOX11 represses ALDH1A1 promoter activity, the fold repression of HOX11-
transfected  samples  compared  to    matched  pEFBOS-transfected  samples  will  be
underestimated, this time due to the fact that normalised RLUs for these samples will be
artificially large.
As an additional complication, it appeared that in HEL cells, HOX11 was capable of
affecting luciferase activity, even in the absence of functional promoter sequences
(Figure 2.7). HOX11 was demonstrated to activate transcription approximately 10-fold
over background (pEFBOS) from the pGL3Basic reporter vector alone in the HEL cell
line,  raising  concerns  that  the  effect  of  HOX11  on  luciferase  activity  may  be
independent  of  inserted  promoter  sequences  (Figure  2.7).  Indeed,  although  the
pGL3Basic  vector  has  been  engineered  with  polyadenylation  sites  upstream  and
downstream  of  the  luciferase  coding  region  in  order  to  minimise  the  effect  of
background read-through via cryptic promoter and enhancer elements, the ability of the
osteoblast-specific transcription factors Cbfa1 and estrogen receptor α to activate the
pGL2- and pGL3Basic luciferase reporter vectors, possibly via randomly occurring cis-
acting  elements  in  the  vector  backbone,  has  been  previously  demonstrated
(Thirunavukkarasu et al., 2000).
Thus, in order to determine whether the effect of HOX11 on the ALDH1A1 promoter
constructs was significantly different from the effect of HOX11 on the pGL3Basic
vector itself, the data was statistically analysed in order to take into account the effect of
HOX11 on the pSV-β-Gal internal control as well as on the pGL3Basic vector. Before
undertaking this analysis, it was first necessary to assess whether β-Galactosidase
expression was equally affected by HOX11 regardless of the pGL3Basic or ALDH1A1
promoter construct used in both the HEL and PER-117 cell lines. Statistical analysis
was performed by Dr Ross Taplin (Division of Science and Engineering, Murdoch
University). Raw β-Galactosidase values were logarithmically transformed (log2) and
expressed as a ratio of the promoter with HOX11 versus the promoter without HOX11.
Each ratio was then expressed by subtracting the corresponding ratio for the pGL3Basic
empty vector control. The mean was taken for triplicate experiments and two sided p-
value testing for the null hypothesis that the values were equal to zero demonstrated at
the P < 0.05 level of significance that the  values were not significantly different from101
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zero. This analysis demonstrated that HOX11 affected the β-Galactosidase internal
control similarly for pGL3Basic as for all ALDH1A1 promoter constructs in both the
PER-117 (Figure 2.8A) and HEL (Figure 2.8B) cell lines, such that the pGL3Basic
empty vector control may be included in subsequent normalisation calculations.
2.3.1.4  Modulation of ALDH1A1 Promoter Transactivation by HOX11 in HEL and
PER-117 Cells
HOX11 has been shown to activate the expression of endogenous ALDH1A1 in PER-
117 cells, and repress the expression of endogenous ALDH1A1 in HEL cells (Greene,
unpublished observations). We therefore examined whether HOX11 could modulate
transactivation of the ALDH1A1 promoter constructs in these cell lines. As described in
the previous section (Section 2.3.1.3), the net effect of HOX11 on ALDH1A1 promoter
activity was calculated by taking a ratio of raw luciferase activity (cps) over raw β-
Galactosidase activity (cps) for each well to obtain normalised RLU values. Following
log2 transformation, values were then expressed as a ratio of the ALDH1A1 promoter
construct with HOX11 vs no HOX11, and all values were expressed by subtracting the
corresponding ratio for the pGL3Basic vector control. This value was then expressed
graphically as a log fold change of individual promoter constructs relative to the
pGL3Basic empty vector control. Two sided p-value testing was then undertaken for
each promoter construct relative to pGL3Basic empty vector and between individual
promoter constructs, using the null hypothesis of no difference. Western blot analyses
were performed on HEL and PER-117 cell lysates, confirming the expression of the
36kDa HOX11 protein in pEFBOSHOX11-transfected cells (Figure 2.9B, 2.10B).
Expression of HOX11 in HEL cells resulted in a modest upregulation of the ALDH1A1
promoter within the smallest construct +1 by a factor of 1.6 fold (P < 0.05). This
activation by HOX11 was sustained in constructs ranging between +1 and -91 and did
not require the CCAAT box at -70, since deletion of this element had no effect (Figure
2.9A). The introduction of additional promoter sequence (-146) abrogated the effect of
HOX11 (P < 0.005), and this was maintained to a greater or lesser extent in all the
progressively longer constructs (Figure 2.9A). These results suggested that HOX11 may
activate transcription through an element located between +1/+42bp of the ALDH1A1
promoter,  in  a  manner  subject  to  negative  regulation by  factors  acting  on a  region103
FIGURE 2.8104
FIGURE 2.9105
FIGURE 2.10106
between -91/-146bp. In contrast, expression of HOX11 in PER-117 cells resulted in the
significant repression of the -91 construct and of progressively larger constructs
encompassing this region by a factor of 2-3.5 fold (P < 0.001). However, no repression
by HOX11 was demonstrated using constructs -50 or those progressively smaller
(Figure 2.10A). Significantly, HOX11-mediated repression was relieved following
deletion of the CCAAT box (P < 0.001), suggesting that the CCAAT box is not only
crucial for ALDH1A1 promoter activity, but may also represent a HOX11 responsive
element in PER-117 cells.
2.3.1.5  Effect of a Homeodomain Mutation on HOX11 Transactivation/Repression
Potential
In order to assess whether DNA binding might be required for HOX11 to mediate
transactivation in HEL cells and repression at the CCAAT box in PER-117 cells, a
DNA binding mutant of HOX11 (pEFBOSHOX11∆H3) was cotransfected with the
empty pGL3Basic and pGL3Basic-91 constructs for both HEL and PER-117 cell lines.
HOX11∆H3 contains a 10 amino acid (aa) deletion (DAQVKTWFQN) within helix 3
of the HOX11 homeodomain, which has been replaced by the dipeptide GT (Masson et
al., 1998). It has been shown by EMSAs to be incapable of binding a HOX11 consensus
site (Heidari et al., 2002). In the first instance, the effect of HOX11∆H3 on β-
Galactosidase activity in HEL and PER-117 was assessed (Figure 2.11). This analysis
revealed that unlike HOX11, which represses the expression of β-Galactosidase in HEL
and  to  a  lesser  extent  in  PER-117  (Figure  2.6A,  2.6B),  HOX11∆H3  stimulated
expression of β-Galactosidase in both HEL and PER-117 compared to the pEFBOS
control (Figure 2.11A, 2.11B). These results confirmed the ability of HOX11 to
modulate the expression of β-Galactosidase,  and  suggested  that  DNA  binding  is
required  for  HOX11-mediated  repression.  By  contrast,  the  ability  of  HOX11  to
transactivate  transcription  is  apparently  independent  of  DNA  binding,  possibly
occurring via protein-protein interactions. Regardless of the mechanism of action,
normalisation of luciferase values through the use of β-Galactosidase would clearly
distort the final interpretation of data when using the HOX11∆H3 mutant. For this
reason, the effect of HOX11∆H3 on the ALDH1A1 promoter is presented as raw
luciferase (cps), without normalisation to β-Galactosidase.107
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In the case of HEL, these analyses revealed that like HOX11, HOX11∆H3 was able to
stimulate luciferase activity from both the pGL3Basic and pGL3Basic-91 construct
(2.12A). Conversely, in the case of PER-117, the removal the DNA binding helix (∆H3)
disabled the ability of HOX11 to repress transcription from the -91 ALDH1A1 promoter
construct, and intriguingly, HOX11∆H3 actually stimulated transcription approximately
5-fold compared to the pEFBOS control (Figure 2.12B). Together, these results support
the hypothesis that HOX11 modulates gene transcription via two distinct mechanisms –
the first involves the ability of HOX11 to repress gene transcription which apparently
requires  DNA  binding,  whereas  the  second  mechanism  involves  transcriptional
activation which appears to be independent of DNA binding.
2.3.2  Identification of Transcription Factor Binding Sites within the Proximal
Promoter of ALDH1A1 by DNase1 Footprinting
DNase1 footprinting is a widely used method for studying the binding of regulatory
proteins to their cognate DNA recognition sequences (Galas & Schmitz, 1978). DNase1
interacts with DNA in the minor groove and in the presence of Ca
2+ and Mg
2+, cleaves a
single strand of double stranded DNA to yield 5’-PO4  and 3’-OH products. This
technique involves the partial digestion by DNase1 of a 
32P-end-labelled fragment
containing putative regulatory sequences of interest, to generate a unique pattern of
fragments, which are subsequently separated on a denaturing acrylamide gel such that
their positions represent the distance from the end label to the points of cleavage.
Sequence specific binding of proteins to DNA sequences on the radiolabelled probe,
protects the region from DNase1 cleavage, thus generating a ‘footprint’ in the pattern of
cleaved fragments. The exact position of the protected region may then be identified by
running a DNA sequencing ladder adjacent to the footprint. Having demonstrated clear
differences in the transcriptional activity of the ALDH1A1 promoter in HOX11-
transfected cells by in vitro luciferase reporter assays, we attempted to characterise the
sequence-specific binding of nuclear proteins to the proximal ALDH1A1 promoter by
DNase1 footprinting and to determine the effect of HOX11 on protein binding within
this region. On the basis of the functional promoter assays performed in Section 2.3.1,
in addition to studies conducted by Yanagawa et al., (1995), two overlapping fragments
(-344/-123bp and -193/+42bp)  encompassing  the  proximal ALDH1A1  promoter  were109
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selected  to  further  investigate  the  regulatory  elements  involved  in  ALDH1A1
expression. Stably transfected cell clones were used for this part of the investigation.
HEL clone 1 and PER-117 clone 1 are HOX11-negative and act as negative controls,
while HEL clone 4 and PER-117 clone 11 are positive for HOX11 expression. Crude
nuclear fractions from HEL[1], HELHOX11[4] and PER-117[1], PER-117HOX11[11]
cell lines were incubated with genomic fragments 
32P-radiolabelled at a single terminus,
such that upon separation of digested fragments during electrophoresis only the DNA
strand extending from the radiolabelled primer was visualised by autoradiography.
2.3.2.1 DNase1 Footprinting Using HEL and PER-117 Nuclear Extracts
The results of footprinting experiments for HEL[1], revealed consistent protection at
two distinct positions (Figure 2.13) and the nucleotide sequence of these sites and the
putative transcription factor binding sites pertaining to these regions are summarised in
Table 2.7.111
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Protected Site Nucleotide Sequence of Protected Regions
and Putative Binding Sites Contained Within
ALDHDIST
-257 to -246
                                     ACACTTATCACA
                TGTGAATAGTGT
                               ACACTTATCACA
                 TGTGAATAGTGT
                                    ACACTTATCACA
                 TGTGAATAGTGT
ALDHPROX
-36 to -27
                                    GCAGATAAAA
             CGTCTATTTT
             GCAGATAAAA
             CGTCTATTTT
Table  2.7.  Nucleotide  Sequences  of  Protected  Sites  Identified  by  DNase1
Footprinting for HEL[1], HELHOX11[4], PER-117[1] and PER-117HOX11[11]
Nuclear Extracts on the Proximal ALDH1A1 Promoter. Potential transcription factor
binding  sites  contained  within  the  footprint  regions  were  identified  using  the
TRANSFAC  (Version  1.3)  database  (http://transfac.gbf.de/index.html),  and  are
indicated by bold type.
The most distal site of protection identified, ALDHDIST, spanned nucleotides ranging
from -257/-246bp (Figure 2.13). Analysis of ALDHDIST on the sense strand (extending
from radiolabelled primer ALDH1PF-344) revealed strong protection characterised by
adjacent hypersensitive sites that was also visualised on the antisense strand (data not
shown). The sequence of ALDHDIST was notable for three reasons. Firstly the
sequence has an axis of symmetry, in which the five flanking bases either side of a
central TA dinucleotide are a direct mirror image (ACACT TA TCACA). Secondly the
sequence harbours one of four putative HOX11 binding sites within the 2.2kb region of
the ALDH1A1 promoter. Finally the sequence contains a putative GATA site.
The  second  region  of  protection  observed  for  HEL[1],  ALDHPROX, extended
protection from -36 to -27bp (Figure 2.13). Analysis of ALDHPROX on the antisense
HOX11
GATA-1
GATA-3
TFIID
GATA-1/2/3113
strand (extending from radiolabelled primer ALDH1PR+42) revealed relatively strong
protection characterised by significant hypersensitivity extending from -47/-37bp and
between -26/-22bp and was also visualised on the sense strand (data not shown).
Sequence analysis of ALDHPROX identified a putative GATA binding site (-34/-29bp)
overlapping a non-canonical TATA box (ATAAAA)(-32/-27bp), potentially capable of
binding  TFIID.  This  appeared  to  be  a  GATA  box  (-34/-28bp),  a  composite
TATA/GATA element, capable of binding both GATA and TFIID proteins (Barton et
al., 1993). The GATA box is therefore distinct from a GATA site, which is only capable
of binding GATA family members. Footprinting experiments using HELHOX11[4]
nuclear extracts revealed identical regions of protection in terms of nucleotide sequence
and associated regions of hypersensitivity, thus HOX11 appeared to have no discernable
effect on protein binding at the two identified sites. No protection was observed within
the region +1/+42bp for either HEL[1] or HELHOX11[4], which was somewhat
surprising, given that this was the minimal region required for the stimulation of
transcription by HOX11 observed in Section 2.3.1.2.
Footprinting experiments with PER-117[1] nuclear extracts revealed identical regions of
protection at -257/-246bp (ALDHDIST) and -36/-27bp (ALDHPROX). For this reason
the results are not shown. Analysis of ALDHDIST on the sense strand revealed identical
protection and associated hypersensitivity to that seen for HEL[1] and similar to
HEL[1], protection was also observed on the antisense strand (data not shown). A
comparison of footprints obtained for PER-117[1] vs PER-117HOX11[11] nuclear
extracts also revealed no observable differences in terms of nucleotide sequences or
associated  hypersensitive  sites  on  either  sense  or  antisense  strands  for  either
ALDHDIST/PROX (data not shown). Surprisingly, DNase1 protection was not observed
at  the  CCAAT  box  for  either  HEL[1]  or  PER-117[1],  despite  this  region  being
identified  as  an  important  cis-regulatory  element  involved  in  the  expression  of
ALDH1A1 in HEL and PER-117 cell lines, as well as representing a possible HOX11-
responsive element in PER-117.114
2.3.3  Characterisation of the Protein Binding at the CCAAT Box by EMSA
It was demonstrated by in vitro luciferase reporter assays that the CCAAT box located
at -74/-70bp is the primary cis-acting element responsible for ALDH1A1 promoter
activity in both HEL and PER-117 cell lines, since the specific deletion of this element
dramatically reduced its transactivation potential. Moreover, the CCAAT box was also
shown to be involved in HOX11-mediated repression in the T-ALL cell line, PER-117.
DNase1 footprinting of the proximal ALDH1A1 promoter (spanning -344 to +42bp)
encompassing the CCAAT box, however, did not reveal protein binding at this site.
Thus, in an attempt to correlate the functional activity of the CCAAT box with protein-
DNA binding, and to assess the effect of HOX11 on complex formation at this site,
electromobility shift assays (EMSAs) were performed using an oligonucleotide probe
spanning the CCAAT box (ALDHCAT). Nuclear extracts from HOX11 negative cell
lines HEL[1] and PER-117[1] were compared to their HOX11-expressing counterparts
HELHOX11[4] and PER-117HOX11[11]. In addition to the CCAAT box, two other
regions of interest identified by DNase1 footprinting experiments were also included in
EMSA analyses, in order to develop a basic model of transcription factor binding at
these sites. These include a region of protection at -257/-246bp (ALDHDIST), in
addition to a region of protection surrounding a putative GATA box at -34/-28bp
(ALDHPROX).
2.3.3.1 EMSA Assays Using PER-117 Nuclear Extracts
Having demonstrated that HOX11 is capable of repressing the ALDH1A1 promoter,
possibly via interactions at the CCAAT box, we sought to investigate the effect of
HOX11 on protein-DNA binding complexes within this region, which may constitute a
transcriptional mechanism for the differential regulation observed in the previous
Section 2.3.1.4. Incubation of the ALDHCAT with PER-117 and PER-117HOX11
nuclear extracts identified eight protein-DNA complex species (A-H), three of which
were deemed specific (A, C and D) following elimination of complexes B, E, G and H
with a 35-fold molar excess of either non-specific competitor 1 (NS1) or 2 (NS2) and
inability of a 35-fold molar excess of unlabelled ALDHCAT probe to efficiently
compete complexes F and G (Figures 2.14, 2.15). Although binding of complexes C and115
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Figure  2.14.  Electromobility  Shift  Analysis  of  PER-117  and  PER-
117HOX11 Nuclear Protein Binding to the ALDH1A1 Promoter CCAAT
Box (-74/-70bp). Radiolabelled ALDHCAT oligonucleotide probes (0.12pmol)
were incubated with 10ug of nuclear extract to reveal complexes A-H (Lanes 2,
3). Specific complexes (A, C and D) were identified following competition
experiments using either a 5 or 35-fold molar excess of unlabelled non-specific
competitor (ALDHDIST; Lanes 4-7; NS1; Lanes 12, 13) or specific competitor
(ALDHCAT; Lanes 8-11).116
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Figure 2.15. Electromobility Shift Analysis of PER-117 and PER-117HOX11
Nuclear Protein Binding to the ALDH1A1 Promoter CCAAT Box (-74/-70bp).
Radiolabelled ALDHCAT oligonucleotide probes (0.12pmol) were incubated with
10ug of nuclear extract to reveal complexes A-H (Lanes 2, 3). Specific complexes
(A, C and D) were identified following competition experiments using either a 5 or
35-fold molar excess of unlabelled specific competitor (ALDHCAT; Lanes 4, 5) or
non-specific competitor (ALDHDIST; Lanes 6, 7, NS2; Lanes 8, 9). Supershift
analysis was performed using monoclonal anti-HOX11 antibody (1-3ul)(Lanes 10-
13).117
D appeared similar for both PER-117 and PER-117HOX11, the much weaker complex
A  was  consistently  shown  to  be  specific  for  PER-117  only,  suggesting  that  the
expression of HOX11 is associated with loss of a transcriptional complex at the
CCAAT box (Figures 2.14, 2.15). In order to investigate the potential of ALDHDIST,
which contains an in vitro HOX11 binding site, to bind factors at the CCAAT box,
competition experiments were also performed using the ALDH1DIST oligonucleotide,
however complexes A, C and D remained intact, suggesting the binding of unique
factors at each site (Figures 2.14, 2.15).
Whilst the expression of HOX11 in PER-117 extracts was not associated with the
acquisition of a HOX11-specific complex, supershift experiments were performed with
monoclonal anti-HOX11 antibody (SantaCruz) in the event that a masked HOX11-
specific complex may be perturbed by antibody binding (or that disruption of HOX11
function by antibody binding may result in the formation of a unique complex).
However, no evidence of a complex involving HOX11 was observed (Figure 2.15). This
may have been due to the HOX11 antibody itself, since although demonstrated to be
specific, it has not been shown to be capable of causing a supershift. In order to confirm
the specific involvement of the CCAAT box in the formation of complexes A, C and D,
competition  experiments  were  performed  using  the  mutant  oligonucleotide
(ALDHCATMut), in which the CCAAT box sequence was replaced with random
nucleotides (GACTG), whilst flanking sequences were left intact (Figure 2.16). Unlike
the specific competitor, the mutant ALDHCATMut oligonucleotide was unable to
efficiently compete complexes A, C and D, confirming that these complexes are indeed
specific to nucleotides comprising the CCAAT box.
Despite previous studies which indicated that the ATAAA sequence located at -32/
-29bp is not a primary regulatory element in Hep3B cells (Yanagawa et al., 1995), our
DNase1 footprinting assays indicated transcription factor binding within this region,
suggesting that it may be involved in the transcriptional regulation of ALDH1A1 in both
the PER-117 and HEL cell lines. In order to investigate protein binding at this site,
PER-117 and PER-117HOX11 nuclear extracts were incubated with the ALDHPROX
oligonucleotide probe encompassing the GATA box (Figure 2.17). Gel retardation
assays  identified  five  complexes (I-M) and  competition  with unlabelled ALDHPROX118
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Figure 2.16. Electromobility Shift Analysis of PER-117 and PER-117HOX11
Nuclear Protein Binding to the ALDH1A1 Promoter CCAAT Box (-74/-70bp).
Radiolabelled ALDHCAT oligonucleotide probes (0.12pmol) were incubated with
10ug of nuclear extract to reveal complexes A-H (Lanes 2, 3). Specific complexes
were identified following competition experiments using a 35-fold molar excess of
unlabelled specific competitor (ALDHCAT; Lanes 4, 5). The specific involvement
of the CCAAT box in complex formation was assessed by competing binding to
the  CCAAT  box  with  a  35-fold  excess  of  unlabelled  ALDHCATMut
oligonucleotide (Lanes 6, 7).
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Figure  2.17.  Electromobility  Shift  Analysis  of  PER-117  and  PER-
117HOX11 Nuclear Protein Binding to the ALDH1A1 Promoter GATA
Box  (-34/-29bp).  Radiolabelled  ALDHPROX  oligonucleotide  probes
(0.12pmol) were incubated with 10ug of nuclear extract to reveal complexes I-
M (Lanes 2, 3). Specific complexes were identified following competition
experiments using either a 5 or 35-fold molar excess of unlabelled specific
competitor (ALDHPROX; Lanes 8-11) and non-specific competitor (NS1;
Lanes 12, 13). The involvement of ALDHDIST in complex formation was
assessed by competing binding to the GATA box with a 35-fold excess of
unlabelled ALDHDIST oligonucleotide (Lanes 4-7).120
and unrelated competitor oligonucleotides confirmed the specificity of complexes I, J, K
and M. Of particular interest was the substantial reduction in the intensity of complexes
I and J in PER-117HOX11 compared to PER-117, whereas the formation of complexes
K and M appeared enhanced in PER-117HOX11 compared to PER-117. Thus, the
expression  of  HOX11  appears  to  be  associated  with  quantitative  (and  possibly
qualitative) differences in transcription factor binding profiles at the GATA box, which
were not detectable by DNase1 footprinting. Although the DNase1-protected region
identified at -257/-246bp (ALDHDIST)  was  not  linked  to  significant  changes  in
transcriptional activity in in vitro luciferase experiments for either HEL or PER-117, a
possible link between ALDHDIST and transcription factor binding at the GATA box
was  identified  following  competition  experiments  using  unlabelled  ALDHDIST.
ALDHDIST was shown to compete efficiently with specific complexes I, J and M and
to a lesser extent K (Figure 2.17). This implicates the involvement of GATA factors in
these complexes, since the only sequence that ALDHDIST and ALDHPROX have in
common  is  a  canonical  GATA  site  (WGATAR).  The  specific  involvement  of
nucleotides  -32/-28bp  (ATAAAA)  in  the  formation  of  these  complexes  was
subsequently  confirmed  by  the  inability  of  an  unlabelled  mutant  competitor
oligonucleotide (ALDHPROXMut) to effectively remove complexes from the wild type
ATAAA sequence (Figure 2.18). In this mutant oligonucleotide, the sequence ATAAA
was replaced with CTCAGC, whilst flanking sequences were left intact. Although, as
expected,  competition  experiments  involving  NS2  oligonucleotide  did  not  affect
formation  of  complexes  I-M,  addition  of  anti-HOX11  antibody  resulted  in  the
appearance of the otherwise absent complex I for PER-117HOX11 (Figure 2.19). These
results imply that HOX11 may be directly involved in the disruption of complexes at
the GATA box, and that inhibition of HOX11 function by antibody binding may enable
the specific reformation of complex I. A summary of protein binding for PER-117 vs
PER-117 HOX11 cell lines at the CCAAT and GATA boxes is outlined in Figure 2.20.
2.3.3.2 EMSA Assays Using HEL Nuclear Extracts
Since the behaviour of the ALDH1A1 promoter in response to HOX11 was radically
different to that observed in PER-117 T-cells, we next sought to examine protein-DNA
complexes in the HEL cell line. EMSA of the ALDHCAT oligonucleotide using HEL
and HELHOX11 nuclear extracts yielded a slightly different DNA binding profile121
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Figure 2.18. Electromobility Shift Analysis of PER-117 and PER-117HOX11
Nuclear Protein Binding to the ALDH1A1 Promoter GATA Box (-34/-28bp).
Radiolabelled ALDHPROX oligonucleotide probes (0.12pmol) were incubated
with 10ug of nuclear extract to reveal complexes I-M (Lanes 2, 3). Specific
complexes were identified following competition experiments using a 35-fold
molar excess of unlabelled specific competitor (ALDHPROX; Lanes 4, 5). The
specific involvement of the GATA box in complex formation was assessed by
competing  binding  to  the  GATA  box  with  a  35-fold  excess  of  unlabelled
ALDHPROXMut oligonucleotide (Lanes 6, 7).
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Figure 2.19. Electromobility Shift Analysis of PER-117 and PER-117HOX11
Nuclear Protein Binding to the ALDH1A1 Promoter GATA Box (-34/-28bp).
Radiolabelled ALDHPROX oligonucleotide probes (0.12pmol) were incubated with
10ug of nuclear extract to reveal complexes I-M (Lanes 2, 3). Specific complexes
were identified following competition experiments using a 35-fold molar excess of
unlabelled  specific  competitor  (ALDHPROX;  Lanes  4,  5)  and  non-specific
competitor (NS2; Lanes 6, 7). Binding activity of proteins to ALDHDIST was
assessed  by  competing  binding  to  the  GATA  box  with  a  35-fold  excess  of
unlabelled  ALDHDIST oligonucleotide (Lanes 8, 9). Supershift analysis was
performed using monoclonal anti-HOX11 antibody (1-3ul)(Lanes 9-12).123
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compared to PER-117 (Figure 2.21). HEL nuclear extracts did not exhibit complexes A
and C, although complex D remained in common between both cell lines. In addition,
HEL nuclear extracts resulted in the gain of two additional complexes, complex O and a
high molecular weight complex N (Figure 2.21, 2.22). Notably, no differences were
observed between the HEL and HELHOX11 cell lines. In a similar manner to PER-117,
supershift experiments with anti-HOX11 antibody did not indicate involvement of
HOX11 binding at the CCAAT box (Figure 2.22). Competition experiments involving
the mutant ALDHCATMut oligonucleotide confirmed the specific involvement of the
CCAAT element in the formation of complexes D, N and O (Figure 2.21).
Gel retardation of the ALDHPROX oligonucleotide with HEL and HELHOX11 extracts
also yielded a DNA binding profile similar to PER-117, including specific complexes I,
K and M, although complex J was absent in HEL and HELHOX11, suggesting that
proteins binding this region may be involved in T-cell specific regulation (Figure 2.23).
Quantitative differences between the degree of complex M binding were also observed
between the erythroid and T-cell lines, with stronger binding activity observed for HEL
regardless of HOX11 expression status, compared to PER-117/HOX11. The specificity
of complex I, K and M binding to the ATAAA residues was subsequently confirmed
following  competition  experiments  with  unlabelled  ALDHPROXMut  mutant
competitor, which was unable to contest binding of proteins to the wild type sequence,
even at a 35-fold molar excess (Figure 2.23). Supershift experiments with HOX11
antibody did not affect complex formation, suggesting that HOX11 is not involved in
DNA-binding complexes at the GATA box, in accordance with the observation of no
difference in I, K or M complexes between HEL and HELHOX11 (Figure 2.24).
Intriguingly,  however,  unlabelled  ALDHDIST  oligonucleotide  was  capable  of
competing complexes I, K and M as effectively as unlabelled specific competitor. This
again highlights the possibility of interactions of GATA factors at ALDHDIST and at
the putative GATA box (Figure 2.24).
In summary, the results presented in this Chapter indicate that the expression of
ALDH1A1 in PER-117 and HEL cells is regulated, at least in part, by the binding of
trans-acting factors at the CCAAT box (-74/-70bp). Although no DNA footprint was
discerned  at this  site, EMSA analysis of  protein-DNA complexes identified binding of125
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Figure 2.21. Electromobility Shift Analysis of HEL and HELHOX11 Nuclear
Protein  Binding  to  the  ALDH1A1  Promoter  CCAAT  Box  (-74/-70bp).
Radiolabelled ALDHCAT oligonucleotide probes (0.12pmol) were incubated with
10ug of nuclear extract to reveal complexes B-O (Lanes 1, 2). Specific complexes
were identified following competition experiments using a 35-fold molar excess of
unlabelled specific competitor (ALDHCAT; Lanes 3, 4). The specific involvement
of the CCAAT box in complex formation was assessed by competing binding to the
CCAAT box with a 35-fold excess of unlabelled ALDHCATMut oligonucleotide
(Lanes 5, 6).
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Figure 2.22. Electromobility Shift Analysis of HEL and HELHOX11 Nuclear
Protein  Binding  to  the  ALDH1A1  Promoter  CCAAT  Box  (-74/-70bp).
Radiolabelled ALDH1PCAT oligonucleotide probes (0.12pmol) were incubated
with 10ug of nuclear extract to reveal complexes B-O (Lanes 2, 3). Specific
complexes were identified following competition experiments using a 35-fold
molar excess of unlabelled specific competitor (ALDH1PCAT; Lanes 4, 5) or non-
specific competitor (NS2; Lanes 8, 9). Binding activity of proteins to ALDHDIST
DNA sequences was assessed by competing binding to the CCAAT box with a 35-
fold excess of unlabelled ALDHDIST oligonucleotide (Lanes 6, 7). Supershift
analysis was performed using monoclonal anti-HOX11 antibody (1-3ul)(Lanes 10-
13).
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Figure 2.23. Electromobility Shift Analysis of HEL and HELHOX11 Nuclear
Protein  Binding  to  the  ALDH1A1  Promoter  GATA  Box  (-34/-28bp).
Radiolabelled ALDHPROX oligonucleotide probes (0.12pmol) were incubated
with 10ug of nuclear extract to reveal complexes I-M (Lanes 1, 2). Specific
complexes were identified following competition experiments using a 35-fold
molar excess of unlabelled specific competitor (ALDHPROX; Lanes 3, 4). The
specific involvement of the GATA box in complex formation was assessed by
competing  binding  to  the  GATA  box  with  a  35-fold  excess  of  unlabelled
ALDHPROXMut oligonucleotide (Lanes 5, 6).
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Figure 2.24. Electromobility Shift Analysis of HEL and HELHOX11 Nuclear
Protein  Binding  to  the  ALDH1A1  Promoter  GATA  Box  (-34/-28bp).
Radiolabelled ALDHPROX oligonucleotide probes (0.12pmol) were incubated with
10ug of nuclear extract to reveal complexes I-M (Lanes 2, 3). Specific complexes
were identified following competition experiments using a 35-fold molar excess of
unlabelled of specific competitor (ALDHPROX; Lanes 4, 5) and non-specific
competitor (NS2; Lanes 6, 7). Binding activity of proteins to ALDHDIST sequences
was assessed by competing binding to the GATA box with a 35-fold excess of
unlabelled ALDH1PHOX11 oligonucleotide (Lanes 8, 9). Supershift analysis was
performed using monoclonal anti-HOX11 antibody (1-3ul)(Lanes 10-13).129
common factors (complex D). Cell-type specific complexes (PER-117; A, C)(HEL; N,
O) were also capable of binding the CCAAT box. In keeping with the luciferase results
which demonstrated that HOX11 affects ALDH1A1 expression via interactions at the
CCAAT  box  in  the  PER-117  but  not  HEL  cell  line,  expression  of  HOX11  was
associated  with  the  loss  of  a  PER-117  specific  complex  (complex  A)  in  EMSA
analyses. In the case of HEL, where only a small specific effect on ALDH1A1 promoter
activity was observed in luciferase assays which did not depend on the presence of the
CCAAT box or the GATA box, there were no observable changes in the protein-DNA
binding complexes due to HOX11 at either of these sites. Analysis of the GATA box
also revealed binding of common factors between PER-117 and HEL (complexes I, K
and M), however, binding of additional factors was also observed in the case of PER-
117 (complex J). Significantly, the presence of HOX11 was associated with quantitative
changes in the formation of complexes I and J in PER-117, whereas protein binding at
this  site  was  again  unaffected  by  HOX11  in  the  HEL  cell  line.  The  ability  of
ALDHDIST to effectively compete ALDHPROX for protein binding, suggests that these
two probes share a common binding site. Given that the only sequence that these probes
have in common is WGATAA, the nuclear protein(s) capable of binding to both may
belong to the GATA family.
2.4  DISCUSSION
Following the identification of ALDH1A1 as a gene transcriptionally activated by
HOX11 in the murine fibroblast NIH 3T3 cell line and physiologically repressed by
Hox11 in the developing spleen, the purpose of this study was firstly to identify
important cis-acting DNA elements within the promoter of ALDH1A1 and to examine
associated trans-acting regulatory proteins and secondly, to investigate the effect of
HOX11 on the transcriptional regulation of ALDH1A1 in both an ALDH1A1-expressing
(HEL) and non-expressing (PER-117) cell line.
A transient reporter assay involving the cotransfection of both promoter and HOX11
expression constructs into both the HEL and PER-117 cell lines, was chosen as the
system to initially characterise cis-acting DNA sequences regulating ALDH1A1 gene
expression for several reasons. Firstly, the transient system is a simple and rapid method
that allows maximal flexibility with regards to the cell line and promoter constructs130
being used to study the regulation of a given gene. Secondly, the introduction of
HOX11 into the cells of interest by transient transfection, as opposed to analysing the
effects  of  HOX11  on ALDH1A1 promoter activity in stably transfected HOX11-
expressing versus non-expressing clones, reduces the likelihood of analysing promoter
effects that may be caused by clonal differences as opposed to differential HOX11
expression. Analysis of nested deletions of the ALDH1A1 promoter in both HEL and
PER-117 cell lines revealed that, in accordance with previous studies in the ALDH1A1-
expressing Hep3B cell line and in Hepa-1 mouse hepatoma cells (Yanagawa et al.,
1995, Elizondo et al., 2000), the main activity of the ALDH1A1 promoter pertains to a
functional CCAAT box located at -74/-70bp, since deletion of this element led to a
reduction in luciferase activity to baseline levels. The CCAAT box is an element
essential for the regulation of a wide variety of eukaryotic promoters and may bind
several nuclear factors including CP1 (NF-Y), CP2, CCAAT box transcription factor
(CTF/NF1), which is thought to play a role in the constitutive expression of certain
genes and the CCAAT/enhancer binding protein (C/EBP), which is thought to activate
genes specifically expressed in the liver.
Although DNase1 footprinting of the proximal ALDHA1 promoter encompassing this
element  did  not  identify  transcription  factor  binding  at  this  site,  EMSA  of  the
ALDHCAT oligonucleotide using PER-117 and HEL nuclear extracts identified three
specific protein-DNA binding complexes for PER-117 (A, C and D) and three specific
complexes for HEL (D, N and O).  Since this probe also harbours an RARα binding
site, which has previously been shown to bind RARα/RXR heterodimers required in
part for ALDH1A1  expression  (Elizondo  et al.,  2000)(Figure  2.2),  competition
experiments were performed using a mutant CCAAT oligonucleotide probe. This
confirmed that these complexes were indeed specific to nucleotides comprising the
CCAAT box (-74/-70bp). Aside from complex D which was common between the two
cell lines, the differential binding activities demonstrated by PER-117 (complexes A
and C) and HEL (complexes N and O), suggested that ALDH1A1 is regulated at the
CCAAT box by additional cell-type specific transcriptional complexes. This may
account for the differential expression of ALDH1A1 in these cell lines. Previous
analyses of protein-DNA interactions at the CCAAT box demonstrated binding by NF-
Y in the Hep3B liver cell line (Yanagawa et al., 1995) and by C/EBPβ binding in liver131
Hepa-1 cells (Elizondo et al., 2000). Since there is precedence for combinatorial
protein-protein interactions between C/EBP and GATA family members (Du et al.,
2002, Tremblay et al., 2002), it is possible that regulation at the CCAAT box involves a
common factor (e.g. C/EBP) in addition to T-lineage (in the case of PER-117) and
erythroid (in the case of HEL)-specific GATA family members (GATA-3 and GATA-1,
respectively).  Future  experiments  involving  supershift  analyses,  using  antibodies
specific for C/EBP, GATA-1 or GATA-3 members, may provide an insight into the
lineage-specific factors important for regulating promoter activity at this site in both the
HEL and PER-117 cell lines.
The identification of specific protein-DNA binding complexes at the CCAAT box by
EMSA but not DNase1 footprinting, highlights the advantage of utilising a combination
of both assays when attempting to characterise trans-acting protein-DNA binding in
vitro, since some DNA binding proteins may only be detected using one method (Carey
& Smale, 2000). For example, in certain instances, physiological levels of a crucial
transcription factor may be at too low a concentration to protect sufficient probe in a
DNase1 footprinting assay to yield a discernable footprint, in which case EMSA is
useful, since binding of protein factors to a small percentage of probe will result in
visible  changes  in  the  migration  of  the  probe.  Protein  binding  may  also  remain
undetected by DNase1 footprinting analysis if the binding site resides within a DNA
region  that  is  relatively  devoid  of  DNase  cleavage  sites,  whereas  EMSAs  may
successfully identify binding activities in these areas. In certain cases where protein-
DNA  complexes  are  unable  to  withstand  gel  electrophoresis,  however,  DNase1
footprinting may be advantageous, since this method relies on interactions in solution
without requiring maintenance of complex formation.
Previous reports demonstrated that the non-canonical TATA box (ATAAA) is not a
primary  regulatory  element  in  the  ALDH1A1-expressing  Hep3B  liver  cell  line
(Yanagawa et al., 1995). Indeed our functional promoter analyses indicated that this
element alone was unable to support ALDH1A1 promoter activity in either HEL or
PER-117 cells. Nevertheless, DNase1 footprinting assays revealed protein binding at
this site (ALDHPROX) for both the HEL and PER-117 cell lines. Moreover, EMSAs
using the ALDHPROX oligonucleotide probe encompassing this site, identified binding
activities specific for ATAAA residues in both HEL and PER-117. In the case of PER-132
117, four specific DNA binding complexes were identified (complexes I, J, K and M),
compared with three specific complexes for HEL (complexes I, K and M). Complex J
may therefore represent a T-cell specific binding activity in a transcriptional complex
involving other common factors. Intriguingly, the ALDHPROX probe encompasses a
putative  GATA  binding  site  and  an  oligonucleotide  probe  spanning  the  DNase1
protected site ALDHDIST, which also harbours a canonical GATA-1/3 binding site,
effectively competed binding of specific complexes I, J and M to the ALDHPROX
oligonucleotide. This indicated the presence of a common binding site in both probes.
Taken together, these results suggest that GATA factors may be involved in the specific
regulation of ALDH1A1 in HEL and PER-117 cell lines at both the ALDHDIST and
ALDHPROX sites. Given the roles of GATA-1 in the differentiation of the erythroid
lineage (Pevny et al., 1991) and of GATA-3 in the regulation of T-cell specific genes
(Ko et al., 1991), it is possible that the differential binding observed between HEL
(erythroid lineage) and PER-117 (T-cell lineage) cell lines may reflect binding of
specific members of the GATA family to these sites. Supershift analyses are now
required to confirm the identity of proteins binding to these elements. It is possible that
the lack of an effect on ALDH1A1 promoter activity upon mutation of the ATAAA box
(Yanagawa  et al.,  1995),  or  upon  removal  of  the  ALDHDIST site in transient
transfection assays (e.g. between constructs -303 and -201/+42), may be due to a degree
of functional redundancy between these sites. Indeed, the initial failure to identify
important control elements in the Ig µ enhancer was partly due to the functional
redundancy of several regulatory elements within this enhancer (Dang et al., 1998). The
effect of simultaneous mutation of both ALDHDIST and ALDHPROX  sites may
therefore provide an insight into the importance of these elements in promoter function.
Given that the GATA site is located at the canonical TATA location in the ALDH1A1
promoter (at -30bp), it is likely that it represents a specialised TATA box, capable of
binding both GATA and members of the basal transcriptional machinery. The existence
of such a dual function element overrepresented among erythroid-specific promoters
has been previously documented, where it is referred to as a GATA box (Fong &
Emerson, 1992, Barton et al., 1993, Aird et al., 1994, Surinya et al., 1997, Tsuchiya et
al., 1997). One model derived from studies of the rat platelet factor 4 (PF4) gene,
suggests that GATA1 or 2 binds at the GATA box to prevent transcription by sterically133
inhibiting the formation of preinitiation complexes, and suggests that the relative levels
of GATA and basal factors may account for tissue specificity of gene expression (Aird
et al., 1994). In a separate study, GATA-1 was shown to regulate the chick β-globin
gene, through GATA sites present in the distal 3’enhancer and at GATA box motif
(-30bp) in the promoter (Fong & Emerson 1992). The binding of both elements
mediated interactions between the enhancer and promoter elements (Fong & Emerson
1992). It is postulated that TFIID and associated adaptor proteins subsequently displace
GATA from the -30bp box and interact with proteins at the erythroid-specific enhancer
to initiate transcription (Fong & Emerson 1992). In the case of ALDH1A1, which is not
normally highly expressed in haematopoietic tissues, it is possible that GATA-1, -2 or
-3 factors may bind the GATA box of the ALDH1A1 promoter in their respective tissues
to inhibit expression of ALDH1A1, whereas in other tissues expressing GATA-4, -5 or
-6 (e.g. heart, gut, urogenital, brain), this GATA site is unoccupied and TFIID is able to
bind and initiate transcription, thereby accounting for the expression of ALDH1A1 in
these tissues. This theory does not explain the high level of endogenous expression of
ALDH1A1 in HEL cells, however this may not be reflective of a normal physiological
situation given that HEL is a transformed cell line.
Having identified regions of the ALDH1A1 promoter important for the activation in
both HEL and PER-117 cell lines, it was then pertinent to assess the effect of HOX11
on ALDH1A1 promoter activity and to identify the specific element(s) responsible for
mediating a HOX11-induced response. Initial experiments were performed in HEL cells
and a comparison of endogenous ALDH1A1 expression in HEL cells stably transfected
with either pEFBOS or pEFBOSHOX11 revealed a significant downregulation of
ALDH1A1 in response to HOX11. This suggested that HOX11 represses ALDH1A1
promoter activity in this cellular background. In contrast, transient transfection of HEL
cells with HOX11 and ALDH1A1 promoter constructs ranging from +1 to -2159/+42bp,
resulted in an apparent activation of the ALDH1A1 promoter in all constructs tested.
Since HOX11 was capable of activating transcription from the pGL3Basic luciferase
vector in the HEL cell background, even in the absence of ALDH1A1  promoter
sequences, statistical analyses were performed. This was done in order to assess
whether the effect of HOX11 on the ALDH1A1 promoter was above the background
effect of HOX11 on the pGL3Basic vector alone. Although the mechanism by which134
HOX11  is  able  to  spuriously  activate  luciferase  expression  remains  unclear,
independent studies have reported high background luciferase expression in the pGL2
and pGL3Basic series of reporter vectors resulting from the interaction of general
transcription  factors  (de  Wet  et al., 1987), or tissue specific factors such as the
osteoblast specific transcription factor Cbfa1 and the estrogen receptor α (ERα), with
cryptic  promoter  elements  in  the  vector  backbone  (Grimm  &  Nordeen,  1999,
Thirunavukkarasu et al., 2000).
Statistical analyses revealed that the effect of HOX11 on the ALDH1A1 promoter was
higher in constructs ranging from +1 to -91/+42bp, than the effect of HOX11 on the
pGL3Basic vector alone. This suggested that HOX11 was capable of transactivating the
ALDH1A1 promoter either directly or indirectly via an element located between
+1/+42bp (Figure 2.25A). Although no consensus binding sites for HOX11 or known
cofactors were identified in this region, future studies involving EMSAs may shed
insight into the mechanism of HOX11-mediated transactivation within this region. The
ability  of  HOX11  to  activate  transcription  above  background  was  sustained  for
ALDH1A1 promoter constructs between +1 and -91 inclusive. However, following the
addition of 55bp to create the -146 construct, the activation potential of HOX11
significantly declined, with a 1.8-fold decrease in activity observed between constructs
-91 and -146 (P=0.001). This suggested that a factor binding between -91/-146bp is
capable of exerting a negative influence on the weak HOX11 transactivation potential
within the +1 construct (Figure 2.25B). Analysis of this region in more detail identified
several elements including an Ets-1 site which is conserved between human, mouse,
marmoset and rat species, however, the specific mechanism by which this occurs will
require further analysis of trans-acting factors within this region and due to time
constraints was not investigated in this study. Notably, the effect of HOX11 on
ALDH1A1 promoter regulation in the HEL cell line did not appear to involve the
CCAAT  box  (-74/-70bp)  or  GATA  box  (-34/-28bp),  and  in  keeping  with  these
observations, we did not observe any differences in DNA binding activities between
HEL and HELHOX11 nuclear extracts at either the CCAAT box or the GATA box by
EMSA.135
Figure 2.25. HOX11 Activates Transcription in the HEL Cell Line. (A) HOX11
stimulates  transcription  from  the  pGL3Basic  vector  alone,  as  well  as  from  the
ALDH1A1 promoter (+1/+42bp) (B) Factor(s) binding the region -146 to -91bp inhibit
the transactivation potential of HOX11 (C) HOX11 stimulates transcription following
deletion of the DNA binding helix (∆H3), suggesting that HOX11 may function as a
transcriptional activator by via protein-protein interactions with members of the basal
transcriptional machinery.
The  ability  of  a  HOX11  DNA-binding  mutant  (HOX11∆H3)  to  transactivate
transcription from the ALDH1A1 promoter in the HEL cell line was subsequently
investigated using the -91 reporter construct, since this construct demonstrated the
greatest transactivation by HOX11 (1.84-fold over the effect of HOX11 on pGL3Basic;
P < 0.001). These experiments revealed that the DNA-binding helix was not required
for  the  activation  function  of  HOX11,  suggesting  that  HOX11  may  stimulate
transcription in a DNA-binding independent manner, possibly via protein-protein
interactions. Intriguingly, HOX11 has been implicated in an in vivo association with a
member of the basal transcriptional complex, TFIIB, following immunoprecipitation of
HOX11 from the T-ALL cell line ALL-SIL and analysis of HOX11-bound factors by
mass spectrophotometry (MALDI-TOF)(Heidari & Greene, unpublished observations).
This  suggests  that  HOX11  may  transactivate  transcription  via  interactions  with
components of the basal transcriptional machinery (Figure 2.25C). The interaction of136
general transcription factors (GTFs) with sequence-specific DNA binding proteins is
thought to constitute a mechanism for establishment of high-level gene expression, and
interactions may involve various regulatory domains of the transcription factor as well
as the DNA binding domain (Sauer et al., 1995). In further support of the notion that
HOX11 may modulate gene transcription by interacting with components of the basal
transcriptional machinery, in vitro transcription assays performed by Owens et al.,
(2003)  demonstrated  that  HOX11  is  capable  of  repressing  transcription  at  the
adenovirus major late promoter, by interacting with one or more components of the
RNA polymerase holoenzyme.
Following these studies, the effect of HOX11 on ALDH1A1 expression was studied in
the T-ALL cell line, PER-117. Although expression of HOX11 induces upregulation of
endogenous  levels  of  ALDH1A1  in  stably  transfected  PER-117  cells  (Greene,
unpublished  observations),  HOX11  repressed  ALDH1A1  promoter  activity  by
approximately 2.3-fold (P < 0.001), via an element contained within the -91 construct in
transient reporter assays. Thus, the transient transfection studies with the ALDH1A1
promoter constructs consistently yielded an effect by HOX11 opposite to that of the
endogenous ALDH1A1 gene. Further refinement of this responsive element by analysis
of progressively smaller deletion constructs of the ALDH1A1 promoter (-50 to +1), in
conjunction with deletion analysis (-91∆CAT), identified the CCAAT box (-74/-70bp)
as the specific cis-regulatory element through which HOX11 mediates repression.
Analysis of protein binding at this site by EMSA, revealed the loss of a specific protein-
DNA binding complex (complex A) in HOX11-expressing cells. This suggested that
HOX11  repressed  transcription  by  interfering  with  the  binding  of  a  specific
transcription factor at the CCAAT box. In contrast to the activation function of HOX11,
which occurred independently of DNA binding, deletion of the DNA binding helix of
HOX11 (∆H3) abolished repressor function, as evidenced for both the -91 and the pSV-
β-Gal internal control reporter constructs. Moreover, this relief in transcriptional
repression was coupled with a concomitant increase (~5-fold) in promoter activity.
Taken together, these results suggest that HOX11 is capable of acting as both a
transcriptional repressor and activator via two potentially independent mechanisms. In
the case of transcriptional repression HOX11 may act either by:137
1)  Passive Repression – HOX11 may interfere with positive trans-acting factors at
the CCAAT box (for example those in DNA binding complex A; Figure 2.26B), for
example by displacement (occlusion), as is the case for the CCAAT-Displacement
Protein/Cut homeobox (CDP/Cux) transcription factor, which is reported to repress a
large number of genes by competing for binding site occupancy (Barberis et al., 1987).
The hypothesis whereby HOX11 disrupts binding of a factor(s) to the CCAAT box was
supported by EMSA of an oligonucleotide encompassing the CCAAT box using PER-
117 and PER-117HOX11 nuclear extracts, which revealed the loss of a specific
complex (A) in the presence of HOX11. One potential candidate for an interacting
factor at this site is CTF1, a ubiquitously expressed CCAAT box binding transcription
factor which is capable of recruiting TBP-DNA complexes and has previously been
shown to interact with HOX11 (Zhang et al., 1999).
2) Active Repression – This may involve inhibition of the formation of a functional
preinitiation  complex,  inhibition  of  adjacently  bound  transcriptional  activators
(quenching), or recruitment of repressor complexes including histone deacetylases
(HDACs),  which  modify  local  chromatin  structure  causing  a  reduction  in  gene
expression (Figure 2.26C). Notably, the transcriptional activation domain at the NH2
terminus  of  HOX11,  harbours  a  binding  domain  for  members  of  the
Groucho/transducin-like Enhancer of split (Gro/TLE) co-repressor family, which are
capable of repressing transcription via the recruitment of HDACs (Yao et al., 2001)
and/or by interacting with members of the basal transcriptional machinery, specifically,
TFIIE (Gromoller & Lehming, 2000). It is of interest to note that the expression of
HOX11 in PER-117 was not only associated with the loss of a complex at the CCAAT
box (complex A), but was also associated with a loss of PER-117-specific complexes I
and J at the GATA box, and the enhancement of complexes K and M. Moreover,
inclusion of anti-HOX11 antibody into EMSA binding reactions reduced the inhibition
of one of these complexes (I), implying that HOX11 is directly involved in the
disruption of complex I at the GATA box. Thus, HOX11 is associated with perturbation
of specific protein complexes at the GATA box. Given that the expression of HOX11 in
our transient assays resulted in transcriptional repression, this data may fit a model in
which HOX11 acts by inhibiting the formation of a functional preinitiation complex.138
Figure 2.26. HOX11 Acts as a Bi-functional Transcription Factor in PER-
117 Cells. (A) Trans-acting factors stimulate transcription of ALDH1A1 via
binding to the CCAAT box. HOX11 is capable of repressing transcription at the
CCAAT box  (-74/70bp) in a DNA-binding dependent manner associated with a
loss in complex A binding, either by passive mechanisms (B) by precluding
binding of positive-acting factors at the CCAAT box or active mechanisms (C)
possibly by recruiting repressor complexes including histone deacetylases
(HDACs). This change in activity is also associated with changes in complex
formation at the GATA box. Upon loss of DNA binding (∆H3), HOX11
stimulates transcription above that effected by complexes A, C and D, possibly
via  protein-protein  interactions  with  members  of  the  basal  transcriptional
machinery (D).139
The models of transcriptional activation and repression described in Figures 2.25 and
2.26  portray  the  effects  of  HOX11  acting  directly  in  concert  with  the  basal
transcriptional machinery or via direct interactions at the CCAAT box. It is also
possible that HOX11 functions to alter ALDH1A1 transcription indirectly by affecting
the expression of genes higher up in a hierarchical transcriptional cascade. Given that
HOX11 is capable of affecting the expression of ALDH1A1 in a plethora of cellular
backgrounds of human and murine origin including murine spleen, NIH 3T3, HEL,
PER-117 and J2E cell lines, however, it seems more likely that ALDH1A1 represents a
direct target of HOX11.
Despite the fact that the ALDH1A1 promoter is repressed by HOX11 in our in vitro
reporter assays in PER-117, which contrasts with the induction of ALDH1A1 by HOX11
in stably transduced PER-117 cells, these studies nevertheless provide insight into cis-
regulatory elements and potential mechanisms by which HOX11 is able to affect gene
transcription. The differences in these in vitro reporter assays as opposed to in vivo
expression levels may reflect the limitations of transient transfection assays and may
relate to the fact that the regulatory sequences under investigation are maintained in an
artificial configuration. That is, they are constrained within a plasmid construct that
does not conform to the appropriate chromatin configuration, which may affect normal
mechanisms of gene regulation. In addition, artificially high copy numbers of the
regulatory  sequence  are  present  following  transfection  into  the  cell,  resulting  in
disequilibrium between the ratio of transcription factors to regulatory elements, which
may also account for this discrepancy. Alternatively, more distal promoter elements not
included in these promoter constructs may be required for appropriate activity, in terms
of repression or activation.
The results of this Chapter indicated that HOX11 represses transcription in a DNA
binding-dependent manner, since deletion of helix 3 of the homeodomain (HOX11∆H3)
abolished the ability of HOX11 to repress transcription from the ALDH1A1 promoter.
However, Owens et al., (2003) demonstrated that homeodomain point mutations shown
to alter or abrogate DNA binding specificity (by mutating residues T47 and K55 of the
homeodomain) had no significant effect on ability of HOX11 to repress transcription
from the SV40 promoter. They concluded that HOX11-mediated repression occurs in140
the absence of DNA binding, possibly via protein-protein interactions. A structurally
intact homeodomain was nevertheless still required for repression, since deletion of
helix 3 abolished repressor function (Owens et al., 2002). Support for this model
derives from studies of the murine homeodomain protein Msx-1 (Catron et al., 1995,
Zhang  et al., 1996). Msx-1 represses transcription in a DNA binding-independent
manner, via direct interactions with the TATA binding protein (TBP)(Zhang et al.,
1996). This interaction is mediated through residues in the N-terminal arm of the
homeodomain that are also required for transcriptional repression, suggesting that the
processes of TBP binding and transcriptional repression are linked (Catron et al., 1995,
Zhang et al., 1996). Thus, although our results suggest that repression of ALDH1A1 by
HOX11 requires DNA binding, it is possible that deletion of helix 3 of the HOX11
homeodomain perturbs the structure of the homeodomain required for protein-protein
interactions  with  members  of  the  basal  transcriptional  machinery.  Alternatively,
although the ability of HOX11 to repress transcription was not affected by T47 and K55
DNA binding-mutant proteins in the SV40 viral promoter model utilised by Owens et
al., (2003), these mutations may abrogate HOX11 repressor function in the context of
physiological target genes, such as ALDH1A1. Indeed, these mutants affected the ability
of HOX11 to induce Aldh1a1 expression in NIH 3T3 cells (Owens et al., 2003). Since
our studies did not incorporate the T47 (specificity) and K55 (DNA contact, repressor
region) HOX11-DNA binding mutants, however, we were unable to assess the effect of
these mutations on the ability of HOX11 to repress the ALDH1A1 promoter and
incorporation of such mutants in future studies may clarify the mechanism by which
HOX11 represses the ALDH1A1 promoter in PER-117 T-cells.
In summary, the work described in this Chapter has shown that HOX11 is capable of
modulating the activity of the ALDH1A1 promoter in a transient transfection assay
involving the cotransfection of ALDH1A1 promoter constructs into HEL and PER-117
cell lines. This strengthens the status of ALDH1A1 as a bona fide target gene of HOX11.
In the case of HEL, expression of HOX11 was associated with a weak transactivation of
the ALDH1A1 promoter within +1/+42bp, however this activation declined with the
addition of promoter sequence between -91 and -146bp, suggesting that factors binding
in this region may exert a negative regulatory influence on HOX11. A significant
activation function for HOX11 was also observed on the empty pGL3Basic vector141
construct  and  was  not  affected  following  deletion  of  the  DNA  binding  helix
(HOX11∆H3). This suggested that activation may occur in a DNA binding-independent
manner,  possibly  via  protein-protein  interactions.  Conversely,  HOX11  repressed
ALDH1A1 promoter activity in the PER-117 cell line, possibly by interfering with
positive-acting factors at the CCAAT box (-74/-70bp) and at the GATA box (-34/28bp).
In contrast to the activation function of HOX11, which was not affected by removal of
the DNA binding helix, the HOX11∆H3 mutant was unable to repress transcription, and
instead switched to a potent transcriptional activator. These results imply that HOX11
mediates repression by participating in a repressor complex that requires helix 3 either
for (1) DNA binding to a specific promoter element or (2) for maintaining stable
interactions with components of the repressor complex. Thus, the inability of the ∆H3
mutant to repress transcription may result from an abrogation of DNA binding potential
or alternatively, the ∆H3 mutant may act in a dominant negative manner to sequester
transcriptional  repressors  whilst  simultaneously  participating  in  a  transcriptional
activation complex. Although the activation and repression activities of HOX11 appear
to differ with respect to the requirement for DNA binding, both mechanisms are likely
to involve interactions with basal transcriptional machinery, with the differential
activity of HOX11 directed by cell-specific factors in the HEL and PER-117 cell lines.
Indeed,  there  is  significant  precedent  for  HOX  proteins  to  display  this  dual
functionality, for example the pancreatic homeodomain-containing factor PDX1, may
act as either a transcripional repressor or activator, depending on the specific PBX
isoform with which it associates (Asahara et al., 1999).142
Chapter 3
FHL1 as a Target Gene of HOX11: Identification of the FHL1 Gene Promoter
and Assessment of its Transcriptional Regulation by HOX11
3.1 INTRODUCTION
FHL1 is a 32kDa protein that  belongs to a specific subclass of LIM-only (LMO)
proteins containing four complete and one amino-terminal half LIM (FHL) domains,
including FHL2, FHL3 and FHL4. FHL family members have proposed roles in
mediating  the  protein-protein  interactions  of  transcription  factors,  signalling  and
cytoskeleton-associated proteins (Brown et al., 1999, Fimia et al., 2000, Kong et al.,
2001). FHL1, previously known as SLIM1 (Striated Muscle LIM protein 1), is expressed
at high levels in adult skeletal muscle and at intermediate levels in the cardiac outflow
tracts of the developing embryonic heart (Brown et al., 1999). It is thought to play a role
in the differentiation of this structure, which gives rise to the aortic and pulmonary
outflow tracts and is later limited to the aorta and atria in the adult heart (Brown et al.,
1999). In addition, FHL1 is also detected as a low abundance transcript in a panel of
other tissues including brain, placenta, lung, liver, pancreas, small intestine, colon and
the ovaries, suggesting a wider expression than previously reported (Brown et al., 1999,
Lee et al., 1999, Greene et al., 1999, Ng et al., 2001).
To date, two additional alternatively spliced human isoforms of FHL1 have been
identified. FHL1B/SLIMMER shares the amino-terminal three and a half LIM domains
with FHL1, but differs at the C-terminus with the addition of three putative bipartite
nuclear localisation signals (NLS), a putative nuclear export sequence (NES) and an
RBP-J  binding  region  (Brown  et  al.,  1999,  Lee  et  al.,  1999).  Like  FHL1,
FHL1B/SLIMMER is highly expressed in skeletal muscle, however, analysis of the
intracellular location of these splice variants in the murine skeletal muscle cell line,
Sol8,  revealed  that  whilst  FHL1   expression  is  predominantly  cytosolic,
FHL1B/SLIMMER shuttles between the nucleus and cytoplasm in myoblasts and
myotubes  respectively  (Brown  et al., 1999). The association of FHL1 with focal
adhesions and actin cytoskeleton in COS-7 cells and the differentiation-dependent
intracellular localisation of FHL1B/SLIMMER, suggests that these isoforms fulfil143
distinct roles in regulating muscle cell function, where FHL1 is required for muscle cell
cytoskeletal structure and FHL1B/SLIMMER acts as a transcriptional regulator in
undifferentiated muscle cells (Brown et al., 1999). A second alternatively spliced
isoform of FHL1, FHL1C (the human homolog of murine KyoT2)(Taniguchi et al.,
1998), comprises the N-terminal two and a half LIM domains of FHL1, followed by a
C-terminal RBP-J binding region (Ng et al., 1999). FHL1C is expressed in human testis
and skeletal muscle and at lower levels in the heart, and is predicted to interact with
RBP-J DNA binding protein, to negatively regulate RBP-J mediated transcription, as
the murine KyoT2 does (Taniguchi et al., 1998, Ng et al., 1999).
The  identification  of  functionally  relevant  target  genes  and  elucidation  of  the
transcriptional complexes controlling the expression of such genes in both physiological
and tumorigenic contexts, is crucial to our understanding of the mechanisms by which
nuclear oncogenes such as HOX11 can induce tumorigenesis. Fhl1 was identified as a
gene that can be transcriptionally upregulated by HOX11 in NIH 3T3 cells (Greene et
al., 1998), however the relevance of this relationship with respect to the normal
regulatory roles of FHL1, or in leukaemogenesis, remains unclear. The requirement for
Hox11 in spleen development during mouse embryogenesis, suggested that Fhl1 and
Aldh1a1, which was also identified as a potential HOX11 target in cDNA RDA
experiments, may play functional roles in spleen development. Intriguingly, the related
family member, FHL2, has recently been found to modulate the activity of another
transcription factor required for spleen organogenesis, WT1 (Herzer et al. 1999).
Furthermore, Hox11 was shown to regulate the expression of Wt1 in the developing
spleen (Koehler et al., 2000), highlighting the possibility that LIM-only transcription
factors may be involved in transcriptional networks regulating spleen development.
However, although an inverse relationship between Hox11 and Aldh1a1 mRNA levels
was identified in the developing spleen, suggesting that Aldh1a1 may represent a
physiological target gene of Hox11 involved in spleen organogenesis, the expression of
Fhl1 did not appear to be affected by Hox11 in wild type or Hox11 null embryos
(Greene et al., 1998). Thus, Fhl1 appears not to be a physiological target gene of
HOX11, at least in the spleen. By contrast, it remains formally possible that FHL1 may
represent an oncogenically relevant target gene, particularly in view of the observed
expression of FHL1 mRNA in eight of twelve T-ALL cell lines as determined by144
Northern blot analysis (Greene et al., 1998). This included two cell lines, ALL-SIL and
PER-255 that overexpress HOX11 as a result of chromosomal translocations involving
the HOX11 locus. Furthermore, a role for FHL members in tumorigenesis has been
suggested following the discovery that the human ACT gene is expressed in numerous
human tumour cells lines derived from melanomas, squamous cell carcinomas and
leukaemias and that FHL2 and FHL3 were also overexpressed in several of these cell
lines (Morgan & Whawell, 2000). The possibility that FHL1 may be an oncogenically
relevant target of HOX11 is given added weight by the fact that there is precedent for
the dysregulation of other LIM-only transcription factors in T-ALL, namely LMO1 and
LMO2 (Sanchez & Rabbitts, 1993).
The significance of the observations with respect to the role of FHL1 in tumorigenesis
to date, are unclear. While correlations in the expression patterns of HOX11 and FHL1
in NIH 3T3 cells and human T-ALL cell lines provide some evidence to support the
case that FHL1 may be a HOX11 target, functional experiments are required to confirm
whether HOX11 has the ability to transcriptionally regulate the FHL1 promoter. To
address the role of FHL1 as a transcriptional target of HOX11, therefore, the ability of
HOX11 to regulate the putative promoter of this gene was assessed in the PER-117 T-
cell  and  HEL  erythroid  cell  lines  using  luciferase  assays  involving  transient
transfection. Since neither the transcriptional start site nor promoter of FHL1 had been
previously characterised, a PCR strategy was first employed to map the startpoint of the
gene and thus reveal its promoter region. Specifically the aims of this Chapter were 1)
to  identify  the  transcriptional  start  site  of  the  human  FHL1  gene  by  5’  rapid
amplification of cDNA ends (5’ RACE), 2) to characterise the proximal promoter of
FHL1 by identifying predicted cis-acting regulatory elements and other relevant core
promoter features and 3) to perform luciferase reporter assays to investigate the activity
of the FHL1 proximal promoter and its possible mechanism of regulation by HOX11 in
order to formally determine its status as a HOX11 target gene.145
3.2 METHODS
3.2.1 5’ RACE
3.2.1.1  Cell Lines
ALL-SIL is an immature, human leukaemic cell line of T-cell phenotype (T-ALL) that
harbours a t(10;14) chromosomal translocation and thus overexpresses HOX11. The cell
line was provided by the Division of CLCR of the TVW Telethon Institute for Child
Health Research (Perth, Western Australia) and was shown to be Mycoplasma-free at
the level of PCR (performed by Jette Ford at the Division of CLCR). Cells were sub-
cultured twice weekly (1:5) in RPMI-1640 Multi-cel Medium (Trace) supplemented
with  10%  (v/v)  FCS  (Trace),  2mM  L-Glutamine  (Trace)  and  50µg/ml
Pencilllin/Streptomycin (Trace). Cells were typically cultured in 75cm
2 filter-top culture
flasks (NUNC
TM) and were maintained at 37
oC with 5% CO2.
3.2.1.2  RNA Isolation
Total  RNA  was  extracted  from  the  ALL-SIL  cell  line  using  TRIZOL
®  reagent
(Invitrogen), which is based on the guanidine isothiocyanate/acid-phenol method
originally described by Chomzynski and Sacchi (1987), according to the manufacturer’s
instructions. Briefly, cells were cultured to mid-log phase (~5 x 10
5 cells/ml) and
approximately 2 x 10
7 cells were collected by centrifugation in 50ml polypropylene
tubes (200 x g, 5min, room temperature)(Eppendorf Centrifuge 5810). The cells were
combined in one tube and subsequently lysed in 4ml of TRIZOL
® reagent by repetitive
pipetting and incubated at room temperature for 5min to allow the complete dissociation
of  nucleoprotein  complexes.  The  cells  were  transferred  to  1.5ml  polypropylene
microcentrifuge tubes (0.5 x 10
6 cells/ml/tube) and 200µl of chloroform/tube was
added. The tubes were then shaken vigorously by hand for 15s and incubated at room
temperature for 3min. Phase separation was achieved by centrifugation (12,000 x g,
15min, 4
oC)(Sigma 1-15) and the upper aqueous layer was removed and transferred to a
fresh 1.5ml polypropylene tube. The RNA was precipitated by mixing with 500µl of
isopropyl alcohol/tube and incubating at room temperature for 10min. The RNA was146
subsequently recovered by centrifugation (12,000 x g, 5min, 4
oC) and following
removal of the supernatant, the pellet was washed with 75% (v/v) ethanol and pelleted
by centrifugation (7,500 x g, 5min, 4
oC). Pellets were allowed to air dry for 10min and
dissolved in sterile, RNase-free dH20 (30µl/pellet). The dissolved RNA pellets were
combined and stored in 30µl aliquots at -80
oC.
3.2.1.3  Quantitative and Qualitative RNA Analysis
RNA integrity and concentration was assessed using the Agilent 2100 Bioanalyzer
instrument and Agilent 2100 biosizing software (Agilent, Palo Alto, CA). Samples were
processed at the Lotteries State MicroArray Facility (Sir Charles Gairdner Hospital,
Perth, WA) using the RNA 6000 LabChip
® Kit (Agilent, Palo Alto, CA). RNA integrity
was also examined by agarose gel electrophoresis as described in Section 2.2.1.2. RNA
samples (1µl) were combined with 5x TBE-Urea Denaturing Sample Buffer [1x](Bio-
Rad Laboratories) immediately prior to loading and electrophoresis was performed in
1x  TAE  buffer  containing  0.1µg/ml ethidum bromide using a Bio-Rad Mini-sub
horizontal gel apparatus (Bio-Rad Laboratories) at constant voltage (70-80V) for 1h.
Following electrophoresis, RNA was visualised using an ultraviolet UV transilluminator
(Gel Doc 1000) and Molecular Analyst software (Bio-Rad Laboratories). Qualitative
analysis of separated RNA samples was assessed by comparison of the intensity of the
28S rRNA band (size ~ 5kB) with the 18S rRNA band (size ~2kB), where a ratio of 2.0
is indicative of high quality RNA.
The  quantitation  of  RNA  samples  in  aqueous  solution  was  achieved  by  UV
spectrophotometry. RNA samples in solution were diluted 1/80 to a total volume of
160µl in dH20. The spectrophotometer (Shimadzu UV Mini 1240 Spectrophotometer)
was blanked with a 160µl aliquot of the sample diluent. Ultraviolet light absorbance of
the diluted RNA sample was then determined at 260nm and 280nm wavelengths, and
RNA concentration and purity was determined using the calculations below;147
where (1 O.D unit = 40µg/ml of ds RNA)
where a ratio of 2.0 indicated a pure RNA solution
3.2.1.4  5’ RACE – System Version 2.0
First strand cDNA was synthesised from 2.5µg total ALL-SIL RNA using one of three
methods.
3.2.1.4.1  SUPERSCRIPT
TM II RT
Briefly, 2.5µg of total ALL-SIL RNA was combined with 2.5pmol of SLIM1(1) primer
(Table 3.1), in a thin-walled, 0.5ml RNase-free polypropylene tube in a final volume of
15.5µl. RNA was denatured by incubation at 70
oC for 10min and the reaction was
placed  on  ice.  Reverse  transcription  was  performed  in  a  final  volume  of  25µl
comprising 10x PCR Buffer [1x; 20mM Tris-HCl (pH 8.4), 50mM KCl](Invitrogen),
2.5mM MgCl2  (Invitrogen), 0.4mM dNTPs (Invitrogen), 0.01M DTT (Invitrogen) and
200U of SUPERSCRIPT
TM II Reverse Transcriptase (Invitrogen), at 42
oC for 50min. The
enzyme was then heat inactivated at 70
oC for 15min, and the RNA template was
subsequently  removed  by  incubation  with  1µl  of  the  supplied  RNase  Mix  (a
combination of RNase H and RNaseT1)(Invitrogen) at 37
oC for 30min and placed on
ice.
Unincorporated dNTPs, SLIM1(1) primer and proteins were then separated from the
cDNA using a GLASSMAX DNA Isolation Spin Cartridge (Invitrogen) supplied with the
kit. The first strand reaction was mixed with 120µl of room temperature equilibrated
Binding   Solution   (6M  NaI)(Invitrogen)   and   the   solution   was   transferred   to   a
RNA Concentration [mg/ml]: O.D260nm x dilution factor x 40
RNA Purity: O.D260nm/O.D280nm148
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GLASSMAX spin cartridge and centrifuged (13,000 x g, 20s, room temperature)(Biofuge
Pico, Heraeus Instruments). The cartridge was then washed by applying cold (4
oC) 1x
Wash Buffer (Invitrogen) to the column and centrifugation (13,000 x g, 20s, room
temperature)(x4 washes). These wash steps were subsequently repeated with cold (4
oC)
70% (v/v) ethanol (x2 washes). Following the final ethanol wash, the column was re-
centrifuged (13,000 x g, 1min, room temperature) to remove traces of residual ethanol.
The purified cDNA was then eluted into a fresh 1.5ml polyproplylene microcentrifuge
tube, by applying 50µl of sterile, preheated (65
oC) dH20 to the spin cartridge and
centrifuging (13,000 x g, 20s, room temperature).
A homopolymeric oligo-dC tail was then added to the 3’ end of the cDNA using
terminal deoxynucleotidyl transferase (TdT)(Invitrogen). GLASSMAX purified cDNA
was initially denatured in a 0.5ml polypropylene tube in a final volume of 24µl,
comprising 10µl of cDNA, 200µM dCTP (Invitrogen), 5x Tailing Buffer [1x; 10mM
Tris-HCl (pH 8.4), 25mM KCl, 1.5mM MgCl2](Invitrogen), by incubating at 94
oC for
3min and subsequently chilled on ice. 1µl of TdT (Invitrogen) was then added to the
reaction, and tailing was allowed to proceed for 10min at 37
oC. The enzyme was then
heat inactivated at 65
oC for 10min and the tailed cDNA was subsequently amplified in a
primary  PCR  using  a  nested  gene  specific  primer  SLIM1(2)  and  the  supplied
deoxyinosine 5’ Abridged Anchor Primer (dI5’AAP)(Invitrogen)(Table 3.1). PCR
reactions were performed with Tth Plus* DNA Polymerase (Fisher Biotech). Reactions
were assembled in a 0.5ml, thin walled polypropylene tube in a final volume of 50µl,
containing  10x  PCR  Reaction  Buffer  [1x;  67mM  Tris-HCl  (pH  8.8),  16.6mM
[NH4]2S04, 0.45% (v/v) Triton
® X-100, 0.2mg/ml gelatin](Fisher Biotech), 1.5mM
MgCl2 (Fisher Biotech), 0.2mM dNTP Mix (Fisher Biotech), 20pmol of SLIM1(2)
primer, 20pmol of dI5’AAP (Invitrogen), 5µl of dC tailed cDNA and 2.75U of Tth
Plus* DNA Polymerase (Fisher Biotech). Samples were denatured for 2min at 94
oC and
then amplified using 30 cycles (94
oC for 30s, 52
oC for 30s and 72
oC for 1min) followed
by a final extension of 72
oC for 7 min (5’RACE)(Appendix 1) in a PTC-100 (MJ
Research Inc.). The specificity of products generated was confirmed by subsequent
nested PCR using SLIM1(3) and the supplied Abridged Universal Amplification Primer
(AUAP)(Invitrogen)(Table  3.1),  in  a  50µl  reaction  volume  containing  10x  PCR
Reaction Buffer [1x], 1.5mM MgCl2, 0.2mM dNTP Mix, 10pmol of SLIM1(3), 0.2µM150
AUAP (Invitrogen), 0.1% (v/v) of the original PCR reaction and 2.75U of Tth Plus*
DNA Polymerase. Samples were denatured for 1:30min at 94
oC and then amplified
(94
oC  for  30s,  63
oC  for  1min  and  72
oC for 1:30min; 30 cycles) with annealing
temperatures decreasing by 1
oC every 2 cycles, and an annealing temperature of 55
oC
for the final 14 cycles, followed by a final extension of 72
oC for 8min (TD1)(Appendix
1).
PCR products were analysed by agarose gel electrophoresis on 0.6-1.5% (w/v) agarose
gels, as described in Section 2.2.1.2. 5’ RACE PCR products were gel purified using the
Qiaex II Gel Purification Kit (Qiagen)(Section 2.2.1.3) and directly sequenced using
SLIM1(3) and AUAP primers as outlined in Section 2.2.1.11.
3.2.1.4.2  THERMOSCRIPT
TM RT
Briefly, 2.5µg total ALL-SIL RNA was combined with 15pmol of SLIM1(1) primer in
a thin-walled 0.5ml RNase-free polypropylene tube in a final volume of 20µl. RNA was
denatured by incubation at 70
oC for 10min and immediately transferred to 50
oC.
Reverse transcription was performed in a final volume of 40µl comprising 5x cDNA
Synthesis Buffer [1x; 50mM Tris acetate (pH 8.4), 75mM potassium acetate, 8mM
magnesium  acetate](Invitrogen),  5mM  DTT  (Invitrogen),  40U  of  RNaseOUT
TM
(Invitrogen), 1mM dNTP Mix (Invitrogen) and 15U of THERMOSCRIPT
TM RT (Invitrogen)
with a Master Mix pre-incubated to 50
oC, at 65
oC for 1h.  The reaction was terminated
by incubation at 85
oC for 5min and the RNA template subsequently removed by
incubating with 1µl of RNase Mix at 37
oC for 30min and placed on ice. The cDNA was
then purified using a GLASSMAX Spin cartridge and tailed as outlined in Section
3.2.1.4.1. Primary and nested PCR was performed using the primer sets described in
Section 3.2.1.4.1. Modifications to the existing PCR Programmes utilised in these
procedures involved increasing denaturation temperatures to 97
oC (5’RACE*, TD2) and
extending the final extension of 72
oC to 10min (TD2)(Appendix 1). PCR products were
analysed by agarose gel electrophoresis on 0.6-1.5%(w/v) agarose gels, as described in
Section 2.2.1.2.151
3.2.1.4.3  Omniscript
TM RT
Briefly, 2µg of total ALL-SIL RNA was denatured in a thin-walled 0.5ml RNase-free
polypropylene tube in a final volume of 12µl, by incubation at 65
oC for 5min and then
immediately transferred to 42
oC. Reverse transcription was performed in a final volume
of 20µl comprising 10x Buffer RT [1x](Qiagen), 0.5mM dNTP Mix (Qiagen), 1µM
SLIM1(1) primer, 10U of RNasin (Promega) and   4U of Omniscript
TM RT (Qiagen)
with a Master Mix pre-incubated to 42
oC, at 42
oC for 2h. The RNA was subsequently
removed by incubating with 1µl of RNase Mix at 37
oC for 30min and placed on ice.
The cDNA was then purified using a GLASSMAX Spin cartridge and tailed as outlined in
Section 3.2.1.4.1.  Primary  and  nested  PCR  was  performed  using  the  primer  sets
described in Section 3.2.1.4.1 and 5’RACE* and TD2 PCR programmes (Appendix 1).
PCR products were analysed by agarose gel electrophoresis on 0.6-1.5% (w/v) agarose
gels, as described in Section 2.2.1.2.
3.2.1.5 5’ RACE - GeneRacer
TM Protocol
3.2.1.5.1 De-phosphorylation of ALL-SIL and HeLa Total RNA
In the first step of this protocol, total ALL-SIL RNA and control HeLa RNA was de-
phosphorylated with calf intestinal phosphatase (CIP) to remove the 5’ phosphate group
from truncated mRNA and non-mRNA species, leaving capped, full-length mRNA.
Removal of the 5’ phosphate group renders these truncated mRNAs incapable of
ligating  with  the  GeneRacer
TM  RNA  Oligo  adapter,  thereby  eliminating  the
amplification of truncated messages and facilitating the amplification of only full-length
transcripts.
 Approximately 5µg of ALL-SIL RNA and 1µg of HeLa RNA was combined in a thin-
walled 0.5ml RNase-free polyproplyene tube in a final volume of 10µl, comprising 10x
CIP Buffer [1x; 50mM Tris-HCl (pH 8.5), 0.1mM EDTA (pH 8.0)](Invitrogen), 40U of
RNaseOUT
TM  and  10U  of  CIP  (Invitrogen)  at  50
oC  for  1h.  The  reaction  was
subsequently precipitated by dilution to 100µl with DEPC treated dH20 and extraction
with 1 volume [1:1; 100ul] of Tris-buffered phenol:chloroform (pH 8.0). The reaction152
was centrifuged (15,000 x g, 5min, room temperature) and the upper aqueous phase
containing RNA was transferred to a fresh 1.5ml polypropylene microcentrifuge tube
and precipitated with 2µl of 10mg/ml mussel glycogen (Invitrogen), 10µl of 3M NaAc
(pH 5.2)(Invitrogen) and 220µl of 95% (v/v) ethanol. Precipitation was enhanced by
incubating on dry ice for 10min and RNA was pelleted by centrifugation (15,000 x g,
20min, 4
oC) and washed once with 500µl 70% (v/v) ethanol. Following centrifugation
(15,000 x g, 2min, 4
oC) the ethanol was removed and the sample was re-centrifuged to
collect  residual  ethanol.  The  RNA  pellet  was  briefly  air-dried  for  1-2min  and
resuspended in 7µl of sterile DEPC-treated water.
3.2.1.5.2  Removing the 5’ Cap Structure from Full-length mRNA
The second part of the GeneRacer
TM protocol involves the removal of the 5’ cap
structure from the full-length RNA generated in Section 3.2.1.5.1 with tobacco acid
pyrophosphatase (TAP), in order to expose the 5’ phosphate group for required for
subsequent ligation of the GeneRacer
TM RNA Oligo. De-capping was performed in a
final volume of 10µl comprising 10x TAP Buffer [1x; 50mM NaAc (pH6.0), 1mM
EDTA, 0.1% (v/v) β-mercaptoethanol, 0.01% (v/v) TritonX
®-100] (Invitrogen), 40U of
RNaseOUT
TM and 0.5U of TAP (Invitrogen) by incubation at 37
oC for 1h. Following
incubation, the RNA was precipitated as outlined in Section 3.2.1.5.1 and resuspended
in 7µl of DEPC-treated water.
3.2.1.5.3  Ligation of the RNA Oligonucleotide Adapter to De-capped mRNA
The third step of this protocol involves the ligation of GeneRacer
TM RNA Oligo to the
5’ end of the mRNA using T4 RNA ligase in order to provide a known priming site for
the GeneRacer
TM PCR primers after the mRNA is transcribed into cDNA. The mRNA
generated in Section 3.2.1.5.2 was incubated with 0.25µg of pre-aliquoted, lyophilised
GeneRacer
TM RNA Oligo (Invitrogen)(Table 3.1) at 65
oC for 5min to relax the RNA
secondary structure and briefly chilled on ice. The ligation was performed in a final
volume of 10µl incorporating 10x T4 RNA Ligase Buffer [1x; 33mM Tris-acetate (pH
7.8), 66mM KAc, 10mM MgAc, 0.5mM DTT](Invitrogen), 40U of RNaseOUT
TM and153
5U of T4 RNA Ligase (Invitrogen) at 37
oC for 1h. RNA was precipitated as outlined in
Section 3.2.1.5.1 and resuspended in 10µl of sterile DEPC-treated water.
3.2.1.5.4  Reverse Transcribing mRNA
First strand cDNA was synthesised from RNA adapter-ligated ALL-SIL and HeLa
mRNA  using  THERMOSCRIPT
TM  RT  (Invitrogen)  and  the  primers  SLIM1(1)  and
GeneRacer
TM Oligo dT respectively (Table 3.1). RNA was combined with 15pmol of
SLIM1(1) primer or 1µl of 50µM GeneRacer
TM Oligo dT (Invitrogen)(Table 3.1) and
1µl of 10mM dNTPs (Invitrogen) in a 0.5ml thin-walled RNase-free polypropylene tube
in a final volume of 13µl, and incubated at 70
oC for 10min to denature RNA. The
reaction was then immediately transferred to 50
oC. Reverse transcription was performed
in a final volume of 20µl incorporating 5x cDNA Synthesis Buffer [1x; 50mM Tris
acetate (pH 8.4), 75mM KAc, 8mM MgAc], 40U of RNaseOUT
TM, 5mM DTT and 15U
of THERMOSCRIPT
TM RT with a Master Mix pre-incubated to 50
oC, at 65
oC for 1h. The
reaction was terminated by incubation at 85
oC for 5min and chilled on ice. The RNA
template was subsequently removed by incubating with 2U of RNase H at 37
oC for
20min.
3.2.1.5.5  PCR Amplification
FHL1-specific transcripts were amplified from ALL-SIL derived cDNA by primary
PCR using the GeneRacer
TM 5’ and SLIM1(2) primer set (Table 3.1). PCR reactions
were performed with Tth Plus* DNA Polymerase (Fisher Biotech) in 0.5ml thin-walled
polypropylene tubes in a final volume of 50µl comprising 10x PCR Reaction Buffer
[1x],  1.5mM  MgCl2,  0.2mM  dNTP  Mix,  20pmol  of  SLIM1(2)  primer,  0.6µM
GeneRacer
TM 5’ primer (Invitrogen), 2µl of ALL-SIL cDNA and 2.75U of Tth Plus*
DNA Polymerase using the modified 5’RACE* PCR programme (Appendix 1). Nested
PCR was then performed using the GeneRacer
TM 5’ Nested and SLIM1(3) primers
(Table 3.1) in a 50µl reaction volume containing 10x PCR Reaction Buffer [1x], 1.5mM
MgCl2, 0.2mM dNTP Mix, 10pmol of SLIM1(3) primer, 0.2µM GeneRacer
TM 5’ Nested
primer (Invitrogen), 1µl of original PCR and 2.75U of Tth Plus* DNA Polymerase
using the TD2 PCR programme (Appendix 1).154
In addition, the 5’ RACE positive control β-Actin was amplified from HeLa derived
cDNA. Primary PCR was performed as described for FHL1 using the GeneRacer
TM 5’
primer [0.6µM] and Control Primer B.1 [0.6µM](Invitrogen)(Table 3.1) and 2µl of
HeLa RT template. Primary products were amplified using the modified 5’RACE* PCR
programme (Appendix 1). PCR products were analysed by agarose gel electrophoresis
on 0.6-1.5% (w/v) agarose gels, as described in Section 2.2.1.2.
3.2.1.6  Cloning of 5’ RACE Products
5’  RACE  PCR  products  generated  in  Sections 3.2.1.4/3.2.1.5 possess single 3’-
adenosine (A) overhangs due to the non-template dependent terminal transferse activity
of Taq Polymerase. This can be utilised to directly clone PCR products into T/A cloning
vectors, which possess 3’ deoxythymidine (T) overhangs capable of participating in
cohesive-end ligation. Freshly  prepared PCR  products were T/A cloned into the
pCR
®2.1  TA  cloning  vector  (Invitrogen)(Appendix  2)  in  accordance  with  the
manufacturer’s instructions. Ligation reactions were performed in 0.5ml polypropylene
tubes in a final volume of 10µl, comprising 1-4µl of fresh PCR product, 50ng of
pCR
®2.1 vector (Invitrogen), Ligation Buffer [1x; 6mM Tris-HCl (pH 7.5), 6mM
MgCl2, 5mM NaCl, 0.1mg/ml BSA, 7mM β-mercaptoethanol, 0.1mM ATP, 2mM DTT,
1mM spermidine](Invitrogen) and 4U of T4 DNA Ligase (Invitrogen) and incubated at
15
oC for 24-48h. Ligation reactions were transformed immediately or stored at -20
oC
prior to transformation.
3.2.1.7  Bacterial Transformation
Ligation reactions were transformed into the TOP10F’ strain [F’ {lacI
qTn10 (Tet
R)}
mcrA ∆(mrr-hsdRMS-mcrBC) Ø80lacZ∆ M15 ∆ lacX74 recA1 deoR araD139 ∆ (ara-
leu)7697 galU galK rpsL (Str
R) endA1 nupG (Invitrogen), which over-expresses the
Lac repressor (lacI
q gene). Previously prepared, chemically competent cells [50µl] were
thawed on ice and combined with 2µl of ligation reaction containing recombinant DNA,
and incubated on ice for 30min. The cells were then subjected to heat shock at 42
oC for
90s and chilled on ice for 2min. To facilitate growth of the transformed bacteria, 250µl
of room temperature equilibrated SOC medium [2% (w/v) Tryptone, 0.5% (w/v) Yeast155
Extract, 10mM NaCl, 2.5mM KCl, 10mM MgCl2, 10mM MgS04, 20mM glucose] was
added to the cells, which were then incubated for 1h at 37
oC. LB agar plates containing
0.1mg/ml ampicillin (Austrapen
®) were prepared for transformation by equilibrating at
37
oC  for  30min  and  spreading  5-bromo-4-chloro-3-indolyl-β-D-galactoside  (X-
Gal)(Promega)[50mg/ml; 40µl/plate) and IPTG (Progen)[100mM; 40µl/plate] onto
plates and allowing to soak for at least 30min. Aliquots (50-200µl) of the transformed
bacterial culture were then spread onto selective LB agar plates and incubated at 37
oC
for 18-20h to allow growth of the recombinant colonies. To facilitate the blue colour
development of non-insert containing colonies, plates were subsequently incubated at
4
oC for 1-2h.
3.2.1.8  PCR Screening of Recombinant DNA Clones
Selected colonies were screened for the presence of inserts by colony lysis and PCR as
described by Sambrook and Russell (2001). Briefly, individual colonies (typically 10-15
colonies per screen) were selected using a sterile pipette tip and used to inoculate a
gridded LB agar plate supplemented with 0.1mg/ml ampicillin and a 1.5ml screw-cap
polypropylene tube containing 30µl of TE- Triton
® X-100 [10mM Tris-HCl (pH 7.5),
1mM EDTA, 1% (v/v) Triton
® X-100] respectively. The bacteria were lysed by boiling
the tubes for 5min, and cellular debris was pelleted by centrifugation (15,000 x g, 2min,
room temperature). The supernatants were removed to fresh tubes and 5µl was used to
screen colonies for the presence of inserts in a standard PCR reaction with Tth Plus*
DNA Polymerase (Fisher Biotech), utilising M13 Forward (M13F-20) and M13 Reverse
(M13R) primers (Table 3.1), which flank the cloning site of the pCR
®2.1 TA cloning
vector. Reactions were performed in a 50µl volume incorporating 10x PCR Reaction
Buffer [1x], 1.5mM MgCl2,  0.2mM  dNTP  Mix,  20pmol  of  M13F-20  and  M13R
primers, 5µl of colony supernatant template and 2.75U of Tth Plus* DNA Polymerase.
Samples were denatured for 1:40min at 97
oC and then amplified (97
oC for 40s, 55
oC for
1min and 72
oC for 1min; 30 cycles), followed by a final extension of 72
oC for 7min
(SEQKIM)(Appendix 1).156
 3.2.1.10 DNA Sequencing
Small scale plasmid DNA samples were prepared using the GenElute
TM Plasmid
Miniprep Kit (Sigma) as described in Section 2.2.1.9 and the inserts were sequenced
using the M13 Forward (-20) and M13 Reverse primers flanking the cloning site of the
pCR
®2.1 TA cloning vector (Section 2.2.1.11), in order to confirm the identity of the
cloned insert as a FHL1  gene  fragment  and  to  determine  the  most  5’  sequence
corresponding to the transcriptional start site/s.
3.2.2 Luciferase Reporter Gene Assays
3.2.2.1 Preparation of FHL1 Promoter Luciferase Reporter Vectors
3.2.2.1.1 PCR Amplification of FHL1 Promoter Insert DNA
FHL1 promoter fragments were created using the sense primers SLIM1F-300, SLIM1F-
928 and a common anti-sense primer SLIM1+73SmaI (Table 3.1), which harbour Sac I
and Sma I restriction endonuclease sites respectively to enable cohesive ligation into the
pGL3Basic Luciferase Reporter Vector. Fragments were amplified from genomic DNA
using  DyNAzyme
TM  EXT  DNA  Polymerase  (Finnzymes)  in  a  50µl  reaction
incorporating Optimized DyNAzyme
TM EXT 10x Buffer [1x; 50mM Tris-HCl (pH 9.0),
1.5mM MgCl2,  15mM  (NH4)2SO4, 0.1% (v/v) Triton
® X-100](Finnzymes), 0.2mM
dNTP Mix (Fisher Biotech), 20pmol of either SLIM1F-928/SLIM1F-300  primers,
20pmol of SLIM1+73R primer, 10% (v/v) DMSO (Finnzymes), 500ng of genomic
DNA  and  0.5U  of  DyNAzyme
TM  (Finnzymes) using a modified touchdown PCR
programme for high GC content (TD2)(Appendix 1).
3.2.2.1.2  Restriction Digestion of FHL1 Promoter Insert DNA
PCR products generated in Section 3.2.2.1.1 were gel purified using the Qiaex II Gel
Purification Kit (Qiagen) as described in Section 2.2.1.3 and digested with Sac I and
Sma I restriction endonucleases (Promega) in a 50µl reaction volume comprising 10x
MULTICORE
TM Buffer [1x; 25mM Tris acetate (pH 7.8), 0.1M potassium acetate,157
10mM magnesium acetate, 1mM DTT](Promega), 0.1mg/ml nuclease-free acetylated
BSA (Promega), 25µl of gel purified fragments, 60U of Sac I restriction endonuclease
(Promega) and 60U of Sma I restriction endonuclease (Promega) at 25
oC for 18h and
subsequently  at  37
oC  for  2h  to  ensure  complete  digestion.  Following  digestion,
restriction endonucleases were heat inactivated by incubation at 65
oC  for  20min.
Digested  PCR  fragments  were  subsequently  purified  using  the  QIAquick  PCR
Purification Kit (Qiagen) according to the manufacturer’s instructions (Section 2.2.1.4).
An aliquot of the purified insert was electrophoresed on a 1.3% (w/v) agarose gel
(Section 2.2.1.2) to estimate DNA integrity and concentration prior to ligation.
3.2.2.1.3  Preparation of pGL3Basic Luciferase Reporter Vector
The pGL3Basic Luciferase Reporter Vector was prepared for sub-cloning by restriction
digestion  of  supercoiled,  pGL3Basic  plasmid  with Sac  I  and  Sma  I restriction
endonucleases (Promega) in a 100µl reaction volume comprising 10x MULTICORE
TM
Buffer [1x], 0.1mg/ml nuclease-free acetylated BSA, 2µg of pGL3Basic plasmid DNA,
60U of Sac I restriction endonuclease and 60U of Sma I restriction endonuclease at
25
oC  for  18h  and  subsequently  at  37
oC  for  2h.  Following  digestion,  restriction
endonucleases were heat inactivated by incubation at 65
oC for 20min and the vector
(100µl) was subsequently purified by agarose gel extraction using the QIAquick PCR
Purification Kit (Qiagen) according to the manufacturer’s instructions (Section 2.2.1.3).
An aliquot of the purified pGL3Basic vector was electrophoresed on a 1.3% (w/v)
agarose gel (Section 2.2.1.2) to estimate DNA integrity and concentration prior to
ligation.
3.2.2.1.4  FHL1 Reporter Construct Preparation
Ligations, screening, sequencing and large scale DNA preparation of FHL1 Promoter
luciferase reporter constructs was performed essentially as described in Sections
2.2.1.6-2.2.1.15.158
3.2.2.2 Luciferase and β-Galactosidase Reporter Gene Assays
HEL-900 and PER-117 cells lines and culture conditions are outlined in Section 2.2.2.
FHL1 promoter activity was assessed in HEL-900 and PER-117 cell lines by transient
transfection with FHL1-promoter luciferase constructs generated in Section 3.2.2.1.
Luciferase and β-galactosidase reporter assays were performed as described in Section
2.2.3. Data analysis was performed as outlined in Sections 2.2.3.5-2.2.3.6.
3.3 RESULTS
3.3.1  ALL-SIL RNA Analysis
The T-ALL cell line, ALL-SIL, which co-expresses HOX11 and FHL1 (Greene et al.,
1998), was chosen for the characterisation of FHL1 transcripts. Total RNA from this
cell line was extracted using TRIZOL
® reagent. TRIZOL
® is based on the propensity of
RNA molecules to remain dissolved in an aqueous solution comprising 4M guanidinium
thiocyanate (pH 4.0) in the presence of a phenol/chloroform organic phase. The latter
retains DNA, whilst proteins and other cellular macromolecules are retained at the
interphase (Gerstein, 2001). This method ensured the efficient isolation of high quality
RNA with minimal protein and genomic DNA contamination, thus maximising the
synthesis of full-length cDNA in subsequent 5’RACE analysis. The integrity of ALL-
SIL RNA was confirmed using conventional agarose gel electrophoresis, by visual
comparison of the intensity of the 28S rRNA band (size ~ 5kB) with the 18S rRNA
band (size ~2kB)(ratio of ~2)(Figure 3.1A). In addition, ALL-SIL RNA quantity, purity
and integrity was assessed using the RNA 6000 LabChip Kit in conjunction with the
Agilent 2100 Bioanalyzer and data is presented as a gel-like image (Figure 3.1B) or as
an electropherogram (Figure 3.1C). ALL-SIL RNA concentration [~2.2ug/ul] was
calculated using associated Agilent software, which compares unknown samples to the
ladder fragments of known concentration. Concentration and purity (A260/A280: ~1.67)
was subsequently confirmed by UV spectrophotometric analysis. ALL-SIL RNA
integrity was confirmed by the presence of distinct 28S and 18S ribosomal peaks and a
calculated rRNA ratio of 1.94, as indicated on the electropherogram (Figure 3.1C). The
absence  of  smaller,  defined  peaks between the two major ribosomal RNAs in addition159
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Figure 3.1. Assessment of ALL-SIL RNA Integrity for Use in 5’ RACE
Analysis. ALL-SIL RNA integrity and concentration was assessed by agarose
gel  electrophoresis  and  Agilent  2100  Bioanalyzer  using  the  RNA  6000
LabChip Kit. (A) Total ALL-SIL RNA (1µg) was analysed by 1.2% agarose
gel electrophoresis in 1x TAE Buffer stained with 0.2µg/ml ethidium bromide
(B) Lane 1. Agilent - RNA 6000 Ladder Standard (150ng) Lane 2. Agilent -
ALL-SIL RNA sample (3µl). 28S and 18S rRNA bands are indicated (C)
Electropherogram of ALL-SIL RNA sample. Major peaks indicate 28S and
18S rRNA bands (rRNA ratio: 1.94).
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to a lack of peaks between 28s and the 18S ribosomal RNA, which correspond to
smaller RNA molecules, are indicative of high quality RNA. 5S and tRNA molecules
are represented peaks between 24-28s (Figure 3.1C) and are commonly present in total
RNA samples prepared by TRIZOL
® extraction.
3.3.2  Identification of the Transcriptional Start Sites of the FHL1 Gene
Identification of the FHL1 transcriptional start site was first necessary in order to
identify the proximal promoter of FHL1 and to characterise the cis-acting regulatory
elements and trans-acting proteins involved in regulating promoter activity. Previous
studies  by  Greene  et al.,  (1999),  in  which  the  genomic  structure  of  FHL1 was
determined by PCR amplification of human genomic DNA using primers designed at
either end of the FHL1 coding sequence, revealed the gene to consist of five coding
exons spanning a region of 4.9kb (E3-E7)(Figure 3.2). Interestingly, introns 3-6 (I3-I6)
disrupt the coding region of FHL1 near the start of each complete LIM domain,
suggesting that exon duplication may have given rise to the tandem LIM domain repeats
(Greene et al., 1999). Following these studies, a cDNA library derived from lung large
cell carcinoma (Library: NIH_MGC_18) from which FHL1 EST clones were identified,
revealed the existence of least two additional non-coding exons (E1, E2) located 58.9kb
and  36.5kb  upstream  of  the  ATG  respectively  (Clone:  MGC:  15297;  Genbank
Accession: NM_001449; Strausberg unpublished results, 2001)(Figure 3.2). Using gene
specific primers located in FHL1 exon 3 (SLIM1(1), SLIM1(2); Table 3.1, Figure 3.2),
the 5’ extent of the human FHL1 transcript was determined utilising a PCR-based
strategy which results in the Rapid Amplification of cDNA Ends (RACE). The aim was
to map the start site(s) of FHL1 in order to subsequently investigate whether the
proximal  promoter  of  FHL1  could  be  regulated  by  HOX11  using  functional
transcription assays.
Rapid Amplification of cDNA Ends (RACE) or ‘anchored’ PCR, is a method for
obtaining full-length sequences from a messenger RNA (mRNA) template between a
defined internal site and unknown sequences at either the 3’ or 5’ end of the mRNA,
and  can  be  used  to  amplify  rare  mRNAs  (30  copies/cell)  that  may  challenge
conventional cDNA cloning methods  (Invitrogen, 2001, Carey  &  Smale, 2000, Loh  et161
FIGURE 3.2162
al., 1989). A number of commercial kits suitable for the rapid amplification of 5’ cDNA
ends were employed in this study. Initial investigations utilised the 5’ RACE System
Version 2.0 (Invitrogen) which involves the generation of first strand cDNA from total
RNA  using  a  gene  specific  primer  (GSP1),  and  the  subsequent  addition  of  a
homopolymeric tail to the 3’ cDNA end catalysed by terminal TdT (Figure 3.3). The tail
then serves as an ‘anchor’ for the PCR amplification of the 5’ cDNA ends using a
nested GSP2 and a complementary homopolymer-containing anchor primer. Subsequent
studies employed a variation of this procedure provided by the GeneRacer
TM  Kit
(Invitrogen),  which  is  based  on  RNA  ligase-mediated  and  oligo-capping  rapid
amplification of 5’ and 3’ cDNA ends (RLM-RACE)(Maruyama & Sugano, 1994,
Volloch et al., 1994, Schaefer, 1995)(Figure 3.4). This technique captures the full-
length  5’  ends  of  the  targeted  cDNA  via  the  selective  ligation  of  an  RNA
oligonucleotide adapter to the 5’ ends of de-capped RNA using T4 RNA ligase.
3.3.2.1 Analysis of the Human FHL1 Transcripts by 5’RACE (Version 2.0)
To map the transcriptional start site(s) of the FHL1 gene, 5’ RACE was initially
performed using the 5’ RACE System for the Rapid Amplification of cDNA Ends
Version 2.0 (Invitrogen), with total RNA isolated from the ALL-SIL cell line. Reverse
transcription (RT) was primed in three independent experiments (RT1, RT2, RT3) from
a sequence located in exon 3 (Figure 3.5) using the supplied SUPERSCRIPT
TM II RT and
the SLIM1(1) gene specific primer. The resultant cDNAs were then amplified by two
rounds of PCR using the primer sets AAP/SLIM1(2) and nested AUAP/SLIM1(3) to
generate major products; RT1(118bp), RT2 (90bp) and RT3 (240bp)(Figure 3.5A). To
rule out the possibility of genomic contamination, no RT controls were performed in
parallel with all 5’RACE reactions (data not shown). Sequence data was obtained for
PCR products generated from RT1 and RT3 which positioned the 5’ FHL1 transcript
start point at positions -160 and -35 relative to the ATG translation initiation codon,
within exons 1 and 2 respectively (Figure 3.5B). Since both of these putative startpoints
were located downstream of the 5’ end of the longest known FHL1 cDNA, it was likely
that cDNA synthesis may have been prematurely terminated using SUPERSCRIPT
TM II RT
This prompted the use of alternative reverse transcriptases, specifically chosen to
overcome RNA secondary structure.163
Figure 3.3. Schematic Representation of the 5’ System for the Rapid Amplification of
cDNA Ends (RACE) Version 2.0 (Invitrogen).
Step 1.     Anneal the first strand Gene-Specific Primer 1 (GSP1) to mRNA
Step 2.    Reverse transcribe the mRNA into cDNA using SUPERSCRIPT
TM II RT
Step 3.    Remove the RNA template in the RNA:cDNA hybrid and single stranded RNA molecules using an
                     RNase Mix (RNase H/RNase T1)
Step 4.    Purify the cDNA from excess nucleotides and primers with GLASSMAX Spin Cartridge. Tail the purified
                      cDNA with dCTP and Terminal Deoxynucleotidyl Transferase (TdT)
Step 5.    PCR amplify dC-tailed cDNA using the Abridged Anchor Primer and nested GSP2
Step 6.    Re-amplify primary PCR product using Abridged Universal Anchor Primer (AUAP) and nested GSP3164
Step 1.   RNA is dephosphorylated with calf intestinal phosphatase (CIP) to remove the 5’ phosphate group from
                  truncated  and non- mRNAs. CIP has no effect on full-length, capped mRNAs
Step 2.   Dephosphorylated mRNA treated with tobacco acid pyrophosphatase (TAP) to remove the 5’ cap structure
                   from intact, full-length mRNAs.
Step 3.   GeneRacer
TM Oligo ligated to the full-length mRNAs using T4 RNA ligase
Step 4.   Ligated mRNA is reverse transcribed with Superscript
TM II RT and a GSP /GeneRace
rTM  oligodT primer
is
                  used to generate RACE-ready first strand cDNA with known priming sites at the 5’ and 3’ends
Step 5.   5’ RACE GSP1 and GeneRacer
TM 5’ primer used to amplify first-strand cDNA in 5’ RLM-RACE to obtain 5’
                  ends. Secondary RLM-RACE is then performed using 5’ RACE GSP2 and GeneRacer
TM 5’ nested primer
Figure 3.4. Schematic Representation of the GeneRacer
TM (Invitrogen) Method for
Obtaining 5’ cDNA Ends.165
FIGURE 3.5166
Early termination of cDNA synthesis in exon 1 using SUPERSCRIPT
TM II RT was probably
caused by the formation of secondary structures associated with the GC-rich content of
FHL1 transcripts. This might explain the different sized products obtained with RT1,
RT2 and RT3 replicates (Figure 3.5). To overcome this, two independent reverse
transcriptases were employed. THERMOSCRIPT
TM RT (GIBCOBRL
®) is an avian RNase H-
minus  RT,  which  demonstrates  a  higher  thermal  stability  (up  to  65
oC)  than  the
SUPERSCRIPT
TM  II  RT  supplied  with  the  5’RACE  Kit  (maximum  recommended
temperature of 50
oC). Omniscript
TM  RT  (Qiagen)  is  a  recombinant  heterodimeric
enzyme expressed in E. coli, which displays a higher affinity for RNA than Moloney
Murine Leukemia Virus (MMLV) enzymes – previously considered to be a standard
efficient reverse transcriptase (Qiagen News, 1999). Indeed, experiments performed by
Korfhage  et al.,  (2000),  demonstrated  that  this  high  affinity  for  RNA  enabled
Omniscript
TM Reverse Transcriptase to read through complex RNA secondary structures
with a high GC content (maize gl2 transcript, 75% GC) that challenged conventional
MMLV RNaseH- RTs.
5’  RACE  products  obtained  utilising  THERMOSCRIPT
TM  and  Omniscript
TM  reverse
transcriptases yielded multiple products (Figures 3.6A, 3.7A, respectively), however,
the largest product obtained independently with both enzymes terminated at a common
position. This mapped the FHL1 transcriptional start site to a position -221bp upstream
of the initiation codon (ATG), extending the known 5’ end of the gene by 11bp (Figure
3.6B, 3.7B). Although other putative transcriptional start sites corresponding to smaller
5’  RACE  products  were  generated  using  the  THERMOSCRIPT
TM  RT,  these  were  not
independently verified using Omniscript
TM RT, an enzyme reported to display a higher
affinity for RNA than other reverse transcriptases, enabling it to read through complex
RNA secondary structures (Korfhage et al., 2000). Given this, and the fact that the
largest products generated with both THERMOSCRIPT
TM RT and Omniscript
TM RT enzymes
used terminated at -221bp, it is likely that this RACE product represents the major
transcriptional initiation site, at least in ALL-SIL T-cells.167
FIGURE 3.6168
FIGURE 3.7169
3.3.2.2 Analysis of the Human FHL1 mRNA Transcripts by 5’ RLM-RACE
In order to confirm the position of the major transcriptional start site identified in
Section  3.3.2.1  (-221bp  upstream  of  the  ATG  initiation  codon),  and  to  further
investigate the possibility that FHL1 gene transcription initiates from multiple start
sites, the GeneRacer
TM Kit for the full-length RNA Ligase-mediated rapid amplification
of 5’ cDNA ends (RLM-RACE) was next employed. This method relies on the principle
that a protective methylated cap is added to the initiating 5’ nucleotide of the primary
transcript, such that upon dephosphorylation of 5’ RNA ends with CIP, truncated
mRNA and non-mRNA species are eliminated from subsequent ligation with the
GeneRacer
TM RNA Oligo. RLM-RACE therefore ensures the amplification of only full-
length mRNA transcripts. Using this method, major products were amplified of 300 to
400bp and 700bp in size (Figure 3.8A), however, only the smaller products were
successfully cloned, despite repeated attempts to enrich and gel purify the larger 700bp
fragment. Sequencing of independent clones of the smaller products identified putative
transcriptional start sites at approximately -225bp, -253bp and -330bp upstream of the
of the ATG initiation codon (Figure 3.8B).
In  summary,  5’  RACE  analyses  using  a  combination  of  THERMOSCRIPT
TM  RT,
Omniscript
TM RT and RLM-RACE to ensure the amplification of only full length
mRNA transcripts, resulted in the identification of at least four transcriptional initiation
start sites at positions -330bp, -253bp, -225bp and -221bp relative to the FHL1 ATG
start codon (summarised in Figure 3.2). For technical reasons, the presence of start sites
even further upstream cannot be ruled out, however given the positions of these start
sites, which are located relative to a CpG island and predicted promoter (Section 3.3.3),
it is likely that these represent authentic transcriptionalstart sites.
3.3.3  Bioinformatic Analysis of the Human FHL1 Proximal Promoter
Computational prediction of a functional promoter for FHL1 was performed using the
Promoter  Inspector  algorithm  (http://www.genomatix.de/softwareservices/software/
PromoterInspector/ PromoterInspector.html)(Scherf et al., 2000). A 12kb region of the
human  FHL1  gene  encompassing  the  putative  transcriptional  start sites identified in170
FIGURE 3.8171
Sections 3.3.2.1/3.3.2.2 (6kb in both 5’ and 3’ directions, centred on exon 1) was
examined using PromoterInspector. This method bases selection on the genetic context
of promoters (transcription factor binding site occurrence and orientation) as opposed to
the  mere  identification  of  core  promoter  elements.  Using  this  method,
PromoterInspector identified a promoter (spanning 696nt) within the same vicinity as
that identified by 5’ RACE analysis conducted within this study (Figure 3.1). Having
identified a putative promoter both by transcription initiation start site mapping and in
silico promoter prediction methods, the DNA sequence surrounding the transcriptional
start sites identified in Sections 3.3.2.1/3.3.2.2 was analysed in further detail, and
revealed that the core promoter region of FHL1 lacks conspicuous promoter elements,
such as a consensus TATA (TATAAA) or CCAAT box. The lack of a TATA box, in
particular, is in keeping with the finding of multiple transcriptional initiation sites.
Given the high G/C content and presence of multiple binding sites for the ubiquitous
mammalian transcription factor Sp1 in the 5’ DNA sequence flanking the start sites
identified in this study, we postulate that FHL1 belongs to class of ‘TATA-less’
promoters that initiate transcription from multiple sites, over a broad initiation window
(Figure 3.9). In further support of this hypothesis, a sequence closely resembling a
MED-1 element (multiple start site element downstream)(GCTCCS; where S= strong
base pair corresponding to a G or C), found in many multiple start site promoters, was
identified at +21 relative to the most 3’ start site identified (GCTCAG)(Figure 3.9).
MED-1 elements typically reside at +20 to +45 from the 3’ end of the transcriptional
initiation window (Ince & Scotto, 1995).
The putative FHL1 promoter identified in this study also exhibited some features of a
single start site promoter (SSS), with a consensus Initiator (Inr)(YYANWYY; where
Y= pyrimidine, N= any base pair, W= weak base pair corresponding to an A or T)
sequence overlapping the most 3’ start site, being identified (Figure 3.9). The initiator
element  appears  to  be  functionally  analogous  to  the  TATA  box  and  can  act  in
conjunction with a downstream promoter element (DPE)(GNNNRGWYGT; where R=
purine), which is typically located ~30bp downstream of the initiation site to direct the
specific initiation of transcription (Carey & Smale, 2000). In keeping with the presence
of a functional Inr, a sequence resembling a consensus DPE (GNNNRGWYGT) was
also identified at  +24  relative  to  the  most 3’  start  site  identified  (GCTCAGTCCG).172
Figure  3.9.  Nucleotide Sequence of the Putative FHL1  Promoter.
Human FHL1 transcriptional initiation sites identified by GeneRacer
TM 5’
RLM-RACE Analysis and confirmed by sequencing are indicated by
arrowheads  (   ).  Nucleotides  are  numbered  relative  to  the  major
transcriptional start site (+1). Putative transcription factor binding sites are
underlined. Partial sequence of exon 1 with highlighted region indicating
the  extent  of  5’  cDNA  obtained  from  Genbank  under  Accession
NM_001449; or as an EST Accession BI559753; dbESTId: 9407273
identified in a cDNA library (Strausberg, 2001). Red brackets indicate a
broad window where transcription is initiated and is typical of a MSS
promoter. Bold letters indicate a consensus initiator (Inr) sequence. Blue
brackets  represent  a  putative  downstream  promoter  element  (DPE).
Forward and reverse primers for the amplification of the FHL1 proximal
promoter are indicated by red and green lettering, respectively.173
Consensus binding sites present in the 1.7kb sequence located upstream of the putative
FHL1  start  sites,  were  identified  using  MatInspector  V2.2,  which  is  based  on
TRANSFAC
TM 4.0 matrices  (http://transfac.gbf.ge/TRANSFAC/index.html)(Wigender
et al., 2000). Putative consensus motifs for several transcription factors including the
Myeloid Zinc Finger-1 (MZF-1), TCF11, Sex-Determining region Y gene product
(SRY), CCAAT Displacement Protein (CDP) and FOXL1were identified (Figure 3.9).
Not unexpectedly, the binding sites of a number of transcription factors specifically
associated with muscle development were also identified, including MyoD, the murine
tinman homolog, cardiac specific homeobox transcription factor, Nkx2.5 and HAND2
(Figure 3.9).
3.3.4 Comparison of Human-Murine FHL1 Promoter Sequences
Cross-species sequence comparisons represent a useful way to determine the presence
of important regulatory elements and/or coding regions, since these are likely to be
evolutionarily conserved. Alignment of the human and murine FHL1 promoters was
therefore performed over a 1,147bp region, spanning the putative transcriptional start
sites identified by 5’ RACE analysis (Section 3.3.2.1/3.3.2.2)(Figure 3.10). This
included sequence located immediately 5’ of human FHL1 exon 1 (exon 1 inclusive)
and the corresponding murine sequence which was obtained by BLAST search of the
murine database with published human FHL1 Exon 1 (81% homology). Comparative
pairwise alignment with the murine FHL1 promoter sequence was performed using the
sequence alignment programme, ClustalX (1.81) and revealed 63.79% overall sequence
identity between the two species. Extensive blocks of homology occur throughout the
promoter  region,  particularly  within  the  first  300bp  upstream  of  the  putative
transcriptional start site(s). Initial sequence analysis revealed that, like the human FHL1
promoter, the murine Fhl1 promoter lacks TATA and CCAAT box elements, however
the MED-1 and Inr elements identified within the human FHL1 promoter (+21, -1,
respectively)  were  conserved  in  mouse.  Moreover,  the  murine  DPE  at  +24
(GCTCAGTCCT)  shared  greater  homology  to  the  consensus  DPE  sequence  in
comparison to its human counterpart. In addition, a number of putative transcription
factor binding sites are highly conserved between the two species including consensus
motifs for Sp1, MyoD, CDP, TCF11, MOK2 and AP2.174
Figure 3.10. Sequence Alignment of the Human and Murine FHL1
Exon 1 and 5’ Flanking Region. Nucleotides with sequence identity are
indicated with an asterisk (*). Conserved putative transcription factor
binding sites are underlined. The four transcriptional initiation sites
identified by 5’ GeneRacer
TM Analysis are indicated by arrowheads (   ).
The previously known extent of exon 1 is highlighted.175
3.3.5 Identification of a HOX11 Responsive Element in the FHL1 Promoter
In Chapter 2, HOX11 was demonstrated to be capable of both activating and repressing
the  transcription  of  the ALDH1A1 promoter in the HEL and PER-117 cell line,
respectively. These results supported the hypothesis that ALDH1A1 is a bona fide target
gene of HOX11, and provided a starting point for addressing the way in which HOX11
acts as a dual-function regulator. Likewise, in order to confirm the status of FHL1 as a
gene  transcriptionally  regulated  by  HOX11,  following  identification  of  the
transcriptional start sites of FHL1, luciferase reporter assays were performed on two
pGL3Basic luciferase reporter constructs containing 297bp and 926bp of 5’ genomic
DNA flanking FHL1 exon1. The aim was to investigate the response of the FHL1
proximal promoter to HOX11 in two different cell backgrounds, namely T-cell (PER-
117) and erythroid (HEL).
In order to firstly assess the activity of the FHL1 promoter in the absence of HOX11,
pGL3BasicFHL1-297 and -926 luciferase constructs, together with a cotransfection
control constitutively expressing β-Galactosidase, were transiently transfected into the
PER-117 and HEL cell lines (neither of which express the endogenous FHL1 gene at
the level of Northern blot). As described in Chapter 2, the results are expressed as
relative transcriptional activity, which represents the ratio of luciferase activity to β-
galactosidase activity. Transfection of the pGL3BasicFHL1-297 construct resulted in a
significant stimulation of promoter activity over the pGL3Basic construct alone,
indicating that positive cis-regulatory elements are present in the first 297bp of the
FHL1 promoter (Figure 3.11). The presence of an additional 629bp of 5’ flanking
sequence (pGL3BasicFHL1-926) resulted in a ~2-fold decrease in promoter activity for
PER-117, suggesting that the region between -297/-926bp may contain a negative
regulatory element(s) that contribute to the cell-type specific silencing of FHL1 in PER-
117. This decrease in expression was not observed in the HEL cell line, however,
implying that distal elements not included in these analyses may repress FHL1 in HEL
cells.176
FIGURE 3.11177
In order to investigate the ability of HOX11 to regulate the FHL1 promoter, the -297
and -926 constructs were subsequently cotransfected with either the empty expression
vector, pEFBOS,  or  a  HOX11-expressing version,  pEFBOSHOX11. As described in
Chapter 2, the results of luciferase experiments are presented as a log-fold change of
normalised individual promoter constructs relative to the pGL3Basic empty vector
control (performed by Dr Ross Taplin, Division of Science and Engineering, Murdoch
University).  Cotransfection  of  pEFBOSHOX11  with  the  pGL3BasicFHL1-297
promoter construct resulted in a modest repression of the FHL1 promoter in PER-117
cells  which  was  augmented  following  the  addition  of  5’  flanking  sequence
(pGL3BasicFHL1-926), suggesting that HOX11 is capable of repressing the FHL1
promoter in PER-117 (Figure 3.12). Slight repression was also demonstrated in the HEL
cell line, although this was only statistically significant in the case of the -926 construct
(Figure 3.12).
Given that HOX11 was capable of repressing transcription from the FHL1 promoter in
the PER-117 cell line, the ability of a DNA binding mutant of HOX11, HOX11∆H3, to
repress transcription was subsequently investigated. Similar to the effect observed for
the ALDH1A1  promoter  in  Chapter  2,  HOX11∆H3  was  incapable  of  repressing
transcription  from  the  -297  and  -926  FHL1  promoter  constructs,  and  instead
demonstrated strong transactivation potential (Figure 3.13). These results corroborate
the dual function of HOX11 observed in Chapter 2, and confirm the requirement for the
DNA binding helix in HOX11-mediated transcriptional repression.178
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3.4  DISCUSSION
Although the expression pattern of FHL1 in skeletal and cardiac muscle indicates a
functional role in development, the identification of FHL1 as a possible target gene of
the T-cell oncoprotein HOX11, expressed at high frequency in T-ALL cell lines
(Greene  et al., 1998), highlighted the need for an increased understanding of the
mechanisms of FHL1 gene regulation in both normal and tumorigenic contexts. The
identification of cis-acting sequence elements and trans-acting proteins responsible for
the regulation of promoter activity in a given cellular environment, is a crucial starting
point in understanding gene expression. These regulatory elements, which constitute the
proximal promoter of the gene, are located within the vicinity of the initiation site
otherwise known as the transcriptional start site (Carey & Smale, 2000). Given the
capacity for many DNA sequences to display above base-line levels of activation in
artificial promoter assays, particularly luciferase assays which are extremely sensitive,
the accurate identification of the FHL1 transcriptional start site was first necessary in
order to undertake subsequent promoter analysis.
5’ RACE was utilised in this study to identify the start site of FHL1, since it provides a
rapid  and  extremely  sensitive  means  for  determining  cDNA  ends.  Although  the
enhanced sensitivity of this PCR-based method facilitates the identification of start sites
for genes that are inefficiently transcribed, the limitations of RACE are related to
artefacts produced as a result of this sensitivity, highlighting the requirement for careful
data analyses to avoid misinterpretation of results. For example, the preferential
amplification of shorter cDNAs generated in the initial reverse transcriptase step, which
may be the result of premature termination or simply represent a shorter authentic
transcript, can be misleading since these smaller products will appear to represent the
major initiation start site (Carey & Smale, 2000). For this reason, our analyses of FHL1
incorporated the use of four independent reverse transcriptases in order to maximise the
probability of obtaining the longest FHL1-specific cDNA present in the ALL-SIL
mRNA population.
A standard 5’ RACE procedure (5’ RACE System Version 2.0; Invitrogen) was initially
employed to identify the 5’ end of the FHL1 encoded mRNA in order to determine its181
transcriptional  start  site.  However,  the  possibility  that  the  cDNA  amplified  was
prematurely terminated as a result of the high GC content associated with the 5’ exon
template of FHL1 or was degraded or cleaved at the 5’ end during handling, resulting in
a false start site position, prompted the use of the GeneRacer
TM technique (Invitrogen).
This method selects for mRNA containing a cap structure, which is added to the 5’ end
of transcripts synthesised by RNA polymerase II, thereby increasing the likelihood of
amplifying authentic start sites. Indeed, the sequences obtained using this refined
method resulted in the identification of transcriptional start sites extending an additional
108bp from the furthest 5’ end identified using the standard 5’ RACE strategy. Overall,
the sequencing of 10 clones, which were obtained using a combination of independent
reverse transcriptases and two different techniques, resulted in the identification of four
transcriptional initiation start sites -329bp, -252bp, -224bp and -221bp upstream of the
FHL1 ATG start codon, within a region spanning 109bp. Although these results may
reflect the inability of the RT to transverse a CG-rich region, resulting in early and
sporadic  termination,  it  was  considered  more  likely  that  they  represent  multiple
transcription initiation sites - a characteristic feature of some ‘TATA-less’ promoters
(Weis & Reinberg, 1992). Known as multiple start site promoters, these typically
possess a ‘window’ of start sites, in addition to a high CpG dinucleotide content and
numerous Sp1 (CCCGCC) binding sites - characteristics shared by the FHL1 promoter
identified  in  this  study.  It  is  postulated  that  Sp1  may  direct  the  formation  of  a
preinitiation complex containing i) general transcription factors (GTFs) RNA Pol II,
TFIIA, TFIIB, TFIID, TFIIE, TFIIF and TFIIH and ii) coactivators and corepressors, to
a region 40 to 100bp downstream of its binding sites by interacting with a component of
TFIID   (Slansky & Farnham, 1996, Smale et al., 1990). This class of TATA-less
promoter is also associated with a MED-1 element - a protein binding sequence located
+20 to +45 downstream of the initiation window that was shown to be necessary, but
not sufficient for multiple start site utilisation (Ince & Scotto, 1995). Indeed, a sequence
closely resembling a consensus MED-1 element was identified +21 relative to the most
3’ FHL1 start site and this was also shown to be conserved in the corresponding murine
Fhl1 sequence. Whilst many TATA-less promoters are associated with ‘housekeeping’
genes, which generally exhibit little cell-type specificity, oncogenes and genes encoding
transcription factors and growth factors are also often TATA-less. An example of the
regulation of a tissue specific gene by a TATA-less promoter is the human Zipper182
protein kinase, which is expressed specifically in the developing brain (Itoh et al.,
2004). Thus, it is entirely plausible that the muscle specific FHL1 is regulated by a
TATA-less promoter, as identified by the 5’ RACE studies.
Alternatively, the identification of highly conserved, consensus Inr (-1) and DPE (+24)
elements relative to the major FHL1 start site identified in this study, suggests that
FHL1 may be regulated by a promoter with an Inr-DPE and no TATA box. The DPE,
which is located between +28 to +34 relative to the transcription initiation site, is
thought to represent a downstream counterpart to the TATA box and is conserved from
Drosophila to humans (Burke & Kadonaga, 1997). In this case, the initiator element
(Inr), which encompasses the start site, acts in conjunction with the DPE to direct the
formation  of  a  preinitiation  complex  in  the  absence  of  a  TATA  box  (Burke  &
Kadonaga, 1996). It has been postulated that TFIID (a multi-subunit protein comprising
TATA box binding protein (TBP) and TBP-associated factors), cooperatively binds Inr
and DPE motifs, thereby nucleating the binding of additional GTFs required for the
initiation of transcription (Burke & Kadonaga, 1996, 1997).
To complement the molecular techniques used to identify the transcriptional start site
and corresponding promoter of FHL1, bioinformatic tools were also employed to search
for promoter-specific characteristics in a 12kb region surrounding the putative FHL1
start site. The development of computer programmes to predict eukaryotic promoters
and identify functional response elements has led to the emergence of a powerful tool
that can be used as an adjunct to experimental gene analysis. The ability to perform
rapid, large-scale sequence analysis renders promoter prediction algorithms such as
PromoterInspector (Scherf et al., 2000), PromFind (Hutchinson, 1996), PromoterScan
(Prestridge, 1995), and Autogene (Kondrakhin et al., 1994), especially useful as ‘pre-
processing’ steps in promoter identification and annotation studies. The predictive
capacity of any given promoter analysis programme is a function of its ‘approach’,
which can be heuristic, core promoter or context driven (Scherf et al., 2000). Heuristic
approaches are based on the recognition of several transcription factor binding sites in
the appropriate orientation and context, however, although this approach detects
promoters with high specificity, it is limited to the identification of a well-characterised
subset of promoter types and is therefore unsuitable for promoter prediction on a183
genome-wide  scale  (Werner,  1999).  In  contrast,  the  core  promoter  approach
demonstrates relatively low specificity, relying on the identification of core promoter
elements including the TATA box, CCAAT box and transcriptional initiation sites
(Fickett & Hatzigeorgiou, 1997). Not only does this approach exclude TATA-less
promoters, but it also yields large proportion of false positive identifications, thereby
limiting its use in large-scale analyses (Fickett & Hatzigeorgiou, 1997). The use of an
algorithm  that  takes  into  account  the  heterogeneity  of  promoter  structure  whilst
recognising contextual similarities is therefore crucial in order to accurately delineate
true polymerase II promoters.
PromoterInspector is a promoter prediction tool developed by Scherf et al., (2000), that
accurately  locates  eukaryotic  polymerase  II  promoter  regions  from  large  input
sequences on the basis of genomic ‘context’. The programme is trained using an
unsupervised technique, to recognise promoter-specific features that are compatible
with nucleosome remodelling and the formation of a preinitiation complex containing
RNA polymerase II, as opposed to identifying mere transcription factor binding
sequences. These shared features form the definition of ‘context’, and since the specific
features of promoter context are unknown, this approach facilitates the prediction of
new, unknown regulatory regions, such that the analysis extends beyond our limited
understanding of what constitutes a functional eukaryotic promoter (Scherf et al., 2000,
Carey & Smale, 2000). A comparison of PromoterInspector with other promoter
prediction  tools  using  a  dataset  reviewed  by  Fickett  &  Hatzigeorgiou  (1997)
demonstrated the accuracy of this heuristic-free approach, which generated a record true
positive to false positive ratio of 2.3 using input sequences up to 300kbp in length
(Scherf et al., 2000). Thus, the identification of a putative promoter within a region of
the FHL1 5’ UTR (exon 1) overlapping the position of several transcriptional start sites
mapped during our 5’ RACE analysis, strongly suggests that the sequence 5’ of
transcriptional  start  site  1  (-329bp)  represents  a  bona  fide regulatory region for
subsequent bioinformatic and functional investigations.
Using the MatInspector V2.2 transcription factor binding site analysis programme,
consensus binding sites, conserved in both human and murine FHL1 promoters were
identified for a number of transcriptional regulators. Sp1 is a sequence specific DNA-184
binding protein that was originally identified as a transcriptional activator of the SV40
early promoter (Dynan & Tjian, 1983), and was later shown to be a widespread
activator of both housekeeping and tissue specific polymerase II genes (Emami et al.,
1998, Pugh & Tjian, 1990, Philipsen & Suske, 1999). Studies reveal that Sp1 is
involved in directly stabilising the binding of TFIID to core promoter elements via
interactions with TBP, hTAFII130 and hTAFII55 and can activate transcription through
both TATA-containing and TATA-less promoters within the human genome (Emami et
al., 1998). In the context of TATA-less promoters, Sp1 specifies the formation of
preinitiation complexes involving the general transcription factor TFIID, within a
window of 40-100bp downstream of its binding sites at DNA sequences that closely
resemble TATA or Inr elements; thereby accounting for the identification of multiple
initiation start sites (Carey & Smale, 2000). Roles for Sp1 in processes such as
chromatin  remodelling  and  cell  cycle  regulation  have  also  been  demonstrated,
highlighting the importance of GC-boxes and the ubiquitously expressed GC box-
binding proteins such as Sp1 in maintaining normal cellular function.
In addition to the multiple Sp1 sites identified within the FHL1 promoter, consensus
motifs for the muscle specific transcription factor MyoD were also identified. MyoD
belongs to the myogenic bHLH family that play an important role in directing the
transcription of muscle-specific genes including the muscle creatine kinase and cardiac
alpha-actin genes (Weintraub et al., 1990, Biesiada et al., 1999). The formation of a
muscle-specific, multi-protein transcriptional complex including MyoD, Sp1, the serum
response factor (SRF) and E12 proteins on muscle-specific promoters, highlights the
emergence  of  a  common  theme  in  muscle  gene  regulation,  that  involves  the
combinatorial binding of tissue specific factors including members of the myogenic
bHLH family, in addition to ubiquitously expressed factors, such as Sp1 (Biesiada et al.,
1999). For example, the simultaneous presence of myogenic bHLH, Sp1 and SRF has
been shown to be essential for the complex formation and transcriptional activation of
human cardiac alpha (HCA) gene (Biesiada et al., 1999). The co-existence of Sp1 and
MyoD binding sites on the FHL1 promoter therefore provides a starting point for
investigating the specific regulation of FHL1 in skeletal and cardiac muscle cells.
Indeed, an in vivo physical interaction between MyoD and Sp1 has already been
demonstrated in muscle cells and studies in Drosophila-derived Schneider cells reveal185
that  Sp1  and  MyoD  act  synergistically  to  transactivate  HCA  promoter  activity
(Sartorelli et al., 1990).
Putative binding sites were also identified for the cardiac-specific NK-Like (NKL)
homeobox protein NKX2.5, which contributes to an array of cardiac developmental
pathways in mammals (Benson et al., 1999). Given that FHL1 is also expressed in the
developing embryonic heart and in adult heart tissue, it is possible that FHL1 may
represent a physiological, cardiac-specific target of NKX2.5 (Brown et al., 1999).
Intriguingly, NKX2.5 was recently shown to be activated in three paediatric T-ALL cell
lines, HPB-ALL, CCRF-CEM and PEER, harbouring the novel cryptic translocation
t(5,14)(q35,q32)(Nagel et al., 2003). These studies also demonstrated that within the
NKL homeobox gene family, which include 14 genes in total, only NXK2.5, HOX11L2
and HOX11 were activated in a panel of T-ALL cell lines. It is tempting to speculate
that these proteins may dysregulate a similar set of oncogenically relevant target genes
to generate the T-ALL phenotype, possibly through a domain shared by these family
members. In addition it is also possible that these related proteins may cross-regulate
tissue-specific target genes, when expressed out of their normal cellular context. This
may account for the identification of a NKX2.5-specific target gene (e.g. FHL1) in a
screen designed to identify HOX11 targets, following the over-expression of HOX11 in
the murine NIH 3T3 fibroblast cell line. Thus, it is plausible that FHL1 may be
regulated  by  NKX2.5  in  normal  cardiac  muscle  development  in  addition  to  a
tumorigenic  scenario  whereby  NKX2.5  is  aberrantly  expressed  in  T-cells;  or
alternatively, FHL1 may represent a true oncogenically relevant target of HOX11,
which is also over-expressed in T-ALL malignancies. It would be of interest to test the
hypothesis that NKX2.5, HOX11L2 and HOX11 are functionally redundant in terms of
regulating the expression of their individual, tissue specific target genes since this might
provide a clue regarding the role that FHL1 may play as a target of NK-like homeobox
proteins.
A consensus binding site for HAND2, a bHLH transcription factor required for heart
development in the chick and mouse (Srivastava et al., 1995) was also identified in the
proximal FHL1 promoter. In the mouse, Hand2 is specifically expressed in the right
ventricle, and mouse embryos deficient in Hand2 display hypoplasia of the right186
ventricle soon after cardiac looping (Srivastava et al., 1997). In the context of FHL1
gene regulation, it is of interest to note that both Hand2 and Nkx2.5, two transcription
factors involved in cardiac development, have been shown to cooperatively regulate the
ventricular-specific homeodomain protein Irx4 (Yamagishi et al., 2001). It is therefore
possible that Nkx2.5/CSX, HAND2 and FHL1 may constitute a transcriptional network
involved in differentiation and function of the developing heart. Functional promoter
analyses in cardiac cell lines is required in order to determine the importance of these
elements in the transcriptional regulation of FHL1, however, and to positively identify
trans-acting proteins at these sites.
Ideally, the FHL1 transcriptional start site positions identified in this study should be
confirmed by independent mapping methods such as primer extension, S1 nuclease or
RNase protection assays. Primer extension involves the elongation of a gene specific 5’
32P-labelled  primer  to  the  5’  end  of  a  specific  mRNA  (Ghosh  et al.,  1978).  By
determining the length of the radiolabelled cDNA products generated on a sequencing
gel, the distance from the 5’ end of the primer to the transcriptional start site can be
estimated with an accuracy of +/- 1 nucleotide (Carey & Smale, 2000). Although this
method is relatively simple and efficient, the problem of premature reverse transcriptase
termination due to the formation of stable secondary structures at GC rich 5’ ends may
still yield incomplete cDNA species. In contrast to 5’ RACE and primer extension
analyses, RNase protection is not reliant on reverse transcription to map 5’ cDNA ends
and thus provides a truly independent method for identifying transcription initiation
sites. This approach involves the generation of an α-
32P[UTP] labelled RNA probe
using a plasmid template containing a genomic fragment spanning the predicted
transcriptional start site for the gene of interest. The radiolabelled probe is then
annealed to the mRNA population to produce thermodynamically stable RNA:RNA
hybrid molecules with single stranded RNA overhangs. These hybrids, which contain
the putative transcriptional start site, are resistant to subsequent digestion with RNase T1
and RNase A, which cleave the single stranded RNA overhangs such that the length of
the protected region can be used to determine the distance of the 5’ end of the probe to
the transcriptional start site (Melton et al., 1984). This method is useful for the
quantitative analysis of transcripts, however it is still prone to artefacts since the probe
can form secondary structures resulting in unwanted RNase-resistant products (Carey &187
Smale, 2000). Finally, S1 nuclease analysis can be used to determine the start site of a
gene. This approach is similar to RNase protection except that the probe is a single
stranded DNA molecule that spans the anticipated start site, as opposed to an RNA
molecule and digestion is performed with nuclease that cleaves single stranded RNA
and DNA (Berk & Sharp, 1977). This method is less frequently used compared to
RNase protection assays, however, since DNA:RNA duplexes are less stable than
RNA:RNA hybrids particularly over long AT rich stretches, and aberrant cleavage
within these regions may contribute to artefacts (Carey & Smale, 2000). In addition the
probe is typically radiolabelled at the 5’ end and not throughout the entire molecule,
such that the procedure is less sensitive, although uniformly labelled probes can be
generated.
In order to correlate the intracellular expression of FHL1 with functional regulatory
elements, and to investigate the ability of HOX11 to regulate the FHL1 promoter in
vitro, an initial investigation was undertaken of the FHL1 promoter using the T-ALL
cell line PER-117, and the human erytholeukaemic cell line, HEL. Luciferase reporter
constructs spanning -297/+73 and -926/+73 of the FHL1  promoter were inserted
upstream of the firefly (Photinus pyralis) luciferase cDNA of the pGL3Basic luciferase
reporter vector and were transiently transfected into the PER-117 and HEL cell lines.
Analysis of the FHL1 promoter revealed that positive cis-regulatory elements may be
required for controlling the transcriptional activity of the FHL1 gene in PER-117 and
HEL, since the 297bp of sequence flanking the 5’ FHL1 transcriptional start site was
active in both the PER-117 and HEL cell lines (Figure 3.11). This region encompasses
numerous Sp1 binding sites, which may account for the normal activation of FHL1 in
the absence of repressor elements. Extension of this sequence to incorporate 926bp of
DNA flanking the 5’ end of Exon 1, however, resulted in a 2-fold decrease in luciferase
activity in PER-117, in contrast with the HEL cell line, which showed no decrease in
promoter activity. These results suggest the presence of a cell type-specific negative
regulatory element located between -297/-926bp, which may function to repress the
expression of FHL1 in T-cells. A number of putative regulatory elements conserved
between  human  and  mouse  species  were  identified  within  this  region  including
additional Sp1 sites, as well as binding sites for TCF11, SRY, MOK2 and NKX2.5 and
MyoD, however further work is required in order to delineate the specific negative188
element involved in silencing FHL1 expression in PER-117 cells. It is possible that a
more distal negative element responsible for the repression of FHL1 in HEL exists,
however, larger promoter constructs were not included in this study.
A primary goal of this Chapter was to determine whether HOX11 can have an effect on
FHL1 promoter activity. This was assessed by cotransfection of the pEFBOSHOX11
expression vector and FHL1 promoter constructs into the PER-117 and HEL cell lines.
Similar to the ALDH1A1 promoter, overexpression of HOX11 resulted in modest
repression of FHL1 promoter activity in PER-117 cells, whilst the effect in HEL was
negligible (Figure 3.12). Although repression by HOX11 was observed in the -297
construct, this effect appeared to be augmented in the -926bp construct, suggesting that
HOX11 may act via elements present in both -297 and -926bp constructs. Given the
presence of multiple Sp1 binding sites spanning -926/+73bp, one possible mechanism
of  repression  may  involve  the  ability  of  HOX11  to  interfere  Sp1-mediated
transactivation.  The  ability  of  homeodomain  proteins  to  suppress  Sp1-dependent
transcription has been previously demonstrated for Msx-1, which was shown to interact
with TBP, Sp1 and CBP and is thought to mediate autorepression by ‘squelching’
components of the transcriptional machinery and by forming an active repressor
complex (Shetty et al., 1999). Experiments performed by Suzuki et al., (2003) also
demonstrate that HoxA11 is capable of repressing Sp1-dependent transcription as well
as  inhibiting  HoxA13  enhanced  transcription,  although  the  mechanism  for  this
repression  is  not  clearly  understood.  The  effect  of  the  HOX11∆H3  mutant  on
transcriptional repression from the FHL1 promoter was also assessed in the PER-117
cell line. In keeping with the results in Chapter 2, HOX11∆H3 was unable to mediate
repression and instead, activated transcription (Figure 3.13). These results support the
hypothesis that transcriptional repression by HOX11 occurs via a mechanism requiring
the  DNA  binding  helix,  and  therefore  possibly  involves  DNA  binding;  whereas
transactivation  occurs  independently  of  the  DNA  binding  helix,  possibly  via  a
mechanism involving protein-protein interactions. The transactivation demonstrated by
HOX11∆H3 may conceivably result from 1) the loss of an active DNA-binding
repressor complex, 2) a dominant negative mechanism whereby HOX11∆H3 sequesters
repressor cofactors from other regions of the promoter and/or 3) by forming an
activation complex. Indeed, the ability of helix 3 mutants of HoxA13 to suppress189
transactivation  by  HoxA13  in  a  dominant  negative  manner  has  been  previously
documented  (Suzuki  et al.,  2003).  Alternatively,  repression  by  HOX11  may  be
independent of DNA binding, and helix 3 of the homeodomain may represent an
interface for the recruitment of corepressors. Thus, upon deletion of this region,
HOX11∆H3 is unable to repress transcription. Notably, the repression mediated by
HOX11 on the FHL1 promoter, contrasts with upregulation of FHL1 by HOX11 in NIH
3T3  cells  and  the  expression  of FHL1 in T-ALL cell lines (including HOX11-
expressing  cell  lines,  ALL-SIL  and  PER-255).  Once  again,  this  may  reflect  the
requirement for additional distal elements not included in the FHL1 promoter constructs
tested for correct regulation by HOX11 or the need for chromatin-specific conditions.
In summary, the work described in this Chapter suggests that the human FHL1 gene is
regulated by a TATA-less promoter that contains several transcriptional initiation start
sites within a 108bp window. Functional promoter analyses suggested that the main
activity of the FHL1 promoter occurs within the first 300bp from the transcription
initiation start site window, which contain multiple sites for the ubiquitously expressed
positive trans-acting Sp1. The existence of negative regulatory elements 5’ of this
region, is likely to account for the repression of FHL1 in both PER-117 and HEL, and
in the case of PER-117, one or more of these elements may exist between the -926 and
-297bp region. Finally, HOX11 was capable of repressing the activity of luciferase
reporter constructs through elements located in the FHL1 promoter, thus supporting the
status of FHL1 as a gene able to be transcriptionally regulated by HOX11.190
Chapter 4
Protein Binding Partners of HOX11
4.1 INTRODUCTION
Our current understanding of the molecular events that lead to T-ALL has greatly
benefited from the identification of transcription factors that are deregulated via
chromosomal translocations involving T-cell receptor loci (reviewed by Hwang & Baer,
1995, Look, 1997). HOX11 is an enigmatic example of a DNA binding protein that
contributes to the development of T-ALL (Lichty et al., 1995). The work presented in
previous chapters, suggests that HOX11 may not be a representative of a simple
activator or repressor of transcription. Through the use of luciferase reporter assays,
HOX11 was shown to repress transcription via elements located in the proximal
promoters of ALDH1A1 and FHL1 in the T-ALL cell line, PER-117. In contrast,
HOX11 activated transcription through the ALDH1A1 promoter in the erythroleukaemic
cell line, HEL. These studies also demonstrated that although the DNA binding helix of
HOX11  is not required for activation, this region is essential for transcriptional
repression, since deletion of the third α-helix switched HOX11 from a transcriptional
repressor to an activator.
The means by which HOX11 can modulate gene transcription remains unknown. There
is thus a need for more extensive examination of the issue, however our understanding
of  HOX11  is  very  much  limited  by  the  absence  of  interacting  partner  proteins.
Transcription factors tend not to operate independently, but rather, are known to
mediate their regulatory effects by forming non-covalently associated multi-subunit
complexes that bind DNA (reviewed by Wilson, 1996). Therefore, a fruitful way
forward to understanding the precise intracellular functions of HOX11, is to identify
protein partners with which it interacts. It is known that HOX proteins can interact with
various classes of transcription factor to achieve functional specificity in vivo, including
other HOX proteins, TALE homeoproteins (e.g. PBX and MEIS), zinc finger proteins
(Durocher et al., 1997), and leucine zipper proteins (Kataoka et al., 2001). At the same
time, HOX proteins can, directly or indirectly, aid the recruitment of components of the191
basal transcriptional machinery and other components that modulate transcriptional
events such as histone acetyl transferases and deacetylases (Sur et al., 2000, Choi et al.,
1999, Towler et al., 1994).
In previous work, HOX11 was shown to associate with the CCAAT-box binding
transcription factor 1 (CTF1) and it was suggested that this leads to an increased
proliferative capacity of haematopoietic precursor cells in vitro (Zhang et al., 1999).
Previous unpublished work from this laboratory and that of Dr Ursula Kees (Division of
CLCR, TVW Telethon Institute for Child Health Research, Western Australia), has
suggested that HOX11 may physically interact with MEIS1, MEIS2 and/or TFIIB.
MEIS1 and MEIS2 were implicated as HOX11 interactors in a yeast-2-hybrid assay
(Milech et al., in preparation), while TFIIB was identified by mass spectrometry in an
ALL-SIL cell immunoprecipitate produced with an anti-HOX11 antibody (Heidari et
al., in preparation). Human general transcription factor TFIIB is a ubiquitous factor
required  by  RNA  polymerase  II  for  transcription  initiation  through  eukaryotic
promoters (Sawadogo & Sentenac, 1990). As the second most common target for
transcriptional regulators (after TFIID), numerous studies have shown that TFIIB is
involved in both gene activation and repression (Blanco et al., 1995, Wang et al. 1996,
Breiling et  al., 2001). TFIIB is a target in the repression of transcription by the
oncoproteins PLZF-RAR, LAZ3/BCL6 and Mad/Mxi-1 (Nagy et al., 1997, Dhordain et
al., 1997, Hong et al., 1997). Transcription factor interactions with TFIIB may lock
central components the transcription initiation apparatus into a non-functional complex
or conformation that is not conducive to transcription (Muscat et al., 1998). Several
studies have shown that transcriptional activator proteins can also interact with TFIIB.
These include myogenic determination factor, MyoD (Heller & Bengal, 1998), c-myc
(McEwan et al., 1996) and c-Jun (Franklin et al., 1995). In support of TFIIB as a
potential target for HOX11-mediated transcriptional regulation, Owens et al., (2003)
recently showed that HOX11 functionally interacts with the basal transcriptional
machinery using artificial reporter assays. This study did not, however, determine which
general factor was targeted by HOX11. Alternatively, since CTF1 has been reported to
interact with HOX11 (Zhang et al., 1999), and CTF1 itself is known to interact with
TFIIB (Kim & Roeder, 1994), the purported interaction of HOX11 with TFIIB may be
indirect via CTF1. The preliminary results from our laboratory, suggesting that HOX11192
may interact with MEIS proteins and/or TFIIB, are potentially significant, given that
these interactions may have functional and clinical significance. They may also shed
light on the mechanism(s) by which HOX11 regulates gene expression, including
ALDH1A1 and FHL1. An interaction with TFIIB, in particular might help to explain
both the work in this thesis and that of Owens et al., (2003), in which HOX11 was
implicated in a direct association with the basal transcriptional apparatus. The main aim
of the work in this chapter, therefore, was to examine whether MEIS1, MEIS2, TFIIB
and HOX11 itself are capable of a direct physical interaction with HOX11. A variety of
methods for studying protein interactions exist, including co-immunoprecipitation (Co-
IP)(Voncken  et al., 1999, O’Neill et al., 2000) and fluorescence resonance energy
transfer (FRET)(Cheung et al., 1991, Souerjik & Berg, 2002). In this study, it was
decided to focus on confirming direct interactions with HOX11 using the Glutathione-S-
Transferase (GST)-pulldown approach. This was due both to the ready availability of
recombinant GST-HOX11 (Heidari et al., 2002), as well as the advantage that it
eliminates the requirement for a highly specific antibody, which is necessary for Co-IP
approaches. GST-pulldown purification has been successfully used to demonstrate
interacting partners of homeodomain proteins (Mitchelmore et al., 2000, Yamada et al.,
1999, Cvekl et  al., 1999) and of HOX11 itself (Zhang et al.,  1999),  and  offers
significant advantages in terms of speed, simplicity and flexibility. As the name
suggests, it involves the fusion of proteins of interest (‘bait’) to a GST purification tag
followed by immobilization on glutathione agarose affinity matrix. The bound fusion
protein can then be used to assay the binding of specific ‘test’ proteins radio-labelled
with [
35S]-methionine by in vitro translation.
4.2 METHODS
4.2.1 GST-Pulldown Assays
4.2.1.1  pCIneo CTF1 and TFIIB Vector Construction
The pCIneo mammalian expression vector (Promega, Genbank
®/EMBL Accession
number: U47120)(Appendix 2) carries the T7 RNA polymerase promoter, which
enables the synthesis of mRNA transcripts in vitro. The pCIneo
r vector utilised in these193
experiments, contained a deletion of sequence within the multiple cloning site (between
EcoR I/Acc I).
4.2.1.1.1  Preparation of pCIneo
r Mammalian Expression Vector
pCIneo
r was prepared for subcloning by restriction digestion with Nhe I restriction
endonuclease (Promega) in a 1.5ml polypropylene microcentrifuge tube in a final
volume of 50µl, containing 10x Nhe I Restriction Digest Buffer [1x; 6mM Tris-HCl (pH
7.5),  50mM  NaCl,  6mM  MgCl2,  1mM  DTT](Promega),  0.1mg/ml  nuclease-free
acetylated BSA (Promega), 1µg of pCIneo
r plasmid DNA and 10U of Nhe I restriction
enzyme (Promega) at 37
oC for 1.5h. Following digestion, restriction endonuclease was
heat  inactivated  by  incubation  at  65
oC  for  20min.  Linearised  5’  ends  were
dephosphorylated to prevent vector re-circularisation by incubation with 1U of CIP
(Roche) at room temperature for 30min, followed by heat inactivation at 75
oC for
10min. An aliquot of the digested pCIneo
r vector (40ng) was electrophoresed on a 1.3%
(w/v) agarose gel (Section 2.2.1.2) to confirm complete digestion prior to ligation with
insert DNA.
4.2.1.1.2  Generation of ALL-SIL and HEL and cDNA
cDNA for PCR amplification of the CTF1 and TFIIB coding regions was generated
using THERMOSCRIPT
TM RT-PCR System (Invitrogen) according to the manufacturer’s
instructions. 2µg of either ALL-SIL or HEL total RNA was combined with 1µl of Oligo
(dT)20 random primer [50µM](Invitrogen) in an RNase-free 0.5ml polypropylene tube in
a final volume of 10µl, and incubated at 65
oC for 5min. The reaction was then chilled
on ice for 5min and reverse transcription was performed at 55
oC for 1h in a final volume
of 20µl comprising 5x cDNA Synthesis Buffer [1x; 50mM Tris acetate (pH 8.4), 75mM
potassium  acetate,  8mM  magnesium  acetate,  stabilizer](Invitrogen),  5mM  DTT
(Invitrogen), 40U of RNASEOUT
TM (Invitrogen), 1mM dNTPs (Invitrogen) and 15U of
THERMOSCRIPT
TM RT (Invitrogen). The reaction was terminated by incubation at 85
oC
for 5min and RNA was removed by incubation with 2U of RNase H (Invitrogen) at
37
oC for 20min. The resultant cDNA was diluted to a final volume of 100µl using
sterile dH20 and stored at -20
oC.194
4.2.1.1.3 PCR Amplification of CTF1 and TFIIB Insert cDNA
For the construction of pCIneo
r-CTF1, the 1523bp human CTF1 cDNA was amplified
from ALL-SIL cDNA generated in Section 4.2.1.1.2 using PfuTurbo
® DNA Polymerase
(Stratagene) according to the manufacturer’s instructions. Reactions were assembled in
thin-walled, 0.5ml polypropylene tubes in a final volume of 50µl, comprising 10x
Cloned Pfu
 DNA Polymerase Reaction Buffer [1x; 20mM Tris-HCl (pH 8.8), 10mM
KCl, 10mM (NH4)2SO4, 2mM MgSO4, 0.1% (v/v) Triton
®X-100, 0.1mg/ml nuclease-
free  BSA]  (Stratagene),  0.2mM  dNTPs  (Fisher  Biotech),  20pmol  each  of
CTF1NheF/CTF1NheR primers (Table 4.1), 2.5µl of ALL-SIL cDNA and 2.5U of
PfuTurbo
® DNA Polymerase (Stratagene). Samples were denatured for 2min at 94
oC
and then amplified (94
oC for 10s, 60
oC for 30s and 72
oC for 2min) for 10 cycles, with
subsequent cycle elongation times increasing by 20s per cycle up to 8:40s, followed by
a final extension of 72
oC for 7min (EXTEND72, Appendix 1). For the construction of
pCIneo
r-TFIIB,  the  979bp  human  TFIIB  cDNA  was  amplified  from  HEL  cDNA
generated in Section 4.2.1.1.2 in a 50µl reaction comprising 10x Cloned Pfu
TM DNA
Polymerase  Reaction  Buffer  [1x],  0.2mM  dNTPs,  20pmol  each  of
TFIIBForNhe/TFIIBRevNhe primers (Table 4.1), 2.5µl of HEL cDNA and 2.5U of
Pfu
TM Turbo Polymerase using the TD1 PCR programme (Appendix 1).195
TABLE 4.1196
4.2.1.1.4  Restriction Endonuclease Digestion of CTF1 and TFIIB Insert cDNA
Full-length CTF1 and TFIIB PCR products generated in Section 4.2.1.1.3 were gel
purified using the Qiaex II Gel Purification Kit (Qiagen)(Section 2.2.1.3) and prepared
for subcloning by restriction digestion with Nhe I restriction endonuclease (Promega) in
a 100µl reaction volume comprising 10x Nhe I Restriction Digest Buffer [1x], 0.1mg/ml
nuclease-free acetylated BSA, 50µl of gel purified CTF1/TFIIB DNA fragments and
30U of Nhe I restriction enzyme at 37
oC for 18h. Following digestion, restriction
endonucleases were heat inactivated by incubation at 65
oC for 20min. Digested PCR
fragments were subsequently purified from unwanted digestion products using a
QIAquick PCR Purification Kit (Qiagen)(Section 2.2.1.4). An aliquot of the purified
insert was electrophoresed on a 1.3% (w/v) agarose gel (Section 2.2.1.2) to estimate
DNA integrity and concentration prior to ligation.
4.2.1.1.5  Cloning of CTF1 and TFIIB cDNA
Subcloning of PCR amplified CTF1 and TFIIB cDNA into the pCIneo
r expression
vector  was  performed  essentially  as  outlined  in  Section 2.2.1.6. Ligations were
performed in 0.5ml polypropylene tubes in a final volume of 20µl, comprising 40ng of
linearised pCIneo
r vector DNA, 3:1 molar ratio of insert CTF1/TFIIB DNA, 10x T4
DNA Ligase Buffer [1x; 30mM Tris-HCl pH 7.8, 10mM MgCl2, 10mM DTT, 1mM
ATP](Promega) and 6U of T4 DNA Ligase (Promega) and incubated at 15
oC for 16-
24h. Ligation reactions were used to transform chemically competent DH5α E.coli
(Section 2.2.1.8) and plasmid Mini-Preps of selected colonies were prepared for
screening using the Sigma GenElute
TM Plasmid Miniprep Kit (Sigma)(Section 2.2.1.9).
The presence and orientation of CTF1 and TFIIB inserts were determined by restriction
digest analysis of a selection of randomly isolated recombinant clones with Nhe I and
Bgl II restriction endonucleases (Promega) respectively. Digests were performed in
1.5ml polypropylene microcentrifuge tubes in a 30µl volume comprising 10x Nhe I/Bgl
II Restriction Digest Buffer [1x](Promega), 0.1mg/ml nuclease-free acetylated BSA,
0.5µg of plasmid miniprep DNA, 10U of Nhe I/Bgl II restriction enzyme (Promega) at
37
oC for 1.5h. Restriction profiles were analysed on a 1.3% (w/v) agarose gel (Section
2.2.1.2) and selected positive clones sequence verified (Section 2.2.1.11).  pCIneo
r-197
HOX11, MEIS1 and MEIS2A plasmids were prepared by Darryl D’Souza (Division of
CLCR of the TVW Telethon Institute for Child Health Research, Western Australia).
4.2.1.1.6  Purification of Plasmid DNA
Plasmid DNA for pCIneoHOX11, MEIS1, MEIS2A, CTF1 and TFIIB constructs was
prepared  for  downstream  in vitro  transcription/translation  procedures  using  the
QIAGEN
 Plasmid Midi Kit (Qiagen) as outlined in Section 2.2.1.12 (grey highlight).
The recovered DNA was resuspended to a final concentration of 0.5µg/ul in nuclease-
free dH20 and stored at -20
oC.
4.2.1.2 Production of 
35S-Radiolabelled Proteins
4.2.1.2.1 In vitro Transcription/Translation
HOX11, MEIS1, MEIS2a, CTF1 and TFIIB were [
35S]-methionine radiolabelled by in
vitro transcription/translation using the TNT
® T7 Coupled Reticulocyte Lysate System
(Promega)  in  accordance  with  the  manufacturer’s  instructions.  Coupled
transcription/translation  reactions  were  assembled  on  ice  in  RNase-free  0.5ml
polypropylene tubes, in a 50µl reaction volume comprising 25µl of TNT
® Rabbit
Reticulocyte Lysate (Promega), 2µl of TNT
® Reaction Buffer (Promega), 1µg of DNA
Template, 0.02mM Amino Acid Mixture minus Methionine (Promega), 20µCi of
Redivue  [
35S]-methionine  (Amersham),  40U  of  RNasin
®  Ribonuclease  Inhibitor
(Promega) and 1µl of T7 TNT
® RNA Polymerase (Promega). Following addition of all
the components, the lysate was gently mixed and in vitro transcription/translation of
proteins was allowed to proceed for 90min at 30
oC. Translated proteins were stored at -
20
oC until required.
4.2.1.2.2  SDS-PAGE Analysis of 
35S-Methionine Labelled In vitro-Translated Proteins
Radiolabelled  protein  samples  (5µl)  were  prepared  for  SDS-PAGE  analysis  by
combining with 2x SDS Sample Buffer [1x; 31.25mM Tris (pH 6.8), 12.5% (v/v)
glycerol,  1%  (w/v)  SDS,  0.005%  (w/v)  bromophenol  blue,  2.5%  (v/v)  β-198
mercaptoethanol] in a 1.5ml screw-cap polypropylene tube and heating at 90-100
oC for
5min  to  denature  the  proteins.  Protein  samples  (10µl)  were  loaded  adjacent  to
Prestained Range MWMs (5µl)(Bio-Rad Laboratories) and resolved by SDS-PAGE as
described in Section 2.2.3.3.3. The gel was removed and incubated in Fixing Solution
[50% (v/v) methanol, 10% (v/v) glacial acetic acid] with gentle agitation for 30min at
room temperature, followed by soaking in Gel Drying Solution [7% (v/v) methanol, 7%
(v/v) glacial acetic acid] for 5min at room temperature, to prevent the gel from cracking
during the drying process. The gel was then placed on a sheet of Whatman
® 3MM filter
paper, covered with Saran wrap and dried under vacuum at 80
oC for 1h using a Bio-Rad
Model 583 Gel Dryer (Bio-Rad Laboratories). Autoradiography was performed using an
intensifying screen (Fuji G-8 EC-AWU Cassette, 27.9x35.6cm; Fuji Medical X-ray film
super HRG30) at -70
oC for 18-36h. Prior to developing, cassettes were allowed to thaw
for 1h at room temperature and films were developed using an SPM 300 developer
(Fuji).
4.2.1.3 Production of Recombinant GST-HOX11 and GST-HOX11∆H3 Fusion
Proteins
4.2.1.3.1 Preparation of Glutathione Sepharose 4B
Glutathione Sepharose 4B (Pharmacia Biotech) is provided as bulk matrix (75% slurry)
for batch purification purposes. Prior to affinity purification, a 50% slurry was prepared
according to the manufacturer’s instructions. Briefly, the Glutathione Sepharose 4B
matrix was resuspended by gentle shaking and a 665µl aliquot (1.33ml 75% slurry/ml of
bed volume required) transferred to a 10ml polypropylene tube. The matrix was
sedimented by centrifugation  (500 x g, 5min, room temperature)(CentraGP8R, IEC)
and washed with 5ml of ice-cold PBS (10ml PBS/1.33ml original slurry) by thorough
inversion.  The  beads  were  collected  by  centrifugation  (500  x  g,  5min,  room
temperature)  and  resuspended  in  500µl of ice-cold PBS to yield a 50% slurry.
Equilibrated beads were stored at 4
oC and remained functional for up to 1 month.199
4.2.1.3.2  Expression  and  Purification  of  Recombinant  GST,  GSTHOX11  and
GSTHOX11∆H3
Parent and recombinant expression vectors (pGEX, pGEX-6P-1/HOX11 and pGEX-6P-
1/HOX11∆H3) were obtained from Mansour Heidari (Murdoch University, Perth
Western  Australia).  Escherichia  coli  strain  ER2566  was  transformed  with  the
expression constructs pGEX, pGEX-6P-1/HOX11 or pGEX-6P-1/HOX11∆H3 and
cultured  for  15-16h  at  37
oC  in  2YT  media  containing  100µg/ml ampicillin with
vigorous shaking (~225rpm). Starter cultures were subsequently diluted 1:100 in
selective 2YT media (2ml starter culture in 198ml of selective 2YT media) and grown
at 37
oC to mid to late log phase (OD600 ~1.35). Fusion gene expression was induced by
adding 0.1mM IPTG to the cultures, and incubation was continued for an additional
1.5h at 37
oC. The cells were then collected by centrifugation (7 700 x g, 10min,
4
oC)(AvantiTM J-25I Centrifuge, Beckman, JA-25-50) and resuspended in 10ml of ice-
cold PBS. Prior to cell lysis the cell suspension was incubated in with 0.1mg/ml of
lysozyme, 4µg/ml of DNase1, 1mM PMSF and 5mM DTT on ice for 5min. The cells
were then lysed by freeze-thaw (3 cycles of liquid N2, 37
oC H20 bath) followed by
ultrasonication on ice (4 cycles of 30s, 1min rest period between each cycle). 1% (v/v)
Triton
®X-100 was added to aid the solubilisation of protein and the suspension was
mixed gently and incubated on ice for 15min. Bacterial debris was then cleared by
centrifugation (12,000 x g, 10min, 4
oC) and the supernatants collected. For purification
of the GST, GST-HOX11 and GST-HOX11∆H3 proteins, clarified bacterial lysates
(~10ml) were applied to 200µl of prepared 50% glutathione sepharose 4B slurry
(Section 4.2.1.3.1) and the matrix was incubated with gentle rotation at 4
oC for 2h. This
initial binding step aimed to remove background E.coli host proteins from the bacterial
supernatants.  The  beads  were  then  collected  by  centrifugation  (500  x  g,  5min,
4
oC)(CentraGP8R,  IEC)  and  the  supernatants  re-applied  to  200µl of fresh 50%
glutathione sepharose 4B slurry and incubated with gentle rotation at 4
oC  for  an
additional 18-20h. The matrix was then washed (x3) with 1ml of Wash Buffer [50mM
Tris-HCl  (pH  8.0),  100mM  NaCl,  10%  (v/v)  glycerol,  1mM  PMSF,  0.05mM β-
Mercaptoethanol]. For GST-pulldown assays which required fusion protein bound to
glutathione sepharose 4B beads, the matrix was resuspended in 200µl of Wash Buffer
and stored at 4
oC for up to 2 weeks. In cases where purified GST fusion proteins were200
required, the matrix was washed (x3) with cold PBS and the recombinant protein eluted
by the addition of 500µl (1 volume) of Glutathione Elution Buffer [50mM Tris-HCl (pH
8.0), 10mM reduced glutathione](Pharmacia Biotech) to the matrix and incubation at
4
oC for 10min. The beads were then collected by centrifugation (500 x g, 5min, 4
oC)
and the supernatant removed to a fresh tube on ice. The elution steps were repeated
twice  more  and  the  supernatants  were  pooled  and  stored  as  aliquots  in  0.5ml
polypropylene tubes at -80
oC.
4.2.1.3.3 Quantitative and Qualitative Analysis of GST Fusion Proteins
The  concentration  of  purified  GST,  GST-HOX11  and  GST-HOX11∆H3  was
determined by measurement of UV light absorbance of diluted samples. Protein samples
in solution were diluted 1/80 to a final volume of 160µl in dH20. The spectrophotometer
(Shimadzu UV Mini 1240 Spectrophotometer) was blanked with a 160µl aliquot of the
sample diluent. Ultraviolet light absorbance of the diluted protein sample was then
determined at 280nm wavelengths, and protein concentration was determined using the
calculations described below;
where (1 O.D unit = 0.5mg/ml of GST)
Fusion protein integrity was confirmed by SDS-PAGE electrophoresis as described in
Section 4.2.1.2.2. Samples (~1µg purified GST fusion protein) were combined with 2x
SDS Sample Buffer in a 1.5ml screwcap polypropylene tube and heated at 90-100
oC for
5min prior to electrophoresis on a 12.5% SDS polyacrylamide gel at 160V for 1h.
Proteins were visualised by staining with Coomassie Blue Dye [0.25% (w/v) Coomassie
Brilliant Blue R-250, 45% (v/v) methanol, 10% (v/v) glacial acetic acid] at room
temperature for 2h followed by destaining [40% (v/v) methanol, 10% (v/v) glacial
acetic acid] for 4h at room temperature. Gel images were taken using the GS-710
Calibrated Imaging Densitometer and associated software (Bio-Rad Laboratories).
GST Fusion Protein Concentration [mg/ml]: O.D280nm x dilution factor x 0.5201
In order to perform GST-pulldown experiments with a known quantity of ‘bait’ protein,
the amount of GST fusion protein retained by the glutathione sepharose 4B beads was
visually estimated by SDS-PAGE. An aliquot of the bound beads was diluted with fresh
glutathione sepharose (GST [1:40], GST-HOX11 [1:10], GST-HOX11∆H3 [1:7]) and
20µl of this bead mix was transferred to a 1.5ml screwcap polypropylene tube and
prepared for SDS-PAGE by combining with 10µl of 2x SDS-PAGE loading buffer and
heating for 5min at 90-100
oC. Samples were centrifuged (13,000 x g, 1min, room
temperature) to collect the beads and the supernatants analysed by SDS-PAGE as
described in Section 4.2.1.2.2. The amount of protein in a 20µl aliquot of mixed beads
was determined by comparison of the intensity of staining between samples and the
Bio-Rad MWM of known concentration. In addition, samples were also compared to
known  quantities  of  purified  GST,  GST-HOX11  and  GST-HOX11∆H3  proteins
produced and quantitated in sections 4.2.1.3.2/4.2.1.3.3.
4.2.1.4 Verification of the Biological Activity of Recombinant HOX11
4.2.1.4.1 Electromobility Shift Assay (EMSA)
In order test the DNA binding capability of rHOX11 produced in Section 4.2.1.3.2,
EMSA was performed using a probe containing HOX11 consensus binding sites
(HOXCon)(Table 4.1). Single stranded oligonucleotide probes (HOXCon) were [γ-
32P]ATP labelled and annealed as described in Section 2.2.5.1. For EMSA, 1.5µg of
purified  GST,  GST-HOX11  or  GST-HOX11∆H3  was  combined  in  a  1.5ml
polypropylene microcentrifuge tube in a final volume of 15µl with radio-labelled,
double stranded HOXCon probe (~3.2ng) in 1x Binding Buffer [20mM HEPES (pH
7.6), 50mM KCl, 1mM EDTA, 1mM DTT, 5% (v/v) glycerol] with 0.5µg of polydI-dC
(ICN Biomedicals). The specificity of protein-DNA complexes identified by EMSA
was assessed using competition assays, which involved the addition of a 33-fold molar
excess of unlabelled specific competitor (HOXCon probe) or non-specific competitor
(randomised HOXCon  probe)(Table 4.1) to the binding reactions. Samples were
incubated  at  4
oC  for  15min  and  complexes  were  resolved  by  non-denaturing
polyacrylamide gel electrophoresis in 0.5x TBE Buffer (17mA/gel for 2h) on a 4% non-202
denaturing polyacrylamide (TBE) gel (Section 2.2.5.3). Gels were dried and developed
as outlined in Section 2.2.5.3.
4.2.1.5 GST-Pulldown Assay
4.2.1.5.1 Binding Reactions
For the in vitro binding assay, 15µg of GST, GST-HOX11 or GST-HOX11∆H3 bound
to glutathione sepharose beads (in a final bead volume of 20µl) was combined in a
1.5ml screwcap polypropylene tube with 5µl of radiolabelled protein in 500µl Binding
Buffer [150mM NaCl, 50mM Tris-HCl (pH 7.5), 0.5mM EDTA, 0.5% (v/v) NP-40,
1mM DTT, 0.5mM PMSF and 0.05% (w/v) BSA] for 18-20h at 4
oC with continuous
rotation. Following incubation, the beads were pelleted (12,000 x g, 2min, 4
oC)(Sigma
1-15 centrifuge) and washed extensively (x3) with 500µl of ice-cold Binding Buffer. To
detect the interaction of radiolabelled proteins with GST, GST-HOX11 and GST-
HOX11∆H3, the bead pellet was resuspended in 10µl of 2x SDS-PAGE loading buffer
and heated at 90-100
oC for 5min to elute the retained protein. The beads were collected
by centrifugation (12,000 x g, 2min, 4
oC) and the resulting supernatant was analysed by
SDS-PAGE  (Section  4.2.1.2.2). Gels were prepared for drying and developed as
described in Section 4.2.1.2.2.
4.3  RESULTS
GST-pulldown purification is based on the principle of affinity chromatography and has
proven to be a relatively simple, yet powerful tool for identifying interacting protein
partners and delineating specific interaction motifs. This technique is often used to
complement other methods for detecting protein-protein interactions, including yeast
two-hybrid, Co-IP and electrophoretic mobility shift assays (EMSA). Proteins of
interest (‘bait’) are fused to a GST purification tag and immobilised on glutathione
agarose affinity matrix, which can then be used to assay the binding of specific ‘test’
proteins radio-labelled with [
35S]-methionine by in vitro translation. This strategy was
employed to further investigate interactions between HOX11 and selected putative
partners, namely MEIS1, MEIS2 and TFIIB, in addition to HOX11 itself. Interaction of203
these proteins with the HOX11 mutant, HOX11∆H3, were also examined in order to
determine whether helix 3 of the homeodomain was important to any interaction
observed.
4.3.1  Production of Recombinant GST Fusion Proteins
Cloning of HOX11 and HOX11ΔH3 cDNAs into the pGEX6P-1 vector (Amersham
Pharmacia Biotech) facilitated the expression of Schistosoma japonicum GST (26kDa)
fused to the cDNA in a lacIq-controlled Tac promoter. The optimal conditions for the
expression and purification of soluble, full-length GST-HOX11 fusion proteins were
previously determined by Heidari et al., (2002). Specifically, optimal growth conditions
involved growing bacterial cultures to mid-late log phase (OD600 of 1.35), prior to
inducing protein expression with the galactose analog, IPTG for 1h only. The GST-
HOX11/HOX11∆H3  fusion  proteins  were  then  purified  from  clarified  bacterial
supernatants by glutathione sepharose affinity chromatography at 4
oC to minimise
protein degradation (Heidari et al., 2002). Under these conditions, relatively pure, full-
length GST-HOX11 and GST-HOX11∆H3 fusion proteins migrating at 60kDa and
59kDa respectively were produced at a final yield of approximately 2mg/L of bacterial
culture (Figure 4.1).
4.3.2 Verification of the Biological Activity of Recombinant HOX11 Fusion
Proteins
The functionality of the recombinant HOX11 fusion proteins (rHOX11) was assessed
by demonstrating the DNA binding capabilities of GST-HOX11 compared to the DNA
binding mutant GST-HOX11∆H3, by EMSA (Figure 4.2). EMSA was performed by
incubating rHOX11 with a radiolabelled, double-stranded DNA probe harbouring a core
consensus HOX11 binding site ‘TAAG’ (HOXCon) previously identified by Tang and
Breitman (1995). As predicted, rHOX11 but not rHOX11∆H3 bound strongly to the
DNA  probe,  subsequently  confirmed  by  competition  assays  using  an  excess  of
unlabelled HOXCon probe, which resulted in the significant diminution of the shifted
complex,  compared  to  an  excess  of  unlabelled  non-specific  probe  (HOXNsc,  a
scrambled  version  of  the  TAAG  core sequence) which did  not  compete,  and in fact204
Figure 4.1. Purification of Recombinant GST Fusion Proteins by Affinity
Chromatography Using Glutathione Sepharose. E.coli strain ER2566 was
transformed  with  either  pGEX-6P-1,  pGEX-6P-1/HOX11  or  pGEX-6P-
1/HOX11∆H3 and following IPTG induction, resulted in the expression of
GST (26kDa), GST-HOX11 (60kDa) or GST-HOX11∆H3 (59kDa) fusion
proteins.  Crude  cell  lysates  (15µl)  and  purified  proteins  (~200ng)  were
analysed  on  an  12%  SDS-PAGE  gel  using  Broad  Range  MWMs
(~500ng/band)(Bio-Rad Laboratories) and stained with Coomassie brilliant
blue R-250.
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Figure 4.2. Verification of HOX11 Biological Activity by Electrophoretic
Mobility Shift Analysis (EMSA). GST, GST-HOX11 or GST-HOX11∆H3
fusion proteins (1.5µg) were incubated with a 
32P-labelled double stranded
TAAG core DNA probe (HOXCon, 3.2ng) that corresponds to a HOX11
consensus sequence. GST-HOX11 but not GST-HOX11∆H3 or GST alone
specifically bound to the probe resulting in the formation of a single retarded
band (arrow). Binding of GST-HOX11 was competed for by addition of a 33-
fold molar excess of unlabelled probe (S, HOXCon) but not non-specific
competitor (NS, HOXNsc).206
Figure 4.3. Quantitative Analysis of GST Fusion Proteins Utilised in GST-
Pulldown Assays. The amount of GST fusion protein bound to Glutathione
Sepharose beads was estimated by analysis of a 20µl (containing ~15µg protein)
aliquot of protein-bound beads (diluted with fresh Glutathione sepharose 4B;
GST 1:20, GST-HOX11 1:5, GST-HOX11∆H3 1:2.5) on a 12% SDS-PAGE gel
stained with Coomassie Blue R-250. Protein Broad Range SDS-PAGE MWMs
(Bio-Rad Laboratories) containing 9 bands of approximately 500ng protein each,
were used to visually verify the quantity of protein utilised in GST-Pulldown
assays.
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enhanced, protein binding (Figure 4.2).
4.3.3   In vitro Characterisation of MEIS1, MEIS2A, HOX11 and TFIIB Binding
to HOX11
The aim of this Chapter was to determine whether MEIS1, MEIS2A, TFIIB and HOX11
itself, could physically interact with HOX11 in vitro. MEIS1 and MEIS2A were
identified in yeast-2-hybrid screens as a potential HOX11 binding partner (Milech et al.,
in preparation), while TFIIB had been implicated as a HOX11 interactor by a co-
immunoprecipitation/MALDI-TOF mass spectrometry approach (Heidari et  al.,  in
preparation).  To  assess  these  interactions,  glutathione  sepharose  coupled  with
approximately 15µg of either GST, GST-HOX11 or GST-HOX11∆H3 (Figure 4.3) was
incubated under stringent conditions with [
35S]-labelled in vitro synthesised MEIS1,
MEIS2A, TFIIB and HOX11 proteins. The TNT
® Coupled Reticulocyte Lysate System
(Promega) utilised for the generation of [
35S]-methionine radiolabelled test proteins,
employs the use of a circular DNA template in which the gene-specific cDNA is cloned
downstream of the T7 promoter within the pCIneo mammalian expression vector
(Promega). This template may then be used to generate [
35S]-methionine radiolabelled
proteins in a one-step process, involving the synthesis of mRNAs in the presence of
nucleoside triphosphates (NTPs) and in vitro rabbit reticulocyte lysate translation. In
order to rule out the possibility of non-specific protein binding to the GST moiety of the
‘bait’ rHOX11 fusion, glutathione sepharose coupled with GST alone (Figure 4.3)
served as a negative control. CTF1 was employed as a positive control since HOX11
and CTF1 had previously been shown to physically associate in both in vitro GST pull-
down assays and Co-IP studies (Zhang et al., 1999).
Specific retention of CTF1, MEIS1, MEIS2A, TFIIB and HOX11 was observed with
GST-HOX11 but not with control GST beads, which suggested that all four proteins are
capable of physically interacting with HOX11 in vitro (Figure 4.4, 4.5). Notably, there
was a considerable difference in the binding efficiencies of these proteins, with CTF1
and HOX11 demonstrating relatively strong binding to GST-HOX11 compared to the
significantly weaker MEIS1, MEIS2A and TFIIB interactions (Figure 4.4, 4.5). The
finding  that  HOX11  is  capable of homodimerisation was completely novel. Based on208
evidence that residues within the homeodomain may be important for homodimeric
HOX protein interactions (Kasahara et al., 2001), we subsequently investigated whether
the helix 3 region of the HOX11 homeodomain crucial for DNA binding, was also
required for the physical association of HOX11 with itself. A comparison of the
interaction between GST-HOX11, GST-HOX11∆H3 (which lacks the DNA recognition
helix of the homeodomain) and in vitro translated HOX11, revealed no detectable
change in binding (Figure 4.5). This suggested that the main region of HOX11 involved
in DNA recognition is distinct from those region(s) involved in homodimerisation.
Given evidence by Owens et al., (2003), as well as the work presented in Chapter 2 and
3 of this thesis, that HOX11 may regulate gene transcription via interactions with
components of the basal transcriptional machinery, in a DNA independent manner, the
effect of this deletion on the interaction observed between HOX11 and TFIIB was also
assessed (Figure 4.5). This revealed that the interaction of HOX11 with TFIIB was
significantly diminished upon deletion of the homeodomain helix 3. These results
suggested that this region may be specifically involved in mediating protein interactions
with TFIIB or alternatively, that this specific interaction requires a structurally intact
homeodomain.209
Figure  4.4. GST-Pulldown  Assay to Assess the Interaction of HOX11 with
Putative Protein Partners. Radiolabelled 
35S-CTF1 
35S-MEIS2A, 
35S-MEIS1 and
35S-HOX11 proteins were produced using the TNT
® T7 Coupled Reticulocyte Lysate
System (Promega). 5µl of translation mix was incubated with 20µl of glutathione
sepharose resin (50:50 slurry) containing approximately 15µg of immobilised GST
fusion protein at 4
oC overnight in Binding Buffer. The resin was washed and
analysed by SDS-PAGE followed by autoradiography. (A) 50% of the input ‘test’
proteins used in in vitro binding assays. Arrowheads indicate sizes of test proteins as
determined  using  Prestained  Broad  Range  SDS  PAGE  MWMs  (Bio-Rad
Laboratories).  (B)  Interaction  of  GST-HOX11  with 
35S-radiolabelled CTF1,
MEIS2A, MEIS1 and HOX11 (Lanes 5-8). GST alone (Lanes 1-4) was used as a
negative control.
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Figure 4.5. GST-Pulldown Assay to Assess the Interaction of HOX11
and HOX11∆H3 with TFIIB and HOX11. Radiolabelled 
35S-TFIIB and
35S-HOX11  proteins  were  produced  using  the  TNT
®  T7  Coupled
Reticulocyte  Lysate  System  (Promega).  5µl  of  translation  mix  was
incubated  with  20µl  of  glutathione  sepharose  resin  (50:50  slurry)
containing immobilised GST fusion protein (~15µg) at 4
oC overnight in
Binding  Buffer.  The  resin  was  washed  and  analysed  by  SDS-PAGE
followed by autoradiography. (A) 50% of the input test proteins used in in
vitro  binding  assays.  Arrowheads  indicate  sizes  of  test  proteins  as
determined using Prestained Broad Range SDS-PAGE MWMs (Bio-Rad
Laboratories). (B)  Interaction  of  GST-HOX11/HOX11∆H3 with [
35S]-
methionine radiolabelled TFIIB and HOX11. GST alone was used as a
negative control.
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4.4  DISCUSSION
The transforming function of HOX11 is likely to involve collaboration with protein
partners and cross-talk with members of the general transcriptional machinery in order
to control the expression of target genes regulating processes of cellular proliferation
and/or differentiation. The purpose of this Chapter was to assess the potential of
HOX11 to physically associate with selected proteins identified previously as potential
cofactors, in order to shed light on the transcriptional role of HOX11. In the first
instance,  both  MEIS1  and  MEIS2A,  members  of  the  TALE  superfamily,  were
confirmed to directly interact with recombinant HOX11 by GST-pulldown, although the
strength of these interactions was relatively weak in comparison to those observed for
the positive control interaction between CTF1 and HOX11 (Figure 4.4). In regard to
MEIS2, the MEIS2A isoform was selected for use in GST-pulldown assays, since this
isoform includes all exons (1-4) and is therefore most likely to contain regions involved
in mediating protein-protein interactions. Although both MEIS1 and MEIS2A were
shown to interact with HOX11, MEIS2A was considered to be of greater interest, since
not only did it appear to bind to HOX11 with greater efficiency than MEIS1, but it was
also shown to be coexpressed with HOX11 in several T-ALL cell lines and primary T-
ALL specimens (D’Souza, Kees and Greene, unpublished observations), and as such
may represent a potentially leukaemic isoform.
The possible relevance of this interaction in terms of HOX11-mediated leukaemic
transformation is underscored by a number of studies that have revealed intriguing links
between Meis1 and Meis2 overexpression and leukaemogenesis. For example, Meis 1
expression  is  activated  by  proviral  integration  in  ~10-15%  of  BHX-2  myeloid
leukaemias (Moskow et al., 1995, Nakamura et al., 1996). Moreover, expression studies
of Meis family members in BHX-2 myeloid leukaemia cell lines revealed exclusive
expression  of  either  Meis1  (due  to  retroviral  integration)  or  Meis2  and Meis3,
suggesting that overexpression of at least one family member may be required for
leukaemic  transformation  (Nakamura et  al.,  1996).  Although  Meis2 and Meis3
expression was not correlated with retroviral integration, mouse mapping studies
suggest that the human homologs of Meis2 and Meis3 map to human chromosomes
19q13  and  15q11  respectively,  regions  harbouring  chromosomal  abnormalities212
associated with human myeloid leukaemia, highlighting the possibility that deregulation
of MEIS  family  members  may  be  a  crucial  event  in  leukaemic  transformation
(Nakamura et al., 1996, Mitelman, 1994). Meis2 is also coactivated with Hoxb8 in the
WEHI-3B murine myelomonocytic cell line, and enforced expression of Hox or Meis
genes in 32Dcl3 cells inhibits myeloid cell differentiation, providing further evidence
that aberrant Meis2 expression may be a contributing factor in leukaemic transformation
(Fujino et al., 2001). More recently, the involvement of Meis1 in leukaemogenesis was
demonstrated following the identification of Meis1 and Hoxa9 as molecular targets of
the oncogenic mixed lineage leukaemia-eleven nineteen leukaemia (MLL-ENL) fusion
protein, which is associated with lymphoid and myeloid leukaemias (Zeisig et al.,
2004). In addition, MEIS1 and MEIS2 genes were also found to be highly expressed in a
panel of neuroblastoma cell lines, suggesting a that the oncogenic potential of MEIS
family members may not be restricted to cells of the haematopoietic lineage (Geerts et
al., 2003).
The relatively weak binding observed between HOX11 and MEIS1/2A might be
explained by the requirement for additional cofactors or specific binding conditions that
may stabilise the interaction between HOX11 and MEIS2. Alternatively, DNA binding
may  be  required  for  transcriptional  complex  formation.  Indeed,  it  has  been
demonstrated  in vitro that protein-protein interactions between Meis and Pbx can
facilitate the formation of Hox-Pbx-Meis trimeric complexes bound to DNA (Jacobs et
al., 1999). PBX2 represents a potential candidate for a third binding partner since PBX2
transcripts have been demonstrated to be exclusively expressed in two human T-ALL
cell lines harbouring the HOX11 10q24 translocation (Allen et al., 2000). In contrast,
other HOX11 overexpressing murine cell lines contained transcripts of two or even
three PBX genes, suggesting that PBX2 may be specifically involved in HOX11-
induced  leukaemic  transformation.  This  is  supported  by  the  observation  that
overexpression of both HOX11 and PBX2 led to a reduction in contact-dependent
growth inhibition in NIH 3T3 cells (Allen et al., 2000). Under the ‘co-selective binding’
model, a number of scenarios involving functional interplay between HOX11, MEIS2
and PBX2 transcription factors might therefore be envisaged. HOX11 may form novel,
dimeric or trimeric complexes with MEIS2 and PBX2, resulting in the activation or
repression of specific target genes harbouring PBX2-HOX11 or PBX2-HOX11-MEIS2213
compound binding sites via the recruitment of coactivators (e.g. CBP) or corepressors
(e.g. NcoR, SMRT)(Asahara et al., 1999)(Figure 4.6A, B).
Based on murine models, which have been unable to convincingly recapitulate the
tumorigenic activity of HOX11 in T-cells, it is evident that additional genetic lesions
are required for the appearance of overt disease. Such secondary events may result in
the activation of cofactors required for HOX11-mediated transcription. It cannot be
discounted, however, that the oncogenic potential of HOX11 stems from it acting alone
or as a homodimer/multimer, and that these additional mutations may involve the
dysregulation of tumour suppressor genes or other genes not directly related to the
transforming activity of HOX11 (Figure 4.6C). Indeed, although the majority of studies
focus on HOX/PBX/MEIS interactions in determining target gene selectivity of HOX
proteins, there is evidence to suggest that Hox proteins may act through binding to
multiple monomer sites via a ‘widespread binding’ model (Biggin & McGinnis, 1997).
Moreover, a number of Hox-regulated structures in Drosophila, in particular the distal
appendages, do not require Exd or Hth activity for normal development, suggesting that
target gene selectivity and activity by HOX proteins may occur via distinct pathways
involving novel, unidentified cofactors or by HOX proteins alone (Azpiazu & Morata,
2000). The finding in this study, that HOX11 is capable of strong self-association, raises
the possibility that HOX11 may utilise alternative regulatory mechanisms, in addition to
those  involving  co-selective  binding  through  interactions  with  PBX  and  MEIS
cofactors,  in  order  to  regulate  gene  transcription.  It  has  been  reported  that  the
homodimerisation of homeodomain transcription factors can increase the protein-DNA
binding affinity for palindromic DNA sites, and add to the complexity of combinatorial
gene regulation in a given cellular environment (Wilson et al., 1993). The role of
homodimers in transcriptional repression is particularly well characterised for the
Drosophila zinc finger transcription factor, Kruppel, which acts as transcriptional
activator in monomeric form and at higher concentrations switches to a homodimeric
repressor, and is now becoming an emerging theme in the field of transcriptional
regulation. For example the mammalian basic helix loop helix factor, Stra 13 actively
represses transcription by binding as homodimers to E-box elements (St-Pierre et al.,
2002), while the homeobox transcription factor Hesx1 acts as a short range monomeric
repressor,   in   addition   to   passively   repressing   transcription  by  blocking  specific214
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transactivation sites as a homodimer (Quirk & Brown, 2002). Indeed, there is evidence
to suggest that other HOX proteins, particularly those belonging to the NKL/POU
cluster, of which HOX11 is a member, including Nkx2.5 (Kasahara et al., 2001), Cdx2
(Suh et al., 1994), Pit1 (Jacobson et al., 1997) and Oct1 (Poellinger et al., 1989), form
functional homodimers. Cooperative dimerisation of homeodomain proteins involves
residues located within the homeodomain as well as regions located outside this motif
(Jacobson et al., 1997, Kasahara et al., 2001). Studies have shown that the presence of
Arg
28  or  Arg
43 conserved in 50% of homeodomain proteins, prevents dimerisation
(Wilson et al., 1993). Intriguingly, HOX11 contains Ser
28 and Ala
43, revealing that it
belongs to a class of homeodomain proteins capable of cooperative dimerisation.
The finding by Heidari et al. (in preparation) that TFIIB was involved in a protein
complex immunoprecipitated by HOX11 antibody, suggested that HOX11 may interact
with TFIIB, a member of the basal transcriptional machinery (Figure 4.6D). TFIIB
functions in the correct positioning of RNA polymerase II at the promoter DNA, and is
a  particularly  intriguing  interactor  given  the  recent  finding  that  transcriptional
repression mediated by HOX11 may involve interactions with basal transcription
factors (Owens et al., 2003). This was deduced following experiments demonstrating
that HOX11 was able to repress transcription from the SV40 early promoter, despite
deletion of various cis-regulatory elements (Owens et al., 2003). Further, S-tagged
recombinant HOX11 repressed basal transcription from the adenovirus major late
promoter, driven by TFIIS affinity purified RNA polymerase II holoenzyme but not by
Gal4-VP16. Since this promoter does not contain any DNA binding sites for HOX11,
these results suggested that HOX11 mediates repression via interaction with one or
more components of the RNA polymerase II holoenzyme (Owens et al., 2003). The
GST-pulldown analyses described in this chapter, suggested a weak interaction between
HOX11 and TFIIB, which may indicate sub-optimal binding conditions required for
efficient binding. Alternatively, the stable interaction of HOX11 with TFIIB may
require additional components of the basal transcriptional machinery or even other
transcription factors. Interestingly, HOX11 has also been shown to interact with the
CCAAT box binding transcription factor (CTF1), a ubiquitously expressed transcription
factor which is capable of recruiting TFIIB during preinitiation complex assembly
(Zhang et al., 1999). Since HOX11 and TFIIB were shown to bind distinct interaction216
surfaces on CTF1, it is possible that the immunoprecipitation of TFIIB by HOX11 may
have required CTF1 as a bridging factor. This hypothesis could be tested in the future
by performing GST-pulldown experiments using GST-HOX11, in vitro translated 
35[S]-
radiolabelled TFIIB and non-labelled CTF1. This interaction may have important
functional consequences for the cell since inhibition of CTF1 affects the proliferative
capacity of HOX11-immortalised hematopoietic precursor cells, suggesting that HOX11
mediated transformation may require cooperative binding with CTF1 and possibly
TFIIB (Zhang et al., 1999).
The radically different behaviour of the HOX11∆H3 mutant in the transcriptional assays
outlined in Chapters 2 and 3 prompted its inclusion in the GST-pulldown experiments to
determine  whether  the  third  helix  of  the  HOX11  homeodomain  is  required  for
homodimerisation. The interaction of in vitro translated HOX11 did not appear to be
affected by a deletion of the DNA recognition helix of the homeodomain (GST-
HOX11∆H3), suggesting that the ability of HOX11 to form homodimers may involve
interaction domains located outside of this region. This is consistent with the formation
of other NKL/POU homodimers, which require residues outside of helix 3 at the C-
terminal end of the homeodomain. Nkx2.5, for example, requires the basic amino acids
Lys
57-Arg
58 for dimerisation (Kasahara et al., 2001), which are present as Arg
57-Arg
58 in
HOX11. A similarly located motif, Arg
58-Val
59-Lys
60, is required for Pit1 dimerisation
on DNA (Jacobson et al., 1997).
Intriguingly,  the  strength  of  the  interaction  of  TFIIB  with  HOX11  was  greatly
diminished upon deletion of the third helix of the homeodomain, suggesting that
residues within this region are important for interactions with this member of the basal
transcriptional machinery. Alternatively, deletion of helix 3 may alter the overall
structure of the homeodomain, which may account for the reduced binding of TFIIB. It
is likely that additional regions outside the helix 3 of the homeodomain are also
involved in TFIIB binding, however, since the interaction was not completely abolished
in  the  HOX11∆H3  mutant.  The  results  in  Chapters  2  and  3  suggested  that  the
transcriptional repression mediated by HOX11 is dependent on helix 3, since the
HOX11∆H3 mutant was unable to effectively repress transcription from the ALDH1A1
and FHL1 promoters in the PER-117, and instead resulted in a strong activation. Given217
that the third α-helix is known to be required for DNA binding, these results initially
suggested that repression was dependent on DNA binding by HOX11. However, in light
of these results it is also formally possible that repression could occur via a DNA-
binding independent mechanism and instead, is dependent upon interactions with TFIIB
and amino acids in the third helix of the HOX11 homeodomain. Indeed, there is
precedent for a mechanism whereby homeodomain proteins interact with members of
the  basal  transcriptional  machinery  to  repress  transcription.  For  example,  the
Drosophila homeodomain protein Even-skipped (Eve) represses transcription by
directly interacting with TBP to block TFIID binding to promoter sequences, and this
interaction is dependent on residues within the Eve homeodomain (Li & Manley et al.,
1998). Moreover, Msx-1-mediated transcriptional repression requires interactions
between residues within the N-terminal arm of the homeodomain and TBP (Zhang et
al., 1996).
Although the GST-pulldown approach is appealing as it is relatively simple to perform
and is cost-effective for assessing multiple protein interactions, since it does not require
specific antibodies, the limitations of this technique render it suitable for preliminary
analysis of protein interactions, and verification using alternative methods for assessing
protein-protein interactions is necessary. In particular, the use of informative negative
controls is crucial in order to avoid misintepretation of results. Glutathione agarose
beads bound to GST alone are often used as a negative control for non-specific retention
of test proteins, however this control does not account for mass action effects, in which
non-specific interactions may occur if the ‘bait’ fusion protein is at a high enough
concentration. Optimally, GST-pulldown assays should be performed using the wild
type bait protein and a variant of the bait protein, which is known not to bind the test
protein  in  vivo.  Alternatively,  a  panel  of  mutant  bait  proteins  harbouring
deletions/substitutions of putative interaction motifs, such as the HOX11∆H3 mutant
employed in these studies, can be used to confirm that positive interactions obtained
using the wild type bait protein are due to the presence of specific protein domains and
not due to artefacts. Future studies may involve testing the effect of deleting specific
regions or interaction motifs on the interactive capacity of HOX11 with selected
proteins, including (1) deletion of the NH2-terminal 50 amino acids, which have been
shown to be crucial for activation function of HOX11 (Masson et al., 1998) (2) the218
glutamine-rich  region  at  the  COOH-terminus  (3)  the  PBX  Interaction  Motif
(PIM)(FPWME),  a  conserved  motif  located  upstream  of  the  homeodomain  that
facilitates interactions with other homeodomain proteins such as PBX (Piper et al.,
1999, Sprules et al., 2003), or (4) the FIL motif which is similar to a previously
described binding domain for members of the Groucho/transducin-like Enhancer of split
(Gro/TLE) co-repressor family, and which are capable of repressing transcription via
the recruitment of HDACs (Yao et al., 2001).
In summary, the physical association of HOX11 with selected putative interactors,
namely CTF1, MEIS1, MEIS2A and TFIIB was confirmed using GST-pulldown assays.
These results suggest that, like other homeodomain proteins, HOX11 interacts with
members of the TALE homeodomain family, specifically MEIS1 and MEIS2A. Such
interactions  may  function  to  enhance  binding  site  specificity,  thus  providing  a
mechanism for HOX11 target gene selectivity. The observed interaction of HOX11 with
TFIIB suggests that HOX11 may also function to regulate gene transcription by
interaction with members of the basal transcriptional machinery and this hypothesis is
supported by studies by Owens et al., (2003), which demonstrate that HOX11 represses
transcription via interactions with components of the RNA polymerase II holoenzyme.
Intriguingly, the human ALDH1A1 promoter, which was previously demonstrated to be
regulated by HOX11 in Chapter 2 of this thesis, harbours a TFIIB recognition element
(BRE)(-40/-34bp) directly upstream of a compound TATA/GATA site (GATA box). In
conjunction with the results presented in this Chapter, a model in which HOX11
interacts with TFIIB to contribute to ALDH1A1 gene regulation may be envisaged.
Finally,  the  ability  of  HOX11  to  strongly homodimerise, provides an alternative
mechanism  by  which  HOX11  may  activate  or  repress  gene  expression,  via  the
formation of monomer/dimers on target gene promoters.219
Chapter 5
The Effect Of Enforced Expression of ALDH1A1 and FHL1 on Murine
Haematopoiesis
5.1 INTRODUCTION
Although the deregulation of HOX11 is believed to be a fundamental event in the
development of leukaemia, attempts to accurately model the transforming capabilities of
HOX11 in T-cells have, to date, been largely unsuccessful. Indeed, most of our
knowledge regarding the mechanism of HOX11 action, derives from retroviral studies
performed by Hawley et al., (1994). These demonstrated that enforced expression of
HOX11 in primary murine bone marrow cells leads to a block in haematopoietic
differentiation, giving rise to IL-3 dependent immature myeloid cell lines. Thus, the
transforming potential of HOX11 appears to derive from its ability to activate or repress
distinct target genes affecting haematopoietic differentiation programmes. Progression
to a fully malignant state, however, is thought to require additional mutations affecting
cell survival or proliferation, since lethally irradiated recipient mice reconstituted with
MSCV-HOX11  infected  bone  marrow  did  not  develop  tumours  after  10  months
(Hawley et al., 1994). Despite the lack of an in vivo animal model that accurately
parallels the T-cell oncogenic activity of HOX11 in humans, the in vitro retroviral
studies performed by Hawley et al., (1994), provide a useful platform for functionally
dissecting the immortalisation capacity of HOX11. With regard to the present study, the
ability of known HOX11-regulated genes to mirror HOX11-mediated perturbations in
haematopoietic differentiation may yield insights into the transcriptional pathways
perturbed by this nuclear oncoprotein.
This study focused on understanding the transcriptional regulation of two candidate
target genes of HOX11, namely ALDH1A1 and FHL1, in order to gain an insight into
the mechanism of HOX11 action. In Chapter 2, it was established that HOX11 is
capable of modulating transcription from the proximal promoter of ALDH1A1, thereby
strengthening the hypothesis that ALDH1A1 is a specific target gene of HOX11. The
confirmation of ALDH1A1 as a target gene of HOX11 is particularly intriguing given220
the precedent for disrupted retinoid signalling in haematopoietic malignancies. The
most well documented case involves the promyelocytic leukaemia zinc finger (PLZF)
gene which was originally identified by the variant translocation t(11;17)(q23;q21) in a
subset  of  patients  with  APL  (Chen  et al.,  1993).  PLZF  encodes  a  zinc  finger
transcription  factor  expressed  in  undifferentiated  myeloid  cell  lines  and  CD34+
haematopoietic progenitor cells and is subsequently down-regulated during lineage
commitment, suggesting that PLZF may have a role in the maintenance or survival of
early haematopoietic stem cells and that subsequent downregulation is required for
normal bone marrow maturation (Reid et al., 1995). Following the translocation, PLZF
is fused to RARα, the RA receptor isoform preferentially expressed in haematopoietic
cells, to generate the chimaeric PLZF-RARα fusion protein, which is predicted to
encode an aberrant retinoid receptor capable of providing a differentiation block due to
the effects of permanent gene silencing. The product of the reciprocal translocation,
RARα-PLZF, has been shown to activate cell cycle regulators and enhance cell growth,
and the combined expression of these proteins, which results in the dysregulation of
RARα and PLZF responsive genes respectively, results in the clonal proliferation of
cells blocked at the promyelocyte stage of development. More recently, the concept of
dysregulated retinoid signalling being involved in T-ALL has been strengthened by the
discovery of ALDH1A2 as a target gene of a transcriptional complex in leukaemic T-
cells including SCL (TAL1) and LMO1 or LMO2, which are transcription factors
specifically implicated in childhood T-ALL (Ono et al., 1998).
The strong and specific modulation of the ALDH1A1 promoter by HOX11, observed in
the haematological cell lines PER-117 and HEL, prompted us to determine whether
overexpression  of  ALDH1A1  alone,  would  result  in  a  perturbation  of  normal
haematopoiesis, consistent with a possible role in HOX11-mediated leukaemogenesis.
Our expectation was that if ALDH1A1 is an oncogenically relevant target gene, then
cells enforcibly expressing ALDH1A1 would adopt at least some features of those cells
transduced by HOX11, most notably a block in differentiation (Hawley et al., 1994,
Greene  et  al.,  2002,  Izon  &  Greene,  unpublished  observations).  The  effect  of
overexpressing FHL1 on murine haematopoiesis was also assessed, given that FHL1
was  also  demonstrated  to  be  transcriptionally  regulated  by  HOX11,  following
transcriptional start site mapping and preliminary functional promoter analyses (Chapter221
3). Thus, as a first step in determining the oncogenic relevance of two candidate
HOX11 target genes, the effect of constitutively overexpressing the retinoic acid-
synthesising  enzyme  ALDH1A1  and  the  LIM-domain  protein  FHL1,  on  the
development of the T-cell, B-cell, myeloid and erythroid haematopoietic lineages was
investigated.  This  was  achieved  by  using  a  murine  retrovirus  harbouring  either
ALDH1A1 or FHL1 cDNA, to stably transduce primary murine bone marrow cells,
which were subsequently transplanted into lethally irradiated recipient mice. The
specific aims of this chapter were 1) to produce functional recombinant retrovirus
capable of efficiently expressing ALDH1A1 and FHL1 genes in primary murine bone
marrow cells and 2) to assess the effects of constitutive ALDH1A1  or FHL1 gene
expression on haematopoiesis, in order to establish whether either of these genes may
account for the ability of HOX11 to predispose T-cells to leukaemic transformation.
5.2 METHODS
5.2.1 Generation of Recombinant Retrovirus
5.2.1.1 MigR1-ALDH1A1/FHL1 Vector Construction
The MigR1 retroviral expression vector utilised in these studies (a gift from Dr Warren
Pear), is derived from the murine stem cell virus based vector (MSCV2.2, CLONTECH;
Hawley et al., 1994), which was modified to contain an internal ribosome entry site
(IRES)  and  the  cDNA  of  enhanced  green  fluorescent  protein  (eGFP) containing
solubility mutations (163; Val Ala) and red shift mutations (64; Phe  Leu, 65; Ser
 Thr; Pear et al., 1998, J. Jacob, unpublished data; Figure 5.1). The resultant vector
facilitates the production of a bicistronic mRNA allowing secondary translation from a
single mRNA transcript, such that green fluorescence protein (GFP) expression may be
used a surrogate marker for transgene expression. The validity of this approach is based
on  previous  studies,  which  demonstrated  that  GFP  expression  correlates  with
intracellular Notch 1 protein expression, following transduction into murine bone
marrow cells (Pui et al., 1999, Izon et al., 2001). The use of a single promoter and the
IRES also increases the likelihood that both proteins will be expressed at equivalent
levels,  since  this  reduces  the  potential  for  promoter  competition, which  may cause222
Figure 5.1. The MigR1 Retroviral Expression Vector Used to Generate
Recombinant Retrovirus Expressing ALDH1A1 or FHL1. (A) The MigR1
vector contains 5’ and 3’ long terminal repeats (LTRs), which contain all the
requisite cis elements for gene expression including the enhancer, promoter,
transcription initiation (capping), transcription terminator and polyadenylation
signals. The vector also contains the gene for ampicillin resistance (Amp
r) for
bacterial propagation, internal ribosomal entry site (IRES) for the production of
bicistronic mRNA and cDNA for enhanced green fluorescent protein (eGFP),
which acts as a surrogate marker for transgene expression. (B) ALDH1A1 and
FHL1 cDNAs were cloned into the multiple cloning site of the MigR1 retroviral
vector, which was used to generate recombinant retrovirus using the Phoenix
TM
Retroviral System.
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downregulation in internal promoter vectors (Schott et al., 1996).
5.2.1.1.1 Preparation of MigR1 Retroviral Expression Vector
The MigR1 retroviral expression vector was prepared for sub-cloning by digestion with
Xho I and EcoR I restriction endonucleases (Promega). Reactions were performed in
1.5ml polypropylene microcentrifuge tubes in final volume of 50µl, containing 10x
Restriction Digest Buffer D [1x; 6mM Tris-HCl (pH 7.9), 0.15M NaCl, 6mM MgCl2,
1mM DTT](Promega), 0.1mg/ml nuclease-free acetylated BSA (Promega), 2µg  of
MigR1 vector plasmid DNA, together with 40U of Xho I and 24U of EcoR I restriction
endonucleases  (Promega)  at  37
oC  for  2h.  Following  digestion,  the  restriction
endonucleases were heat inactivated by incubation at 65
oC for 20min. An aliquot of the
digested MigR1 vector (40ng) was electrophoresed on a 1.3% (w/v) agarose gel
(Section 2.2.1.2) to confirm complete digestion prior to ligation with insert DNA.
5.2.1.1.2  PCR Amplification of ALDH1A1 and FHL1 Insert cDNA
For the construction of MigR1-ALDH1A1, the 1506bp ALDH1A1 coding region was
amplified from HEL cDNA generated in Section 4.2.1.1.2 using PfuTurbo
®  DNA
Polymerase (Stratagene) according to the manufacturer’s instructions. Reactions were
performed in thin-walled 0.5ml microcentrifuge tubes in a final volume of 50µl,
comprising 10x Cloned Pfu DNA Polymerase Reaction Buffer [1x; 20mM Tris-HCl
(pH 8.8), 10mM KCl, 10mM (NH4)2SO4, 2mM MgSO4, 0.1% (v/v) Triton
® X-100,
0.1mg/ml nuclease-free BSA](Stratagene), 0.2mM dNTPs (Fisher Biotech), 20pmol
each of ALDH1XhoF2/ ALDH1EcoR primers (Table 5.1), 2.5µl of HEL cDNA and
2.5U of PfuTurbo
® DNA Polymerase (Stratagene). Samples were denatured for 2min at
94
oC and then amplified (94
oC for 10s, 60
oC for 30s and 72
oC for 2min) for 10 cycles,
with subsequent cycle elongation times increasing by 20s per cycle up to 8:40s,
followed by a final extension of 72
oC for 7min (EXTEND72, Appendix 1). For the
construction of MigR1-FHL1, the 848bp human FHL1 coding region was amplified
from ALL-SIL cDNA generated in Section 4.2.1.1.2 in a 50µl reaction comprising 10x
Cloned Pfu DNA Polymerase Reaction Buffer [1x], 0.2mM dNTPs, 20pmol each of
SLIMXhoF/SLIMEcoR  primers  (Table 5.1),  2.5µl  of  ALL-SIL  cDNA  and  2.5U  of224
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PfuTurbo
® DNA Polymerase using the EXTEND72 PCR programme described above
(Appendix 1).
5.2.1.1.3 Restriction Endonuclease Digestion of ALDH1A1 and FHL1 Insert cDNA
Full-length ALDH1A1 and FHL1 PCR products generated in Section 5.2.1.1.2 were gel
purified using the Qiaex II Gel Purification Kit (Qiagen; Section 2.2.1.3) and prepared
for sub-cloning by restriction digestion with Xho I and EcoR I restriction endonucleases.
Digestions were performed in 1.5ml polypropylene microcentrifuge tubes in a final
volume of 100µl, comprising 10x Restriction Digest Buffer D [1x], 0.1mg/ml nuclease-
free acetylated BSA, 50µl of gel purified ALDH1A1/FHL1 cDNA, 40U of Xho I and
24U of EcoR  I  restriction  endonucleases  at  37
oC  for  18h.  Following  digestion,
restriction endonucleases were heat inactivated by incubation at 65
oC  for  20min.
Digested PCR fragments were subsequently purified from unwanted digestion products
using the QIAquick PCR Purification Kit (Qiagen; Section 2.2.1.4). An aliquot of the
purified insert was electrophoresed on a 1.3% (w/v) agarose gel (Section 2.2.1.2) to
assess DNA integrity and to estimate concentration prior to ligation.
5.2.1.1.4 Cloning of ALDH1A1 and FHL1 cDNA into the MigR1 Retroviral Vector
Sub-cloning of PCR amplified ALDH1A1 and FHL1 cDNA into the MigR1 retroviral
expression vector was performed essentially as outlined in Section 2.2.1.6. Ligations
were performed in 0.5ml polypropylene microcentrifuge tubes in a final volume of
20µl, comprising 40ng of linearised MigR1 vector DNA, a 3:1 molar ratio of insert
ALDH1A1/FHL1 cDNA [31ng, 17.5ng respectively], 10x T4 DNA Ligase Buffer [1x;
30mM Tris-HCl (pH 7.8), 10mM MgCl2, 10mM DTT, 1mM ATP](Promega) and 6U of
T4 DNA Ligase (Promega) and incubated at 15
oC for 16-24h. Ligation reactions were
used to transform chemically competent DH5α E.coli (Section 2.2.1.8) and small scale
plasmid Mini-Preps of selected colonies were prepared for screening using the Sigma
GenElute
TM Plasmid Miniprep Kit (Sigma) according to the manufacturer’s instructions
(Section 2.2.1.9).  The presence of ALDH1A1 and FHL1 inserts was determined by
restriction digest analysis of a selection of randomly chosen clones with Xho I and
EcoR I restriction endonucleases. Digests were performed in 1.5ml polypropylene226
microcentrifuge tubes in a final volume of 30µl, comprising 10x Restriction Digest
Buffer D [1x], 0.1mg/ml nuclease-free acetylated BSA, 0.5µg plasmid DNA and 10U
each of Xho I and EcoR I restriction endonucleases at 37
oC for 1.5h. Restriction profiles
were analysed on a 1.3% (w/v) agarose gel (Section 2.2.1.2) and selected recombinant
clones were sequence-verified using MigR1SeqFor and MigR1SeqRev primers flanking
the cloning site of MigR1 (Table 5.1; Section 2.2.1.11). MigR1, MigR1-ALDH1A1 and
MigR1-FHL1 vector construct DNA was prepared for retrovirus production using the
QIAGEN
  Plasmid Midi Kit according to the manufacturer’s instructions (Section
2.2.1.12; grey highlight). The recovered DNA was resuspended at a final concentration
of 0.5µg/ul in sterile dH20 and stored at -20
oC.
5.2.1.2  Phoenix
TM Retrovirus Production
MigR1, MigR1-ALDH1A1 and MigR1-FHL1 recombinant retrovirus was produced by
transient transfection of the Phoenix
TM retrovirus producer cell line, Phoenix
TM-Eco
(Orbigen), by calcium phosphate co-precipitation as previously described by Pear et al.,
(1993)(Figure 5.2).
5.2.1.2.1 Growth and Passage of Phoenix
TM-Eco Cells
The Phoenix
TM-Eco cell line is based on the 293T human embryonic kidney cell line,
and contain episomes for the production of gag-pol (introduced with hygromycin as a
co-selectable marker) and envelope protein (with diptheria resistance as a co-selectable
marker) for ecotropic viruses. Cells were subcultured twice weekly (1:10) to 70-80%
confluence, in DMEM Multi-cel Medium (Trace) supplemented with 10% (v/v) FCS
(Trace), 2mM L-glutamine (Trace) and 50µg/ml pencilllin/streptomycin (Trace) in
75cm
2 filter-top culture flasks (NUNC
TM) and maintained at 37
oC with 5% CO2. To
passage cells, medium was removed and the cells were trypsinised with a 0.05% (v/v)
Trypsin/0.53mM  EDTA  solution  (Trace)  until  cells  detached  from  flask  surface
(approximately 30s). Trypsinisation was then quenched using an equal amount of
complete DMEM medium and cells were sub-cultured into fresh complete DMEM
medium. Prior to transfection, Phoenix
TM-Eco cells were expanded in complete DMEM
medium   supplemented   with  10µg/ml  ciprofloxacin   (ICN  Biomedicals),  500µg/ml227
Figure 5.2. Production of Recombinant Retrovirus Using the Phoenix
TM Eco
Packaging  Cell  Line.  (1)  MigR1  and  MigR1-ALDH1A1/FHL1  retroviral
expression vectors were transfected into the Phoenix
TM Eco packaging cell line by
CaPO4 precipitation. (2) Transcription is initiated within the 5’ LTR and the
mRNA is polyadenylated and processed using signals in the transcribed regions
from the 3’LTR. (3, 4, 5) Viral mRNA, which contains a packaging signal (ψ+) is
bound by group antigen (gag)-derived proteins produced by the packaging cell
line, and incorporated into a retroviral particle at the cell surface. The Phoenix
TM
Eco cell line expresses viral proteins gag, which form the viral core structure, pol,
a reverse transcriptase which converts the RNA genome to double stranded DNA
pre-integrate form and performs integrase functions and env, which resides in the
lipid layer of the viral envelope and determines viral tropism.
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hygromycin (Sigma) and 1µg/ml diptheria toxin (Sigma) to treat potential mycoplasma
infection and to upregulate gag, pol and env viral genes respectively, for a period of two
weeks. Following selective treatment, Phoenix
TM-Eco cells were maintained in long-
term storage by cryopreservation as outlined in Section 2.2.2.4, or used to generate
retrovirus for up to one month.
5.2.1.2.2 Transfection of Phoenix
TM-Eco Cells With MigR1 Retroviral Constructs
The initial plating of Phoenix
TM-Eco cells is a crucial step in order to obtain high
retroviral titres. Prior to plating, cells should not be allowed to become over-confluent,
since clumping results in an uneven cell distribution following replating, reducing
transfection efficiency. Additionally, all procedures involving plated cells (removing
and replacing growth medium, addition of CaPO4 precipitate) were performed gently,
since the Phoenix
TM-Eco cells are easily detached from the flask surface, thereby
affecting the production of retrovirus. Cells were evenly plated at a density of 2.5-3 x
10
6 into 25cm
2 culture flasks (NUNC
TM) in 10ml complete DMEM media, 18-24h prior
to  transfection.  MigR1,  MigR1-ALDH1A1  and  MigR1-FHL1 DNA [10µg]  was
prepared for application to cells by pre-mixing with 61µl of 2M CaCl2 in a final volume
of 500µl. This solution was added dropwise to 500µl of 2x Hepes Buffered Saline
(HBS; pH 7.0) whilst continuously bubbling, and immediately applied to the sub-
confluent (60-70%) Phoenix
TM-Eco cells, by gently pipetting the solution into the
growth media, without directly contacting the cell monolayer. The flask was rocked
gently to evenly distribute DNA/CaPO4 particles and incubated for 18h at 37
oC/5%CO2.
The media was then removed and the cells were gently overlaid with 3.5ml of fresh
complete DMEM media to collect the retrovirus. The retroviral supernatant was
harvested 48h post-transfection. The supernatants were pooled and single-use 1ml
volumes (viral titre drops by half per freeze-thaw cycle) were aliquoted into 2ml
polypropylene tubes on ice. Aliquots were snap-frozen in liquid N2 and the virus stock
was stored at -80
oC.229
5.2.1.2.3 Determination of Retrovirus Titre
Murine fibroblast NIH 3T3 cells (2 x 10
5) were seeded in 60mm petri dishes (NUNC
TM)
12h prior to retroviral infection with the supernatant. The following day, media was
removed and replaced with 2ml of complete DMEM media containing 200µl of
retroviral supernatant and 8µg/ml Polybrene (Sigma), and the cells were incubated for
24h at 37
oC. Following infection, fresh complete DMEM media (4ml) was added and
the cells were incubated for a further 24h at 37
oC. The cells were then assayed for
expression of GFP by fluorescence activated cell sorting (FACS) analysis. The cells
were trypsinised, washed with PBS and resuspended in 500µl of the same solution. Cell
suspensions were temporarily incubated on ice prior to FACS analysis, or alternatively,
fixed in PBS containing 1% (v/v) paraformaldehyde and stored at 4
oC for postponed
FACS analysis. The percentage of pooled clones that had stable integration of the
MigR1 or MigR1-ALDH1A1/FHL1 constructs was determined by applying single cell
suspensions (2 x 10
5 cells) onto a FACS Calibur Flow cytometer equipped with MAC
CELLQUEST software (Becton Dickinson, CA, USA; http://www.bd.com). Retroviral
supernatants  yielding  >20%  GFP  expressing  cells  were  utilised  in  downstream
applications.
5.2.2  Bone Marrow Reconstitution
5.2.2.1 Haematopoietic Cell Transduction by Spinofection
C57BL/6 12-24 week-old female mice were purchased from the Animal Resource
Centre (ARC). Bone marrow cells were extracted by flushing tibias and femurs with
PBS (8ml/mouse) using a 26” gauge needle (Becton Dickinson) and resuspended to
achieve a single cell suspension. The cell suspension was transferred to a 10ml
polypropylene tube, pelleted by centrifugation (394 x g, 3min, 25
oC; Eppendorf 5810)
and  resuspended  in  2ml  PBS.  Bone  marrow  cells  were  then  separated  from
contaminating red blood cells by equilibrium density gradient centrifugation with
Ficoll-Diatrizoate sodium (FicollPaque
TM)  or  by  lysis  method.  The  first  method
involved  layering  1ml  aliquots  of  the  cell  suspension  on  4ml  of  human  grade
FicollPaque
TM PLUS (Amersham) in a 10ml polypropylene tube and centrifuging at230
1000 x g for 10min at 25
oC (no brake). Cells were then collected at the interface and
washed once with 8ml of PBS (394 x g, 5min, 25
oC) and resuspended in 2ml of
complete DMEM medium. The second method involved purification of lymphoid cells
by lysis of contaminating red blood cells. The cells were resuspended in 0.165M
NH4Cl2 (~20ml/mouse) in a 50ml polypropylene tube and incubated on ice for 30min
with intermittent mixing. The purified cells were subsequently pelleted (394 x g, 5min,
25
oC) to remove lysis solution, washed once with 10ml of complete DMEM media, and
filtered using 70uM nylon cell strainers (BD Falcon) to remove debris. Cells were then
pelleted (394 x g, 5min, 25
oC) and resuspended in 2ml of complete DMEM media.
Approximately 4 x 10
6 cells were seeded/well into a 12 well culture plate (NUNC
TM) in
a final volume of 2.2ml complete DMEM media and pre-incubated for 52h prior to
spinofection with 50ng/ml SCF (Peprotech), 6ng/ml IL-3 (Peprotech), 4ng/ml IL-1β
(Peprotech) and 1ng/ml IFN-γ (Peprotech). Following this incubation, cells were gently
resuspended by pipetting and divided into two wells (~2 x 10
6 cells/well). Retroviral
infection  of  bone  marrow  cells  was  performed  by  pre-mixing  1ml  of  retroviral
supernatant with 50ng/ml SCF, 6ng/ml IL-3, 1ng/ml IFN-γ, 4ng/ml IL1-β and 6µg/ml
polybrene and transferring to the appropriate wells. The cells were then spin infected
(spinofection) by centrifugation at 1010 x g for 50min at 25
oC (Rotina 46R, Hettich)
and incubated for a further 24h at 37
oC/5% C02.
5.2.2.2  Reconstitution of Mice With Transduced Bone Marrow Cells
Recipient female mice (C57BL/6) were primed for reconstitution with transduced bone
marrow cells by incorporating 1.1µg/L of neomycin sulfate (Sigma) and 126mg/L of
polymyxin B sulfate (Sigma) antibiotics into the drinking water at least four days prior
to irradiation. On the day of reconstitution, mice were subject to lethal irradiation
(546.1cGy/1:10s; two doses separated by 3h)(Gammacell
® 3000 Elan, MDS Nordian).
Retrovirally transduced bone marrow cells were transferred to a 10ml polypropylene
tube and prepared for injection by centrifugation (394 x g, 3min, 25
oC) to remove
growth media, and resuspended at a final concentration of 5 x 10
5 -1 x 10
6 cells/300µl
PBS. Cells were maintained on ice until injection. Typically, 5 x 10
5 -1 x 10
6 transduced
bone marrow cells were injected via the tail vein into each irradiated recipient. Mice
were then housed under ‘quarantine conditions’ in micro-isolator cages and provided231
with autoclaved food and antibiotic supplemented drinking water for a period of 1
month. Experimental retroviral constructs (MigR1-ALDH1A1, MigR1-FHL1)  were
tested in triplicate and MigR1 control transplant recipients were generated a total of 6
times in 2 independent experiments.
5.2.3 FACS Analysis
5.2.3.1 Tissue Processing
Mice were sacrificed in groups of three (one each of control MigR1 and test MigR1-
ALDH1A1 and MigR1-FHL1  transplant  recipients),  33,  36  and  38  days  post-
transplantation, and tissues were immediately harvested. Spleen, thymus and bone
marrow were extracted and stored on ice in 1.5ml polypropylene tubes containing PBS.
Cell suspensions of spleen and thymus were then prepared by emulsifying tissues in 5ml
of PBS, between pre-wetted microscope slides (25.4 x 76.2mm; Sail Brand), using the
ground edges of the slides. Bone marrow cells were extracted by flushing tibia and
femur sections with PBS (10ml /mouse) using a 26” gauge needle and homogenous cell
suspensions were obtained by repetitive pipetting. Spleen, thymus and bone marrow cell
suspensions  were  then  transferred  to  10ml  polyproplyene  tubes  and  pelleted  by
centrifugation (394 x g, 5min, 25
oC) and resuspended in 2ml FACS buffer [PBS
containing 5% (v/v) BSA, 0.02% (w/v) NaN3] prior to filtration to remove cellular
debris. Cell counts were performed by the trypan blue exclusion method. An aliquot of
the  cell  suspension  was  diluted  in  Trypan  Blue  Stain  (GIBCO  BRL  Life
Technologies)(typically, spleen and bone marrow samples were diluted 1:10 and
thymus samples were diluted 1:2 with Trypan Blue Stain) and the cells were counted
using a haemocytometer counting chamber, excluding contaminating red blood cells
(RBCs). Cell suspensions were maintained at 4
oC prior to immunophenostaining.
5.2.3.2 Immunophenostaining of Transplant Recipient Cells
Cells obtained from murine spleen, thymus and bone marrow tissues were analysed for
expression of TCRβ, CD4, CD8, CD19, B220, Gr1, Mac1, CD71, Ter119, Sca1 and c-
kit cell surface markers by multi-parameter flow cytometry, using fluorochrome-232
conjugated antibodies according to previously described protocols (Coligan et al.,
1992)(Appendix 3). All antibodies were purchased from Pharmingen and diluted to
optimised working concentrations in FACS buffer. Approximately 1 x 10
6 cells/well
were stained in a 96 well, round-bottomed microtitre plate (NUNCLON
TM) and all
centrifugation steps were performed at 320 x g for 5min at 6
oC (Rotina 46R, Hettich).
Cells were pelleted by centrifugation and the supernatant was discarded by flicking the
plate and inverting briefly on absorbent paper to remove excess liquid. Non-specific
antibody interactions were blocked by incubating the cells with unconjugated anti-Fcγ
antibody (30µl/well) for 10min at 4
oC.  Cells were pelleted by centrifugation and at this
point negative controls for each tissue were resuspended in 500µl FACS buffer and
transferred to 5ml polystyrene FACS tubes (12 x 75mm; BD Falcon) at 4
oC. Test
samples were then incubated with specific monoclonal antibody cocktails to antigens
present on the surface of mature blood cell lineages (20µl/well; Appendix 3) for 20min
at 4
oC. Following incubation, primary antibodies were removed by washing the cells
with FACS buffer (200µl/well) and centrifugation. The cells were then incubated with
the appropriate secondary antibodies (20µl/well) for 10min at 4
oC (Appendix 3). At this
point, cells not requiring secondary reagents were resuspended in 500µl FACS buffer,
transferred to FACS tubes and maintained at 4
oC. Secondary antibodies were removed
by washing the cells with FACS buffer (200µl/well) and the cells were pelleted by
centrifugation and resuspended in 500µl FACS buffer. Propidium Iodide (PI)(Sigma)
was added at a final concentration of 1ug/ml to all cell samples in order to exclude dead
cells from subsequent analysis. In the case of T-cell analysis, however, PI was not
included in the immunostaining procedure since the PI emission spectrum overlaps the
FL3 channel, thus interfering with CD8-PerCP.
5.2.3.3 Flowcytometric and FlowJo Analysis
For flow cytometry, single cell suspensions of ~ 1 x 10
6 cells prepared as in Section
5.2.3.2 were run on a FACS Calibur flow cytometer equipped with CELLQuest software
(Becton Dickinson, CA, USA; http://www.bd.com). This system permits rapid, highly
sensitive flow cytometric analysis for up to six separate parameters including forward
scatter (FSC), side scatter (SSC), FL1 (530nm), FL2 (585nm) and FL3 (>650nm),233
which use an argon laser beam (488nm), in addition to the fluorescence parameter, FL4
which uses the optional red diodide laser (635nm)(Table 5.2).
Table 5.2. Fluorochromes Used for Immunophenotyping with the BD FACS
Calibur. The emission wavelength maxima of the dye (nm), the detector configured
optimally for the dye and the optical filters installed in front of each detector are
outlined.
As individual cells pass through the 488-nm light beam of the argon-ion laser, forward
light is scattered by the cell in proportion to cell size and 90
oC light is scattered
according to cellular complexity (cellular granularity, surface texture, refractive index).
Cells stained with specific antibodies, which are covalently linked to fluorochromes
(fluorescent dyes), emit light over a broad range of wavelengths, and these fluorescence
emission signals are detected by a photomultiplier tube (PMT), by virtue of a set of
spectrally selective optical filters corresponding to individual fluorescence detectors
(FL1, FL2, FL3, FL4). The signal is subsequently amplified (linearly or logarithmically)
and acquired by associated computer software.
Prior to sample analysis, instrument settings for non-fluorescent parameters (FSC and
SSC detector levels) were adjusted using an unstained bone marrow sample, such that
only relevant events displaying characteristics of cells are detected. The forward scatter
threshold was adjusted to a low level (52) to enable visualisation of all populations,
including dead cells, RBC, lymphocytes and granulocytes, and FSC/SSC amplifier
gains were adjusted to place the majority of cells at the midpoint of each axis. A gate
was then defined on the live cell population of interest, using the polygon region tool
and the FL1 (GFP) PMT voltage was adjusted so that cells were located within the first
decade of the dot plot. The fluorescence channels were then adjusted (compensation)
Fluorochromes Emission Peak
(nm)
Detector Filter
GFP (green) FL1 530/30
R-Phycoerythrin (PE) 575 (orange-red) FL2 585/42
Propidium Iodide (PI) 620 (red) FL2,FL3 585/42
PerCP 674 (red) FL3 670LP
PE-Cy5 670 (red) FL3 670LP
APC 660 FL4 661/16234
using single colour controls for individual fluorochromes, to eliminate the overlap of
fluorescence signals that may occur with brightly positive samples. Data files were
acquired with 100,000 events collected for each sample and flow cytometry data was
analysed with FlowJo software (Tree Star).
5.3 RESULTS
The hypothesis that the transforming capacity of HOX11 stems from its ability to
perturb haematopoietic differentiation is supported by several studies. These have
demonstrated that overexpression of HOX11 in murine bone marrow and embryonic
stem cells leads to the generation of growth factor-dependent myeloid progenitor and
erythroid cell lines, respectively (Hawley et al., 1994, Keller et al., 1998). Moreover,
enforced expression of HOX11 in murine J2E erythroid cells resulted in the imposition
of an immature phenotype, suggesting that despite being a T-cell oncoprotein, HOX11
is capable of affecting the differentiation of several cell lineages (Greene et al., 2002).
Although  details  of  the  mechanism(s)  by  which  HOX11  induces  leukaemic
transformation following dysregulated expression in T-cells are fragmentary, it is likely
that the inappropriate expression of downstream target genes contributes to neoplastic
transformation. Thus, in order to investigate the ability of HOX11-regulated genes to
alter  the  differentiation  potential  of  haematopoietic  precursors,  the  effects  of
constitutive ALDH1A1 and FHL1 expression were analysed in lymphoid, myeloid and
erythroid cell lineages, following the reconstitution of lethally irradiated mice with
retrovirally  transduced  (MigR1-ALDH1A1, MigR1-FHL1)  primary  murine  bone
marrow cells (Figure 5.3). This approach has been used to study the effects of several
ectopically expressing genes that may predispose cells of the haematopoietic system to
leukaemic transformation. This includes the flt3 ligand (Hawley et al., 1998), the stem
cell  leukemia  protein  (SCL)(Kunisato  et al., 2004), the Notch target gene, Hes
(Kawamata  et  al.,  2002),  Hoxa9  (Thorsteinsdottir  et  al.,  2002)  and  HOXB4
(Schiedlmeier et al., 2003).235
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Figure 5.3. Schematic Outline of Retroviral Transduction of Murine Bone
Marrow and Subsequent Reconstitution. Following the production of recombinant
retrovirus using the Phoenix
TM Retroviral System, primary bone marrow cells were
harvested and pre-incubated with cytokines for 52h. The cells were subsequently
transduced  with  retrovirus  by  spin  infection,  and  incubated  for  18h,  prior  to
reconstitution of lethally irradiated recipient by tail vein injection. Mice were
sacrificed after 1 month and the development of haematopoietic lineages was
analysed by multiparameter flow cytometry.236
The production of high-titre retroviral supernatants is crucial in order to maximise the
transduction rates of appropriate haematopoietic progenitors, specifically multipotent
HSCs. These comprise a rare population and are required in sufficient numbers for the
long-term reconstitution of lethally irradiated recipients (Spangrude, 1994). Since the
production  of  high-titre  recombinant  retrovirus  involves  a  high  level  of  plasmid
expression, the efficiency of transfection of control and test MigR1 retroviral constructs
into the Phoenix
TM  Eco  packaging  cell  line  was  first  assessed  by  estimating  the
percentage of cells expressing GFP by immunofluorescence light microscopy (MRC-
1024 UV Confocal Microscope, Bio-Rad). As shown in Figure 5.4, the transfection of
the viral constructs into the Phoenix
TM Eco cells was successful. Given this, viral
supernatants were collected and titres were subsequently determined by infection of
NIH 3T3 murine fibroblasts with a 1:10 dilution of retroviral supernatant, where GFP
expression of at least 20% of transduced cells was taken as a lower limit for an
acceptable viral titre. The percentage of GFP-expressing cells for individual retroviral
constructs was determined by FACS analysis, and viral titres within the desired range
were obtained for MigR1 (23%), MigR1-ALDH1A1 (55%) and MigR1-FHL1 (53%)
constructs.
5.3.2 Stable Transduction of Bone Marrow Cells with Retrovirus and Effects on
Different Haematopoietic Lineages
In order to transduce murine haematopoietic progenitors, the MSCVMigR1 vector was
used to express the ALDH1A1 and FHL1 cDNAs (Figure 5.1). This vector employs a
specially designed long terminal repeat (LTR) from the murine stem cell PCMV virus,
which  enables  high  level,  constitutive  gene  expression  in  transduced  immature
haematopoietic cells including myeloid and lymphoid progenitors, in addition to
haematopoietic stem cells capable of long term multi-lineage reconstitution of lethally
irradiated recipients (Hawley et al., 1994, Hawley et al., 1995, Hawley et al., 1996)
(http://www.vectors.clontech.com). Moreover, sustained transgene expression has been
observed in human HSCs transduced with an MSCV-based retroviral vector expressing
the nerve growth factor receptor (NGFR) reporter gene and in differentiated  erythroid237
and myeloid cells derived from these progenitors (Cheng et al., 1998).
(A)
Figure 5.4. Transfection of MigR1 Retroviral Constructs into Phoenix
TM-
Eco  Producer  Cells.  Transfection  efficiency  of  (A)  MigR1-GFP (B)
MigR1ALDH1A1-GFP and (C)  MigR1FHL1-GFP into Phoenix
TM  Eco
producer  cells  was  assessed  by  visualising  GFP  expression  48h  post-
transfection by confocal microscopy.
(B)
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The bone marrow reconstitution experiments largely employed conditions previously
optimised by Pear et al., (1998) to enhance the likelihood that transduced progenitors
would stably express the provirus. This included the pre-incubation of donor cells with
cytokines  24h  prior  to  retroviral  transduction  to  induce  stem  cell  cycling  and
transduction of bone marrow cells by spin infection (spinofection). Nevertheless, some
preliminary experiments were first required in order to determine the optimal dosage of
radiation and number of cells needed for the repopulation and subsequent detection of
transgene-expressing cells. The reconstitution of sub-lethally irradiated recipients (mice
subjected to a single dose of radiation of 550cGy) with 0.5 x 10
6 cells/mouse, yielded
healthy mice, however, no GFP was detected by FACS analysis of peripheral blood
cells  1  month  post-transplantation  (data  not  shown).  A  second  method  involved
reconstitution of lethally irradiated recipients (mice subjected to two doses of radiation
of 546.1cGy/1min,10s; separated by 3h) with 0.5 x 10
6 cells/mouse. However, these
mice showed signs of illness after 3 weeks, and analysis of various lineages by
immunostaining and FACS analysis revealed perturbations in the development of all
major haematopoietic lineages (data not shown). Taken together, these results suggested
that  depletion  of  recipient  haematopoietic  cells  by  sub-lethal  irradiation  and
reconstitution with 0.5 x 10
6 cells/mouse, was not sufficient for donor-derived cells to
competitively reconstitute recipient haematopoietic lineages. More cells were required
in order re-establish even short term reconstitution in lethally irradiated recipients,
therefore subsequent experiments utilised a combination of lethal irradiation and
injection of 1.5 x 10
6 transduced bone marrow cells/mouse.
In order to confirm the expression of ALDH1A1 and FHL1 in retrovirally transduced
haematopoietic progenitors derived from transplant recipients, the percentage of cells
expressing the surrogate marker, GFP, were determined by FACS analysis. Since GFP
is coexpressed with ALDH1A1/FHL1 as a bicistronic mRNA, it therefore provides a
direct measure of transgene expression. GFP expression as directed by the MSCV 5’
LTR, was analysed in four different cell lineages (B-cells, T-cells, myeloid and
erythroid cells) extracted from the bone marrow and spleen tissues of control (MigR1)
and test (MigR1-ALDH1A1, MigR1-FHL1)  mice  (Figure  5.5A,  B  and  C).  The
percentage of GFP-expressing cells was typically higher in mice reconstituted with239
MigR1-ALDH1A1 and MigR1-FHL1 constructs, compared to the MigR1 negative
control alone, in accordance with the higher viral titres obtained for MigR1-ALDH1A1
and  MigR1-FHL1  retroviral  supernatants  (Section  5.3.1). The intensity of GFP
fluorescence, which is an indication of the level of expression of the integrated virus
was also assessed. This analysis revealed that in MigR1-ALDH1A1 mice analysed by
flow cytometry, the major peak of GFP-expressing cells (for bone marrow and spleen
samples) was contained within the intensity range of 25-500 on the GFP histogram. In
contrast,  the  major  peak  of  GFP-expressing  cells  from  MigR1-FHL1 mice was
contained within the intensity range of 100-10,000, suggesting that FHL1 was expressed
at a higher level than ALDH1A1. In the case of the control GFP-expressing retroviral
vector, MigR1, the expression pattern of GFP encompassed a broader range (40-2000).
Expression of both ALDH1A1-GFP and FHL1-GFP  constructs was lower in bone
marrow and spleens of mice sacrificed at 38 days compared to mice examined at 33 and
36 days, however no change in the expression of MigR1-GFP was observed (Figure
5.5A, B and C). These results may reflect the inability of transduced cells to sustain
long-term  transgene  expression,  possibly  due  to  due  to  silencing  mechanisms.
Alternatively,  this  phenomenon  may  be  attributed  to  the  infection  of  short-term
progenitors as opposed to long-term repopulating stem cells.
5.3.3  Effect of ALDH1A1 and FHL1 Expression on Different Haematopoietic
Lineages
The first step in haematopoiesis involves commitment of a pluripotent, haematopoietic
stem cell (Lin-negative, c-kit positive, Sca-1 positive, and CD34 negative) to either a
common  myeloid  progenitor  (CMP)  or  a  common  lymphoid  progenitor  (CLP).
Following  this  commitment,  CMPs  and  CLPs  are  guided  by  specific  sets  of
transcription factors to form all the elements of the blood, with CMPs giving rise to
myeloid, erythroid, megakaryocyte and mast cell lineages, and CLPs differentiating into
T-cells and B-cells. In order to assess the effects of overexpressing either of two target
genes  of  the  T-cell  oncoprotein  HOX11,  namely  ALDH1A1 and FHL1  on
haematopoietic differentiation, the maturational status  of  cells  from  the  spleen,  bone240
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Figure 5.5A. Contribution (%) of MigR1-GFP, MigR1ALDH1A1-GFP
and MigR1FHL1-GFP transduced cells in spleen, bone marrow and
thymus  tissues  33  days  after  transplantation  (Replicate  #1).  GFP
Fluoresces in the FL1 channel.
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Figure 5.5B. Contribution (%) of MigR1-GFP, MigR1ALDH1A1-GFP
and MigR1FHL1-GFP transduced cells in spleen, bone marrow and
thymus  tissues  36  days  after  transplantation  (Replicate  #2).  GFP
Fluoresces in the FL1 channel.
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Figure 5.5C. Contribution (%) of MigR1-GFP, MigR1ALDH1A1-GFP
and MigR1FHL1-GFP transduced cells in spleen, bone marrow and
thymus  tissues  38  days  after  transplantation  (Replicate  #3).  GFP
Fluoresces in the FL1 channel.
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marrow and thymus tissues of control (MigR1; x 3 mice) and test (MigR1-ALDH1A1
and MigR1-FHL1; x 3 mice each) mice was analysed by immunophenotyping with
lineage-specific antibodies.
Firstly, the effect of ALDH1A1 and FHL1 expression on the myeloid lineage was
assessed by staining cells from the spleen and bone marrow of recipient mice for the
expression of myeloid-specific cell surface markers Gr1 and Mac1. The overexpression
of ALDH1A1 in haematopoietic progenitors appeared to be correlated with an increase
in mature granulocytes, coexpressing high levels of Gr1 and Mac1, when compared to
control MigR1 mice (Figure 5.6). This was evident in both the spleen (mean of 5.8+
1.3% vs 23.7+1.8%, n = 3; Figure 5.6A) and bone marrow (mean of 33.3+8.6% vs
56.6+2.5%, n = 3; Figure 5.6B), although the effect was more pronounced in the spleen
(~4-fold) compared to the bone marrow (~1.7-fold). Unlike ALDH1A1, overexpression
of FHL1 in haematopoietic progenitors was not associated with a significant change in
myeloid differentiation compared to MigR1 control mice in either the spleen (mean of
5.8+1.3% vs 10.5+5.6%, n = 3; Figure 5.6A) or bone marrow (mean of 33.3+8.6% vs
26.6+3.3%, n = 3; Figure 5.6B).
B-cell differentiation was next assessed by analysing the cell surface markers CD19 and
B220. B-cell development occurs in the bone marrow in the following order; pro-B
cells, which represent the first committed B-cell precursor expressing B-cell-specific
genes CD19+ and B220+, pre-B-cells and immature B-cells, which enter the splenic
follicles where they differentiate into mature plasma cells or germinal centre B-cells
(reviewed in Wang & Clarke, 2003). In contrast to the stimulatory effect of ALDH1A1
on the myeloid compartment, B-cell development appeared to be inhibited by the
overexpression of ALDH1A1 in haematopoietic progenitors, as evidenced by the
reduced numbers of CD19
+B220
+ cells in MigR1-ALDH1A1 mice compared to MigR1
control mice in the spleen (mean of 53+13.6% vs 21.4+3.8%, n = 3; Figure 5.7A) and
bone marrow (mean of 27.1+15.1% vs 5.1+0.9%, n = 3; Figure 5.7B). These results
suggest that ALDH1A1 may affect the extent of contribution to mature cells from CLP
or CMP lineages, since this increase in the myeloid compartment was associated with a
concomitant  decrease  in  one  of  the  lymphoid  compartments.  Indeed,  although
ALDH1A1 did not  appear  to  affect  the  differentiation  profile  of T-cells compared to244
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Figure 5.6A. Myeloid Immunophenotyping of Cells Obtained From the
Spleens of Lethally Irradiated Mice 4 Weeks Post-Reconstitution With
Either MigR1, MigR1-ALDH1A1 or MigR1-FHL1 Transduced Bone
Marrow. Cells were stained with phycoerythin (PE)-labelled Gr1 and biotin
(Bio)-labelled Mac1 mAbs, which fluoresce in the FL2 and FL1 channels
respectively. Mice reconstituted with MigR1-ALDH1A1 transduced bone
marrow displayed elevated numbers of mature (Mac1
+Gr1
+) myeloid cells,
compared with control MigR1 mice in spleen (mean of 5.83+1.3% vs
23.7+1.8%, n=3). No significant difference in myeloid differentiation was
detected in mice reconstituted with MigR1-FHL1 transduced bone marrow
compared to MigR1 control mice (mean of 5.8+1.3% vs 10.5+5.6%, n=3).
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Figure 5.6B. Myeloid Immunophenotyping of Cells Obtained From the
Bone Marrow of Lethally Irradiated Mice 4 Weeks Post-Reconstitution
With Either MigR1, MigR1-ALDH1A1 or MigR1-FHL1 Transduced
Bone Marrow. Cells were stained with phycoerythin (PE)-labelled Gr1 and
biotin (Bio)-labelled Mac1 mAbs, which fluoresce in the FL2 and FL1
channels respectively. Mice reconstituted with MigR1-ALDH1A1 transduced
bone marrow displayed elevated numbers of mature (Mac1
+Gr1
+) myeloid
cells, compared with control MigR1 mice bone marrow (mean of 33.3+8.6%
vs 56.6+2.5%, n=3). No significant difference in myeloid differentiation was
detected in mice reconstituted with MigR1-FHL1 transduced bone marrow
compared to MigR1 control mice (mean of 33.3+8.6 vs 26.6+3.3, n=3).
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Figure 5.7A. B-cell Immunophenotyping of GFP+ve Cells Obtained From
the Spleens of Lethally Irradiated Mice 4 Weeks Post-Reconstitution With
Either  MigR1,  MigR1-ALDH1A1 or MigR1-FHL1  Transduced  Bone
Marrow. GFP+ve cells were stained with phycoerythin (PE)-labelled CD19 and
biotin (Bio)-labelled B220 mAbs, which fluoresce in the FL2 and FL1 channels
respectively.  Mice  reconstituted  with  MigR1-ALDH1A1  transduced  bone
marrow  demonstrate  perturbations  in  B-cell  development  as  evidenced  by
reduced numbers of CD19
+B220
+  B-cells, compared with control MigR1 mice in
spleen (mean of 53+13.6% vs 21.4+3.8%, n=3). No significant difference in B-
cell  differentiation  was  detected  in  mice  reconstituted  with  MigR1-FHL1
transduced bone marrow compared to MigR1 control mice (mean of 53+13.6%
vs 45.9+15.9%, n=3).
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Figure 5.7B. B-cell Immunophenotyping of GFP+ve Cells Obtained From
the  Bone  Marrow  of  Lethally  Irradiated  Mice  4  Weeks  Post-
Reconstitution With Either MigR1, MigR1-ALDH1A1 or MigR1-FHL1
Transduced Bone Marrow. GFP+ve cells were stained with phycoerythin
(PE)-labelled CD19 and biotin (Bio)-labelled B220 mAbs, which fluoresce in
the FL2 and FL1 channels respectively. Mice reconstituted with MigR1-
ALDH1A1 transduced bone marrow demonstrate perturbations in B-cell
development as evidenced by reduced numbers of CD19
+B220
+ B-cells,
compared with control MigR1 mice in bone marrow (mean of 27.1+15.1+ vs
5.1+0.9%,  n=3).  No  significant difference in B-cell differentiation was
detected in mice reconstituted with MigR1-FHL1 transduced bone marrow
compared to MigR1 control mice (mean of 27.1+15.2% vs 19.4+7.7%, n=3).
Bone Marrow248
control MigR1 mice (Figure 5.8), a reduction in the contribution of ALDH1A1-GFP-
expressing cells towards the thymus compared to the bone marrow and spleen, was
observed at three different timepoints post-reconstitution (Figure 5.5A, B, C). This is in
keeping with a model whereby ALDH1A1 affects the commitment of HSCs to either the
myeloid or lymphoid lineage. Alternatively, ALDH1A1 may inhibit thymic colonisation
by  T-cell  precursors.  In  contrast,  the  percentage  of  MigR1-GFP  and  MigR1-
FHL1/GFP-expressing cells was relatively consistent in all three tissues examined
(Figure 5.5A, B, C). Nor was overexpression of FHL1 associated with a change in B-
cell differentiation, in either spleen (mean of 53+13.6% vs 45.9+15.9%, n = 3; Figure
5.7A) or bone marrow compartments (mean of 27.1+15.2% vs 19.4+7.7%, n=3; Figure
5.7B). Similar to ALDH1A1, overexpression of FHL1 did not appear to affect T-cell
development (CD4+ and CD8+; Figure 5.8).
Notably, in the case of ALDH1A1, there appeared to be a slight trans-effect, in which
the effect of ALDH1A1 expression on the myeloid and B-cell compartments extended to
neighbouring GFP/ALDH1A1-negative cells. This effect was most pronounced in the
myeloid compartment, where the GFP/ALDH1A1-negative population was expanded in
mice transduced with MSCV-ALDH1A1 transduced bone marrow compared to GFP-
negative cells taken from MigR1 control mice (Figure 5.9).
Finally, the effect of ALDH1A1 and FHL1 overexpression on the maturational stage of
differentiating erythroblasts was examined by staining for erythroid-specific CD71 and
Ter119 cell surface markers. Erythropoiesis occurs in the order: proerythroblast, to
basophilic and polychromatophilic erythroblasts, and then the orthochromatophilic
erythroblast, giving rise to reticulocytes by enucleation (Fawcett, 1997). The transferrin
receptor CD71 is expressed at high levels by early erythroid precursors and at the
proerythroblast stage, but is downregulated during erythrocyte maturation (Ponka &
Lok, 1999). Conversely, the cell surface erythroid specific Ter119 antigen is first
expressed at the proerythroblast stage and is highly expressed at all later stages of
differentiation (Kina et al., 2000). Overexpression of ALDH1A1 did not appear to have
a  significant  effect  on  erythropoiesis  as  assessed  by  calculating  the  means  for
Ter119/CD71  double  positive  cells  in  either  the  spleen  (mean  of  27.5+9.1  vs
34.5+4.3%, [n=3], 5.10A) or bone  marrow  (mean  of  22.8+2% vs 22.1+3.4%,  [n=3];249
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Figure 5.8. T-Cell Immunophenotyping of GFP+ve Cells Obtained From
the Thymus of Lethally Irradiated Mice 4 Weeks Post-Reconstitution With
Either  MigR1,  MigR1-ALDH1A1 or MigR1-FHL1 Transduced  Bone
Marrow. GFP+ve cells were stained with phycoerythin (PE)-labelled CD4 and
biotin (Bio)-labelled CD8 mAbs, which fluoresce in the FL2 and FL1 channels
respectively. No significant difference in T-cell development was detected in
mice reconstituted with MigR1-ALDH1A1 or MigR1-FHL1 transduced bone
marrow compared to control MigR1 mice.
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Figure  5.9.  Trans-effect  of  ALDH1A1  Expression  on  Myeloid
Differentiation. GFP-ve cells obtained from the spleens of lethally irradiated
mice 4 weeks post-reconstitution with either MigR1, MigR1-ALDH1A1  or
MigR1-FHL1 transduced bone marrow were stained with phycoerythrin (PE)-
labelled Gr1 and biotin (Bio)-labelled Mac Abs, which fluoresce in the FL2 and
FL1  channels  respectively.  Mice  reconstituted  with  MigR1-ALDH1A1
transduced bone marrow displayed elevated numbers of mature (Mac1
+Gr1
+)
myeloid cells compared to MigR1 control or MigR1-FHL1 mice in the spleen.
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Figure 5.10B). In the case of FHL1, however, there appeared to be a significant increase
in erythropoiesis in the bone marrow (mean of 22.8+2% vs 41.4+6.1%, [n=3]; Figure
5.10B), however this effect was not observed in the spleen (mean of 27.5+9.1% vs
26.7+8.5%, [n=3]; Figure 5.10A). Although the bone marrow is the most important
erythropoietic organ under resting or stimulated conditions, there appeared to be
abnormally high numbers of Ter119/CD71 double positive erythroid cells in the spleen,
suggesting that extramedullary haematopoiesis was taking place. This may reflect a
state of anaemia, which is thought to trigger compensatory mechanisms resulting in the
increased erythropoiesis, principally in the spleen (Kam et al., 1999), and indicates that
haematopoietic homeostasis had not occurred 4 weeks post-transplant. Nevertheless,
analysis at this timepoint has the advantage of enabling the acute effects of transgene
expression to be identified.
In summary, the reconstitution of lethally irradiated recipients with primary murine
bone marrow overexpressing the HOX11 target gene, ALDH1A1, resulted in enhanced
myelopoiesis and a suppression of B-lymphopoiesis, whilst erythroid development
appeared  unaffected.  Although  ALDH1A1  did  not  appear  to  affect  T-cell
differentiation, overexpression of ALDH1A1 was associated with a quantitative decrease
in cells contributing to the T-cell compartment, as measured by GFP expression. In
contrast, the overexpression of a second HOX11 target, FHL1, was associated with an
increase in erythropoiesis in the bone marrow, whereas myeloid, T-cell and B-cell
compartments remained unaffected.252
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Figure  5.10A.  Erythroid  Immunophenotyping  of  GFP+ve  Cells
Obtained From the Spleens of Lethally Irradiated Mice 4 Weeks Post-
Reconstitution With Either MigR1, MigR1-ALDH1A1 or MigR1-FHL1
Transduced Bone Marrow. GFP+ve cells were stained with phycoerythrin
(PE)-labelled CD71 and biotin (Bio)-labelled Ter119 mAbs, which fluoresce
in the FL2 and FL1 channels respectively. Mice reconstituted with MigR1-
ALDH1A1  demonstrated  no  change  in  the  numbers  of  Ter119
+CD71
+
erythroid cells compared with control MigR1 mice in spleen (mean of
27.5+9.1% vs 34.5+4.2%, n=3). Similarly, mice reconstituted with MigR1-
FHL1 demonstrated no change in the numbers of Ter119
+CD71
+ erythroid
cells compared with control MigR1 mice in spleen (mean of 27.5+9.1% vs
26.7+8.5%, n=3).
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Figure  5.10B.  Erythroid  Immunophenotyping  of  GFP+ve  Cells
Obtained From the Bone Marrow of Lethally Irradiated Mice 4 Weeks
Post-Reconstitution With Either MigR1, MigR1-ALDH1A1 or MigR1-
FHL1  Transduced  Bone  Marrow. GFP+ve cells were stained with
phycoerythrin (PE)-labelled CD71 and biotin (Bio)-labelled Ter119 mAbs,
which  fluoresce  in  the  FL2  and  FL1  channels  respectively.  Mice
reconstituted  with  MigR1-ALDH1A1  demonstrated  no  change  in  the
numbers of Ter119
+CD71
+ erythroid cells compared with control MigR1
mice in the bone marrow (mean of 22.8+2% vs  22.1+3.4%, n=3). An
increase  in  Ter119
+CD71
+  cells  was  observed  for  MigR1-FHL1 mice
compared to MigR1 control mice (mean of 22.8+2% vs 41.4+6.1%, n=3).
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5.4 DISCUSSION
Elevated levels of ALDH1A1, a retinoic acid-synthesising enzyme, have been detected
in most primitive human haematopoietic progenitor cells (Kastan et al., 1990, Jones et
al., 1995, Storms et al., 1999), while ALDH1A1 has been reported to be downregulated
in a number of tumour cell lines and in murine hepatocellular and lung tumours (Banfi
et al., 1994, Dragani et al., 1996). Despite this, the role of ALDH1A1 in haematopoiesis
and leukaemic transformation remains largely uncharacterised. Indeed, although there
have been numerous studies investigating the effects of exogenously applied RA on
haematopoietic differentiation under in vitro culture conditions (Gratas et al., 1993,
Smeland et al., 1994, Douer et al., 2000, Purton et al., 2000), there have been no such
studies on the effects of modulating RA availability in vivo, via the induction or
repression of RA synthesising enzymes. Similarly, although the role of retinoic acid
receptors (RARα, β, and γ and their isoforms) and retinoid X receptors (RXRα, β and γ)
in haematopoiesis and associated malignancies involving dysregulation of specific
target genes by dominant negative mutant forms of these receptors has been studied in
great detail (Pandolfi et al., 1991, Pitha-Rowe et al., 2003), very little attention has been
paid to the involvement of other aspects of retinoid metabolism in tumorigenesis. It is
plausible that dysregulation of RA synthesis, which is tightly controlled by a select
group of enzymes including ALDH1A1, as well as the closely related ALDH1A2
(RALDH2),  may  interfere  with  processes  regulating  cellular  differentiation  and
proliferation, thereby contributing to the tumorigenic phenotype. In a separate role,
ALDH1A1 may also affect the drug sensitivity of specific tumours to chemotherapeutic
agents, since aldehyde dehydrogenases catalyse the oxidation of the drug metabolite
aldophosphamide to the inactive form, carboxyphosphamide (Bunting et al., 1994).
 In this thesis, ALDH1A1 was confirmed to be functionally linked to HOX11 as a
subordinate target gene. We therefore assessed the in vivo effects of dysregulated
ALDH1A1-expression on the differentiation of the various haematopoietic lineages at
early  progenitor  and/or  mature  stages  of  development.  This  was  achieved  by
transplanting lethally irradiated mice with bone marrow cells transduced with an
ALDH1A1-expressing retrovirus (MigR1-ALDH1A1). The differentiation profiles of the
myeloid, erythroid and lymphoid (T-cell and B-cell) lineages were then examined by255
immunophenotypic analysis of cells taken from test (MigR1-ALDH1A1) and control
(MigR1) mice. When analysed one month post-transplant, primary MigR1-ALDH1A1
recipients had a significantly higher number of myeloid cells in samples obtained from
spleen and bone marrow, compared to control MigR1 animals (Figure 5.6A, B). Since
the overall number of myeloid cells increased in both tissues, albeit by different
magnitudes,  it  is  possible  that  overexpression  of  ALDH1A1  induces  the
proliferation/differentiation  of  myeloid  precursors.  Presumably,  given  the  known
physiological function of this enzyme, this effect is mediated via altered RA synthesis.
Indeed, the effects of RA on the granulocytic lineage are well documented, with studies
by  Douer  and  Koeffler  (1982)  revealing  that  the  addition  of  supraphysiological
concentrations of ATRA (micromolar range) to unseparated human bone marrow
mononuclear cell cultures, increased the number of myeloid progenitor CFU-GM
colonies induced by colony stimulating factors by approximately 2-fold. Later studies
by the same group using CD34+ enriched bone marrow cells, confirmed that ATRA
stimulates the growth of myeloid progenitors from less mature CFU-GMs in the
presence of IL-3 and GM-CSF colony stimulating factors, and accelerates the terminal
granulocytic maturation of these progenitors (Douer et al., 2000). Interestingly, ATRA
was found to inhibit the growth of more mature G-CSF-induced myeloid progenitors
from purified CD34+ cells stimulated with various cytokines, suggesting that the
growth stimulating and differentiation properties of ATRA are targeted at less mature
myeloid progenitors and decreases as cells begin to differentiate (Tohda et al., 1991,
Smeland et al., 1994). Although the mechanism by which ATRA increases the number
of early myeloid progenitors in culture is not known, the ability of ATRA to shift the
differentiation of human foetal liver CD34+ cells from a mixed/erythroid/monocytic
pathway towards the granulocytic lineage, raises the possibility that ATRA may redirect
multi-lineage progenitors to alternative programmes of differentiation (Tocci et al.,
1996).
The overexpression of ALDH1A1 in haematopoietic progenitors was also associated
with reduced numbers of CD19/B220 double positive B-cells (~2.5-fold) in the spleen
and bone marrow of MigR1-ALDH1A1 mice compared to MigR1 controls (Figure 5.7A,
B). The inhibitory effect of constitutive ALDH1A1 expression observed in this study is
supported by studies in which exogenous application of physiologic levels (10pmol-256
10nM) of all-trans or 9-cis RA resulted in growth inhibition of human (CD19+IgM-)
and murine (Lin-B220+) B-cell precursors in vitro, by more than 50% (Fahlman et al.,
1995). The inhibition of B-cell proliferation by RA was not due to toxicity, since the
effect was reversible after 24h, even after exposure to concentrations as high as 1uM.
Moreover, Blomhoff et al., (1992) demonstrated that incubation of purified human B-
cells with RA [30nM-3uM], led to growth inhibition of normal B-cells (as estimated by
incorporation of [
3H]-thymidine during DNA synthesis) without affecting cell viability.
Analysis of cell cycle events known to occur at distinct points in the G1 phase of B-cell
activation revealed that RA inhibits lymphoid cell-cycle progression at the mid-G1
phase (Blomhoff et al., 1992), by affecting components of the cell-cycle machinery at
the transcriptional level, via nuclear RARs (Naderi & Blomhoff, 1999). Specifically,
RA was shown to downregulate cyclins E and A, which are required for the activation
of the late G1 phase cyclin dependent kinase, CDK2 and to induce the expression of the
cyclin kinase inhibitor (CKI) p21
Cip1 (Naderi & Blomhoff, 1999). These events are likely
to account for the growth inhibition by RA, since cyclin dependent kinases are key
regulators of pRB phosphorylation, which is a critical event in G1/S progression. In
addition, application of RA appeared to reduce the number of S.aureus plaque-forming
cells, indicating that retinoids may affect normal B-cell differentiation as well as
proliferation (Blomhoff et al., 1992). In a separate study, ATRA was shown to inhibit
the in vitro differentiation of purified B-cells from patients with macroglobulinemia,
which spontaneously differentiate in vitro to plasma cells (Levy et al., 1994). Taken
together, these results indicate an important role for vitamin A and its biologically
active derivatives in the regulation of B-cell lymphopoiesis.
As an alternative to the hypothesis that ALDH1A1 induces the expansion of myeloid
progenitors and inhibits the differentiation and growth of B-cells, it is possible that
ALDH1A1 may affect the commitment of haematopoietic stem cells to either the
myeloid (CMP) or lymphoid (CLP) lineages, thereby accounting for an increase in the
myeloid compartment at the expense of the lymphoid compartment. In support of this
hypothesis, the percentage of GFP-expressing cells was reduced in cells taken from the
thymus of MigR1-ALDH1A1 mice compared to spleen and bone marrow samples,
suggesting that overexpression of ALDH1A1 may be associated with a quantitative
reduction in the T-cell compartment. Such a role has previously been reported for the257
stem cell leukaemia protein (SCL/TAL1), which, like ALDH1A1, is also expressed in
HSCs, and is essential for haematopoietic cell differentiation into myeloid, erythroid
and megakaryocyte lineages (Hoang et al., 1996, Elwood et al., 1998, Kunisato et al.,
2004). Kunisato et al., (2004) performed HSC transplantation experiments using stem
cells retrovirally transduced with either wild type SCL or a dominant negative form of
SCL.  The  overexpression  of  wild  type  SCL  was  associated  with  an  increase  in
myelopoiesis (Mac1+/Gr1+) and concomitant decrease in lymphopoiesis (B220+,
Thy1.2+),  whereas  in  contrast,  overexpression  of  the  mutant  form  of  SCL,
corresponding to a downregulation of SCL, resulted a shift from myelopoiesis to
lymphopoiesis (Kunisato et al., 2004). These results suggested that SCL is capable of
influencing the commitment of a HSC to either the myeloid or lymphoid lineage, by
controlling the generation of CMPs and CLPs (Kunisato et al., 2004). In order to more
accurately determine whether ALDH1A1 affects the commitment of HSCs to myeloid or
lymphoid lineages or alternatively, affects the expansion of myeloid progenitors, the
ability of ALDH1A1-expressing HSCs to generate T-cells, B cells and myeloid cells
might be assessed in future work using a multilineage progenitor (MLP) assay. The
MLP assay is a clonal assay system which employs a modified foetal thymic organ
culture (FTOC) capable of supporting the development of T, B and myeloid cells
(Kawamoto  et  al.,  1997).  Thus,  the  developmental  potential  of  individual
haematopoietic  progenitors  towards  T,  B  or  myeloid  lineages,  following  the
transduction of HSCs with ALDH1A1-expressing retrovirus may be assessed. Given that
the overexpression of SCL and ALDH1A1 resulted in an expansion of the myeloid
compartment and a decrease in B220+ cells, it is tempting to speculate that these genes
may regulate haematopoiesis via a common mechanism. Intriguingly, SCL has been
shown to regulate the transcription of a gene encoding a second RA-synthesising
enzyme, ALDH1A2, better known as RALDH2 (Ono et al., 1998). It therefore seems
plausible that overexpression of SCL, and hence RALDH2, phenocopies the effect of
overexpressing ALDH1A1. Furthermore, given that RALDH2 has been shown to be a
target of a complex involving SCL in T-ALL cell line, HPB-ALL, and that the status of
ALDH1A1 as a target gene of T-cell oncoprotein HOX11 has been confirmed, it is
possible that both SCL and HOX11 may affect the expression of RA synthesising
enzymes  when  dysregulated  in  T-ALL,  converging  on  a  central  theme  for
haematopoietic perturbation via altered RA signalling.258
Intriguingly, overexpression of Hoxa9 in murine bone marrow transplantation assays
results in an increase in mature granulocytes (Mac1
+) and a partial block in B-cell
differentiation at the pre-B progenitor stage (Thorsteinsdottirr et al., 2002). This is
similar to the effect demonstrated for ALDH1A1 in our study. It is interesting to note
that ALDH1A1, Hoxa9 (Lawrence et al., 1997) and SCL are all expressed in primitive
HSCs, and that HOX11 has been cloned from HSC mRNA (Moretti et al., 1994), and
that overexpression of these genes in haematopoietic progenitors results in perturbations
in the myeloid and B-cell compartments. Moreover, both SCL and HOXA9 genes are
involved in chromosomal translocations in human leukaemias (Begley & Green, 1999,
Nakamura et al., 1996), suggesting that genes responsible for regulating the functions of
HSCs may also facilitate leukaemic transformation.
As stated above, the effect on haematopoietic differentiation demonstrated by the
enforced expression of ALDH1A1 was most likely to have occurred via altered RA
synthesis. Some support for this notion was provided by an analysis of GFP negative
(i.e. ALDH1A1 negative) cells from mice that had been reconstituted with MSCV-
ALDH1A1  bone  marrow.  This  revealed  that,  similar  to  the  GFP  positive  cells,
GFP/ALDH1A1  negative  samples  taken  from  the  spleen  demonstrated  enhanced
myelopoiesis as compared to the corresponding cells of control mice (Figure 5.9). Such
a trans-effect may be explained by the fact that RA is a diffusible morphogen. This
would mean that cells lacking the ALDH1A1 transgene could still be affected to some
degree by the RA produced by neighbouring transgene-expressing cells.
The finding that constitutive expression of HOX11 in murine haematopoietic precursors
results in the immortalisation of cells belonging to the myeloid lineage (Hawley et al.,
1994) and the discovery in the present study that overexpression of ALDH1A1, a
downstream target of HOX11 also affects the myeloid compartment, is intriguing and
adds weight to the argument that ALDH1A1 may represent not only a physiological
target in spleen development, but possibly an oncogenic target. Indeed, the well-
documented role of retinoids in the development and disorders of haematopoietic cells
makes ALDH1A1 a likely candidate for dysregulation, since the subversion of retinoid
signalling pathways leading to the development of leukaemia is firmly established
(reviewed  by  Oren  et  al.,  2003).  The  question  thus  arises;  if  the  transforming259
capabilities of HOX11 derive from the ability of HOX11 to cause a block in myeloid
differentiation, how is this reconciled with the stimulatory properties induced by
overexpression  of  ALDH1A1?  Although  our  results,  in  conjunction  with  studies
investigating the effect of retinoids on normal haematopoiesis in vivo, suggest that RA
stimulates granulopoiesis (van Bockstaele et al., 1993), there are also reports that RA
inhibits the proliferation and differentiation of myeloid precursors (Bradley et al., 1983,
Tohda et al., 1991). These studies highlight the pleiotrophic effects mediated by RA,
which may be dependent on the maturational status of precursors present in the original
population under investigation (Purton et al., 1999). The primary bone marrow cells
utilised  in  these  experiments  represented  multiple  lineages  at  various  stages  of
differentiation. As such, the effects of overexpressing ALDH1A1 may not be truly
reflective of an in vivo situation whereby cells harbouring the HOX11 translocation
resulting in altered ALDH1A1 expression, are blocked at a defined stage in development
to  yield  a  predictable  phenotype.  A  detailed  understanding  of  the  effect  of
overexpressing ALDH1A1 in the various lineages at specific stages of development may
yield insight into the potential for aberrant RA synthesis to cause differentiation or
proliferative abnormalities associated with leukaemic transformation. Thus, in order to
circumvent problems associated with using heterogenous bone marrow populations,
future studies should involve transduction of ALDH1A1 containing retrovirus into
purified populations of cells representing the different lineages/maturational stages in
development, thereby yielding a clearer phenotype. Future work to test the hypothesis
that HOX11 and ALDH1A1 are linked within a transcriptional hierarchy capable of
perturbing haematopoiesis and possibly causing T-cell tumours, would ideally require a
definitive murine model capable of recapitulating the tumorigenic capacity of HOX11
in T-ALL.
Despite reports that physiological levels of ATRA are capable of stimulating the
proliferation of human peripheral blood T-cells (Naderi & Blomhoff, 1999), no changes
in the T-cell profile between MSCVMigR1 and MSCVMigR1-ALDH1A1 mice were
observed in these studies. Since a progressive maturation of T-cells in both control and
test  mice  sacrificed  on  38  days  post  transplantation  (Replicate  3;  Figure  5.5C),
compared to mice analysed on 33 days post transplantation (Replicate 1; 5.5A) was
evident, an observable T-cell phenotype may have been masked by the incomplete260
regeneration of the T-cell compartment following engraftment with transduced bone
marrow. Indeed, thymuses extracted 33 days post transplantation, were visibly smaller
than those taken 38 days post transplantation, suggesting that thymic reconstitution was
not complete within the first set of mice. It is possible that the lack of a discernable T-
cell phenotype in MSCVMigR1-ALDH1A1 mice may be due to the requirement for
deregulation of a second gene. Alternatively, it is possible that the failure of ALDH1A1
to  perturb  T-cell  development,  reflects  the  requirement  for  specific  timing  of
overexpression or the level of ALDH1A1 expression. Indeed, preliminary studies by
Izon et al., (unpublished observations), suggest that low level overexpression of HOX11
alone in murine bone marrow, is capable of inducing T-cell leukaemias. The use of an
inducible  retroviral  vector  allowing  for  the  temporal  and  quantitative  control  of
HOX11/ALDH1A1 expression, would therefore be useful in future overexpression
analyses for studying human leukaemias in murine models. Thus, although these studies
demonstrate that the overexpression of ALDH1A1 in primary murine bone marrow has
the  ability  to  perturb  normal  haematopoietic  differentiation  in vivo,  resulting  in
increased myeloid differentiation and inhibition of B-cell development, the oncogenic
relevance of ALDH1A1 as a target gene of HOX11 in a T-cell background has yet to be
established.
Although  the  over-expression  of ALDH1A1 in primary murine bone marrow is
associated with phenotypic changes in both myeloid and B-cell lineages, the exact
mechanism/s underlying these changes remains unknown. Since RA serves as a ligand
for inducible transcriptional regulators (RARs, RXRs)(Giguere et al., 1987), analysis of
the changes in expression of the various receptor subtypes and their isoforms, which are
often auto-regulated in order to amplify the RA response, following over-expression of
ALDH1A1, may yield insights into transcriptional networks perturbed by aberrant RA
synthesis. Indeed, there is precedence for altered retinoic acid nuclear receptor activities
in the development of cancer (Kakizuka et al., 1991, Dejean et al. 1986). One particular
study demonstrated that RARβ is inducible by RA in a hormone-dependent breast
cancer cell line and is responsible for mediating the growth inhibitory effects of
retinoids, partly by inducing apoptosis, such that loss of RARβ may facilitate cancer
development (Liu et al., 1996). These studies highlight the fact that alterations in the
cellular complement of retinoid receptors, as regulated by RA, can result in abnormal261
cellular differentiation and proliferation associated with tumorigenesis. Presumably, the
aberrant signalling effected by RA involves the ligand-induced regulation of specific
target genes by RAR-RXR heterodimers, and as such these studies would optimally be
coupled with an investigation into genes differentially expressed following changes in
ALDH1A1 expression. Given the precedence for RA to affect cell cycle machinery and
the proliferative capacity of lymphoid cells, it would be of interest to analyse the effects
of  over-expressing  ALDH1A1  on  intracellular  levels  of  cyclins,  CKIs  and  the
phosphorylation status of pRB.
In  this  study,  only  the  acute  effects  of  transgene  expression  on  haematopoietic
differentiation were  assessed  one  month  post-transplantation. This  approach  was
advantageous from the perspective that high levels of transgene (as estimated by GFP
expression levels) were still observable in transduced cells. However, ideally, the
functional phenotype of transduced cells should also be assessed following long-term
reconstitution, to allow irradiated animals sufficient time to re-establish haematopoietic
homeostasis and to observe chronic effects (e.g. development of leukaemias). In order
to ensure long-term reconstitution, the repopulation of lethally irradiated recipients with
sufficient numbers of virus transduced long-term self-renewing haematopoietic stem
cells (LT-HSC) is crucial. Studies by Klug et al., (2000) demonstrated that as few as 30
LT-HSC are required to establish long-term haematopoiesis from donor derived cells.
However, standard bone marrow reconstitution experiments result in the injection of
significantly less LT-HSCs, which may be detrimental to the long-term repopulating
ability of these stem cells, since overt differentiation pressure is placed on these cells in
order to reconstitute a lethally irradiated recipient (Hawley et al., 1996). Transduction
of FACS-purified, LT-HSC (Sca-1
+, Lin
-, Thy-1.1
lo, c-kit
+) with retroviral supernatants
and sorting of cells for GFP expression prior to injection into irradiated mice may
improve the success of future long-term transplant experiments. This will minimise the
risk of potentially oncogenic integration events into differentiated haematopoietic cells,
which do not contribute to long-term repopulation, but may obscure a transgene-
mediated phenotype (Klug et al., 2000). Alternatively, the use of a novel lentiviral
vector with a hybrid MSCV/HIV LTR, capable of transducing human CD34+ cells with
greater efficiency than an MSCV-based vector when assayed with normalised viral
titres under the same transduction conditions may also improve the success of long term262
transplant experiments. This is because HIV-based lentiviral vectors are capable of
transducing  non-dividing  cells  and  are  therefore  more  suited  to  slowly  dividing
haematopoietic stem cells  (Choi et al., 2001). Although standard HIV vectors driven
from an internal cytomegalovirus (CMV) promoter express transgenes 100-1000 fold
less than MSCV based vectors, the hybrid vector containing the MSCV/HIV LTR
expresses the transgene 10-100 fold higher than the original HIV-based vector and the
researcher may choose to forfeit lower transgene expression for sustained expression
(Choi et al., 2001).
In contrast to the effects observed by ALDH1A1, the overexpression of FHL1  in
primary murine bone marrow was not associated with perturbations in either the
myeloid or lymphoid lineages. The expression of FHL1 was, however, associated with a
small, yet reproducible increase in the erythroid compartment when compared to the
vector control. It is possible that FHL1 represents a physiological target gene of
HOX11,  and  may  not  be  associated  with  the  tumorigenic  function  of  HOX11.
Intriguingly, however, FHL1 was shown to be expressed in 7 out of a panel of 12 T-
ALL cell lines tested by Northern blot, which is noteworthy considering that FHL1 is
normally expressed at low levels in lymphoid tissues (Greene et al., 1998, Greene et al.,
1999). Moreover, there is precedence for the involvement of another family of LIM-
domain proteins in T-ALL, namely, LMO1 and LMO2 (reviewed by Sanchez-Garcia &
Rabbitts,  1993).  Despite  these  interesting  observations,  the  relationship  between
HOX11 and FHL1 in T-ALL remains unclear, and further work is required to establish
the relevance of FHL1  as  a  target  gene  of  HOX11,  in  either  a  physiological  or
oncogenic setting.
In summary, the work described in this Chapter was aimed at assessing whether
ALDH1A1 and FHL1, two genes transcriptionally linked to HOX11 (Greene et al.,
1998) could mimic the phenotypic effects previously observed for HOX11 on murine
haematopoiesis (Hawley et al., 1994). Retroviral transduction of primary bone marrow
cells coupled with in vivo reconstitution was chosen for this task, as it is a powerful
method  for  assessing  the  effects  of  oncogenes  on  haematopoietic  differentiation
(Hawley et al., 1994). Although the data presented in this Chapter are only suggestive
of ALDH1A1 being able to account for the ability of HOX11 to perturb haematopoiesis263
and cause cellular immortalisation, the finding that enforced expression of ALDH1A1 in
bone marrow cells produces phenotypic effects reminiscent of that previously reported
for HOX11, is an important first step in addressing this question.264
Chapter 6
General Discussion
Despite the increasing body of evidence supporting the role of HOX11 as a transcription
factor involved in the genesis of T-ALL, the mechanism(s) by which HOX11 induces
T-cell tumours remain enigmatic (Kees et al., 2003). It is likely that the dysregulation of
downstream  target  genes  controlling  processes  of  cellular  differentiation  and
proliferation, accounts for the ability of HOX11 to potentiate cellular transformation
and ultimately leukaemogenesis. As such, the identification and characterisation of
relevant target genes is essential if our knowledge of HOX11 as a developmental
regulator and a nuclear oncogene is to increase. Class 1 Aldehyde Dehydrogenase
(Aldh1a1) and Four and a Half Lim Domain Protein 1 (Fhl1), were identified as genes
transcriptionally upregulated by HOX11 in the murine NIH 3T3 fibroblast cell line
(Greene et al., 1998). Aldh1a1 was also shown to be physiologically regulated by
Hox11 in the developing spleen (Greene et al., 1998). Although HOX11 has been
shown to affect the endogenous expression of ALDH1A1 in different cellular milieu
(Greene et al., 2002, Greene, unpublished observations), the ability of HOX11 to
specifically  regulate  the  transcription  of  ALDH1A1 and FHL1  has  not  been
demonstrated.
The first aim of this study, therefore, was to investigate the transcriptional regulation of
ALDH1A1 and FHL1 by HOX11, by identifying HOX11 responsive elements within the
5’ regulatory regions of these genes. Such information would not only serve to validate
the status of ALDH1A1 and FHL1 as target genes of HOX11, providing an insight into
the  complex  gene  networks  controlled  by  HOX11,  but  would  also  increase  our
knowledge of the transcriptional properties of HOX11 and the mechanisms of gene
regulation utilised by this T-cell oncoprotein. A complete understanding of the role of
HOX11  and  downstream  target  genes  in  normal  blood  cell  development  is  also
paramount to our understanding of the functions disrupted by HOX11 in T-ALL. A
second major objective of this study, therefore, was to assess the ability of ALDH1A1
and FHL1 to perturb haematopoiesis, in order to determine whether either of these265
target genes might account for the ability of HOX11 to predispose cells to leukaemic
transformation.
The identification of ALDH1A1 as a putative target gene of HOX11 is of interest, given
the role of ALDH1A1 in regulating the delicate balance of retinoic acid, a potent
modulator of cell growth, differentiation and apoptosis, within the cell. The ability of
HOX11 to modulate ALDH1A1 promoter activity was assessed by luciferase reporter
assays, following transient introduction of nested deletions of the ALDH1A1 promoter
(ranging from -2159 to +1/+42bp) and a HOX11 expression vector into either the T-
ALL cell line, PER-117, or the human erythroleukaemic cell line, HEL (Chapter 2). In
the case of PER-117, HOX11 repressed transcription for promoter constructs ranging
between -2159 to -91/+42bp. Deletion of a functional CCAAT box (-74/-70bp) resulted
not only in a massive decline of promoter activity, but was also associated with a loss of
HOX11-mediated repression. Given that the CCAAT box is the primary cis-regulatory
element within this region, we hypothesised that the observed repression of ALDH1A1
by HOX11 occurred through the CCAAT box, via either direct (involving HOX11
itself) or indirect (involving transcription factors whose expression is affected by
HOX11 higher in a transcriptional hierarchy) mechanisms. This may occur by a passive
mechanism, involving the competition for transcription factor binding sites (occlusion),
or through active mechanisms, via the specific  inhibition  of  the  formation  of  a
functional  preinitiation  complex,  inhibition  of  adjacently  bound  transcriptional
activators  (quenching),  or  recruitment  of  repressor  complexes  including  histone
deacetylases (HDACs), which modify local chromatin structure causing a reduction in
gene expression.
Given that the expression of HOX11 in PER-117 was associated with the loss of a
protein binding complex at the CCAAT box (complex A) and at the putative GATA box
(-34/-28bp)(complexes I and J), and that inclusion of HOX11 antibody was associated
with a quantitative increase in complex I, it was hypothesised that HOX11 directly
represses transcription by interfering with trans-acting factor(s) at the CCAAT box
(passive repression), and with components of the basal transcriptional machinery at the
GATA box (active repression). In support of a model whereby HOX11 displaces
CCAAT  box  binding  transcription  factors,  a  DNA-binding  site  selection  assay266
performed by Zhang et al., (1999), using in vitro  translated  HOX11,  enriched  a
consensus  sequence  (TGGCANNNNGCCAA)  for  the  CCAAT-box  binding
transcription factor (CTF). Since no sequences corresponding to a consensus HOX11
binding site were obtained, this group suggested that HOX11 physically interacted with
CTF in the binding assay, and later demonstrated that HOX11 and CTF1 did indeed
associate in vitro and in vivo (Zhang et al., 1999). However, it is also possible that this
site represents a novel HOX11 recognition sequence, in which case HOX11 may
mediate repression by occlusion of CTF1 (or other CCAAT box binding factors) at the
CCAAT  box.  The  direct  interaction  of  HOX11  with  members  of  the  basal
transcriptional  machinery  has  also  been  documented,  with  Owens  et al.,  (2003)
demonstrating the ability of HOX11 to repress transcription from the SV40, HSVtk,
CMV and neu promoters by interacting with the RNA polymerase II holoenzyme. In
accordance with this, evidence was provided to suggest that HOX11 physically interacts
with TFIIB, a member of the basal transcriptional machinery, that functions in the
correct positioning of RNA polymerase II at promoter DNA (Chapter 4, Heidari,
unpublished observations). Consistent with our mutant (HOX11∆H3) studies, Owens et
al., (2003) also demonstrated that the DNA binding helix of HOX11 was required for
transcriptional repression. Since homeodomain point mutations previously shown to
abrogate or alter DNA binding were capable of repressing transcription as effectively as
wild type HOX11, however, Owens et al., (2003) postulated that repression was
mediated via protein-protein interactions as opposed to a mechanism requiring sequence
specific DNA binding. In support of their finding, the interaction between HOX11 and
TFIIB was significantly reduced upon deletion of the DNA binding helix in our in vitro
GST-pulldown assays (Chapter 4). Future studies to address the role of the HOX11
homeodomain in transcriptional repression, specifically the DNA binding helix 3, may
clarify the exact requirements for HOX11-mediated repression. Thus, HOX11 appears
to repress ALDH1A1 transcription in PER-117 cells by inhibiting/enhancing the
formation of specific complexes at the CCAAT and GATA boxes resident within the
proximal promoter of this gene. Although the homeodomain recognition helix is
required for this activity, it is unlikely to be due to the need for HOX11 to bind DNA
since no new complexes were formed in the presence of HOX11. Rather, Helix 3
appeared to be required for protein-protein interactions, as was the case for TFIIB. The
likelihood that TFIIB assembles at the GATA box is strengthened by the presence of a267
TFIIB  recognition  element  (BRE)(SSRCGCC)  immediately  in  front  of  this  site
(Lagrange et al., 1998).
BRE Consensus S S R C G C C T A T A
ALDH1A1 C C G T G C A G A T A
Figure 6.1. The Human ALDH1A1 Promoter Contains a Sequence Resembling a
TFIIB Recognition Element (BRE). The putative TFIIB recognition element lies
immediately in front of the TATA/GATA box, denoted by green letters. Nucleotide
matches are denoted by red letters.
The ability of HOX11 to regulate ALDH1A1 promoter activity in the HEL cell line was
also assessed by transient luciferase reporter assays. In contrast to the repression
observed  for  PER-117,  HOX11  weakly  activated  the ALDH1A1  promoter within
+1/+42bp, in the HEL cell line. Given that HOX11 was also capable of activating
transcription from the empty pGL3Basic luciferase vector, which has been specifically
engineered to prevent read-through of transcription from cryptic elements within the
vector backbone, we hypothesised that the activation function of HOX11 may occur
independently of DNA binding, again possibly via protein-protein interactions with
members of the basal transcriptional machinery. This activation was sustained for
promoter constructs up to -91/+42bp, however the addition of 55bp of 5’ promoter
sequence (-146/+42bp) resulted in a decline in promoter activity. This suggested that the
region between -146 to -91bp binds a factor capable of exerting a negative regulatory
influence on HOX11.
These studies highlight the potential for HOX11 to act as both a transcriptional
repressor and a transcriptional activator, in a manner apparently dependent on both the
cell-type  specific  transcription  factors  available.  HOX11  may  also  be  subject  to
different post-translational modifications (e.g. phosphorylation) depending on the cell
background, thereby accounting for the differential action observed between PER-117
and HEL. Intriguingly, Western blot analyses of HOX11-transfected cell lysates to
verify the expression of full length HOX11 in transient transfection assays identified an
additional band of lower mobility than the major HOX11 band in HEL cells. This
additional band was not present in HOX11 negative cell lysates nor in the PER-117
lysates. Future experiments to identify this band, which might represent a post-
translationally modified of HOX11, may reveal a mechanism for the dual functionality268
demonstrated by HOX11 in transient assays. It is well documented, for example, that
phosphorylation status may affect the transcriptional properties of regulatory proteins
(Yokoyama et al., 2002). The use of a HOX11 mutant lacking the third helix of the
homeodomain  revealed  further  differences  between  the  activation  and  repressor
functions of HOX11; in that repression was dependent on the DNA binding helix,
whereas activation occurred independently of this domain. Moreover, deletion of this
region switched HOX11 from being a repressor into a potent activator of transcription.
Taken together, these results indicate that transcriptional repression may occur via a
mechanism requiring DNA binding, whereas activation may occur in a DNA-binding
independent manner, possibly via protein-protein interactions. Alternatively, an intact
homeodomain may be required for interactions with specific cofactors, as appears to be
the case for TFIIB.
Notably, transient transfections assays to assess ALDH1A1 promoter activity in PER-
117 and HEL cell lines consistently yielded an effect opposite to that of the endogenous
ALDH1A1 gene. For example ALDH1A1 expression is upregulated by HOX11 at the
level of PCR in the PER-117 T-cell line, however luciferase reporter assays indicated
that HOX11 represses the proximal ALDH1A1 promoter when analysed in isolation.
Conversely, ALDH1A1 expression is downregulated by HOX11 in HEL cell line, as
assessed by Northern blot, contrasting with the activation observed in luciferase reporter
assays. The reasons for this discrepancy are likely due to the inherent limitations
associated with transient luciferase reporter assays. Specifically, the introduction of
multiple copies of the promoter sequence under investigation (ALDH1A1) and protein
expression vector (HOX11, HOX11∆H3) far exceeds the in vivo cellular contextual
requirements for endogenous gene expression. This is likely to affect the delicate ratio
of cofactors within the cell, which in turn may affect specific DNA-binding capabilities
and interactions with members of the basal transcriptional machinery (Mercola et al.,
1985). In addition, distal regulatory elements not included within the luciferase reporter
constructs, may be required to recapitulate the effect of HOX11 on endogenous gene
expression. Finally, it should be noted that the episomal nature of the plasmid reporter
constructs mean that the promoter sequences under investigation are constrained within
an artificial configuration that may not be subject to chromatin specific mechanisms of
gene regulation (Smith & Hager, 1997). As such, an extension of these promoter studies269
might involve the analysis of specific promoter constructs in a stable transfection
system, which would circumvent artefacts associated with artificial configuration and
high copy numbers (Smith & Hager, 1997). There are, however, still limitations
associated with stable transfection assays, particularly those involving the integration
site of the reporter gene construct, which may affect the accessibility of the promoter
sequence to transcription factors required for normal gene regulation. As such, a
combination of both types of assay may be necessary to definitively assess regions of
the ALDH1A1 promoter important for cell-type specific regulation and responsiveness
to HOX11.
The role of HOX11 in T-ALL, via the deregulation of ALDH1A1 remains unclear. The
repression of Aldh1a1 by Hox11 in splenic precursor cells appears requisite for normal
splenogenesis, and it has been postulated that the inappropriate expression of Aldh1a1
in the spleen primordium of Hox11 null mice may contribute to splenic involution,
possibly via pathway of programmed cell death, since the ability of retinoids to inhibit
cell survival by inducing apoptosis has been previously demonstrated (Greene et al.,
1998). More recent studies by Kanzler and Dear (2001), however, suggest that splenic
involution observed in Hox11
-/- mice is not due to apoptosis, but rather an arrest in
spleen development, with splenic precursors contributing to surrounding tissues, and in
this  context  it  is  also  possible  that  changes  in  cellular  levels  of  RA,  a  crucial
morphogen,  may  be  responsible  for  altered  cell  fate.  In  the  context  of  T-cell
development, which involves the positive selection and ‘default cell death pathway’ of
T-cell clones in the thymus, RA may act as either an inducer or an inhibitor of
TCR/CD3-mediated apoptosis, depending on the levels of 9-cis RA, which neutralises
the inhibitory effect of RARα on activation-induced apoptosis (Iwata et al., 1992,
Szondy et al., 1997).  Since the conversion of all-trans RA to 9-cis RA only occurs at
high cellular concentrations of RA, the dysregulation of ALDH1A1, hence perturbation
in  RA  levels  in  developing  T-cells,  may  therefore  affect  T-lineage  apoptotic
programmes or differentiation programmes, thereby predisposing cells to leukaemic
transformation.
With respect to the link between changes in ALDH1A1  expression  and  cellular
immortalisation associated with leukaemic transformation, Owens et al., (2003) suggest
that since there are crucial differences between domains of HOX11 required for the270
activation of Aldh1a1 in NIH 3T3 cells and those required for the immortalisation
function  of  HOX11,  Aldh1a1 is unlikely to represent a target gene involved in
leukaemogenesis. Considering that HOX11 has been shown to differentially affect the
expression of endogenous levels of ALDH1A1 in the HEL cell line (downregulation) as
compared  to  the  PER-117  cell  line  (upregulation),  and  given  the  differential
requirement for the DNA binding helix for activation and repression activities, it is
likely that HOX11 utilises distinct mechanism(s) to regulate ALDH1A1 expression.
Therefore the regions of HOX11 involved in Aldh1a1 upregulation in NIH 3T3 cells are
possibly different to those involved in transcriptional repression demonstrated in the
PER-117 model, neither of which necessarily reflect a situation whereby HOX11 is
deregulated  in  leukaemic  T-cell  precursors.  The  relationship  between  HOX11
overexpression and ALDH1A1 gene expression in relation to T-ALL remains unclear,
however. Although ALDH1A1 upregulation was not observed in a small panel of T-
ALL cell lines expressing HOX11, at the level of Northern blot (Greene et al., 1998), it
remains unclear whether HOX11 activates or represses ALDH1A1 in a tumorigenic
setting, and by what magnitude. Moreover, evolution of in vitro cultured cell lines may
complicate gene expression studies. Future work using primary patient T-ALL tumour
specimens should help to clarify whether HOX11 or ALDH1A1 expression patterns are
correlated.
The second putative target investigated in this study, FHL1, previously known as
SLIM1 (Striated Muscle LIM protein 1), encodes a LIM domain protein required for
muscle differentiation and function (Brown et al., 1999). Following the identification of
the transcriptional start site of FHL1, the effect of HOX11 on the 5’ regulatory region
was undertaken using transient luciferase reporter assays. These studies indicated that
HOX11 was capable of repressing FHL1 promoter activity in the PER-117 cell line,
supporting the finding that FHL1 is indeed regulated by HOX11. Given the presence of
multiple Sp1 binding sites in the proximal region of the promoter (-928/+73bp), it is
possible that HOX11 may interfere with Sp1-mediated transactivation. Precedent for
homeodomain proteins to suppress Sp-1 dependent transcription has been demonstrated
for transcription factors Msx-1 (Shetty et al., 1999) and Hoxa11 (Suzuki et al., 2003),
however further experiments to determine the specific mechanism(s) by which HOX11
represses FHL1 transcription are required.271
With  the  studies  described  above  indicating  that  both  ALDH1A1 and FHL1 are
regulated by HOX11, the next step was to determine whether a link exists between these
target genes and leukaemic transformation. Initial investigations to evaluate the ability
of ALDH1A1 and FHL1 to perturb murine haematopoiesis were therefore undertaken
(Chapter 5). The reconstitution of lethally irradiated recipients with primary murine
bone  marrow  overexpressing  ALDH1A1  resulted  in  a  significant  increase  in
myelopoiesis and a suppression of B and T-lymphopoiesis, compared to control mice.
This may reflect the ability of RA to stimulate the growth and differentiation of myeloid
progenitors from less mature CFU-GMs (Douer et al., 2000) or the inhibitory effect of
RA on B-cell precursors (Fahlman et al., 1995). Alternatively, the observed increase in
the myeloid compartment and decrease in the lymphoid compartment in MigR1-
ALDH1A1 mice may reflect the ability of RA to affect the commitment of HSCs to
either  the  myeloid  (CMP)  or  lymphoid  (CLP)  lineage.  Indeed,  such  a  role  has
previously been described for the Stem Cell Leukaemia (SCL/TAL1) protein, which has
been shown to regulate the transcription of ALDH1A2/RALDH2,  a  second  RA-
synthesising  enzyme.  This  highlights  the  possibility  of  a  central  theme  for
haematopoietic perturbation via altered RA synthesis. It was also noteworthy that the
effect of ALDH1A1 overexpression on the myeloid compartment was reminiscent of the
abnormal myeloid cell differentiation observed following the overexpression of HOX11
in primary murine bone marrow (Hawley et al., 1994). However, further investigations
are required to establish whether dysregulated retinoic acid metabolism following the
ectopic  expression  of  HOX11  is  capable  of  predisposing  T-cells  to  malignant
transformation. Unlike ALDH1A1, the overexpression of FHL1 was not associated with
perturbations in myelopoiesis or lymphopoiesis, suggesting that FHL1 may represent a
physiological, as opposed to an oncogenic target gene of HOX11.
To date, attempts to recapitulate the tumorigenic activity of HOX11 in murine T-cells
have been unsuccessful. It is possible that HOX11 requires the deregulation of a second
gene, perhaps one encoding a protein partner, since the transforming function of
HOX11 most likely involves the collaboration with protein cofactors to modulate
oncogenically relevant target genes. The finding that HOX11 is capable of associating
in vitro with the TALE homeodomain family members, MEIS1 and MEIS2A, provides
a starting point for investigating mechanisms of HOX11-mediated transcriptional272
regulation. In addition, the novel discovery that HOX11 homodimerises in vitro,
provides an alternative mechanism by which HOX11 may regulate gene transcription.
For example, HOX11 may act similarly to the Drosophila transcription factor Kruppel,
which at low concentration, exists as a monomer with activator properties, whereas at
higher concentrations, Kruppel forms homodimers with repressor function (Sauer &
Jackle, 1993). The development of a murine T-cell model that would enable the
coexpression of HOX11 with several candidate protein partners, or the overexpression
of putative downstream target genes, is therefore necessary to identify which of these
candidates is oncogenically relevant in HOX11-mediated tumorigenesis. The generation
of inducible T-cell transgenic mice would provide a valuable in vivo model to more
accurately determine which candidate protein partners or target genes may account for
the oncogenic effect of HOX11. Alternatively, retroviral foetal thymic organ culture
(FTOC), which involves the in vitro culture of foetal thymuses, which have been
reconstituted with foetal liver derived haematopoietic stem cells retrovirally transduced
with the gene(s) of interest and subsequent analyses of T-cell development by flow
cytometry,  may  be  employed.  This  technique  has  the  advantage  of  speed  (high
throughput) and is less expensive than current transgenic options.
Conversely, the failure of HOX11 to cause T-cell tumours in murine models involving
the overexpression of HOX11 in bone marrow (Hawley et al., 1994) and transgenic
mice where HOX11 was targeted to the thymus using CD2 regulatory elements (Greene
&  Rabbitts,  unpublished  observations),  may  reflect  the  requirement  for  specific
expression parameters not achieved in these models. This may relate to the timing of
overexpression or the level of HOX11 expression. Indeed, preliminary bone marrow
transplant experiments by Izon et al., (unpublished observations), suggest that low level
overexpression of HOX11 alone in murine bone marrow is capable of inducing T-cell
leukaemias. This is in keeping with the high proportion of T-ALL specimens that have
been reported to express HOX11 at a low level (Kees et al., 2003), although an
explanation is still required for the high levels of HOX11 expression observed in those
tumours with a translocation involving the HOX11 locus. The requirement for low-level
expression for the induction of relevant human leukaemias in mice has also been
documented for other oncogenes including PML-RARα and TEL/ABL (reviewed by
Ren, 2004). The use of an inducible retroviral vector allowing for the temporal and273
quantitative  control  of  gene  expression,  would  therefore  be  useful  in  future
overexpression analyses for studying human leukaemias in murine models.
The identification of relevant target genes is crucial if our understanding of HOX11 as a
regulator of normal developmental processes including spleen organogenesis, and as a
nuclear oncogene, implied by its overexpression in a significant proportion of patients
with T-ALL and ability to immortalise haematopoietic progenitors in vitro, is to
increase. To this end, the use of screening techniques such as cDNA representational
difference analysis (RDA), has aided the identification of novel candidate target genes
(Greene et al., 1998). More recently, the use of conventional cDNA microarray analysis
to assess the network of genes affected by transcription factors deregulated in the
leukaemic transformation process, has aided the classification of various leukaemia
subtypes, in addition to providing an insight into the common pathways disrupted in
many leukaemias (Ferrando & Look, 2003). Such studies do not enrich for direct targets
of the overexpressed transcription factor, however, and the altered gene expression
profiles often represent global cytoskeletal and metabolic alterations in the cell’s
physiology that provide little insight into the original pathways disrupted in hierarchical
order. Although the functional promoter analyses performed in this study confirmed the
status of ALDH1A1 and FHL1 as genes transcriptionally regulated by HOX11, it is not
known whether this is a result of direct interactions between HOX11 and cis-regulatory
elements/trans-acting proteins within the ALDH1A1 promoter, or an indirect effect of
HOX11 on genes higher in a transcriptional hierarchy. Given that ALDH1A1 expression
is modulated by HOX11 in numerous cellular systems ranging from murine spleen to
immortalised cell lines of both erythroid and T-cell origins, it is likely that ALDH1A1
represents a direct target of HOX11, however additional experiments, for example,
chromatin immunoprecipitation (ChIP), which involves PCR amplification of specific
regulatory regions bound by the transcription factor of interest, should clarify the status
of ALDH1A1 as a direct target gene of HOX11.
Future studies of HOX11 function are likely to benefit from the identification and
characterisation of direct targets, which provide a necessary platform upon which to
study specific cis-regulatory elements and transcriptional complexes involving protein-
protein interactions between HOX11 and cofactors. Such studies will provide necessary
insights  into  HOX11  function  in  either  normal  or  leukaemic  settings.  Although274
ALDH1A1 may represent one such target, ChIP-CHIP, which incorporates current
technologies of Affymetrix arrays in combination with ChIP, may be used to isolate
novel,  direct  target  genes  of  HOX11.  This  method  involves  chromatin
immunoprecipitation  of  HOX11-DNA  complexes  and  hybridisation  of  labelled,
immunopurified  DNA  to  a  CpG  island  microarray  CHIP.  The  advantage  of  this
approach is that it can be used to identify HOX11-regulated promoters that harbour both
consensus and non-consensus binding sites, therefore providing an unbiased approach in
the elucidation of new, direct targets. The success of this technique, which is designed
to increase the speed and number of significant targets isolated, has been demonstrated
in the yeast system using yeast genomic arrays and now, with the development of
mammalian CpG island arrays, should provide a high throughput method for the
identification of in vivo target promoters (Ren et al. 2000, Cross et al., 1994).
In  conclusion,  the  ability  of  HOX11  to  repress  the  proximal  promoters  of  both
ALDH1A1 and FHL1 in PER-117 cells provides further evidence that these genes
represent bona fide target genes of HOX11. In the case of ALDH1A1, HOX11 was
shown  to  repress  ALDH1A1  promoter  activity,  either  directly  or  indirectly  via
interactions with activation complexes at a crucial cis-acting element, the CCAAT box
(-74/-70bp). The expression of HOX11 was also associated with the disruption of
specific complexes at the GATA box (-34/-29bp). Given the ability of HOX11 to
interact with TFIIB and the presence of a TFIIB recognition element immediately 5’
upstream of the GATA box, it is possible that HOX11 represses transcription by
interfering  with  members  of  a preinitiation complex on the ALDH1A1 promoter.
Transcriptional repression and protein-protein interactions with TFIIB were dependent
on homeodomain binding helix 3, and deletion of this region changed HOX11 from a
repressor to a potent activator of transcription, suggesting that HOX11 requires DNA
binding for repression or that this region is important for repressor-specific interactions.
In contrast to the repressive effect of HOX11 on the ALDH1A1 promoter in PER-117,
HOX11 activated transcription from ALDH1A1 promoter constructs in addition to the
empty pGL3Basic reporter vector in a DNA-binding independent manner in the HEL
cell line. Thus, HOX11 is capable of acting as both an activator and a repressor of
transcription, via distinct mechanisms, in a cell-type specific manner. Although the
ability of HOX11 to predispose T-cells to malignant transformation by disrupting the
balance of RA synthesis within the cell remains unclear, given the ability of ALDH1A1275
to affect various aspects of murine haematopoiesis, it remains formally possible that
ALDH1A1 represents an oncogenic target of HOX11. Conversely, although the FHL1
promoter appears to be transcriptionally regulated by HOX11, overexpression of FHL1
in murine bone marrow was not associated with perturbations in murine blood cell
development, suggesting that FHL1 may represent a physiological target gene of
HOX11.276
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Vector Constructs Maps
pCR
®2.1-TOPO
® Cloning Vector
pCI-neo Mammalian Expression Vector.
(Genbank
®/EMBL Accession Number: U47120)322
pGL3Basic Luciferase Reporter Vector
(Genbank
®/EMBL Accession Number: U47295)
                     
pSV-β-Galactosidase Control Vector
(Genbank
®/EMBL Accession Number: X65335)323
Monoclonal Antibodies Used For Flow Cytometric Analysis.
Lineage Tissue Antibody Markers
CD4-APC CD4 is a differentiation antigen expressed
on most thymocytes and a subpopulation of
mature T lymphocytes
CD8-PerCp The CD8α chains form heterodimers with
the CD8β chain on mature T lymphocytes
T-cell Thymus
TCRβ-Pe The TCRβ chain is a component of the TCR
receptor complex on T lymphocytes
B220-Bio B220 is a member of the Protein Tyrosine
Phosphatase (PTP) family and is expressed
on  B  lymphocytes  from  pro-B  through
mature and activated B-cells
B-cell BM, Spleen
CD19-Pe CD19 is a transmembrane glycoprotein and
is  expressed  from  pro-B  cell  through  to
mature B-cell stages; also reported to be
more  restricted  to  the  B-cell  lineage  that
B220
Mac1-Bio Mac1 is an adhesion glycoprotein (165kDa)
expressed  on  activated  lymphocytes,
monocytes, granulocytes and a subset of
NK cells
Myeloid BM, Spleen
Gr1-Pe Gr1  is  a  myeloid  differentiation  antigen
expressed on the monocyte lineage in the
bone  marrow  and  neutrophils/eosinophils
and monocytes in the periphery
Ter119-Bio TER119  is  expressed  on  erythroid  cells
from  the  early  erythroblast  through  to
mature erythroid stages in embryonic yolk
sac,  fetal  liver,  adult  bone  marrow,  adult
peripheral blood and adult lymphoid organs
Erythroid BM, Spleen
CD71-Pe CD71 is a transferrin receptor. Although it is
not erythroid specific it is expressed at high
levels  in  early  erythroid  precursors  and
levels decrease with maturation
Sca1-Pe Sca1  is  a  phosphatidylinositol  anchored
protein  (18kDa)  expressed  on  the
multipotent  HSC  found  in  adult  bone
marrow and fetal liver
c-kit-APC c-Kit is a trans-membrane tyrosine kinase
receptor  expressed  on  HSC,  progenitors
commited to the myeloid/erythroid lineages
and precursors of T and B lymphocytes
Haematopoietic
Stem Cell
BM, Spleen
LinNeg-Bio A  cocktail  of  monoclonal  antibodies  to
exclude lineages with the following suface
cell  markers,  CD3,  CD4,  CD8,  Mac1,
Ter119, B220.
Streptavidin-Allophycocyanin (SA-APC)
Streptavidin-PhycoerythrinCy5 (SA-PeCy5)